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Abstract
Development of drug resistance is a major limitation of chemotherapeutic treatment of 
cancer Resistance arises as a consequence of the genomic instability of tumour cells, 
and usually relies on the perversion of mechanisms used by normal cells to protect 
themselves against environmental toxic agents One of these mechanisms is the 
increased expression of xenobiotic metabolising enzymes, in an attempt to reduce 
drug activation or enhance its detoxification Cytochromes P450 are a family of 
enzymes responsible for biotransformation of both xenobiotic and endogenous 
compounds These enzymes can metabolise a number of chemotherapeutic drugs 
and thus they have the potential to influence the sensitivity of tumour cells to 
anticancer agents
Incubation of Adriamycin and Vincristine with recombinant cytochrome P450 3A4 
(CYP3A4) was shown to decrease their toxic effects on A549 cells Epithelial lung 
BEAS-2B cells transfected with CYP3A4 cDNA showed a modest increase in 
resistance to Adriamycin, which was reversed when simultaneously treated with the 
CYP3A inhibitor 17a-ethynyl oestradiol (17 AEE) Treatment of HL60 cells with the 
CYP1B1 inducer 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) did significantly increase 
mRNA expression and ethoxyresorufm-O-deethylase (EROD) activity of this enzyme, 
but failed to induce changes in the toxicity profiles of 5-fluorouracil, Cisplatin, Taxol or 
Taxotere Pulse selection of MCF-7 cells with Taxotere increased Taxotere resistance 
and greatly enhanced expression of CYP1B1 mRNA and EROD activity Knock-down 
of CYP1B1 expression by siRNA resulted in decreased cell survival, but did not 
substantially enhance Taxotere toxicity The role of P450 NADPH reductase was also 
investigated, and it was found that MDA 231 cells transfected with this enzyme were 
more sensitive to Mitomycin C, Adriamycin and 5-fluorouracil-induced toxicity This 
appeared to be due to increased oxidative stress as evidenced by lower NADPH 
levels and increased ROS production in MDA R4 cells Expression of a set of key 
enzymes involved in glutathione turnover was also found to be altered in a panel of 
drug-selected cell lines In order to study the mechanisms involved in the 
development of resistance, two metabolically competent cell lines were pulse-selected 
with Taxol, Taxotere and Cisplatin These cells showed increased resistance to the 
drugs they were pulsed with and also displayed cross-resistance to taxanes and 
Vincristine Expression of CYP3A4 and CYP3A5 was increased in pulse-selected cells 
as compared to their parental counterparts, the same was found of MDR1 To analyse 
the role of these proteins in drug resistance, combination assays were performed with
cytotoxic drugs in the presence of a CYP3A inhibitor, an MDR1 inhibitor or both 
Simultaneous treatment with 17 AEE did not appreciably affect Taxol toxicity in any of 
the cell lines tested, however, combination of Taxotere with the MDR1 inhibitor 
GF120918 dramatically enhanced the toxicity of the anticancer drug The study of 
xenobiotic metabolism enzymes in tumours could result in the discovery of novel and 
attractive targets for adjuvant therapy that can maximise the effect of 
chemotherapeutic agents and circumvent some types of resistance
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Section 1.0
Introduction
1 1 Cancer chem otherapy
Cancer treatment has seen much progress in the past years Certain types of cancer 
are now almost completely curable thanks to developments in therapy over the last 10 
years, however, other types remain difficult to treat Surgery can be an effective cure 
for certain types of cancer, but it is not always a possible therapeutic option some 
tumours are inoperable, as are non-solid tumours such as leukaemia and advanced 
(metastatic) cancers In these cases, chemotherapy and radiotherapy are the 
alternatives, and they have been used quite successfully
Development of drug resistance is the major limitation of chemotherapeutic treatment 
of cancer Cancer cells can use a number of different mechanisms to attenuate or 
altogether overcome the cytotoxic effects of anticancer agents This usually comes as 
a consequence of the genomic instability of these cells replication is accelerated and 
usual controls of DNA fidelity are defective or no longer functional Mutations, 
amplifications and/or deletions occur, many of which are lethal, but a subpopulation of 
cells in the tumour can be rendered resistant by these alterations, sometimes to more 
than one chemotherapeutic agent Resistance usually relies on the perversion of 
mechanisms used by normal cells to protect themselves against environmental toxic 
agents
Resistance to one or more drugs is referred to as intrinsic if the drug elicits no initial 
response, or as acquired if the tumour is initially responsive to therapy, but later turns 
refractory to treatment (Clynes et a/, 1998) A number of mechanisms mediate 
resistance in cancer cells, the best known are
• Alteration of cellular target
• Alteration of apoptosis pathways
• Enhanced DNA repair
• Drug efflux
• Kinetic resistance
• Enhanced drug inactivation or decreased drug activation
Other mechanisms do not involve alterations of isolated cells but rather of the tumour 
as a whole, such as low vascularisation, which prevents chemotherapeutic drugs from 
reaching the cells inside the tumour, and hypoxia, which reduces the cytotoxic 
potential of free radical-generating drugs or radiation
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111 Drugs used in cancer treatment
Platinum compounds
The best known members of this class of drugs are Cisplatin (also known as cis- 
diamminedichloroplatinum) and Carboplatin (diammine [1,1- 
cyclobutanedicarboxylato(2-)-0, 0']-platinum), discovered over 30 years ago and still 
widely used in cancer chemotherapy Both compounds are platinum (II) complexes 
with two ammonia groups located in the c/s- position, while in one of the newer 
members of this class, Oxaliplatm, platinum is complexed by a 1,2-diammo 
cyclohexane and an oxalate ligand
For many years, the exact mechanism of action of platinum compounds remained 
unclear, it is now accepted that these drugs exert diverse biological effects via a 
number of different mechanisms Upon entrance to the cell, one or both platinum 
bonds are hydrolysed, and this hydrolysed species is the active metabolite 
responsible for the toxic effects (Lau et a l, 2005) The main effect is probably the 
DNA damage caused by platinum adducts, evidence suggests that platinum chelates 
nitrogen and oxygen atoms present in single guanine molecules, while others claim 
that the binding of adjacent guanine bases by the metal is also responsible for the 
damage (Kelman et a/, 1979) The resulting mtra- and inter-strand crosslinking 
interferes with normal transcription and replication of DNA, and if the damage is not 
repaired, the cell will undergo apoptosis This type of damage can be reverted by the 
nucleotide excision repair pathway, but this activity has been shown to be low 
(Zamble et a/, 1996) Other mechanisms by which platinum compounds could be 
toxic to cells include binding and subsequent disruption of phospholipids and 
phosphatidylsenne in the cell membrane, and of RNA and sulphur-containing 
molecules in the cytoplasm (Fuertesa e ta l, 2003)
Cisplatin has been successfully used to treat epithelial malignancies such as ovary, 
bladder and testicular cancer, and also in prostate, cervix, head and neck tumours 
(Wernyj et a l, 2004) Platinum complexes are very toxic to normal cells, and their side 
effects include peripheral neurotoxicity (which is the dose-limiting side effect), renal 
tubular damage, nausea and vomiting, ototoxicity and mild haematological toxicity 
(McKeage e ta l, 1995)
Resistance to platinum compounds, much like their biological effects, involves a 
number of different mechanisms (Wernyj et a/, 2004) The compounds can be 
metabolically inactivated by conjugation with sulphur-containing molecules, mainly 
glutathione (GSH) and metallothionein Alternatively, the drug or some of its
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metabolites can be pumped out of the cells by different transporters, including the 
multidrug resistance protein 2 (MRP2) and the P-type adenosine triphosphatase 
ATP7B copper transporter Enhanced DNA repair by enzyme overexpression has also 
been reported to confer resistance to platinum compounds Contradictory reports exist 
regarding the role of p53 in Cisplatin resistance, with most of the evidence pointing to 
wild-type p53 acting as a pro-resistance factor Other survival-related proteins with 
altered expression in platinum-resistant cells are XIAP, Bcl-2, AKT, Bcl-xl, Fas-L and 
NF-kB
Camptothecins
Camptothecms are synthetic analogues of the plant alkaloid Camptothecin, which is 
extracted from the bark, wood and fruit of the Asian tree Camptotheca acuminata 
(Pizzolato et a/, 2003), the most commonly used are Topotecan (9- 
[(dimethylamino)methyl]-10-hydroxy camptothecin) and Irinotecan (7-ethyl-10-[4-(1- 
piperidino)-1-piperidino] carbonyloxy camptothecin) They were developed in recent 
years during the search for a replacement of Camptothecin, both compounds retain its 
anticancer properties but are much less toxic to normal cells 
The DNA replication enzyme Topoisomerase I has been found to be the target of 
camptothecins, explaining the S-phase specific toxicity of these drugs (Hsiang et a l, 
1988, Li et a l, 1972) They stabilise the cleavable complex formed between DNA and 
Topoisomerase I during the process of separation and relaxation of the DNA strands 
for replication Complexes formed in this way generate single strand breaks that can 
be repaired and do not result in cell death, however, when one of these complexes 
meets a replication fork along the DNA strand, irreversible double strand breaks are 
generated which are impossible to repair, thereby inducing cell cycle arrest and 
apoptosis
Irinotecan is a water-soluble analogue of Camptothecin that is widely used in 
combination with 5-fluorouracil for the treatment of advanced colorectal cancer It is 
also commonly used in combination with Cisplatin against a number of gastrointestinal 
malignancies, non-small and small-cell lung cancer, mesothelioma, ovarian and head 
and neck cancer Once in the organism, carboxylesterases present in the liver and 
gastrointestinal tract cleave its dipiperidino side-chain, generating the active 
metabolite SN-38 This metabolite can be as much as 1000-fold more potent than 
Irinotecan, however, Irinotecan is not considered to be a prodrug, since some of the 
anticancer effects it exhibits cannot be attributed to SN-38 (Takeda et a l, 1992) SN- 
38 is inactivated by glucuromde conjugation, carried out mainly by the uridine
4
diphosphate glucuronosyltransferase 1A1 (UGT1A1) isozyme The main side effects 
observed after treatment with Irinotecan are myelosuppression and diarrhoea 
Decreased intracellular drug concentrations, slower progression through the cell cycle 
and decreased total activity of Topoisomerase I have all been implicated in resistance 
against Irinotecan (Kanzawa et a l , 1990) Other reported mechanisms include 
decreased conversion of Irinotecan into SN-38 (Niimi et a/, 1992), and activation of 
the NF-kB (Cusack et a f, 2000) and the PI3K/Akt pathways (Koizumi et a l, 2005)
Anthracyclines
The anthracyclines are antibiotic compounds produced by bacteria of the 
Streptomyces species, they are weak bases of complex structure, with an ammo 
sugar attached to the anthraqumone planar nucleus (Nielsen et a l, 1996) Adnamycm 
(also known as Doxorubicin) is a semisynthetic compound derived from an 
anthracycline originally isolated from Streptomyces peucetius var caesius 
Like platinum compounds, anthracycline toxicity is mediated by a number of different 
mechanisms, the most important of which has yet to be elucidated It has been 
suggested that the primary effect is the stabilisation of the cleavable complex between 
Topoisomerase II and DNA strands, resulting in double strand breaks However, this 
is not the only mechanism of anthracyclme-induced DNA damage because of its 
planar structure, it is believed that these drugs can intercalate directly between DNA 
bases, altering nucleic acid structure and function It can also bind covalently to DNA 
forming adducts, adding to the damage In addition, bioreductive activation of these 
drugs generates free radicals, which are extremely toxic to cells Because of their 
hydrophobicity, it has also been suggested that anthracyclines bind directly to cell 
membranes and induce lipid peroxidation
In general, anthracyclines have been successfully used in the treatment of 
leukaemias, such as acute myeloid leukaemia (Monneret, 2001), and in the case of 
Adriamycin, also in solid tumours such as breast, bile duct, endometrium, 
oesophagus, liver, osteosarcoma, soft tissue sarcoma and non-Hodgkin’s lymphoma 
(Gewirtz, 1999) The mam side effect of Adriamycin is cardiotoxicity, while nausea, 
vomiting, alopecia and secondary acute myeloid leukaemia have also been reported 
Resistance to Adriamycin and its sister drug, Daunorubicin, can arise as a result of 
reduced intracellular drug concentration by active efflux by both multidrug resistance 
P-glycoprotein (MDR1) and multidrug resistance protein 1 (MRP1), increased drug 
inactivation (particularly by GSH and GSH transferases), decreased availability of
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intracellular targets either by reduced expression or mutation, and reduced 
susceptibility to apoptosis (Den Boer et a l, 1998)
Mitoxantrone
Mitoxantrone is a synthetic anthracenedione initially developed as a Adriamycin 
analogue, which explains their similar structure (Fox, 2004) It is the only compound of 
its kind to be approved for clinical use (Faulds et a l, 1991) The mechanism of action 
is also similar to that of the anthracyclines its main effects appear to be intercalation 
into DNA and inhibition of Topoisomerase II (Hande et a/, 1998), it has also been 
shown to exert immunosuppressive and anti-inflammatory effects However, it is not 
as efficient as the anthracyclines in the generation of free radicals, overall lower 
toxicity, including cardiotoxicity, as compared to Adriamycin has also been 
demonstrated
Mitoxantrone has been used in the treatment of metastatic breast cancer, acute and 
chronic leukemias and non-Hodgkin’s lymphoma, although it does have some activity 
against Hodgkin’s lymphoma, myeloma, melanoma, bladder, prostate, liver, head and 
neck and non-small cell lung cancer (Poirier, 1986) Some cross-resistance between 
Mitoxantrone and the anthracyclines exists, although Mitoxantrone can be active 
against some anthracycline- refractory tumours In some cases, it can altogether 
replace Adriamycin in sensitive patients, because of its lower toxicity 
Myelosuppresion, nausea, vomiting and cardiotoxicity are the mam side effects
Epipodophyllotoxins
This family is comprised of drugs originally isolated from the mandrake plant 
(Podophyllum peltatum) and their analogues, Etoposide (also known as VP-16) and 
Temposide are the best known members The anticancer properties of the natural 
extracts were discovered as early as the 19th century (Hande et a l, 1998), it was their 
toxicity that prevented them from being used in cancer treatment and started the 
search for analogues with similar activity and better toxicity profiles Etoposide and 
Temposide were synthesised in the 1960s
Initially, it was thought that these toxins exerted their anticancer effects by inhibiting 
microtubule assembly, however, they did so at concentrations much higher than those 
achieved in tumoral tissue In 1984, it was finally discovered that the target of 
epipodophyllotoxins was Topoisomerase II (Ross et a l, 1984, Glisson et a/, 1984) 
These drugs stabilise the interaction between the enzyme and DNA, thereby inducing
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single and double strand breaks, the ultimate consequence of this is cell cycle arrest 
and induction of apoptosis The effect is more pronounced when cells are dividing 
rapidly, hence the selectivity against tumour cells
Etoposide is used in the treatment of acute myeloid leukaemia, Hodgkin’s and non- 
Hodgkin’s lymphoma, small cell and non-small cell lung cancer, breast, gastric and 
ovarian cancer Its main toxic effect is myelosuppression Resistance to Etoposide 
and other epipodophyllotoxins arises as a consequence of drug efflux by MDR1 
and/or MRP1, alterations in Topoisomerase II that affect drug binding and kinetic 
resistance (i e , slow growing tumours) (Hande et a l, 1998)
5-fluorouracil
5-fluorouracil (5-FU) is a pyrimidine analogue belonging to the family of the 5-fluoro 
pyrimidines It was firstly synthesised after observations that rat tumours incorporated 
more uracil than normal tissue (Rutman et a/, 1964) The difference between 5-FU 
and native uracil lies in the presence of a fluorine atom instead of hydrogen at the 
carbon-5 position of the pyrimidine ring
Due to its virtually identical structure to uracil, 5-FU participates in reactions that lead 
to thymidine synthesis, reactions it actually needs to exert its toxic effects, the drug 
itself is not toxic, but its metabolites are Upon entrance into the cell, 5-FU can be 
converted into two different metabolites 5-fluorouridine (FUrd) and 5-fluoro-2’- 
deoxyuridine (FdUrd) FdUrd can then be used as a substrate by thymidilate 
synthase, a key enzyme in pyrimidine synthesis FdUrd forms a stable, covalent 
complex with the enzyme, inhibiting it Inhibition of thymidylate synthase is one of the 
mam mechanisms of 5-FU-mediated cytotoxicity, impairment of pyrimidine synthesis 
results in inhibition of DNA synthesis and repair, increased concentration of 
thymidylate synthase substrates (i e , uridine triphosphate or UTP) and their 
incorporation into DNA, causing further damage All these events ultimately lead to 
programmed cell death (Grem et a l , 2000)
On the other hand, FUrd undergoes phosphorylation to form 5-fluorouridine 
triphosphate (FUTP), which can be incorporated into RNA, and this effect correlates 
with cytotoxicity (Glazer et a/, 1982) Numerous consequences arise from this, 
including alterations in RNA secondary structure, impaired conversion of nuclear RNA 
into ribosomal RNA, altered splicing and inhibition of mRNA polyadenylation, which 
decreases its stability These effects of course impair the ability of the cell to 
synthesise proteins Also, FUTP residues present in RNA can be transferred to 
cytoplasmic enzymes, resulting in their inhibition (Grem et a l, 2000) A study by Jin et
1
al (1996) suggests that 5-FU could inhibit nitric oxide production without any 
detectable effect on nitric oxide synthase, it appears that this could be translated into 
growth inhibition
The clinical use of 5-FU is widespread now, alone or in combination The mam 
indication is still colorectal cancer, but also pancreatic, gastrointestinal, breast and 
head and neck tumours (Longley et a l, 2003) Several mechanisms can confer 
tumours increased resistance against 5-FU, among them are increased synthesis of 
thymidylate synthase (Peters et a l, 2002), decreased activation of 5-FU by thymidine 
phosphorylase and increased catalysis of 5-FU active metabolites by 
dihydropyrimidine dihydrogenase (Banerjee et a l, 2002)
Vinca alkaloids
Vincristine and Vinblastine were isolated over 40 years ago from the leaves of 
Catharanthus roseus, also known as Vinca rosea, synthetic analogues Vmdesme, 
Vinorelbine and Vinflumne have been developed more recently 
All members of this family can bind tubulin with high affinity After entenng the cell, 
Vincristine binds to the growing end of microtubules, alteratmg their dynamics, and 
thus interfering with mitosis Vinblastine also affects microtubule kinetics by binding to 
tubulin, yet it does so at a different site Moreover, it appears to induce a 
conformational change, this change could increase microtubule stability, ultimately 
blocking mitosis (Jordan et a l, 2004) At higher concentrations, they can also induce 
microtubule aggregation and even the formation of crystals
In spite of their very similar structures, Vincristine and Vinblastine have different 
spectra of activity, with Vincristine being succesfully used against childhood 
leukaemia and Vinblastine in the treatment of solid tumours (Hacker ef a/, 1991) 
They also differ in their toxicity, with leukopenia being the dose-limiting effect for 
Vinblastine and peripheral neuropathy for Vincristine All Vinca alkaloids are widely 
used as single agents in the treatment of rapidly growing tumours such as childhood 
and adult leukaemias and lymphomas, as well as in some solid tumours Cancer cells 
can acquire resistance against Vincristine by increasing drug efflux through MDR1 
and MRP1 proteins, alteratmg the drug target through mutations m a and il-tubulm, 
overexpressmg certain isotypes of tubulin that are less sensitive to alkaloid binding 
and changing expression levels of microtubule regulatory proteins In addition, it 
seems that resistance can also be mediated by other tubulin isotypes (y, 5 and e-
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tubulin), which are associated to the centrosome, although it is not yet clear in which 
way this happens (Jordan et a l, 2004)
Taxanes
Paclitaxel (also known as Taxol) is a natural plant product initially isolated from the 
bark of the pacific yew tree (Taxus brevifoha), because of its successful use in the 
treatment of several cancers, a semisynthetic analogue, Docetaxel (Taxotere) was 
developed shortly afterwards, derived from a similar compound found in the european 
yew tree which has quite similar, albeit not identical, properties 
In a similar way than that of Vincristine, the taxanes exert their toxic effect by binding 
to ft-tubulm, alterating microtubule dynamics, however, while Vinca alkaloids have a 
tendency to destabilise these structures, taxanes appear to stimulate and stabilise 
microtubule polymerization (Schiff et a l, 1979) it seems that their ability to cause this 
effect is related to the conformational change they induce in tubulin upon binding, this 
conformational change increases tubulin affinity for itself (Nogales et a l, 2001)
Taxol has been successfully used in the treatment of breast, ovary, non-small cell 
lung cancer and Kaposi’s sarcoma, while Taxotere is currently being used in brain, 
prostate and lung tumours Their main side effects, similar to the Vinca alkaloids, are 
myelosuppression and neurotoxicity It also shares a number of resistance 
mechanisms with the Vinca compounds, i e , efflux out of the cell by MDR1 (but not 
MRP1), molecular alterations in tubulin that lead to decreased drug binding, 
expression of endogenous microtubule-depolymerising agents and changes in 
microtubule dynamics (Jordan et a/, 2004), alongside more general mechanisms 
such as decreased susceptibility to apoptosis, changes in lipid composition and 
increased secretion of interleukin-6 (Yusuf et a l, 2003)
Mitomycin C
Mitomycin C is a natural product isolated from Streptomyces lavendulae Its chemical 
structure contains an aziridine functional group, consisting of a heterocycle with an 
amino group and two methylene groups
This drug undergoes activation by a number of intracellular enzymes including P450 
NAD PH reductase (P450R), DT-diaphorase and NADPH cytochrome c reductase 
(Cummings et a l, 1998) In this reaction, the quinone group is reduced to a 
semiquinone by the addition of one electron, or to a hydroquinone by the addition of 
two When oxygen is present, the semiquinone will enter a redox cycle and produce
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reactive oxygen species (ROS) that, although harmful to the cell, do not appear to 
significantly contribute to cytotoxicity In the absence of oxygen, the semiquinone 
rearranges to form the hydroquinone, a more stable structure, and this compound, 
together with downstream metabolites, generates mono- and bis-DNA adducts The 
mechanism of activation for Mitomycin C implies that this drug is more toxic to 
oxygen-deprived, hypoxic cells, which are usually found in solid tumours This is the 
molecular basis for the selective toxicity towards tumour cells displayed by Mitomycin 
C
Mitomycin C has shown a wide antitumoral spectrum and is active against breast, 
head and neck, cervical, prostate, bladder, pancreatic, gastric and non-small cell lung 
cancer (Verweij et a/, 1990, Bradner, 2001) The main toxic side effects observed 
with its use are thrombocytopenia and leucocytopema, although uremic-haemolytic 
syndrome, renal and cardiopulmonary toxicity have also been reported 
Mitomycin C is an MDR1 substrate, so overexpression of this efllux pump renders 
cells resistant to the drug Decreased activity of bioactivating enzymes has also been 
reported as a resistance mechanism in cultured tumour cells (Singh et a1, 1996), as 
well as the aberrant expression of DNA damage response proteins (Johnson et a l, 
1997)
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1.2 Multidrug resistance in cancer
A well-known phenomenon observed in cancer cell lines is that, when cultured in the 
presence of constant or increasing concentrations of a toxic agent, such as a 
chemotherapeutic drug, cells develop resistance to this toxin Since most anticancer 
agents are mutagens, it is very likely that prolonged culture in the presence of the 
drug would induce mutations in the cells, some of these will have no effect on cell 
survival, some may even be lethal, but certain mutations can help cells adapt to their 
toxic environment and become resistant to the effects of the drug Another 
explanation for the development of resistance in chemotherapy-exposed cell lines is 
that treatment with anticancer agents can actually select an intrinsically resistant 
subpopulation within the cells Tumours are known to be heterogeneous, and it is not 
unreasonable to suppose that different phenotypes expressed by cell subpopulations 
will often display differential sensitivity to chemotherapy drugs 
When evaluating the toxicity of different drugs on these resistant cell lines, it is often 
found that cells display resistance to the drug they were selected with and also to a 
number of others, whether or not structurally and/or mechanistically related This 
phenomenon gave rise to the expression Multi-drug resistance (MDR) The 
importance of this observation was shown when a similar behaviour was observed in 
tumours indeed, cancers that were treated with a particular drug often became 
resistant to it after a certain period of time Resistance was later shown to extend also 
to a number of anticancer agents that had not been used for the treatment 
Although several different mechanisms are involved in the development of resistance, 
MDR is more often than not associated with certain proteins known as ATP binding 
cassette (ABC) transporters Members of this superfamily of proteins can act as efflux 
pumps and actively extrude a number of different compounds, including anticancer 
agents, from the inside of the cell, thereby reducing their toxic effects As their name 
suggests, efflux is active and depends on ATP hydrolysis, which provides the energy 
required for the transport process As the transport is active, these proteins can pump 
chemical compounds against a concentration gradient
All of these proteins are located in the plasma membrane albeit in different regions of 
polarized cells, with only a small fraction found in the Golgi apparatus (Schinkel et a! , 
2003) They can be divided in four classes according to their morphological structure
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MRP4.5
Figure 121 Comparative structures of ABC transporters superfamily members (From Schmkel et a l , 
2003), where NBD stands for nucleotide binding domain Branches represent sites of NNinked 
glycosilation
Overall structures of different ABC transporters are quite similar (Fig 12 1), 
displaying a variable number of the six transmembrane segment core connected by 
intra and extracellular loops, and containing one or more nucleotide binding domains 
(NBDs) The most obvious differences are in MRP 1,2 and 3, which have an additional 
domain, complete with five transmembrane segments (but lacking an extra NBD), and 
in BCRP, which is formed by a single domain Areas of heavy N-glycosylation can be 
found in all four classes, although they do not appear to be necessary for efflux 
(Schinkel et a l, 1993) However, it is very likely that N-glycosylation acts as a signal 
for routing the protein to the plasma membrane, stabilising it
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12 1 Multidrug resistance protein (MDR1)
This protein has received several alternative names, such as P-glycoprotein (Pgp), 
PGY1 and GP170 (Schmkel et a l, 2003) It is a 170 kDa protein with heavy N- 
glycosylation in the extracellular loop closer to the N-terminal The structure is formed 
by six transmembrane segments connected by a short polypeptidic section which 
features phosphorylation sites for a variety of protein kinases and one of the two ATP 
binding sites, the other being located at the C-terminal
Substrates of MDR1 are extraordinarily diverse in structure, with only a few common 
factors amongst them they are relatively small organic compounds (the highest 
molecular weight that is actually transported is around 2kDa) which are amphipatic 
and usually uncharged or weakly basic, although some acidic compounds (i e , 
methotrexate, phenytom) are also substrates of MDR1, albeit poor ones There is 
evidence that compounds are transported by binding to the intracellular side of MDR1 
and then being flipped to the outside of the cell (Higgins et a/, 1992), the fact that 
virtually all substrates are amphipatic supports the notion that MDR1 ts a flippase It 
should be noted that the great majority of these substrates are hydrophobic and, as 
such, have the ability to diffuse passively through cell membranes, the presence of a 
pump makes it possible for them to be transported against a concentration gradient 
MDR1 is usually located in secretory surfaces (Bosch et a l, 1996), and this protein 
can be readily detected in high levels in liver (particularly in biliar canaliculi), proximal 
tubules of the kidney, intestinal and colonic epithelium, pancreatic ducts, bronchial 
mucosa, prostatic epithelia, ovarian follicles and pregnant uterine epithelium, as well 
as »n the luminal face of endothelial cells that form the blood-brain barrier and also the 
blood-testis and blood-nerve barrier (Bosch et a l, 1996, Schinkel eta1, 2003) In all of 
these tissues, the physiological function of MDR1 appears to be that of protecting 
sensitive cells or organs from potential damage from toxins by excretion of these into 
the bloodstream, urine, faeces or other secretions
A number of chemotherapeutic drugs are MDR1 substrates, including anthracyclines 
(e g , Adriamycin), taxanes (Paclitaxel), Vinca alkaloids (Vincristine, Vinblastine), 
epipodophillotoxins (Etoposide) and other drugs, such as Topotecan and Actinomycm 
D This points to a potential involvement of MDR1 in chemotherapy resistance 
Indeed, transfection or transduction of MDR1 cDNA is sufficient to confer multidrug 
resistance, as shown by various studies (de Graaf et a l , 1996, Mahon et a l , 2003, 
Findlmg-Kagan et a l, 2005) Overexpression of MDR1 is a common finding in cell 
lines cultured in the presence of chemotherapeutic drugs, inhibition of the high 
expression levels by antisense oligonucleotides or ribozyme transfection usually
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restores sensitivity to cytotoxic drugs (Gao et a l, 1998, Pan et a l, 2001, Wang et a l, 
2003) A number of tumours have been shown to express high levels of this protein 
and this overexpression was directly correlated with poor prognosis (Ling et a l, 1997) 
Expression of MDR1 in breast cancer was also found to correlate with tumour staging 
(Leonessa et a l, 2003)
Implication of MDR1 activity in drug resistance opened the door to the development of 
a number of inhibitors, in the hope that coadministration with these compounds would 
improve the efficacy of chemotherapy The first compounds to show inhibitory activity 
against MDR1 were already known drugs, such as the calcium channel blocker 
Verapamil and the immunosuppressive drug Cyclosporin A These drugs were quickly 
replaced by second generation inhibitors, which were specifically designed for this 
purpose, these compounds display higher affinity for MDR1 and reduced 
pharmacodynamic effects A third generation of MDR1 inhibitors is now available, with 
even higher efficiency, examples of third generation MDR1 inhibitors are LY335979 
and GF120918 (Hyafil et a l, 1993, Dantzig et a l, 1996)
12 2 The Multidrug Resistance Protein (MRP) family
The multidrug resistance protein (MRP) family comprises so far 9 members 
denominated MRP1 to MRP9 They can be divided according to their structure in two 
types MRP4, MRP5, MRP8 and MRP9 have a similar structure to MDR1 (i e , two six 
segment transmembrane domains and two NBDs), while MRP1, MRP2, MRP3, MRP6 
and MRP7 possess an extra five segment transmembrane domain 
Expression of MRP1, MRP4 and MRP5 can be found in several different types of 
tissue, whereas MRP2, MRP3 and MRP6 appear to be restricted to kidney, liver and 
gastrointestinal tract (Borst et a/, 1999) These pumps can also be divided in two 
types according to their position on the cell membrane while MRP2 is located on the 
apical side of the plasma membrane, in a similar way to MDR1, MRP1, MRP3 and 
MRP5 are preferentially expressed on the basolateral side MRP1 is not exclusively 
found on the plasma membrane, with a fraction expressed in intracellular vesicles 
(Flens et a/, 1996)
The physiological function of MRPs appears to be very similar to that of MDR1 in 
protecting vital areas from the toxic effects of circulating compounds, this has been 
demonstrated for MRP1 by experiments performed with MRP1 knock-out mice 
However, a protective role of MRP2-6 against xenobiotics has not yet been confirmed 
The fact that some of these proteins are expressed on the basolateral side of the cell
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membrane does not interfere with their protective function, since toxins can be 
excreted out of the epithelium by pumping them into the circulation, this is true of the 
testicular tubes and the choroid plexus (Borst et a/, 1999) Substrates of MRPs are 
organic anions that, unlike MDR1 substrates, do not diffuse passively through cell 
membranes Examples of physiological substrates of MRPs are leukotriene C4 
(LTC4) and organic acids present in bile and liver cells
It has been demonstrated that MRP1 transports GSH, glucuronate and sulphate 
conjugated drugs, which would suggest that the pump has a binding site for these 
conjugating compounds However, several drugs transported by MRP1 are not 
conjugated m vivo This apparent contradiction has been explained by a number of 
studies, which have concluded that efficient export of substrates by MRP1 requires 
GSH This has been demonstrated by treatment of MRP1 overexpressing cells with 
GSH depleting agents, resulting in decreased resistance Moreover, increased 
expression of MRP1 in cells diminishes GSH levels, indicating that there is a basal 
export of GSH out of the cell even in the absence of drugs It js now believed that 
compounds pumped out of the cell by MRP1 are co-transported with GSH (Borst et 
al, 1999)
Several anticancer drugs have been reported as MRP1 substrates these include 
Vincristine, Vinblastine, Etoposide, Adriamycin, Cisplatm, Mitoxantrone and 
Methotrexate (Schinkel et a/, 2003) Indeed, knock-out mice for MRP1 display 
increased sensitivity to the toxic effects of Etoposide (Wijnholds et a l, 1997) Breast 
tumours positive for MRP1 expression were shown to have a lower response to 
chemotherapy than MRP1 negative tumours (Nooter et a l, 1997b) Furthermore, two 
separate studies found a negative correlation between MRP1 protein expression and 
relapse-free survival (Nooter et a/, 1997a, Frifpits e ta l, 1999)
A number of inhibitors or MRP1 are now in experimental use, most of them well 
known drugs such as Sulfinpyrazone and Probenecid Indeed, Sulindac has been 
shown to considerably increase the cytotoxicity of anthracyclmes, Vincristine and 
Etoposide when administered in combination, this effect has been attributed to the 
inhibitory effect of the anti-inflammatory agent on MRP1 (Duffy et a1, 1998)
MRP2 transport is, like that of MRP1, dependent of GSH levels, as shown by 
experiments with GSH-depleting agents (Cui et a l, 1999) Expression of MRP2 in 
lung cancer cells has been reported to correlate with resistance to Adriamycin and 
Cisplatin (Kool et a/, 1997) Further confirmation of the role of MRP2 in drug 
resistance was obtained by transfecting HepG2 hepatoma cells with an MRP2 
antisense construct, transfection resulted in sensitisation of cells to Cisplatin, 
Irinotecan and its derivative SN-38, Vincristine and Adriamycin (Koike et a l, 1997) In
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another study, MDCK cells transfected with MRP2 developed 5 to 10-fold resistance 
to Etoposide, Vincristine, Adriamycin and Cisplatin
MRP3 expression was shown to correlate strongly with resistance to Adriamycin and 
less substantially, albeit significantly, with resistance to Vincristine, Etoposide and 
Cisplatin (Young et a/, 1999) Transfection of MRP3 can render cells resistant to 
Etoposide, Temposide and Methotrexate, and also to Vincristine, albeit at lower levels 
(Kool et a! , 1999, Zeng et a/, 1999) This type of transport appears not to be 
dependent on GSH levels, since cotreatment with GSH-depleting agents did not result 
in decreased resistance
Few studies exist on the relationship between MRP4 expression and anticancer drug 
resistance, overexpression of this protein was reported to confer resistance to the 
nucleotide analogues 6-Mercaptopurine and Thioguamne (Chen et a/, 2001) 
Similarly, HEK293 cells transfected with MRP5 displayed weak resistance to the same 
agents (Wijnholds et a l, 2000)
MRP6, MRP7, MRP8 and MRP9 have been discovered very recently and their role in 
tissue protection and drug resistance has not yet been established
16
1.3 Drug metabolism
The body responds to noxious stimuli from the environment by activating a defense 
mechanism, the nature of this mechanism depends on the size of the agents that 
cause the stimulus Large foreign substances such as proteins, viruses and bacteria 
are dealt with by the immune system, while small chemical compounds can be 
enzymatically inactivated
The enzymatic detoxification system is for small molecules what the immune system 
is for bacteria and viruses it protects the body from environmental hazards The 
target molecules are extraordinarily variable in size and physicochemical 
characteristics therefore, the system must be very flexible, and allow for all sorts of 
substrates to be processed It is believed that families of enzymes involved in 
detoxification evolved from a single gene by amplification and mutation in response to 
environmental pressure, this explains why there are several enzyme isoforms The 
existence of different enzymes with similar activity leads to high metabolic efficiency 
as a result of overlapping activities a single substrate is metabolised by several 
enzymes and a single enzyme is able to biotransform a number of different 
compounds
Low specificity and overlapping of substrates are usually cited as advantages of the 
metabolic system, however, when different drugs are administered to a patient, 
competition for certain reactions can arise, with unexpected results in drug 
pharmacokinetics and toxicity It is therefore essential to check the metabolic 
pathways of all different drugs given to a patient at the same time, in order to avoid 
metabolic interactions and potential toxicity
An increase in water solubility will detoxify most hydrophobic compounds, hydrophilic 
compounds have reduced penetration into cells, while they are very soluble in urine 
and sweat, for example, this makes such compounds easier to excrete Hydrophobic 
substances can diffuse easily across cell membranes and accumulate inside the cell, 
where they can remain indefinitely, interfering in the complex homeostasis of the cell 
The detoxification process is achieved in two phases In Phase I reactions, a small 
functional group is either added to or unmasked in the molecule, which usually results 
in changes in activity Phase II reactions involve the attachment (conjugation) of a 
large group to a reactive functional group present in the drug metabolites formed in 
this way can then be excreted in the urine, sweat or faeces Phase I reactions are 
believe to be preparative, that is, to make a certain chemical a better substrate for 
Phase II, which is the main detoxification step
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Sometimes these reactions result in the formation of more active compounds, and this 
can lead to harmful (i e , if the toxicity of the metabolite is greater than that of the 
parental compound) or beneficial effects (for example, activation of a prodrug) It is 
mostly Phase I reactions that can activate a chemical, while Phase II metabolism will 
almost always result in detoxification
The liver is the major site of detoxification in the body, and is also where most 
enzymes related to drug metabolism are expressed However, since vanous types of 
tissue are exposed to foreign substances, expression of these enzymes can be found 
throughout the body as means of protection, especially in lung, kidney and 
gastrointestinal tract
Phase 1 Oxidation 
Reduction 
Hydrolysis 
Hydration 
Dethioacetylation 
Isomérisation
Small increase in hydrophilicity
Phase II Glucuromdation/glucosidation Large increase in hydrophilicity
Sulfation
Méthylation
Acétylation
Amino acid conjugation
Glutathione conjugation
Fatty acid conjugation
Condensation
Table 13 1 Classification of metabolic reactions as Phase I or II (adapted from Gibson et al)
131 Phase I metabolism
As previously mentioned, these reactions prepare chemicals by adding or unmasking 
a polar group A xenobiotic can be modified in a number of different ways, as shown 
by the variety of Phase I reactions that exist These reactions can be carried out by 
cytochromes P450, by far, the most important Phase I effectors, or by other enzymes
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1311  Cytochromes P450
Cytochromes P450 are a family of enzymes implicated in the biotransformation of 
both xenobiotics and endogenous compounds Their primary functions are the 
synthesis of steroids and bile acids and the detoxification of several substances, such 
as drugs and environmental agents Mammalian P450s are membrane-bound They 
can be located in the endoplasmic reticulum of the cell or in mitochondria 
Over 500 cytochromes have been described Even though the drug metabolising 
system of animals is similar to that of humans, there are several differences regarding 
isoforms and substrate specificity Mammals can express different sets of P450 
isoforms and each one of these can be identical or completely different to the human 
counterpart For example, CYP2E1 is expressed in human, rat and rabbit liver, but 
while CYP3A6 is the only 3A member detected in rabbit tissues, humans can express 
3A4, 3A5 and 3A7 isoforms Also, differences can be found regarding which isoform 
metabolises a particular substrate
Structure
All P450s possess a heme moiety as a prosthetic group (Fig 13 1) The heme group 
can bind carbon monoxide very tightly, and it is known that carbon monoxide-exposed 
microsomes will show a very strong absorption band at 450 nm in a difference 
spectrum, hence the name P450, where P stands for pigment
Figure 131 Heme group (from www newark rutgers edu)
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P450s can be grouped into three classes according to the redox partner they use 
(Graham-Lorence et a l, 1996), class I P450s require two redox cofactors, an iron- 
sulphur protein (ferredoxin) and a FAD-contaming NAD(P)H-ferredoxin reductase for 
their catalytic activity, class II P450s need a FAD/FMN-containmg NADPH-P450 
reductase, and class III do not require a separate protein or proteins for reduction 
Examples of class I P450s are bacterial enzymes such as CYP101 (also known as 
P450cam) and CYP108, and mammalian enzyme CYP11A, which is involved in 
steroid synthesis Drug metabolising P450s such as the members of the CYP1, CYP2 
and CYP3 family are all class II enzymes, as are steroidogenic microsomal P450s like 
CYP17 and CYP19 Finally, class III P450s include thromboxane synthase CYP5 and 
allene oxide synthase CYP74
The typical structure of cytochromes P450 can be seen in a simplified scheme in Fig 
13 2 P450s are composed of two domains one has a predominant a-helix structure 
and comprises about 70% of the protein, while the other is formed mainly by p-sheet 
The a-helical domain comprises helices B’ to K, helix L and also sheets P3 to P5, the 
p-sheet domain contains the sheets pi and 2, and helices A, B and K’ There is also a 
region in the protein termed the meander, which is a 14 or 15-residue section at the 
end of the K helix
The conserved residues among the P450 superfamily are only three, and consist of 
the cysteine located in the heme binding region, which helps coordinating the iron 
present in the heme group and is surrounded by a highly conserved sequence, and 
glutamine and arginine residues located in the K helix, facing the meander Highly 
conserved residues that are not present in all members of the P450 superfamily can 
also be found, including a threonine residue facing the active site and an acidic 
residue (usually glutamine or aspartate) located very close to it, which appear to be 
involved in molecular oxygen binding and bond-splitting (Raag et al ,1991)
Key structural features of P450s can be found when comparing the three-dimensional 
structures of enzymes belonging to different classes (Graham-Lorence et a/, 1996) 
These features compose what is known as the core structure of the cytochrome, and 
are namely a four a-helix bundle, formed by three parallel helices (I, L and D) and an 
antiparallel one (E), helices J and K, sheets p1 and p2, the cysteine-containing heme 
binding loop and the meander The a-helical domain is topped by six helices, while 
another three a-helices and two p-sheets can be found at the bottom of this structure 
The fact that these features are so highly conserved among different family members 
suggests that they play important roles in protein folding and heme binding As 
expected in these proteins, the regions displaying the highest diversity and the lowest
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conservation are those involved in substrate binding and recognition, and also in the 
binding of the different redox partners. In these cases, the core structure remains 
unchanged, but the helices and sheets adopt different lengths and positions in order 
to accommodate diverse compounds and cofactors.
Figure 1.3.2: Typical structure of cytochromes P450 (from www.its.caltech.edu).
Catalytic cycle
Cytochromes P450 are the most important enzymes carrying out Phase I reactions. 
The families involved in drug metabolism are CYP1, CYP2 and CYP3. Cytochromes 
P450 catalyse a number of different reactions, such as hydroxylation, epoxidation, 
dealkylation and deamination, of which the most significant is probably hydroxylation. 
P450s are monooxygenases because they incorporate a single oxygen atom to the 
substrate. To do this, they must first break the bond between the two atoms of 
molecular oxygen: they achieve this by reducing the iron atom present in the heme 
group with two electrons donated by an accessory protein. Two electron-donor 
proteins usually work as P450 cofactors: the NADPH-cytochrome P450 reductase 
(P450R), present in the endoplasmic reticulum, and the Ferredoxin/Ferredoxin 
reductase complex located in mitochondria. The presence of these proteins is 
essential for P450 activity, as is also the presence of a lipid component, believed to 
influence substrate binding, electron transfer, conformational change and anchorage 
of the cytochrome (Nisimoto et a/., 1983). Cytochrome b5 is also considered as a 
P450 cofactor; even though it does not appear to be involved in all P450 reactions, it
A
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can modulate catalysis by a number of different mechanisms (Schenkman et a l, 
2003) This battery of components works together as a system, known as the mixed 
function oxidase (MFO) system, of which cytochrome P450 is the terminal oxidase 
The P450 catalytic cycle is a very complex one, performed in several steps (Fig 
13 3) Firstly, the substrate is bound to the iron atom located on the heme, which is 
in the ferric form (Fe3+) This atom is coordinated by six different ligands, the catalytic 
activation of oxygen will only occur at a very precise location, specifically at the site of 
the sixth ligand, which is exchangeable (White et a l, 1980) A first reduction is then 
carried out on the ferric atom with an electron donated by P450R, which obtains it 
from the reduction of NADPH In the adrenal gland mitochondria, this reaction is 
carried out in a slightly different way, with an extra protein, Adrenodoxm, transporting 
the electron from the NADPH-adrenodoxm reductase to the P450
ROH
Fe3*
Fe3* ROH
/  Hao
FeOH3* R* 2e -2H^
Fe2+02 RH 
H20 x
F€RH H "'’S "  RH Fe3+ RH + 0 2'
H’ i t  /
Fe2+ RH + 02 - * H20 2
Figure 13 3 P450 Oxidation cycle (from Yun et a l, 2000)
After the iron atom has been reduced to its ferrous form, it is coupled with an oxygen 
molecule, generating an unstable oxy-ferrous complex A redox reaction between the 
ferrous atom and the oxygen molecule ensues, where the ferrous atom returns to the
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ferric state, while still bound to the substrate A second electron is incorporated, 
although the donating protein has yet not been identified, some suggest it is 
transported from the NADH-cytochrome b5 reductase to cytochrome b5 and then to 
P450s, while others claim it is donated by P450R There is a subsequent electron and 
oxygen rearrangement, by which an oxygen atom is incorporated to the substrate 
After the final step, the hydroxylated substrate is released into the cellular space, 
together with a water molecule
Certain substrates can induce uncoupling of the P450 cycle under specific conditions, 
resulting in the electrons being incorporated to the oxygen molecule, ultimately 
generating hydrogen peroxide This phenomenon is also known as the peroxide shunt 
(Coon et a l, 1992)
Reactions
The following oxidation reactions are carried out by cytochromes P450
• Aliphatic oxidation
• Aromatic hydroxylation
• Epoxidation
• N-, 0-, S- dealkylation
• Deamination
• /V-hydroxylation
• Sulphoxidation
• Desulphuration
• Oxidative dehalogenation
Even though the principal reactions carried out by P450s are oxidative ones, they can 
also carry out reductive metabolism, particularly under low oxygen tensions In this 
case, electrons will be donated directly to the substrate with the participation of 
NADPH-cytochrome P450 reductase These reactions can result in chemical 
activation rather than detoxification, as is the case with organic compounds like 
carbon tetrachloride and halothane This is similar to what happens when the 
intestinal microflora reduces already detoxified compounds, reactivating them and 
restoring their toxicity
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Contribution of partner enzymes to drug metabolism
P450R is a flavin-containing monooxygenase that, contrary to cytochromes P450, 
does not posses a heme group (Ziegler et a!.} 1971). Its major function is to act as an 
electron bridge between NADPH and electron acceptors, using its cofactors, flavin 
adenine dinucleotide (FAD) and flavin mononucleotide (FMN), as electron acceptors 
and donors. The catalytic cycle is shown in Fig. 1.3.4.
NADPH P450RED P450RED
FMNH V *  FMNH __^  fm n h 2 /  ^  FMNH . FMNH, /  FMNH
FAD ^  ^  fa d h 2 FADH W FADH FAD f  ^  FAD
1e NADP+ 3« 3d P450OX 2« 2« P450OX 1«
Figure 1.3.4: Sequential transfer of 2 electrons from NADPH to cytochromes P450 by P450R, using the 
FAD and FMN cofactors (from www.uky.edu/Pharmacy/ps/porter/CPR.htm).
The main acceptors of P450R are cytochromes P450, although other microsomal 
proteins such as cytochrome b5, heme oxygenase and fatty acid elongase might also 
be reduced by P450R. Cytochrome c, ferricyanide and certain lipids may also act as 
electron acceptors for P450R (Sevanian et a/., 1990; Backes, 1993; Shen et a/., 
1993).
P450R is located in the endoplasmic reticulum of the cell and its expression is 
abundant in the liver, although it is widely expressed in the body, present in all 
different types of tissue studied. Expression of P450R appears to be regulated by the 
pithuitary-thyroid axis, as thyroid hormone is needed to sustain P450R expression 
(Waxman et al., 1989). This means that expression of P450R is independently 
regulated from that of cytochromes P450, although some inducers are common to 
both types of enzyme. It is also important to notice that the p450r gene encodes a 
single protein that is able to interact with all different isoforms of cytochromes P450 
(Shen et al., 1993). In most tissues, P450R is expressed at much lower levels than 
cytochromes P450, and so constitutes a limiting factor for the reactions carried out by 
these enzymes.
P450R can carry out reductive metabolism of chemicals independently of P450s. 
Quinone anticancer agents such as Adriamycin and Mitomycin C are known to be
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activated in this way to form an unstable intermediary that ultimately reverts to the 
quinone form, generating free radicals in the process The free radicals produced in 
this reaction appear to contribute to the toxic effects of these drugs, but the observed 
cytotoxicity is mainly due to the unstable intermediary, which acts as an alkylating 
agent, binding DNA and generating harmful adducts
Cytochrome b5 is a cylindrical membrane protein consisting of 6 helices and 5 p 
strands (Lu et a l, 1995) There are 15 different forms of cytochrome b5, but the 
sequence is very well preserved across species (Schenkman et a l, 2003) Its main 
function is to act as an intermediary in the transference of electrons between 
cytochromes P450 and reductases Cytochrome b5 can increase P450 activity in 
three different ways by transferring two electrons directly to P450 enzymes 
independently of P450R, by transferring a second electron to the oxyferrous form of 
P450s either from P450R or from cytochrome b5 reductase, and by allosterically 
stimulating P450 function without electron transfer (Porter, 2002)
Cytochrome b5 can also carry out reductive drug metabolism using NADH as a 
cofactor Chemical groups that can be reduced in this way are halogenated 
hydrocarbons, epoxides, heterocyclic azo (N=N) and mtro (N=0) compounds P450s 
and NADPH-cytochrome P450 reductase are also capable of catalysing azo- and 
mtro-reduction, involving substrates such as Chloramphenicol
1 3 1 2  Other Phase I enzymes 
Oxidative enzymes
Enzymes other than P450s or the other components of the MFO system can carry out 
oxidative metabolism These enzymes are also located in the main organs 
responsible for detoxification, i e , kidney, lung and especially liver
• Alcohol dehydrogenase although the MFO system carries out some ethanol 
metabolism, particularly after induction, this enzyme is the major 
detoxification route under normal circumstances It uses NAD+ as a cofactor 
to oxidise alcohols to aldehydes, a reaction that is reversible Other 
substrates are acetaldehyde and lipid peroxidation products Another role of
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this enzyme, which is not related to drug metabolism, is in the synthesis of 
retinol (Ashmarin et a l, 2000)
• Aldehyde dehydrogenase aldehydes generated in a previous step by 
alcohol dehydrogenase can be further oxidised to carboxylic acid by 
aldehyde dehydrogenase type 2, which is located in mitochondria and has 
low substrate affinity (Yokoyama et a l, 2003) The other isoform is referred 
to as formaldehyde dehydrogenase and is not as relevant in drug 
metabolism The same oxidative reactions can also be carried out by 
aldehyde oxidase and xanthine oxidase
• Xanthine oxidase this enzyme is involved in the metabolism of a broad 
range of substrates, although its main role is in the oxidation of all xanthine- 
containmg drugs, such as caffeine, and also purine analogues It catalyses 
the oxidation of hypoxanthine to xanthine and the oxidation of xanthine to 
uric acid This enzyme is expressed in milk-related tissues, although its role 
in milk production remains unclear (Martin et a l, 2004)
• Aromatases these enzymes generate benzoic acid from cyclohexane- 
contaming chemicals They require that the substrate is first derivatised with 
coenzyme A, and use molecular oxygen and FAD as cofactors
• Alkylhydrazine oxidase rearrangement and decomposition of alkyl 
hydrazines is of importance because these compounds are very toxic and 
can induce severe liver damage (Rumyantseva et a l, 1991) Several 
commonly used drugs are hydrazine derivatives, including Isomazide, 
Phenelzine and Hydralazine Their activation usually yields toxic and 
carcinogenic compounds
• Prostaglandin synthetase-mediated oxidation the synthesis of 
prostaglandins from arachidomc acid involves a two-step oxidation 
performed by the enzyme prostaglandin synthetase Co-oxidation of 
chemicals may occur as a side effect of these reactions, although this 
pathway may not be relevant in the detoxification of the drug Other 
peroxidases such as Myeloperoxidase and Lactoperoxidase also couple the 
oxidation of a substrate to the reduction of H20 2 and lipid hydroperoxidase
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• Amine oxidases these enzymes can be divided into three groups, the flavin- 
contaming monooxygenases (FMOs), the monoamino oxidases (MAOs) and 
the diamine oxidases This last group reacts mainly with endogenous 
substrates, and its role in xenobiotic metabolism is not relevant 
Similarly, the MAOs metabolise endogenous amines such as adrenaline and 
other catecholamines, and also other compounds like tyramine, which is 
incorporated with the diet, but not amphetamines, which are MFO 
substrates Only two isoforms exist, MAO A and MAO B, which differ in their 
substrate specificity, both use FAD as a cofactor Amines are transformed 
into aldehydes with the addition of an oxygen atom, which is not taken from 
molecular oxygen, but from water (Benedetti et a l, 2001)
The most important group is that of the FMOs, which metabolise compounds 
that contain nucleophillic nitrogen, sulphur, selenium or phosphorus (Hines 
et a l, 1993) Five variants of this enzyme exist in humans, each with a 
particular location within the body, though most of the enzymatic activity is 
found in the liver All FMOs reside in the endoplasmic reticulum and require 
NADPH and molecular oxygen for catalysis Uniquely, these enzymes 
possess oxygen complexed to their active site in the absence of substrates, 
which means they are permanently activated Oxidation reactions can then 
be carried out with little or no extra energy, which explains why FMOs 
metabolise such a broad range of compounds
Hydrolases
Hydrolysis reactions involve the decomposition of a particular substance by water, 
facilitated by the presence of a hydrolytic enzyme It can also occur non- 
enzymatically, especially if nucleophillic groups surround the reactive site of the 
chemical When the cleavage is enzymatic, it is often stereoselective Esters, amides, 
hydrazides and carbamates are all good substrates for hydrolysis
• Esterases these enzymes can belong to two types, specific esterases that 
hydrolyse particular groups of compounds and non-specific esterases with 
broad substrate specificity The former are expressed in the liver, while the 
acetylcholinesterases, pseudocholinesterases and other esterases present in 
plasma comprise the latter
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• Amidases amidases present in the liver microsomal fraction are responsible for 
the metabolism of most amide drugs However, the specificity of the plasma 
esterases is so low that they can actually hydrolyse amides as well Hydrolysis 
of amides is usually slower than that of esters
• Hydrazide and carbamate hydrolases these carry out the inactivation of less 
common functional groups in drugs such as the hydrazide group in Isomazide
Hydration related enzymes
Hydration is similar to hydrolysis in that it involves inactivation of chemical compounds 
via reaction with water However, in the case of hydration the chemical is not 
dissociated by water, rather, the water molecule is added to the chemical Hydration is 
of particular importance in the detoxification of epoxides, which is mediated by 
epoxide hydrolases
• Epoxide hydrolases epoxides are very unstable chemical species generated by 
the chemical or enzymatic addition of oxygen to a double carbon bond These 
compounds are extremely reactive, and have been implicated in mutagenesis 
and carcinogenesis, their detoxification is then of maximal importance for the 
body
Five forms of this enzyme exist in mammalian tissues, namely microsomal 
cholesterol 5,6-oxide hydrolase, hepoxilin A3, hydrolase, leukotriene A4 
hydrolase, soluble hydrolase and microsomal expoxide hydrolase (Fretland et 
al, 2000) Their localisation is either microsomal or cytosolic, and their 
endogenous substrates are epoxides derived from steroids, cholesterol and 
arachidomc acid
These are the main Phase I metabolic reactions, other reactions of less importance 
also take place and are listed in Table 1 3 1
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Other Phase I metabolic 
reactions
Ring cyclisation
A/-carboxylation
Dimérisation
Transamidation
Isomensation
Decarboxylation
Dethioacetylation
Disulfide reduction
Sulfoxide reduction
Table 13 1 Additional Phase I reactions 
13 2 Phase II metabolism
Phase I) reactions are often denominated as biosynthetic, since a new molecule is 
formed when drugs are combined with endogenous substrates such as glucuronic 
acid, sulphate, glutathione, ammo acids and acetate, among others These groups 
cannot be used as such by the transferases involved m these reactions, in general, an 
activated form of the conjugating group is needed
13 21 Glutathione conjugation
Conjugation with glutathione (GSH) has been reported as one of the major Phase II 
reactions in mammalians (Kaplowitz et a/, 1985) GSH is the most abundant non- 
protein molecule in the cell, it is formed by the amino acids Glycine, Cysteme and 
Glutamic acid Its synthesis and turnover are mentioned m detail m Section 15 2 
Several endogenous and exogenous electrophiles can be conjugated with GSH This 
reaction is catalysed by the GSH transferases (GSTs), which have broad substrate 
specificity and low affinity These properties ensure that toxic compounds of vanous 
ongins and structures will be detoxified, but it also means that a number of metabolic 
enzymes can be activated m response to a certain compound, some of which will not 
be relevant for its detoxification
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In humans, there are six classes of GSTs, named alpha (a), mu (^), pi (71), theta (x), 
zeta (£) and omega (<o), each class division can contain one or more isoforms 
Expression levels of the different isoforms have been found to be tissue-specific 
(Salinas et a /, 1999) GSTs are predominantly found in liver, although they are also 
present in other cell types and tissues, such as kidney, erythrocytes and intestinal 
cells
Two different GSH conjugation pathways exist one of them involves displacement of 
the halogen, sulphate, sulphonate, phospho or mtro group by GSH, while in the other 
case the conjugating group is added to an activated double bond or a strained ring 
system GSH conjugates can be directly excreted in urine or bile, but they usually 
undergo further transformation in the form of glutamate and glycine removal by y- 
glutamyl transpeptidase, and subsequent /V-acetylation of the cysteine conjugate This 
can be followed by cleavage of the C-S bond by the C-S lyase present in intestinal 
microflora, S-methylation and oxidation
Examples of chemical groups susceptible of GSH conjugation are epoxides, 
haloalkanes, mtroalkanes, alkenes, and aromatic halo- and mtro- compounds A wide 
range of xenobiotics can be conjugated with GSH, including endogenous substrates, 
such as oestrogens and cholesterol-5,6-oxide, and the carcinogen acrolein, pesticides 
such as DTT and the drugs Cisplatin and Acetaminophen Some compounds, such as 
bilirubin and heme, are transported but not metabolised by these enzymes, which 
earned them the name “ligandins” (Litwack et a l, 1971) This is of importance in the 
matter of chemotherapy resistance it has been widely reported that GSTs can protect 
several cell types from anticancer agents, yet no conjugated drug can be found in 
these cells It has been suggested that the enzyme binds the drug and then 
sequesters it away from its target (Meyer et a l, 1992)
1 3 2 2 Conjugation with sugars 
Glucuromdation
Conjugation with the activated, energy rich form of a-D-glucuromc acid -  uridine 
diphosphate (UDP)-glucuromc acid - is the major route of sugar conjugation and the 
most important Phase II transformation pathway It is carried out by UDP- 
glucuronosyltransferases (UGTs) these enzymes transfer UDP-glucuromc acid to a 
wide range of substrates, both endogenous, such as steroids, bile acids, bilirubin,
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hormones and dietary compounds, and foreign-like drugs, environmental toxins and 
carcinogens Transfer of glucuronic acid generates a p-D-glucopyranosiduromc acid, 
also known as a glucuromde derivative (Tukey et a l, 2000) The bond between the 
functional group and the glucuromde is sensitive to the enzymatic action of p- 
glucuromdase present in the intestinal microflora, which means that already detoxified 
compounds excreted in the bile or faeces can be reactivated and reabsorbed, this 
phenomenon is known as enterohepatic circulation
P-D-glucuromdes can be attached to several different functional groups, including 
hydroxyl (alcohols or phenols), carboxyl, sulphuryl, carbonyl, and amino groups O- 
glucuromdes are formed from phenols, alcohols and carboxyhc acids, the first two 
generate glucuromde ethers, while acids form glucuromde esters They are often 
secreted into the bile, which makes it possible for them to be reactivated N- 
glucuromdes are the result of conjugation with primary, secondary or tertiary amines, 
amides and sulphonamides Thio! groups present in drugs such as Antabuse are 
substrates of S-glucuromdation Direct conjugation of carbon can also occur 
Although conjugation with glucuromdes usually inactivates the chemical and facilitates 
its excretion, a few examples of activation by glucuromdation are known, the most 
studied being morphine-6-glucuromde, which is a more potent analgesic than 
morphine itself
50 different UGTs have been characterised in vertebrates, which have been grouped 
in the UGT1 and UGT2 families, isoforms are included in a family when they share 
55% sequence homology with the established members UGTs grouped in 
subfamilies share 60% sequence homology
There are 16 human UGTs identified up to date (Table 1 3 2), nine of them are
grouped in the UGT1A subfamily, while seven of them belong to the UGT2 family
UGT1A9 is probably the most important isoform for drug metabolism
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Human UGTs
UGT1 family UGT2 family
UGT1A1 UGT2A1
UGT1A3 UGT2B1
UGT1A4 UGT2B7
UGT1A5 UGT2B10
UGT1A6 UGT2B11
UGT1A7 UGT2B15
UGT1A8 UGT2B17
UGT1A9
UGT1A10
Table 13 2 Human UDP glucuronyl transferases
UGT activity is mainly found in the liver microsomal fraction, although other sites of 
glucuromdation have been descnbed, including intestine, kidney and colon This is 
probably a consequence of the widespread distnbution of UDP-glucuromc acid, which 
is an intermediary of glycogen synthesis and, as such, is present in all different 
tissues of the body
Conjugation with other sugars
Conjugation reactions carried out with other sugars have great importance in plant 
and insect metabolism, but their relevance to mammalian biotransformation of foreign 
compounds is limited Glucose, xylose and nbose are used as substrates and 
generate the corresponding N- or O-nboside or xyloside, reactions are analogous to 
glucuromdation, and the activated, UDP-bound form of the sugar is used as sugar 
source
1 3 2 3 Conjugation with sulphates
The transference of a sulphuryl (SO3) group to a suitable functional group present in a 
drug is a Phase II reaction performed by sulphotransferases They require the 
activated form of sulphate for transference, which is 3’-phosphoadenosine-5’-
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phosphosulphate (PAPS) PAPS is generated in the cytosol in two steps from ATP 
and sulphate by the sequential action of ATP sulphurylase and APS-kinase 
The catalytically active enzyme is a homodimer, and the reaction is earned out in a 
sequential mechanism involving a ternary complex between the enzyme, the 
substrate and PAPS After a chemical rearrangement, the substrate is released with a 
sulphuryl group attached to it, while the phosphoadenosine monophosphate (PAP) 
can be rephosphorylated and take part in other reactions
Sulphotransferases can be divided into two groups cytosolic or membrane-bound 
Cytosolic transferases metabolise small compounds, such as hormones and drugs, 
while membrane-bound enzymes are responsible for the biotransformation of 
carbohydrates and proteins (Chapman et a l, 2004) Human sulphotransferases are 
listed in Table 13 3
Human
sulphotransferases
SULT1A1
SULT1A2
SULT1A3
SULT1B1
SULT1C1
SULT1C2
SULT1E1
SULT2A1
SULT2B1a
SULT2B1b
Table 13 3 Human sulphotransferases
Functional groups susceptible to sulphuryl conjugation are mainly phenols, although 
alcohols, amines and thiols have also been reported Paracetamol is the best known 
example of a drug metabolised by sulphurylation, while endogenous substrates 
include hormones, bioamines and steroids A number of drugs can be either 
' glucuromdated or sulphated, and the two pathways will then compete for the 
substrate Glucuromdation is generally considered as a low affinity, high capacity
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system, while the opposite happens with sulphurylation, competition will then depend 
on the availability of PAPS and the drug concentration
1 3 2 4 Methylation
This reaction involves the transference of a methyl group to an N, O, Cor S moiety by 
methyltransferases This is only a minor pathway in drug metabolism, and it can often 
result in an increase in the drug hydrophobicity The co-factor S-adenosyl methionine 
(SAM) is required to provide the methyl radical SAM is a high energy intermediate 
and is synthesised from L-methionme and ATP by the L-methiomne 
adenosyltransferase Several forms of methyltransferases exist, which are listed in 
Table 1 3 4
Human methyltransferases
Phenol O-methyltransferase 
Catechol O-methyltransferase 
Imidazole N-methyltransferase 
S-methyltransferase 
N-methyltransferase 
Hydroxyindole O-methyltransferase
Table 13  4 The human methyltransferases
Most methyltransferases have very restricted substrate specifies, except for the non­
specific A/-methyltransferase expressed in lung and the S-methyltransferase, which 
metabolise several known drugs
1 3 2 5 Acetylation
Arylamine A/-acetyl transferase (NAT) is best known as the enzyme responsible for 
Isoniazide metabolism, although other arylamines, including carcinogens, are 
substrates of this reaction Two forms of this enzyme exist in humans, known as
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NAT1 and NAT2 (Sim et a l, 2000) and both utilise Acetyl-CoA as a cofactor in the 
transference of an acetyl group onto an aromatic amine, hydrazine or hydroxylamme 
moiety NAT1 is expressed in almost all types of tissues in the body and is 
responsible for p-aminosalicylate and p-ammobenzoic acid metabolism, it is 
considered that this enzyme plays an important role in the metabolism of endogenous 
compounds, although not many substrates have been identified In contrast, NAT2 is 
expressed in liver and intestinal epithelium and catalyses the acetylation of Isomazide, 
Dapsone, certain sulphonamides and carcinogenic arylamines NAT2 is a polymorphic 
enzyme, and the acetylation rates depend on the alleles expressed, this is translated 
into differential toxicity of Isomazide between individuals (Upton e ta l, 2001)
Even though this is the major route for the metabolistm of aromatic amines, 
acetylation can also result in reduced water solubility of their metabolites, which can 
increase their toxicity
1 3 2 6 Conjugation with amino acids
Some drugs, such as carboxylic acids, can react with acetate to form CoA derivatives 
such as Acetyl CoA These derivatives can then be conjugated to amino groups, like 
those present in amino acids Ammo acid conjugation can then be a reverse form of 
A/-acetylation, in which the substrate is activated before being attached to a functional 
group present in an endogenous molecule
A different pathway of ammo acid conjugation also exists, in which an aromatic amine 
or hydroxylamme moiety can be conjugated to the carboxyl group of an ammo acid, 
this reaction requires prior activation of the amine by ATP
Both reactions are carried out by ammo acid acyl transferases Glycine, glutamine, 
ornithine, arginine, proline, serine and taurine are the most common ammo acids 
participating in both types of reactions Ammo acid conjugates such as serine or 
proline N-esters of hydroxylamines can be unstable and degrade into active 
electrophiles, which can be carcinogenic
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1 3 2 7 Conjugation with lipids
Fatty acids like palmitic and stearic acid can be attached to some Phase I metabolites, 
such as those derived from cannabmoids Carboxylic acid groups present in drugs 
can also be conjugated to form fatty acid or cholesteryl esters
1 3 2 8 Condensation
Some amines and aldehydes appear to react spontaneously to form larger molecules 
The best-studied case is that of Dopamine, which condenses with its own metabolite 
to form an active alkaloid Condensation could also be of enzymatical origin, although 
very little is known about these reactions
13 3 Phase III metabolism
Phase III metabolism would involve the further transformation of Phase II metabolites 
A/-acetylcysteine conjugates derived from GSH conjugates that underwent further 
metabolism are sometimes considered Phase HI products Others believe that 
enzymatic reactions performed by the intestinal microflora belong in a separate class, 
referred to as Phase III metabolism In any case, only Phase I and Phase II are firmly 
established as essential steps in drug metabolism
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1.4 The cytochrome P450 superfamily
The cytochrome P450 superfamily is composed of 57 human CYP genes and 
29 pseudogenes (a pseudogene being a defective gene that does not produce a 
functional protein) They have been grouped in families and subfamilies according to 
the following criteria two cytochromes belong to the same family if they share at least 
40% of sequence homology, and to the same subfamily if they share at least 50% of 
sequence homology In total, 18 families and 43 subfamilies have been identified The 
different human families, their members and their functions are listed in Table 1 4 1
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Family/
Subfamily
Members Function
CYP1 2 subfamilies, 3 genes, 1
pseudogene 
CYP2 13 subfamilies, 16 genes, 16
pseudogenes 
CYP3 1 subfamily, 4 genes, 2
pseudogenes 
CYP4 5 subfamilies, 12 genes, 10
pseudogenes 
CYP5 1 subfamily, 1 gene
CYP 7 A 1 subfamily member
CYP 7B 1 subfamily member
CYP 8A 1 subfamily member
CYP 8B 1 subfamily member
CYP11 2 subfamilies, 3 genes
CYP17 1 subfamily, 1 gene
CYP19 1 subfamily, 1 gene
CYP20 1 subfamily, 1 gene
CYP21 1 subfamily, 1 gene, 1
pseudogene 
CYP24 1 subfamily, 1 gene
CYP26A 1 subfamily member
CYP26B 1 subfamily member
CYP26C 1 subfamily member
CYP27A 1 subfamily member
CYP27B 1 subfamily member
CYP27C 1 subfamily member
CYP39 1 subfamily member
CYP46 1 subfamily member
CYP51 1 subfamily, 1 gene, 3
pseudogenes
Drug metabolism, arachidonic acid and
eicosanoid metabolism
Drug metabolism, arachidonic acid and
eicosanoid metabolism
Drug metabolism, arachidonic acid and
eicosanoid metabolism
Arachidonic acid, eicosanoid and fatty
acid metabolism
Thromboxane A2 synthesis
Bile acid biosynthesis/ 7-a hydroxylation
of steroid nucleus
Brain-specific form of 7-a hydroxylation
Prostacyclin synthesis
Bile acid biosynthesis
Steroid biosynthesis
Steroid biosynthesis (17-a hydroxylase,
17/20-lyase)
Steroid biosynthesis (Aromatase) 
Unknown
Steroid biosynthesis (21-hydroxylase)
Vitamin D degradation (24-hydroxylase) 
Retinoic acid hydroxylation 
Probably retinoic acid hydroxylation 
Probably retinoic acid hydroxylation 
Bile acid biosynthesis 
Vitamin D3 1-a hydroxylation 
Unknown
24-hydroxycholesterol 7a-hydroxylase 
Cholesterol 24-hydroxylation 
Cholesterol biosynthesis (Lanosterol 14- 
a demethylase)
Table 1.4.1: The human P450 families (adapted from Nebert et al., 2002).
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141 Enzyme induction
A prominent characteristic of the P450 system is that many compounds are able to 
induce the expression of the enzymes responsible for their metabolism Induction is 
then unspecific, meaning that a single substrate can induce several enzymes at a 
time In some cases, these enzymes need not be cytochromes P450 some CYP3A4 
inducers also increase expression of MDR1, an efflux pump (Schuetz et a l, 1996) 
Certain cytochromes are involved in steroid hormone synthesis this includes the sex 
hormones Expression of these cytochromes is therefore regulated in a sex- and age- 
specific manner (Jarukamjorn et a/, 2001) However, P450s involved mainly in drug 
metabolism such as CYP1A2, CYP2B6 and CYP3A4 also show sex-specific 
regulation (Van Schaik, 2005), the reason for this regulation remains to be found 
There are several mechanisms of induction, of which the aryl hydrocarbon receptor 
(AhR) pathway for the CYP1 family and the so-called orphan nuclear receptor 
pathway for CYP2, CYP3 and CYP4 families are probably the best studied 
The AhR is a cytosolic protein that can bind ligands with high affinity, usually 
polycyclic aromatic hydrocarbons (PAHs) When the receptor-ligand complex is 
formed, it translocates to the nucleus with the aid of the AhR nuclear translocator 
protein (ARNT), and can subsequently bind to xenobiotic responsive elements in 
DNA But the AhR is involved in more important functions a study by Dohr et al 
(1997) showed coordinated regulation of mRNA expression of the AhR and cell cycle 
genes, suggesting that this receptor might be implicated in the regulation of cell 
proliferation Another report demonstrated that the AhR binds the retinoblastoma 
protein, known to induce cell cycle arrest (Puga et a l, 2000), and together they have a 
synergic inhibitory effect on cell proliferation The retinoblastoma protein has recently 
been recognised as an AhR coactivator (Hankinson, 2005)
The orphan nuclear receptor superfamily is composed of constitutive androstane 
receptor (CAR), pregnane X receptor (PXR), steroid and xenobiotic receptor (SXR), 
peroxisome proliferator-activated receptor (PPAR), liver X receptor (LXR) and 
farnesoid X receptor (FXR), and they mediate the induction of CYP2, CYP3, CYP4 
and CYP7A (Blumberg et a l, 1998, Kliewer et a l, 1999) The mechanism is common 
to all of them upon binding their specific ligand, these orphan receptors 
heterodimerise with the retinoid acid receptor (RXR) and then bind to specific 
sequences in DNA, activating the transcription of the respective family members Of 
these, the most relevant ones for drug metabolism are CAR, PXR and SXR 
CAR can activate transcription of target genes even in the absence of any 
exogenously added ligand, and this basal activity is blocked by testosterone
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metabolites This suggests that CAR-activated transcription is turned off upon 
hormone binding Expression of CAR is readily detected in the liver and the receptor 
is believed to regulate expression of CYP2B, which is a steroid hydroxylase, thus 
raising the possibility of CAR being involved in steroid homeostasis CAR has also 
been shown to activate expression of CYP3A genes, indicating that even though this 
receptor is mainly a CYP2B regulator, it can also affect the transcription of different 
P450 families (Xie et a l, 2000)
Endogenous ligands of PXR are C21 steroids, known as pregnanes, such as 
progestagens, estrogens and corticosteroids It is not known whether PXR has a 
specific ligand for which it has high affinity or if its ability to bind several different 
steroidal ligands renders it as a general steroid sensor PXR is expressed in liver and 
intestine, tissues in which CYP3A expression can be induced, where it binds several 
different xenobiotics that modulate CYP3A expression Activation of PXR results in 
induction of CYP3A transcription and steroid (or drug) metabolism 
SXR is closely related to PXR, showing a high degree of sequence homology 
(Blumberg et a l, 1998) It is expressed mainly in the liver and also in lung, kidney and 
intestine (Miki et a l, 2005), it has also been detected in breast carcinoma, but not 
normal tissue (Miki et al, 2006) Steroids such as corticosterone, oestradiol, 
dihydrotestosterone and pregnenolone are endogenous ligands of this receptor, while 
1,25-dihydroxy vitamin D3 is not, traditional inducers of CYP3A4 such as 
dexamethasone, rifampicin and nifedipine also activate this receptor This receptor 
mainly modulates expression of CYP3A genes although, similar to CAR, can also 
induce the expression of CYP2B subfamily members (Xie et a l, 2000) The finding 
that SXR can also activate the expression of MDR1 (Synold et a l, 2001) shows the 
intimate connections that he between the genes involved in cellular defence against 
xenobiotics
The intracellular vitamin D receptor (VDR) has been recently found to play a role in 
P450 induction Vitamin D is an active modulator of cell growth, proliferation and 
calcium homeostasis, and cytochromes P450 are responsible for its activation and 
catabolism It is not surprising then that vitamin D would induce its own metabolism by 
increasing CYP3A4 and also CYP2B6 and CYP2C9 expression via activation of VDR 
and heterodimensation with RXR (Pascussi et a l, 2003)
Down-regulation of CYP450 expression can also occur, as it has been reported that 
several proinflammatory cytokines, namely IL-1, IL-4, IL-6, TNFa and IFNy, can 
suppress cytochrome expression in hepatocytes (Abdel-Razzak et a l, 1993) This 
could be a major issue for cancer treatment, since many patients with advanced 
disease have high circulating concentrations of proinflammatory cytokines (Slaviero et
40
al f 2003), expression of these mediators can be stimulated by or released directly 
from the tumour Down-regulation of P450s occurs through several mechanisms, 
including decreased transcriptional activation or enhanced degradation by heme 
oxygenase and not only does it affect the overall P450 expression, but also its 
susceptibility of induction A recent study by Zhou et al (2006) shows that SXR and 
the key regulator of inflammation NF-kB reciprocally inhibit each other’s activation, 
providing a molecular explanation for the observed decrease in P450 levels Several 
theories have been put forward to explain this phenomenon, but the reasons behind 
P450 down-regulation by cytokines remain the subject of speculation (Renton et a l,
2001)
A recent report also shows that activation of Fas receptor suppresses CYP3A4 mRNA 
and protein expression (Chun et a l, 2003), loss of detoxification mechanisms could 
make cells more sensitive to apoptotic stimuli
14 2 Enzyme inhibition
Inhibition of P450s can be competitive or non-competitive Competitive inhibition 
usually takes place when two (or more) drugs that are substrates of the same isoform 
are administered together and inhibit each other’s metabolism Non-competitive 
inhibition can occur through different mechanisms, such as interference with an 
enzyme cofactor, suicide inhibition (i e , inactivation of the enzyme by the inhibitor), 
etc
Several commonly used drugs can inhibit P450s, this is of great importance in 
pharmacology, since co-administration of a P450 inhibitor, such as Ketoconazole, will 
impair the metabolism of other drugs, resulting in longer half lives and increased 
toxicity Much as with redundancy and overlapping phenomena observed with 
metabolism, several different drugs can inhibit one isoform
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14 3 The P450 families
1 4 3 1 The CYP1 family 
CYP1A
This subfamily is composed of two members, CYP1A1 and CYP1A2, involved in the 
metabolism of polycychc hydrocarbons, aromatic and heterocyclic amines, among 
other compounds
CYP1A1 metabolises mainly polycychc hydrocarbons Its expression is very low in 
liver and it is believed to be present almost exclusively in extra-hepatic tissue, and this 
at extremely low levels (Nebert et a l, 2004) A recent study has contradicted these 
findings by demonstrating CYP1A1 protein expression and activity in 8 liver samples 
(Stiborova et a l, 2005) Induction of enzymatic activity, usually referred to as aryl 
hydrocarbon hydroxylase (AHH) activity, occurs in response to treatment with 
polycychc aromatic hydrocarbons (PAHs) such as benzo[a]pyrene, 2,3,7,8- 
tetrachlorodibenzo-p-dioxin (TCDD) and 3-methyl cholanthrene These xenobiotics 
are well known carcinogens and can be found in cigarette smoke and smog 
(Hankmson, 2005) PAHs can activate the transcription of CYP1A1 mRNA and 
therefore induce their own metabolism
There is evidence of cross talk between the AhR and the estrogen receptor (ER) 
pathways steroids are able to induce CYP1A1 transcription via an ER-mediated 
process This is probably an Ah-dependent pathway, as expression of ERa is 
believed to enhance CYP1A1 expression in breast cancer cells, rather than induce it 
per se (Spink et a/, 1998) It has also been reported that testosterone and TCDD 
pathways negatively regulate each other's activity in the prostate cancer cell line 
LNCaP (Jana efa/,2000)
CYP1A2 is involved in the metabolism of aryl amines and amides, and also of 
aromatic amines, caffeine, oestradiol and certain drugs, such as Phenacetin, 
Clozapine and Propanolol It is also responsible for the activation of the 
antiandrogemc drug Flutamide, which is widely used in the treatment of prostate 
cancer Although a precise function for this enzyme in physiological or developmental 
pathways has not been described yet, CYP1A2 is highly conserved among mammals, 
and knock-out of the gene appears to be lethal in mice (Pmeau et a l , 1995) Knock­
out mice for CYP1A2 die very early in their development from respiratory distress and 
display signs of lung immaturity, including expression of abnormal surfactant protein in 
the lung
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CYP1A2 expression is constitutive in liver, where it accounts for about 15% of the 
total P450 content (Van Schaik, 2005), and negligible in extra-hepatic tissue 
Consistent with this, activity is readily detected in the liver in the absence of any 
inducers, while PAHs can significantly increase CYP1A2 activity levels in 
gastrointestinal tract, nasal epithelium and brain, and also in the liver (Nebert et a l,
2004) Induction of this gene is also regulated by the AhR, although several 
differences exist between CYP1A1 and CYP1A2 regarding susceptibility of induction 
Both enzymes present overlapping activities, but their specific reactions are carried 
out faster than the shared ones They are also induced by the same compounds, with 
the exception of Isosafrole, which is a specific inducer of CYP1A2 but not of CYP1A1 
(Boulenc e ta !, 1992)
CYP1B
CYP1B1 is the only member of this subfamily, sharing a 40% sequence homology 
with CYP1A1 and CYP1A2 It can hydroxylate 17-p-estradiol in C4 and is involved in 
testosterone biotransformation It is also known to metabolise xenobiotics such as 
ethoxyresorufm, theophylline and caffeine
CYP1B1 mRNA is constitutively present in mammal steroidogenic tissues, such as rat 
granulosa cells (Dasmahapatra et a l, 2002) Its expression can be induced by peptide 
hormones, cAMP and ligands of the AhR, in a similar way to that of CYP1A1 
induction As with CYP1A1, there also seems to be cross talk between the ERa and 
the CYP1B1 expression pathways (Spink et a/, 1998) There seems to be a tissue- 
specific regulation of the expression, since treatment with TCDD induces 1B1 mRNA 
in MCF-7 cells but not in HepG2 cells (Spink et a l, 1994) Expression of CYP1B1 can 
be inhibited by treating cells with 2,4,3\5,-tetramethoxystilbene (TMS), which shows a 
50-fold selectivity for CYP1B1 over CYP1A1, and 500-fold selectivity over CYP1A2 
(Chun et a/, 2001) Other non-selective inhibitors of CYP1B1 activity are a- 
naphtoflavone and Ketoconazole More recently, regulation of CYP1B1 expression by 
micro RNAs (miRNAs) has been described (Tsuchiya et a l, 2006), it was discovered 
that transfecting MCF-7 cells with an antisense for the miRNA miR-27b, which has a 
matching sequence to that of the 3’ untranslated region of CYP1B1, increased 
CYP1B1 expression and activity Furthermore, expression of miR-27b and CYP1B1 
were found to be inversely correlated in breast tissue samples 
A number of studies have failed to detect presence or activity of functional CYP1B1 
protein in normal (non-tumoural) tissue (Murray et a l, 1997, McFadyen et a l, 1999) 
Murray et al (1997) have performed immunohistochemistry using a CYP1B1-specific
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antibody in a number of clinical samples of cancerous and normal adjacent tissue 
from a wide range of tissues, namely bladder, breast, colon, oesophagus, kidney, 
lung, ovary, skin, stomach, uterus, connective tissue, lymph node, brain and testis 
CYP1B1 was detected in 122 tumour samples out of 127, and it was present in all 
different types of cancer However, the enzyme could not be detected in any of the 
130 samples of normal tissue, not even in liver These results lead researchers to 
believe that CYP1B1 is a tumour-specific isoform, however, expression of CYP1B1 in 
normal tissue has been reported, albeit in much lower levels than in tumour tissue 
(Muskhelishvili et a l, 2001, Gibson et a l, 2003) Differential expression of 
cytochromes P450 in normal and tumoral tissue is further discussed in Section 1 4 5 
Defects in the cyplbl gene have been linked to primary congenital glaucoma It has 
been speculated that this enzyme is required to eliminate a signalling molecule failure 
to do so could lead to high concentrations of this molecule that would in turn lead to 
glaucoma The affected molecule may be a steroid (Stoilov et a l, 1997)
1 4 3 2 The CYP2 family
The human CYP2A subfamily has three genes, CYP2A6, CYP2A7 and CYP2A13, 
and a pseudogene, CYP2A18P Of these, CYP2A6 is the most important isoform for 
drug metabolism and is expressed mainly in liver, with only very low levels detected in 
extrahepatic tissues (nasal mucosa, skin), and its substrates include coumarin, 
nicotine and the carcinogen aflatoxin B1, among other agents, this isoenzyme is also 
responsible for the activation of the 5-FU-prodrug Tegafur CYP2A6 is also 
responsible for the endogenous metabolism of retinoic acid, arachidomc acid and 
progesterone (Du et a l, 2004)
The human CYP2B isoforms are CYP2B6, CYP2B7 and CYP2B8 CYP2B6 is 
expressed in liver, while CYP2B7 is found in lung, especially in Clara cells, and 
CYP2B8 in liver and intestine There is also a pseudogene, CYP2B7P, which contains 
a premature stop codon in its sequence Induction of expression is via the CAR 
orphan nuclear receptor, which can be activated by Phenobarbital Expression in 
humans is also regulated by growth and thyroid hormones Substrates metabolised by 
CYP2B6 include nicotine, coumarin, retinoic acfd, 17ft-estradiol, estrone and 
testosterone
CYP2C8, CYP2C9, CYP2C18 and CYP2C19 comprise the CYP2C subfamily, which 
is one of the most important for drug metabolism, together, these four enzymes 
metabolise more than half of all frequently prescribed drugs There are also 8
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pseudogenes, but they are all believed to be non-functional, except for CYP2C9-de1b. 
The reason for the multiplicity of members in this subfamily could be their tendency to 
recombination, conversion and transplicing, which even results in some isoforms 
being a hybrid of two different sequences (Finta et a/., 2000).
All members of this subfamily are constitutively expressed in liver, while CYP2C8 and 
CYP2C9 are also expressed in the intestinal tract. A recent immunohistochemical 
study using an antibody that reacts with CYP2C8, CYP2C9, CYP2C18 and CYP2C19 
detected positive staining in samples of epithelium of the small and large intestine, 
gastric epithelium, bile duct, nasal mucosa, salivary glands, tracheobronchial glands, 
prostate, uterine cervix, kidney and adrenal cortex (Yokose et a/., 1999). The 
members of this subfamily are involved in retinal, arachidonic and linoleic acid and 
steroid metabolism, e.g. testosterone, oestradiol and progesterone, but they also 
contribute to the biotransformation of several drugs, such as Warfarin and 
Tolbutamide.
CYP2D6 is the only member of the CYP2D subfamily expressed in humans. Two 
other cytochrome genes are located upstream of cyp2d6, cyp2d7 and cyp2d8, but the 
first is defective and is not expressed, while the second is a pseudogene. CYP2D6 is 
not detectable in all human livers, and this is probably because mutations that 
inactivate the gene are not lethal and therefore not subjected to selection pressure. 
This isoform is responsible for the metabolism of the noradrenaline- blocking drug 
Debrisoquine, along with several other drugs used in psychiatric treatment. Like the 
other CYP2 subfamilies, it is also involved in the biotransformation of retinal and 
steroids, along with tryptamine and its derivatives.
Only one member of the CYP2E subfamily is present in humans, although three 
transcripts have been detected in tissue samples (Botto et al., 1994); it has been 
concluded that they all originate from the same gene. CYP2E1 is constitutively 
expressed in the liver, and its expression can be induced by a number of xenobiotics 
including ethanol, acetone and Pyrazole. Induction with these chemicals does not 
increase mRNA levels, so the net increase in protein expression is believed to be a 
combination of enhanced protein stabilization and decreased turnover. The most 
important role for this isoform is in the metabolism of ethanol, although it is also 
involved in the transformation of several compounds, such as the carcinogen N- 
nitrosodimethylamine, oestradiol, fatty acids, prostaglandins, ketone bodies and 
acetone. Even though in basal conditions the alcohol dehydrogenase and aldehyde 
dehydrogenase enzymes carry out most of the ethanol metabolism, CYP2E1 
metabolism is rapidly and effectively induced by ethanol, and so takes over after 
significant alcohol ingestion.
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Two CYP2F and two CYP2G loci have been found in humans, but only CYP2F1 
appears to be functional, and is expressed mainly m lung epithelium It appears to 
have a protective function against pneumotoxins such as tobacco-derived 
mtrosamines (Du et a/, 2004) Two pseudogenes have also been identified as 
members of the CYP2T subfamily, cyp2t2p and cyp2t3p, none of these genes 
appears to be functional
One CYP2J protein has been detected in humans, expressed in lung, skin and 
gastrointestinal tract, where it appears to be involved in first-pass intestinal 
metabolism (Zeldin et a l, 1997) The endogenous substrates identified for CYP2J2 
are fatty acids, such as arachidonic acid and linoleic acid, and testosterone Recently, 
CYP2J2 has also been identified as a vitamin d 25-hydroxylase (Alba et a l, 2006) 
The biologically active eicosanoids generated from arachidonic acid metabolism by 
CYP2J2 appear to be involved in a number of physiological functions such as 
vasoprotective effects, protection against oxidative stress, endothelial cell growth and 
angiogenesis (Yang et a l, 2001, Wang et al ,2005, Spiecker et a l, 2006)
A novel cytochrome P450, CYP2S1, has been detected in human lung and skin, while 
its mRNA is also present in trachea, stomach, small intestine and spleen (Karlgren et 
a l, 2003) An interesting feature of this isoform is that its expression appears to be 
induced by polycyclic aromatic hydrocarbons and dioxin, much as the CYP1 family 
Furthermore, napthtalene has been identified as a CYP2S1 substrate, supporting the 
notion of this isoform’s involvement in the metabolism of complex organic compounds 
Retmoic acid has also been identified as an endogenous substrate 
CYP2R1, CYP2U1 and CYP2W1 have been recently identified in humans (Karlgren et 
a l , 2003) CYP2R1 is the best studied of the three, and appears to be a vitamin D 25- 
hydroxylase (Cheng et a l , 2003) High levels of its mRNA have been detected in 
pancreas, liver and kidney CYP2U1 expression was detected in thymus, heart and 
brain (Helvig et a l, 2003), and its endogenous substrates are long chain fatty acids 
Little is known about CYP2W1, mRNA expression could not be found in any of the 
human tissues tested, although a transcript was detected in HepG2 hepatoma cells, 
and also in other transformed tissues, suggesting an association with cancer 
(Karlgren et a l, 2003)
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1.4.3.3 The CYP3 family
The CYP3A is the most abundantly expressed P450 subfamily in metabolically active 
tissues, fundamentally liver but also small intestine and renal epithelium. The 
metabolic reactions carried out by its members include C- and A/-dealkylation, C- 
hydroxylation, dehalogenation, dehydration and nitroreduction. Adding another 
xenobiotic can stimulate the catalytic activity for a certain substrate: this phenomenon 
is known as positive cooperativity, and it is a unique feature of the CYP3A enzymes. 
The spectrum of substrates metabolised by this subfamily is incredibly broad, 
including drugs, steroids and carcinogens. Substrate specificity is similar to that of 
MDR1 but overlap is not complete.
This subfamily comprises the CYP3A4, CYP3A5, CYP3A7 and CYP3A43 isoforms. 
The major isoform is CYP3A4, probably the most important of all P450 cytochromes, 
responsible for the metabolism of roughly 50% of all known drugs and also of 
carcinogens and endogenous steroids: it presents the broadest catalytic selectivity of 
any P450. It is expressed mainly in the liver, where it accounts for 30% of total 
protein, and also in the small intestine, its expression then decaying along the 
remainder gastrointestinal tract. It is also present in renal tissue, although only in 30% 
of tested human samples.
CYP3A5 is the predominant isoform in kidney and colon, but its expression in the liver 
is polymorphic, found in only 10-30% of human livers. The total amount of CYP3A5 
hepatic protein, when present, is usually about 25% of that of CYP3A4. Recently, it 
was shown that the lack of CYP3A5 expression is due to the presence of a genetic 
polymorphism in this enzyme (Van Schaik, 2005); it is believed that about 80% of the 
Caucasian population are homozygous for this CYP3A5 form with defective 
expression.
CYP3A7 is the major isoform found in foetal liver and it can also be detected, albeit in 
low levels, in the adult organ. It is also expressed in adult endometrium and placenta. 
In the majority of individuals, CYP3A7 expression is repressed immediately after birth, 
but a polymorphism which results in the expression of CYP3A7 being under the 
control of the CYP3A4 promoter has been described (Van Schaik, 2005); this would 
result in CYP3A7 expression in the adult.
The previously described CYP3A3 isoform was for some time considered as a 
sequencing artefact; however, it was recently cloned and is now considered a bona 
fide member of the CYP3A subfamily (Gellner et a l 2001). Its expression has been 
demonstrated in adult liver, kidney, pancreas and prostate, albeit at extremely low 
levels. The contribution of CYP3A43 to drug metabolism is thought to be negligible.
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The selectivity of the different isoforms is quite poor, with overlapping substrate 
specificity, however, some differences in the catalytic activity exist For example, 
although Taxotere is metabolised by both CYP3A4 and CYP3A5, metabolism of Taxol 
appears to be carried out exclusively by CYP3A4 There is also considerable mter- 
individual variability in both the enzymatic activity and the susceptibility of induction 
Genetic polymorphisms of CYP3A isoforms also exist, leading to major inter-patient 
differences in the pharmacokinetics of commonly used drugs 
Induction of these isoforms is usually through transcriptional activation, although 
increase of protein levels by stabilization might occur There is also a broad spectrum 
of inducers, some of which are substrates of these enzymes, such as anticonvulsant 
agents, barbiturates, pesticides, macrolide antibiotics, etc The induction process is 
mediated by the orphan nuclear receptors PXR and SXR and appears to be tissue- 
specific for example, expression of CYP3A4 is inducible in liver but not in colon 
The CYP3A enzymes can be inhibited by a large number of compounds, the only 
common features amongst them being lipophillicity and relatively large molecular size 
Inhibition can be competitive or non-competitive, and the active compounds include 
macrolide antibiotics, antidepressants, glucocorticoids, antifungals, estrogens and 
Vinca alkaloids, among others
48
1.4.4 P450 activity and cancer
Several anti-cancer drugs are metabolised by the P450 system (Table 1.4.2), usually 
generating less or non-toxic derivatives, although some activation occurs. This is 
particularly important for oxazaphosphorines such as Cyclophosphamide or 
Ifosfamide, which require P450-mediated activation to exert their cytotoxic effect (De 
Raat et al., 1977), and also for drugs like Tegafur, which is metabolised to 5- 
fluorouracil by the P450s (Ikeda et al., 2000).
CYP450 Substrates
CYP1A2
CYP2A6
Flutamide (activation), Erlotinib, Procarbazine, 
Tamoxifen, VP-16
Tegafur (activation), Cyclophosphamide, Ifosfamide
CYP2B6 Cyclophosphamide (activation), Procarbazine, 
Ifosfamide (activation), Tamoxifen
CYP2C8 Taxol, Cyclophosphamide, Ifosfamide
CYP2C9 Cyclophosphamide, Ifosfamide, Tamoxifen, Tegafur 
(activation)
CYP2C19 Thalidomide, Cyclophosphamide, Ifosfamide, 
Tamoxifen
CYP2D6 Tamoxifen (activation), Adriamycin, Gefitinib/lressa
CYP2E1
CYP3A4/5
VP-16, Tamoxifen
Cyclophosphamide, ((in)activation), Ifosfamide 
((in)activation), Taxotere, Adriamycin, VP-16, 
Flutamide, Gefitinib/lressa, Imatinib/Gleevec, Erlotinib, 
Irinotecan, Taxol, Teniposide, Tamoxifen, Vinca 
alkaloids, Busulfan
Table 1.4.2: Anticancer agents and P450 metabolism (adapted from Van Schaik, 2005).
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Measurable P450 activity is readily detected in cell lines, P450 activity was studied in 
the NCI human tumour cell line panel (Yu et a/, 2001) All cell lines exhibited 
significant P450 and P450R activity A negative correlation was found between 
general P450 activity and chemosensitivity to 10 standard anticancer agents, thereby 
suggesting that the cytochromes were contributing to cell resistance, probably by 
inactivating the drugs
CYP1A
The role of CYP1A1 in lung and colon cancer has been recently established The 
enzyme, expressed in lung and also along the gastrointestinal tract, is induced by the 
presence of polycyclic hydrocarbons present in cigarette smoke and charred foods, 
and also in polluted air Induction leads to enhanced activation of these compounds, 
and the activated metabolites are known to be carcinogenic (Nebert et a l, 2004) 
Involvement of CYP1A1 in carcinogenesis was further confirmed after the discovery of 
a genetic polymorphism in the cyplal gene that results in three different phenotypes, 
A, B and C Alleles A and B are far less inducible than allele C, and the homozygous 
individuals for allele C were found to be at increased risk of developing cancer (Goto 
etal, 1996)
Other types of polymorphisms also exist, the most important of them probably being a 
point mutation in exon 7 of the cyplal gene The mutation results in and isoleucme to 
valine substitution and renders a far more active enzyme this can in turn lead to 
enhanced activation of environmental xenobiotics and a higher risk of developing 
cancer (Taioli et a l, 1995) However, many anticancer drugs require activation by the 
target cell, and the mutation could result in a more efficient biotransformation of the 
drug and consequent enhanced effect Thus, the mutation in exon 7 could be a 
marker of anti-cancer drug sensitivity for certain tumours (Peters e ta l, 1997)
The role of CYP1A1 in other types of cancer remains somewhat obscure Expression 
of CYP1A enzymes was detected in 39% of breast tumour tissue samples, only in 
areas of invasive carcinoma (Murray et a l, 1993), suggesting a relationship between 
enzyme expression and invasive phenotype Breast tumour 7-ethoxyresorufin O- 
deethylase (EROD) activity, mainly catalysed by CYP1A1, was not significantly 
different from that of normal tissue Moreover, no correlation was found between 
tumour EROD activity and stage or grade of malignancy (Iscan et a l, 1999) On the 
other hand, expression of CYP1A was detected in 68% of urinary bladder tumour 
samples, and it was correlated with tumour grade (Murray et a l, 1995)
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A recent report by Leung et al. (2005) might explain some of the differences observed. 
The authors detected a novel spliced variant of CYP1A1, named CYP1A1v, which 
presents an 84bp deletion. This variant showed similar enzymatic activity when 
compared with CYP1A1; however, expression of CYP1A1v was not restricted to the 
endoplasmic reticulum, like that of CYP1A1, but rather it was detected in the nucleus 
and in mitochondria of ovarian cancer cells. Apparently, the deletion results in the 
creation of a translocation signal that alters intracellular distribution of CYP1A1. 
Involvement of CYP1A1 in the development of resistance to chemotherapy also 
remains undefined. Expression of CYP1A1 and CYP1B1 enzymes was found to be 
high in anti-estrogen resistant human breast cancer cell lines; no gene amplification 
had occurred, so this was regarded as a regulatory alteration (Brockdorff et al., 2000). 
However, expression of CYP1A1 was decreased in an Adriamycin-resistant variant of 
the MCF-7 breast cancer cell line as compared to the parental cells. This was also a 
regulatory phenomenon, as no mutation was detected in the gene and transfection 
with CYP1A1 cDNA did not result in an increase of enzymatic activity. No mRNA was 
detected following induction with TCDD, not that of CYP1A1 or other PAH-induced 
enzymes, which suggests an alteration in the regulation of several genes. MCF-7 cells 
with low levels of resistance to Adriamycin still displayed low AHH activity, implying 
that the loss of CYP1A1 expression is not necessary for the development of 
resistance. Metothrexate-resistant MCF-7 cells had also lost AHH activity, which 
made the authors suggest that this alteration occurs in response to general cytotoxic 
stress, rather than to specific Adriamycin effects (Ivy et al., 1988).
CYP1B
Because of its ability to activate environmental procarcinogens, CYP1B1 has been 
proposed to play a role in carcinogenesis (Li et al., 2000). However, if the functional 
protein is not expressed in normal tissue, this might not be an important factor.
The significance of CYP1B1 overexpression in cancer is not yet fully understood, but 
the fact that it can metabolise a number of relevant anti-cancer drugs suggests that it 
might be important in the development of resistance to chemotherapy. Rochat et al. 
(2001) have found that CYP1B1 is able to metabolise Flutamide, an antiandrogen 
used in the treatment of prostate cancer, with high efficiency, inactivating it. Also, 
McFadyen et al. (2001) found a significant decrease in the sensitivity of CYP1 B i­
transfected cells to Taxotere compared to the parental cell line. Cytotoxicity was 
restored by pretreating the cells with the CYP1 inhibitor a-naphtoflavone.
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In a recent study, Tsuchiya et al (2006) studied the expression of miR-27b, an miRNA 
that has been shown to decrease CYP1B1 expression, in tissue samples from breast 
cancer and normal adjacent tissue A great proportion of patients showed decreased 
expression of miR-27b in cancerous tissue, accompanied by CYP1B1 overexpression, 
analysis of normal adjacent tissue did not show such a decrease, suggesting that 
downregulation of this miRNA was a specific tumoral event
CYP2
Since the members of the CYP2A subfamily are able to metabolically activate 
environmental procarcinogens, a role in tumour development has been proposed for 
them Given that nicotine and some mtrosamines commonly found in tobacco are 
good substrates of the CYP2A6 isoform, a recent study tried to find an association 
between sequence polymorphisms in the cyp2a6 gene, smoking habits and lung 
cancer development Data suggest that a mutation in cyp2a6 that results in a less 
active enzyme could lower the risk of developing smoking-induced lung cancer 
(Raumo et a l, 2001) On the other hand, reduced activity of CYP2A6 could mean 
decreased activation of anticancer drugs like Tegafur, indeed, such an occurrence 
was reported for a patient with a reduced activity enzyme (Daigo et a l , 2002) 
Distribution of CYP2A6 was studied in human hepatocellular carcinoma samples 42% 
of them were positive for CYP2A6 protein Staining was very heterogeneous, and a 
survival analysis showed a tendency towards a more favourable prognosis in patients 
with CYP2A6-expressing tumours compared to those without detectable enzyme 
expression (Raumo et a/, 1998) Expression of CYP2A enzymes has also been 
detected in a human glioma cell line (Vasquez e ta l, 1998), although its importance in 
tumour development or outcome was not studied
CYP2B6 is also associated with carcinogenesis induction of its expression was 
correlated with tumour development in rat liver (Diwan et a l, 2001) and thyroid (Diwan 
et a1, 1996) Also, selective inhibitors of CYP2B6 were able to block carcinogenic side 
effects of Tamoxifen (Stiborova et a l, 2002) No correlation has been found to date 
between CYP2B6 expression and development of resistance to chemotherapy, 
although higher levels of CYP2B6 expression found in females as compared to males 
correlate with increased Ifosfamide activation (Schmidt et a l, 2001) which might have 
therapeutic implications
The CYP2C subfamily is able to activate procarcinogens such as aflatoxin B1 and 
benzo[a]pyrene, which raises the possibility of a correlation between enzyme activity
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and carcinogenesis However, no association has been found so far Sequence 
polymorphisms in cyp2c9 and cyp2c18 genes have been detected, and even though a 
correlation was found between polymorphic alleles and differences in the catalytic 
activation of cyclophosphamide (Chang et a l, 1997), the influence of these mutations 
in chemotherapy outcome is still unknown
Nearly 5-10% of the Caucasian population carry a polymorphism in the cyp2d6 gene 
that results in a low-activity enzyme this condition is denominated Debrisoquine 
polymorphism, because Debrisoquine metabolism is compromised in these 
individuals Several studies have linked this polymorphism with increased risk of 
developing leukaemia and bladder malignant melanoma (Smith et a/, 1991, Wolf, 
1991) This polymorphism might also have a role in chemotherapy outcome poor 
Debrisoquine metabolisers have lower levels of circulating Endoxifen, the active 
metabolite of Tamoxifen, which might result in lower therapy efficacy (Jin et a l, 2005)
It has been reported that CYP2E1 can activate a large number of toxins and 
carcinogens, such as N-nitrosodimethylamine and benzene, and (t has been 
suggested that polymorphisms in the cyp2e1 sequence can be linked to increased 
incidence of lung, gastric or oesophageal cancer (Kato et a l, 1992) Indeed, this 
enzyme appears to be dramatically induced by cigarette smoke (Villard et a l, 1998) 
The same study also reports that pretreatment of mice with a CYP2E1 inhibitor before 
exposing them to tobacco smoke reduced the formation of DNA single strand breaks, 
suggesting that this isoform might be involved in lung DNA damage in smokers On 
the other hand, a recent report indicates that a polymorphism in cyp2e1 may confer 
some protective effect against gastric cancer (Gonzalez et a l , 2002) More recent 
reports also show that different allelic forms of CYP2E1 are associated with both 
increased and decreased risk of cancer (Cai et a l, 2005, lizasa et a l, 2005, Li et a l, 
2005), and often were not independent predictory factors, but they were associated 
with lifestyle issues, such as smoking status Thus, the role of this enzyme in 
carcinogenesis remains undefined
It has recently been proposed that CYP2J2 has a role in the pathogenesis of cancer 
Indeed, transfection of this enzyme into cancer cells in vitro increased proliferation 
and protected cells from apoptosis induced by TNFa (Jiang et a l , 2005) The same 
effects were observed after the exogenous addition of epoxyeicosatrienoic acids 
(EETs), which are products of CYP2J2 metabolism These derivatives of arachidomc 
acid activated the MAP kinase pathway, as well as the PI3-kinase/Akt pathway, and 
also increased the level of phosphorylation of the EGF receptor Moreover, these 
EETs have potent angiogenic effects, as shown by their ability to promote proliferation
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and migration of endothelial cells, as well as capillary tubule formation (Wang et a l,
2005)
Expression of CYP2R1, CYP2S1, CYP2U1 and CYP2W1 has been found to be 
increased in tumour as compared to normal tissue (Dowme et al 2005, 
Kumarakulasingham et al 2005, Saarikoski et al 2005, Aung et al 2006, Karlgren et 
al 2006), moreover, CYP2W1 has emerged as a tumour-specific P450 These 
findings are revised in detail in Section 14 5 2
CYP3A
Association of sequence polymorphisms with increased risk of tumorigenesis and/or 
poor chemotherapy outcome has recently shown the importance of CYP3A4 in cancer 
development However, the precise role of this enzyme in carcinogenesis and/or 
cancer treatment is difficult to establish, since reports are sometimes contradictory 
Epipodophyllotoxms are substrates of the CYP3A4 isoform, individuals carrying a 
CYP3A4-V genotype (a sequence polymorphism in the 5’ region of the cyp3a4 gene) 
have a decreased risk of developing leukaemia after treatment with these drugs (Felix 
et a l, 1998) On the other hand, the same polymorphism was associated with higher 
TNM (Tumour-Node-Metastasis) stage in prostate cancer patients (Rebbeck et a l ,
1998)
The fact that CYP3A4 is involved in the metabolism of several anti-cancer drugs 
raises the possibility of its expression influencing chemotherapy outcome Taxotere 
has been found to induce CYP3A4 expression both in hepatocytes and in peripheral 
mononuclear cells (Nallam et a/, 2001, Fujitaka et a l, 2001), le induce its own 
metabolism This could lead to reduced drug availability
Two studies suggest a prominent role for CYP3A4 in influencing cell sensitivity to 
anticancer drugs In the first one, Chinese hamster ovary cell lines were transfected 
with a CYP3A4 expression plasmid, which rendered them able to metabolise 
Vinblastine with a similar or higher efficiency than that of human liver microsomes 50 
and 35% of transfected cells remained viable after being exposed to 100 nM of 
Vincristine or Vinblastine, respectively, whereas over 90% of the parental cells were 
killed in these conditions (Yao et a/, 2000) According to the second study, 
pretreatment of Caco-2 cells with antisense phosphorodiamiate morpholino oligomers 
(PMO) targeted to inhibit CYP3A4 expression resulted in an inhibition of 
Cyclophosphamide cytotoxicity and an enhancement of Taxol toxicity (Arora et a l,
2002)
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P450R
P450R is an integral part of cytochromes P450-mediated reactions, as well as an 
independently acting enzyme able to metabolise several commonly used drugs Many 
of the substrates of P450R are involved in cancer treatment, such as Mitomycin C 
This drug is activated into a much more toxic form mainly by P450R (Bligh et a l, 
1990) and indeed, a correlation has been shown between P450R expression and 
Mitomycin C activity in bladder cancer (Gan et a l, 2001) Other anticancer agents like 
Tirapazamine show a requirement for P450R activity in order to exert their toxic 
effects (Patterson et a l, 1995, Patterson et a/, 1997) The role of P450R in 
Adriamycin-induced toxicity remains controversial In this case, P450R plays a dual 
role, decreasing Adriamycin toxicity by reducing the anthracycline ring and causing 
the loss of the sugar moiety attached to it, but it also transforms the drug into the 
semiquinone form, producing an active DNA-alkylatmg agent and also generating 
toxic free radicals in the process
However, it should be noted that, as is the case with cytochromes P450, P450R can 
also activate toxic chemical compounds that are harmful to the cell and may even 
induce transformation Pro-carcinogenic compounds such as Nitrofurazone and 
dimtropyrenes present in diesel engine emissions are activated by P450R into DNA- 
damaging compounds, resulting in the promotion and/or progression of 
carcinogenesis (Hiraku et a l , 2004, Murata et a l, 2004) Moreover, DNA damage and 
genomic instability were reported in cells overexpressing P450R in the absence of any 
substrate or toxic agent, suggesting that the very presence of this enzyme might result 
in transformation even in the absence of environmental toxins (Heme et a l, 2006)
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14 5 P450 expression in normal and cancer tissue
Detoxifying enzymes are usually found in the liver, though not exclusively many 
different tissues express cytochromes P450, especially those in close contact with 
environmental agents These include the lungs and the gastrointestinal tract, but also 
the renal epithelium Transformed cells do keep some of their normal characteristics, 
and cytochrome expression can be readily detected in several different types of 
cancerous cells (Murray et a l, 1993, Murray et a l, 1995, Murray et a/, 1997)
Several studies have been conducted to detect P450 mRNA and protein in normal 
and tumoral tissue, and also to establish whether the expression patterns are 
changed during malignant transformation Some of these studies report 
overexpression of one or more P450s, while others indicate that the chronic 
inflammation that accompanies most solid tumours down-regulates P450 expression 
Even though there are a considerable number of articles on the subject, there is not 
yet enough information about cytochrome expression in normal and tumoral tissue, 
and thus it is difficult to make conclusions about their relevance
14 51 Techniques used for the study of CYP expression
Several different techniques can be used for detection of P450 expression amongst 
them are biochemical assays, such as activity measurement, reverse transcription- 
polymerase chain reaction (RT-PCR), Western blotting and immunohistochemistry 
(Murray et at, 1995)
Of these, biochemical assays such as activity measurement are the only ones that 
can demonstrate enzyme functionality, but they require a fairly large size of sample, 
preserved in excellent conditions Western blotting offers the advantage of easy 
identification of tissue proteins by combining antibody detection with molecular weight 
determination, but also requires significant amounts of sample RT-PCR is a good 
method for screening of numerous samples as it can provide extremely specific 
information, since there is no antibody cross-reaction that can interfere, however, 
mRNA expression does not always correlate with protein expression, for it does not 
take post-transcriptional regulatory events into account
The main drawback of these methods is that heterogeneous samples, such as those 
obtained from biopsies, are difficult to analyse These techniques cannot show the 
protein or mRNA of interest in a particular cell type, and for tumours there is always 
the risk of contamination with normal adjacent tissue Immunohistochemistry is the
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method of choice when dealing with small samples (such as needle biopsies), from 
tissues with low content of the protein of interest, or in which the target is in small 
proportion It also allows precise location to a particular cell type and even to certain 
subcellular structures The main disadvantages of this technique are the possibility of 
cross-reaction with other proteins and the inability of some antibodies to work in 
paraffin-embedded tissue samples, the commonest preservation method
14 5 2 P450 Expression in normal and cancer tissue 
Enzyme-specific expression studies
Some expression studies have focused on particular cytochrome isoforms and studied 
their expression in hepatic and various extra-hepatic tissues A study of CYP1B1 
expression was carried out on a large cohort of paired samples (cancer and normal 
tissue) of bladder, breast, colon, oesophagus, kidney, lung, ovary, skin, stomach, 
uterus, connective tissue, lymph node, brain and testis (Murray et a l, 1997) No 
CYP1B1 protein was detected in normal tissue, while expression of this enzyme was 
very common in all types of tumours, with positive staining in all samples, or ail but 
one, of each particular type These results prompted the authors to suggest that 
CYP1B1 could be a tumour-specific isoform Recent studies, however, contradict this 
theory indeed, CYP1B1 appears to be overexpressed by tumours, but its presence is 
detectable in normal tissue by in situ hybridisation and immunohistochemistry (Gibson 
et a/, 2003, Muskhelishvili et a/, 2001) These contradictory results could be 
explained by the use of different antibodies and/or primers, and by post-transcriptional 
and/or translational modifications of CYP1B1
Another study of CYP2C and CYP3A expression in several neoplastic and non- 
neoplastic tissues was carried out by immunohistochemistry (Yokose et a l, 1999) 
They found that hepatocytes, epithelium of the small and large intestine, bile duct, 
nasal mucosa, kidney and adrenal cortex all expressed enzymes of both subfamilies 
Epithelium of salivary glands, oesophagus, stomach, small intestine, colon, rectum, 
nasopharynx mucosa, prostate and uterus, plus serous cells of the respiratory tract, 
hepatocytes, myeloid cells, neutrophils and basophils stained positively for CYP2C, 
while epithelium of stomach, small intestine, colon, rectum, pancreas and gallbladder, 
plus hepatocytes, chief cells of the parathyroid, proximal kidney tubules, plasma cells 
and the corpus luteum of the ovary all reacted with the CYP3A antibody The 
presence of CYP3A was detected in carcinomas of six different organs, including
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colon and liver carrcmoma, while CYP2C was present in 7 types of carcinomas of 
different tissue origin, indicating that P450s are present in both normal and tumoral 
tissue
Expression of novel members of the CYP2 family has been evaluated in recent 
studies Little is known about CYP2S1, a recently discovered P450 (Rivera et a/, 
2002, Rylander et a l, 2001) In spite of being classified as a member of the CYP2 
family based on DNA sequence homology, it is induced by dioxin and able to 
metabolise aromatic hydrocarbons, which makes it more similar to members of the 
CYP1 family Expression of CYP2S1 was studied by both immunohistochemistry and 
in situ hybridisation, which showed comparable expression patterns, in a variety of 
human tissues (Saarikoski et a l, 2005) Staining of this particular enzyme was 
strongest in skin, tissues associated with the respiratory tract (nasal cavity, bronchus 
and bronchioli) and areas of the gastrointestinal tract, namely stomach, duodenum, 
colon and exocrine pancreas Moderate staining was found in uterine cervix, 
oesophagus, small bowel, rectum, bladder and adrenal glands Testis, prostate, 
ovary, breast, liver, kidney, spleen, lymph nodes and thyroid all displayed weak 
staining for CYP2S1, while the enzyme was undetectable in endometrium, 
myometrium and heart tissue Overall, CYP2S1 appeared to be mainly restricted to 
epithelial cell types and also in organs of epithelial origin, such as exocrine glands 
Staining was also performed in tumour tissue, revealing strong expression of CYP2S1 
in ovarian tumours and in squamous cell carcinoma of the uterine cervix, while 
expression in lung carcinoma was variable
CYP2J2 is also a novel member of the CYP2 family, involved in the synthesis of 
eicosanoids, derivatives of arachidomc acid involved in tissue homeostasis and 
carcinogenesis (Wu et a/, 1996) Its expression appears to be widespread and has 
been detected at the mRNA and/or protein level in lung, liver, kidney, ileum, jejunum, 
colon, stomach, pancreas, pituitary gland and especially in the heart, where it appears 
to regulate vascular homeostasis (Capdevila et a/, 2000, Fleming, 2001, Wu et a/, 
1996) A recent study (Jiang et a/, 2005) showed that CYP2J2 and its products 
promote cell proliferation and inhibit apoptosis, which prompted the authors to analyse 
the expression of this enzyme in human tumour samples CYP2J2 expression was 
increased in tumour compared to adjacent normal tissues in all of those samples 
where the enzyme expression was detectable, both at mRNA and protein level 
Elevated expression was observed in all types of tumour tested, including 
oesophageal carcinoma and adenocarcinoma, pulmonary carcinoma and 
adenocarcinoma, colon adenocarcinoma, breast, stomach and liver carcinoma 
However, samples of hyperproliferative non-tumoral tissues displayed no detectable
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CYP2J2 expression CYP2J2 therefore appears to be involved in the development of 
cancer at a late stage
A recent study has suggested that expression of CYP2W1 is strictly tumour-specific 
(Karlgren et a/, 2006), in contrast with other P450 isoforms that appear to be 
overexpressed in cancer samples but are also expressed in normal tissue This P450 
has been only recently discovered (Karlgren et a l, 2005) and yet had been shown to 
be overexpressed in gastric cancer samples as compared to normal tissue by serial 
analysis of gene expression (SAGE) and quantitative RT-PCR (Aung et a/, 2006) 
Indeed, CYP2W1 mRNA expression was detected in 54% of all human tumours 
examined, with highest prevalence in adrenal gland and especially in colon tumours 
(Karlgren et a l, 2006) Expression of CYP2W1 in colon tumours was also detected by 
Western blotting This enzyme was also present in HepG2 hepatoma cells at mRNA 
and protein levels, but not in other cell lines, absence of expression was later found to 
be due to hypermethylation of the CYP2W1 promoter No immunoreactivity was 
detected in normal tissue samples at mRNA or protein levels, not even in liver 
microsomes, supporting the fact that this isoform is tumour-specific 
A recent study analysed the expression of CYP2C19 mRNA and protein in a panel of 
tumour and normal adjacent normal tissue from liver, colon, stomach, breast, 
oesophagus, lung, uterus, brain, pancreas, ovary and kidney (Wu et a l, 2006) 
CYP2C19 mRNA was only found in liver and hepatic carcinoma samples, with 
significantly higher levels present in tumour as compared to normal samples Western 
blotting confirmed that the same expression profile was observed at protein levels
Brain
Expression of P450R, CYP1A1 and CYP1B1, among others, was demonstrated in the 
central nervous system in early reports (Rieder et a l, 1998, Strobel et a l, 1995, Yun 
et a/, 1998) In a small study comprising 10 brain tumour samples, expression of 
CYP2C9 was detected in all samples, while CYP3A5 was detected in only 3 out of 10 
(Knupfer et a l, 1999) No immunoreactivity was shown for CYP3A4 All samples also 
expressed IL-1 and IL-6 receptors, suggesting that the lack of expression of certain 
P450s might be due to downregulation by these cytokines
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Breast
In an early report, expression of CYP1A and CYP3A in primary breast cancer was 
studied with antibodies that could not distinguish between different P450 isoforms 
(Murray et al., 1993). It was found that 39 and 22% of tumours expressed CYP1A and 
CYP3A protein, respectively. In both cases, staining was only found in areas of 
invasive carcinoma, which poses an interesting question as to whether P450s could 
be involved in invasion and/or metastasis.
Another report analysed mRNA expression of CYP1, 2 and 3 families by RT-PCR in 
human breast tissue and tumours (Huang et al., 1996). In this case, CYP1A1 mRNA 
was found in roughly half of all normal samples and tumours, but the most interesting 
finding of this experiment was that higher levels of the enzyme were found in normal 
tissue adjacent to the tumour. This suggests that tumours may actually be able to 
stimulate expression of P450s by normal tissue. These results were confirmed by a 
later study (El-Rayes et al., 2003), which showed that CYP1A1, CYP2E1 and 
CYP3A4 expression was significantly lower in malignant tissue as compared to 
normal adjacent tissue samples, as detected by Western blotting. Expression of 
CYP2B6 was also evaluated in the same samples and appeared to be higher in 
oestrogen receptor positive tumours than in negative ones.
Expression of CYP1B1 mRNA in normal breast and tumour tissue was present in all 
but one sample; CYP2C was present in every sample, while CYP2D6 was present in 
almost all normal and tumoral tissues (Huang et al., 1996). Members of the CYP3A 
family CYP3A4 and CYP3A5 were found more often in normal samples than in 
tumours, but their expression was not coincidental, suggesting differential regulation. 
In another report, the expression profile of all major CYP forms was analysed in 
breast tumour and surrounding normal tissue (Iscan et al., 2001). The levels of 
CYP1A1 mRNA were very low in normal and tumour samples, while CYP1B1, 
CYP2B6, CYP2C, CYP2D6 and CYP2E1 were readily expressed in both types of 
tissue. CYP2A6, CYP2A7, CYP2A13, CYP2F1, CYP3A4, CYP3A5 and CYP3A7 
could not be detected in normal or tumoral tissue.
These results are in contradiction with those of a later study (Kapucuoglu et al., 
2003a), which assessed CYP3A4 expression in 25 paired set of breast tumour and 
surrounding tumour-free tissue by immunohistochemistry. The authors showed that all 
of the breast tumours evaluated and 68% of normal samples were positive for 
CYP3A4, with the mean score values for tumour staining being significantly higher 
than those of non-tumour tissue. This discrepancy might be explained by the 
existence of CYP3A4 variants. Indeed, in another study CYP3A4 RT-PCR revealed
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two variants of enzyme mRNA a 380-bp present in 4 out of 5 tumour samples, and a 
260-bp associated with normal tissue (Miller et a l, 2003) This suggests that 
differential transcriptional and/or post-transcriptional regulation of the enzyme in 
tumoral tissue might affect expression results
Expression of P450s may also vary with different ethnic groups, as shown by a recent 
study (Oyama et a l, 2005) the authors did not found detectable CYP3A in any of the 
34 breast cancer specimens belonging to Japanese patients, contrary to the 
approximately 20% present in samples from Caucasian women This study also 
showed very low CYP2A6 prevalence (only present in one sample), while CYP1B1 
was present in 82% of samples, especially in those from earlier stages of disease 
The authors failed to find a significant correlation between p53 and P450 expression 
in their breast tumour samples
The physiological importance of CYP3A4 expression was highlighted when it was 
shown that expression levels of CYP3A4 mRNA in breast cancer tumour could be 
inversely correlated with response to Taxotere, measured as reduction of 50% or 
more of the original tumour size (Miyoshi et a l, 2002) This study suggested that 
tumoral CYP3A4 mRNA levels could be used as a predictor of therapeutic outcome 
Supporting these results, measurable P450 activity in breast cancer tissue was 
demonstrated by Ifosfamide turnover in tumour microsomes (Schmidt et a l, 2004) 
CYP3A4 and CYP2C9 were detected in all analysed breast tumour samples by 
western blotting, while CYP2B6 was undetectable Enzymatic assays showed that 
Ifosfamide was metabolised by tumour microsomes, thus suggesting that intratumoral 
P450 activity should be considered as a potential factor that can influence therapeutic 
efficiency Furthermore, activity of P450R, necessary for P450-mediated metabolism, 
was increased in breast tumour tissues as compared to normal adjacent tissues in a 
recent study performed in 50 patients (Kumaraguruparan et a l, 2006) The highest 
activity levels were detected in lower stage tumours and in those tumours present in 
premenopausal women, suggesting that upregulation of this enzyme is related to 
hormonal status and that it is an early event in tumour development 
Another study focused on the co-expression of CYP2C family members and IL-6 
(Knupfer et a/, 2004) CYP2C8 and CYP2C9 mRNAs were detected in all the 
analysed breast cancer samples, while none of the tumours expressed CYP2C18 or 
CYP2C19 The CYP2C9 protein was detected in 9 out of 10 tumours, albeit weakly 
The low levels of P450 expressed were explained by the concomitant presence of IL-6 
and its receptor in all of the samples
CYP1B1 expression has been associated with increased risk of carcinogenesis after it 
was found to catalyse conversion of 17fl-estradiol to 4-hydroxy estradiol, which is a
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genotox/c compound The levels of this metabolite are elevated in breast and uterine 
cancer, suggesting enhancement of CYP1B1 activity in these tissues, maybe as a 
result of the carcinogenic process (Liehr et a l, 1995) It is known that signalling of 
CYP1A1 and CYP1B1 expression involves cross talk with the oestrogen receptor and 
depends on the receptor status of the cell line
Immunohistochemical detection of CYP2E1 was performed on 25 paired samples of 
infiltrating ductal carcinoma and surrounding normal tissue (Kapucuoglu et a l, 2003b), 
revealing the presence of the enzyme in all tumours and in all but one of the normal 
tissue samples However, expression of CYP2E1 in tumours was found to be 
significantly higher than in non-tumour tissue
Low expression of CYP1A1, CYP1A2, CYP1B1 and CYP3A4/5 was also found using 
immunohistochemistry in a large study comprising primary breast carcinoma samples 
from 393 patients (Haas et a l , 2006) However, expression of CYP2E1 was detected 
in 44% of samples Correlation between P450 expression and disease features was 
also evaluated CYP3A4/5 expression was found to be associated with positive nodal 
status, while a positive correlation was established between CYP1B1 expression and 
poor tumour differentiation
Colon and Small intestine
Identification of rifampicin-inducible CYP3A in biopsies from small bowel mucosa was 
reported in an early study (Kolars et a l, 1992), the same authors reported presence of 
CYP3A4 and CYP3A5 at both protein and mRNA levels in a later study (Kolars et a l, 
1994) CYP3A4 was reported to be the major isoform present in small intestine as 
early as in 1987 (Watkins et a/, 1987) This finding was later confirmed by the 
characterisation of the P450 enzymatic profile of human enterocytes (Zhang et a I,
1999) Although CYP1A1, CYP1B1, CYP2C, CYP2D6, CYP2E1, CYP3A4 and 
CYP3A5 mRNAs were present in all samples, only CYP2C and CYP3A4 protein could 
be detected by Western blotting CYP3A4 was found to be the major P450 form 
expressed in small intestine
CYP3A5 was later identified as the predominant CYP3A isoform expressed in colonic 
tissue and cell lines (Gervot et a l, 1996), while CYP3A7 was weakly detected in only 
some of the samples CYP3A4 was not found in any of the cell lines tested nor in 
colonic tissue samples Expression of CYP3A5 and CYP3A7 was not induced by 
rifampicm or dexamethasone, while hepatic CYP3A induction was observed after 
treatment with these agents, indicating differential regulation of CYP3A family
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members A recent report showed measurable CYP3A activity in human normal 
colorectal epithelium and cancer, albeit with high intenndividual variability (Martinez et 
a l, 2002) The tumoral enzyme characteristics, such as affinity and turnover, were 
similar to those of normal CYP3A enzyme found in colonic or hepatic tissue 
Presence of CYP1A1 in human small bowel was analysed by measuring 7- 
ethoxyresorufm O-deethylase (EROD) activity in a bank of microsomal preparations 
(Paine et a/, 1999) Only 6 out of 18 samples displayed measurable EROD activity, 
and immunoreactive CYP1A1 protein was detected by Western blot only in those 
samples with the highest metabolic rates, CYP3A4 activity and protein were readily 
detected in all samples The great intenndividual variability of CYP1A1 expression 
could not be attributed to smoking habits or concomitantly administrated medication, 
however, information about patient dietary habits was not available to the researchers 
Expression of CYP1B1 was found to be significantly higher in 61 human colorectal 
adenocarcinomas as compared to 14 normal human large bowel samples by 
immunohistochemistry performed with two different antibodies (Gibson et a l, 2003) 
Correlation could not be established between CYP1B1 expression, tumour stage or 
degree or lymph node invasion Presence of CYP1B1 in normal tissue was 
demonstrated, albeit at low levels Although the enzyme was mainly detected in colon 
epithelia, blood vessels also showed immunoreactivity Interestingly, CYP1B1 was 
expressed at higher levels in tumour as compared to normal vasculature 
Proteomics constitutes a novel approach for the simultaneous analysis of multiple 
proteins in a sample Advantages of this technique include unequivocal identification 
of protein spots by liquid chromatography and mass spectrometry Identification of 
several different P450s in colorectal tumours and their corresponding liver metastases 
was performed using proteomic techniques (Nisar et a l, 2004), revealing the 
presence of fourteen different P450s from the subfamilies CYP1A, CYP2A, CYP2B, 
CYP2C, CYP2D, CYP2E, CYP3A, CYP4A, CYP4F, CYP8B and CYP27A in 3 out of 6 
samples (the other three samples were apparently too small to be suitable for this 
study) An interesting finding was that the same enzyme pattern was detected in the 
liver metastasis and the surrounding, tumour-free liver tissue, indicating that the 
tumour environment is able to regulate intratumoral expression of different P450s 
Recently, expression of a number of different P450s was studied in 264 primary 
colorectal cancers, 91 lymph node metastases and 10 normal colorectal samples by 
immunohistochemistry using a panel of P450-specific antibodies (Kumarakulasingham 
et a l, 2005) The aim of this study was to detect an enzyme that might act as a 
prognostic marker It was found that all of the P450s studied were expressed tn both 
normal and colorectal cancers, with the exception of CYP2F1, CYP3A7 and CYP4Z1,
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which were absent in normal tissue. These results contradict previous findings, but 
discrepancies could be attributed to the use of different antibodies. Staining for 
CYP1B1, CYP2S1, CYP2U1, CYP3A5 and CYP51 was significantly stronger in 
colorectal cancer as compared to normal samples; this was a novel finding for 
CYP2U1. Similarly, all P450s were detected in lymph node metastasis, with CYP2S1 
and 3A4 being the most commonly upregulated P450s. Expression of CYP51 and 
CYP2S1 was found to be associated with poor prognosis, with CYP51 emerging as an 
independent prognostic marker. Interestingly, for most P450s there was no correlation 
between expression in the primary tumours and their corresponding metastases, once 
again indicating that the tumour environment significantly affects expression of these 
enzymes.
Expression of P450s at the mRNA level does not always correlate with findings in 
protein expression. Indeed, expression of CYP2C, CYP2E1, CYP3A4 and CYP3A5 
was studied in colon mucosa of normal and adenomatous tissue, revealing that only 
CYP3A5 mRNA appeared to be upregulated in adenoma as compared to normal 
adjacent tissue (Bergheim et al., 2005). However, no differences were found at the 
protein level in the same samples. Interestingly, protein levels of CYP2C8, CYP3A4 
and CYP3A5, but not 2E1, were much lower in normal tissue adjacent to tumour than 
in normal mucosa from disease-free patients, suggesting that the presence of the 
tumour might influence expression of these three P450s.
Kidney
Expression of CYP3A4 and CYP3A5 was demonstrated in human kidney by 
immunohistochemistry and Western blotting (Schuetz et al., 1992). Later, CYP3A5 
was shown to be the most prominent CYP3A subfamily member present in this tissue 
(Haehner eta!., 1996).
Renal tumours are known to respond poorly to chemotherapy, for they display intrinsic 
resistance to anticancer agents. Several studies were carried out in order to find 
alterations in P450 expression that could explain this increased resistance. Two 
reports compared P450 expression in paired samples of renal cancer and 
corresponding normal tissue in primary tumours of different histological types and 
staging. Immunohistochemical analysis demonstrated CYP3A presence in the 
cytoplasm of all tumour cells, with no differences in staining patterns amongst the 
various histological types (Murray et al., 1999). CYP3A was also detected in normal 
renal tissue, in proximal tubular epithelial cells and collecting duct epithelium. Western
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blot analysis confirmed these findings RT-PCR showed expression of CYP3A5 and 
CYP3A7 mRNA in all samples, normal and tumoral, without noticeable difference 
between malignant and non-malignant CYP3A4, however, was found in 90% and 
65% of normal and tumour samples, respectively Where normal samples did not 
express CYP3A4, mRNA of this isoform was detected in the paired tumour samples 
The findings of these authors show that renal tumours have a much higher frequency 
of CYP3A expression than many other types of cancer
A similar analysis was carried out for CYP1A2 and CYP1B1 (Cheung et a/, 1999) 
While CYP1B1, AhR and ARNT mRNA were found in all samples with no apparent 
difference between normal and tumoral, CYP1A2 expression was only present in 19% 
of tumours and 22% of normal tissues But the interesting finding of this study was the 
differential expression of CYP1A2 when CYP1A2 was present in the normal sample, 
it was not present in the paired tumour, and vice versa This suggests a complex 
regulatory phenomenon Expression of AhR and ARNT does not appear to play a role 
in this type of regulation, since their expression levels do not accompany the changes 
observed in CYP1A2 levels
However, when EROD activity was measured in 11 samples of renal cell carcinoma 
paired with corresponding normal adjacent tissue, together with a further 15 tumour 
samples, it was found that 70% of tumour samples displayed measurable EROD 
activity (McFadyen et a l, 2004) Activity was inhibited by the CYP1B1 inhibitor alpha- 
naphtoflavone, indicating that this isoform was responsible for the increase No such 
activity was detected in any of the normal samples This study also detected 
measurable P450R activity in all normal and tumour samples
Liver
Liver is of course the main P450-expressmg tissue, since it is the major detoxificatmg 
organ in the body But malignant transformation appears to deeply affect the liver’s 
ability to metabolise drugs, since it was shown that primary and secondary hepatic 
tumours have decreased expression of several P450s and also of other Phase I and II 
enzymes (Philip et a l, 1994) However, a recent report showed increased expression 
of multiple P450s hepatocellular carcinoma samples, as compared to normal adjacent 
liver tissue (Furukawa et a l, 2004) Expression of the same P450s in peripheral blood 
leukocytes did not correlate at all, except for CYP4B1, indicating that this particular 
enzyme might be used as a marker of induction of P450 expression in the liver
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Two recent reports have highlighted the importance of CYP2E1 expression as a 
prognostic biomarker Firstly, a human liver arrayed library was hybridised with probes 
generated from the mRNA isolated from hepatocellular carcinoma and normal 
adjacent tissues (Man et a l, 2004) this method revealed that CYP2E1 was only 
expressed in normal liver, but not in cancerous tissue and only weakly in cirrhosis 
samples It appears that CYP2E1 expression decreases with the progression of 
malignant disease Another study showed low levels of CYP2E1 at both protein and 
mRNA levels in hepatocellular carcinoma samples as compared to normal adjacent 
tissue (Ho et a l, 2004) Low expression of CYP2E1 correlated with aggressive tumour 
phenotype (poor differentiation, absence of capsule and younger age of patients), and 
was an independent prognostic factor for disease-free survival Again, expression of 
CYP2E1 was found to decrease with progression of malignant disease 
A recent screen in the human genome found that 2 5% of individuals showed gams 
between 7q21 1 and 7q22 1, the chromosomal location of CYP3A4 (Lamba et a/,
2006), a search for amplification of CYP3A4 was then performed in normal human 
livers, primary and secondary human tumours, human hepatic cell lines and 
immortalised cell lines CYP3A4 copy number was found to be normal in all samples, 
except for one cell line, primary human hepatocellular carcmomal cell line 
TONG/HCC This cell line showed an approximately 10-fold increase in CYP3A4 
mRNA expression and also in catalytic activity Increase m the number of genomic 
copies, although it does occur, does not appear to be a common mechanism of 
CYP3A4 upregulation
Lung
Normal lung tissue is known to express CYP3A5 and CYP3A7, amongst other 
enzymes involved m xenobiotic metabolism (Kivisto et a l, 1995) This is not 
unexpected, since this tissue is exposed to environmental toxins and therefore needs 
the metabolic machinery to protect itself from damaging agents However, not all 
P450s are present in pulmonary cells, as the same authors could not detect 
expression of CYP2D6 m normal or tumoral lung samples (Kivisto et a l, 1996) 
Meanwhile, expression of CYP3A was detected in both normal and malignant tissue in 
this small study comprising 32 patients
Another study focused in the analysis of CYP1B1 expression by RT-PCR and 
immunoblotting m human tumour and non-tumour tissue (Spivack et a/, 2001) 
CYP1B1 protein was detected in all individuals, but more tumours were shown to
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express the enzyme than normal samples, suggesting a role for CYP1B1 in malignant 
transformation of the lung No correlation could be found between CYP1B1 
expression and gender, smoking history and/or tumour histology These results were 
confirmed more recently when expression of CYP1A1 and CYP1B1 was analysed by 
a novel qualitative specific RT-PCR and also by Western blotting on a set of paired 
tumour and normal tissue samples from 45 patients (Spivack et a l, 2003) CYP1B1 
was detected at both mRNA and protein levels in all female tumour samples and 
about 90% of male tumour samples, whereas expression in normal tissue ranged from 
72 to 78% in both male and female samples, furthermore, expression of CYP1B1 was 
correlated with smoking status and estrogen receptor p  expression Staining for 
CYP1A1 was infrequent and did not appear to be differentially regulated in tumours 
with respect to normal tissue samples
Low and infrequent expression of CYP1A1 in normal lung tissue could be explained 
by méthylation status, indeed, complete or partial méthylation of the CYP1A1 
promoter was found in 98% of non-smokers, 71% of light smokers and 33% of heavy 
smokers involved in this study (Anttila et a l, 2003) Quitting smoking resulted in 
méthylation of the CYP1B1 promoter as early as after 1-7 days The lack of 
méthylation found in heavy smokers was reflected in the higher levels of EROD 
activity found in pulmonary tissue
On the other hand, CYP1A1 expression was found to be in the same levels for 
smokers as ex-smokers in a small study (Kim et a l , 2004) Indeed, quitting smoking 
did not appear to decrease expression of CYP1A1, while protein levels in non- 
smokers were significantly lower Expression of CYP1B1 was also low in non- 
smokers, slightly (albeit not significantly) increased in smokers and dramatically 
increased in ex-smokers, suggesting that induction of this P450 by tobacco smoking 
has lasting effects
In contrast with the previous results showing that méthylation of the CYP1B1 promoter 
in peripheral white blood cells was unaffected by smoking (Anttila et a l, 2003), 
another study showed that peripheral leukocytes from cancer patients displayed 
higher levels of CYP1A1 and CYP1B1 mRNA than leukocytes from non-cancer 
subjects (Wu et a l, 2004), indicating that P450 expression in peripheral blood cells 
might be affected by the presence of malignancies, if not by smoking 
Expression of P450s may also be dependent on tumour type, it was found that 
CYP1B1 expression was more common in adenocarcinomas than in squamous cell 
carcinomas of the lung, with over 50% of non-small cell lung carcinomas displaying 
positive immunohistochemical staining In contrast, only 3 out of 19 samples of normal 
lung expressed CYP1B1 (Lin et a l, 2003)
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A study performed on peripheral blood lymphocytes from 87 patients with non-small 
cell lung cancer found that CYP2E1 expression correlated with better survival, but 
only in those patients presenting the wild-type allele (Haque et a l, 2004) This is 
consistent with the association of CYP2E1 with better prognosis in hepatocellular 
carcinoma
Oesophagus
A recent study demonstrated expression of CYP1A2, CYP3A4, CYP2E1 and 
CYP2C9/10 in normal oesophageal squamous mucosa, but not in cells within the 
basal proliferative zone (Hughes et a l, 1999) This suggests that P450 expression is 
linked with the differentiated state of oesophageal cells Analysis of Barret’s 
oesophageal metaplasia, considered an intermediate step in tumour development, 
showed prominent expression of the same proteins in the basal glandular regions, 
containing actively proliferating cells Furthermore, double staining showed co- 
localization of P450s and PCNA (proliferating cell nuclear antigen) expression in 
Barret’s metaplasia, indicating that the presence of P450s is limited to proliferating 
cells, while the opposite is true for normal squamous epithelium RT-PCR studies 
confirmed the presence of P450 mRNA These results indicate an alteration in the 
localization pattern of P450s, but the significance of such alteration is still unclear
Ovary
Ovarian cancer usually has a poor prognosis due to the unpredictability of its 
response to chemotherapy In a major study involving samples from 167 patients, 
CYP1B1 protein was detected by immunohistochemistry in the vast majority of 
tumours (92%), most of them displaying moderate or strong staining (McFadyen et a l, 
2001a) Expression was found in all histological tumour subtypes and some 
correlation with tumour staging could be observed CYP1B1 was also detected in 
almost all of metastases analysed (94%), while expression in normal ovary tissue 
could not be demonstrated
In a recent study a novel splice variant of CYP1A1 that presents an 84bp deletion, 
named CYP1A1v, was detected in ovarian cancer samples (Leung et al 2005) This 
variant showed similar enzymatic activity when compared with CYP1A1, however, 
expression of CYP1A1v was not restricted to the endoplasmic reticulum, like that of
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CYP1A1, but rather it was detected in the nucleus and in mitochondria of ovarian 
cancer cells Apparently, the deletion results in the creation of a translocation signal 
that alters intracellular distribution of CYP1A1 Expression of CYP1A1 in a series of 
27 human ovarian cancers showed both nuclear and cytoplasmic staining in the 
majority of serous and mucinous carcinoma samples, while weaker staining was 
found in lower malignancy carcinomas Expression of CYP1A1 was absent in normal 
human ovary and in benign serous cystadenoma These results suggest that the 
presence of CYP1A1v, with its unique nuclear expression pattern, might be involved 
in the development of ovarian malignancies
Expression of 23 different P450s and also of P450R was evaluated in ovarian cancer 
using a panel of antibodies on an ovarian cancer tissue microarray consisting of 99 
primary epithelial ovarian cancers, 22 peritoneal metastasis and 13 normal ovarian 
samples (Dowme et a l, 2005) Stromal cells in the normal ovary displayed weak 
expression of all P450s tested, with CYP2U1 and CYP3A4 being the most prominent 
Ovarian cancer samples also displayed positive staining for all P450s included in this 
study, and this staining was found to be higher and more frequent than in normal 
ovary for all isoenzymes excepting CYP1A1, CYP4F11, CYP24 and CYP39 
Significant increases were detected for CYP1B1, CYP2A/2B, CYP2R1, CYP2U1, 
CYP3A5, CYP3A43, CYP4Z1, CYP26A1 and CYP51A1 Similar to the findings in 
normal ovary samples, the P450s with strongest and most frequent staining were 
CYP2U1 and CYP3A7 Samples obtained from metastatic sites displayed strong 
immunoreactivity for CYP2A/2B, CYP2S1 and CYP3A7, with CYP2S1 and P450R 
being the only enzymes significantly upregulated in samples of metastatic origin as 
compared to primary tumour samples From this analysis, strong staining for 
CYP2A/2B and no staining for CYPAZ1 were found to be significantly correlated with 
better survival, emerging as independent prognostic markers for ovarian cancers
Prostate
P450 subfamilies CYP1A, CYP2C and CYP3A were detected in prostate tumours in 
an early report (Murray et a l, 1995b) More recently, a study has been conducted to 
analyse CYP1B1 expression in prostate carcinoma, premalignant prostatic 
intraepithelial neoplasia and other non-cancerous tissues (benign prostatic 
hypertrophy (BPH), metaplastic prostatic urothelium and hyperplastic prostatic 
urothelium) CYP1B1 was detected in 75% of prostate carcinomas, always located in 
the cytoplasm and absent from surrounding stromal tissue It was also present in all of
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the non-cancerous premahgnant samples, except for those of benign prostatic 
hyperplasia, where the enzyme was found in 82% of the samples CYP1B1 was not 
detected in normal prostate tissue, suggesting a link between its expression and 
malignant transformation (Camell et a i, 2004)
It should be taken into account that expression of P450s may depend on the different 
origin of samples within the prostate, it is known that prostate cancer arises mainly 
from the peripheral zone, while BPH is more common in the transitional zone 
CYP1B1 expression was found to be 2 to 6-fold higher in the peripheral zone as 
compared to the transition zone in twelve human prostate tissue sets, with staining in 
epithelial and stromal cells (Ragavan et a/, 2004) Expression of CYP1B1 was 
extremely variable among individuals (up to 10-fold) This study also detected 
quantifiable CYP1A1 mRNA expression in 75% of samples, while CYP1A2 mRNA, 
although detectable, was unquantifiable
An explanation for the elevated expression of CYP1B1 may be found in increased 
transcription due to promoter hypomethylation, a recent report also found 
immunostainmg for CYP1B1 to be significantly stronger in prostate cancer samples 
than in those coming from BPH patients (Tokizane et a/, 2005) The authors also 
analysed 175 prostate cancer samples and 96 BPH samples for methylation using 
specific primers, they found that, while CpG sites were unmethylated in cancer 
samples, CpG sites, transcription factor Sp1 binding sites and dioxin responsive 
elements were all methylated in BPH samples, thus pointing to a probable mechanism 
forCYP1B1 increased expression
No detectable CYP1A1 expression was found in either normal and primary tumour 
prostate cells (Sterling et a l, 2004), however, treatment with benzo[a]pyrene induced 
expression of this enzyme in both cell types In contrast, while CYP1A2 constitutive 
expression was detected in normal cells and was largely unaffected by 
benzo[a]pyrene treatment, CYP1A2 was absent from untreated tumour cells and yet 
showed significant induction after hydrocarbon treatment These data suggest 
differential regulation of CYP1A2 after malignant transformation
Stomach
Stomach cancer is one of the commonest tumours of the gastrointestinal tract, and it 
has a limited response to chemotherapy It is thought that environmental factors play 
a relevant role in tumour development and since the stomach is in contact with a
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number of toxic substances of dietary origin, P450s are likely to be induced in this 
type of tumours
Indeed, this has been shown by an immunohistochemical study where a total of 39 
tumours were analysed, all of them primary adenocarcinomas with different TNM 
(tumour, nodes, metastasis) staging CYP1A and CYP3A were found in 51% and 28% 
of tumours respectively, while expression of CYP2E1 could not be detected in any of 
the samples (Murray et a/, 1998) Staining was always present in the cytoplasm of 
tumour cells, and there was no correlation with histological type or staging On the 
other hand, no P450 expression could be demonstrated in normal tissue, although 
CYP3A was present in mast cells within the stomach walls Samples of intestinal 
metaplasia, an intermediate stage between normal and malignant transformation, 
were also analysed to gain insight into the changes undergone by cells during the 
transformation process These samples also displayed CYP3A expression, 
suggesting that P450 induction accompanies tumorigenesis Another study (Yokose et 
a l, 1998) also demonstrated CYP3A4 expression in the foveolar epithelium of the 
human stomach with intestinal metaplasia by immunohistochemistry, Western blotting 
and RT-PCR This enzyme was not detected in other sections of the stomach or in 
foveolar epithelium without intestinal metaplasia, which again suggests a role for 
CYP3A4 in stomach carcinogenesis
A higher proportion of samples expressing CYP1A1 was recently described this 
enzyme was detected by immunohistochemistry in 86% of gastric cancers, 57% of 
atrophic gastritis and intestinal metaplasia and in 7 7% of non-cancerous mucosa in 
43 gastric cancer cases (Zhang et a l, 2004), results were confirmed by RT-PCR and 
Western blot Moreover, EROD activity was also increased in cancerous or 
premalignant tissues as compared to normal tissue ones These results support the 
notion of a role for CYP1A1 in carcinogenesis
Urinary bladder
This is a very common malignant tumour and it is usually recurrent, there is scant 
information about its response to anticancer drugs
An early study performed on 25 samples of tumoral tissue showed CYP1A, CYP2C 
and CYP3A immunoreactivity in 68%, 28% and 68% of tumours, respectively (Murray 
et a/, 1995a) No P450 expression was detected in normal bladder, but only 5 
samples were available for analysis The staining was again uniformly cytoplasmic, 
and a correlation was established between CYP1A expression and tumour grade
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A more recent report (Carnell et a l , 2004) detected CYP1B1 expression in all bladder 
carcinoma samples tested (n=22) Protein expression was heterogeneous and 
cytoplasmic, present exclusively in tumour cells P450R was also evaluated in tumour 
specimens from 92 bladder cancer patients and correlated with response to Mitomycin 
C, a bioreductive drug know to be activated by this enzyme (Basu et a l, 2004), most 
tumours presented moderate to high immunoreactivity, but this did not correlate with 
drug response, suggesting that other factors are more relevant for chemotherapy 
outcome
Other tissues
CYP3A4/5 expression in osteosarcomas, the most common paediatric primary bone 
tumours, was shown to be significantly higher in patients with more aggressive 
cancers, and was associated with development of distant metastases and poor 
prognosis (Dhaim et a l , 2003) These particular isoforms could therefore be used as 
biomarkers to predict clinical outcome
Expression of CYP1A1, CYP1A2, CYP2B6, CYP2C8/9/19, CYP2D6, CYP2E1 and 
CYP3A4 was analysed in a group of pancreatic samples, including normal tissue, 
chronic pancreatitis and pancreatic cancer specimens (Standop et a/, 2003) 
Immunoreactivity for all P450s except CYP1A2 was detected in cancer samples at a 
higher frequency than in normal tissue, while a similar pattern was observed for the 
pancreatitis samples, suggesting a link between inflammation and P450 induction 
Enzymatic activity is detectable in primary cultures from human head and neck 
squamous epithelium (Farm et a l, 1995) A recent study analysed expression of 
CYP1A1, CYP3A4 and CYP2E1 in samples from squamous cell cancer of the head 
and neck (SCCHN) and compared the results to those obtained from paediatric 
tonsillitis samples (All et a/, 2004), immunohistochemistry revealed increased 
expression of CYP1A1 and CYP3A4 in cancer samples compared to samples from 
patients with tonsillitis, while no difference in CYP2E1 expression was detected 
However, expression of CYP1A1 and CYP3A4 was much lower in the tumour tissue 
than in adjacent normal tissue Interestingly, expression of CYP1A1 and CYP3A4 was 
significantly correlated, even though these two enzymes have very different induction 
pathways
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Tissue type Upregulated P450s Dowregulated P450s
Breast CYP1B1 CYP1A1
CYP2E1 CYP1A2
CYP3A4 CYP1B1
CYP3A5 CYP2E1
P450R CYP3A4
CYP3A5
Colon CYP1B1
CYP2S1
CYP2U1
CYP3A5
Kidney CYP1B1 CYP3A4
Liver CYP2C19 CYP2E1
Lung CYP1B1
Ovary CYP1A1v
CYP1B1
CYP2A/2B
CYP2R1
CYP2U1
CYP3A5
CYP3A7
CYP1A1
Prostate CYP1B1
Stomach CYP1A1
CYP3A4
CYP2E1
Bladder CYP1A
CYP2C
CYP3A
Head and neck CYP1A1
CYP3A4
General CYP1B1
CYP2J2
CYP2W1
Table 1 4  3 Summary of reported changes in P450 expression in tumour tissue as compared to normal 
tissue
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1.5 Glutathione
15 1 Role of Glutathione
All aerobic organisms need oxygen to obtain maximal amounts of energy from 
metabolic reactions, but the use of oxygen generates dangerous by-products and 
highly reactive intermediates, such as hydrogen peroxide, superoxide and free 
radicals (Anderson et a l, 1980) All these can induce serious damage to the cell, 
usually by oxidation of lipids in the cell membranes
On the other hand, low levels of reactive oxygen species (ROS) can actually stimulate 
cell growth, although the mechanism by which they can do this is still unknown, S- 
thiolation of growth regulatory proteins by oxidated glutathione (GSSG), or direct 
chemical modifications of reactive cysteines have been suggested as possible 
intermediate steps It appears that the way a cell responds to ROS - whether it 
stimulates proliferation, stress response and damage repair, or apoptosis - depends 
on the nature and extent of the damage received (Tew et a l, 1999)
Glutathione (GSH) is the major soluble antioxidant present in mammalian cells and as 
such, it is usually the first line of a defensive antioxidant system developed in aerobic 
organisms throughout evolution But GSH plays more roles in cell physiology than that 
of a simple antioxidant it can be attached (conjugated) to endogenous compounds or 
xenobiotics as means of detoxifying them, it can mediate signalling pathways that 
modulate cell proliferation, differentiation and apoptosis and ultimately can be one of 
the multiple factors involved in the development of resistance to chemotherapy
15 2 Biochemistry
GSH is a tripeptide produced naturally in the organism, formed by the amino acids 
glutamic acid, cysteine and glycine It is the most abundant non-protein molecule in 
the cell, with a concentration of 1-10 mM in mammalian cells (Balendiran et a l, 2004) 
GSH concentrations can be increased by exogenous administration of precursors 
(glutamine and/or cysteine), glutathione esters or glutathione itself It should be taken 
into account that not only is the absolute concentration of GSH important to cell 
physiology, but also the capacity to synthesise it resistance to Adnamycm depends 
on the ability of the cell to resynthesise GSH rather than on a steadily increased
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concentration (Vallis et a/, 1997, Tipms et a l, 1999) Regulation of GSH levels is 
usually cell type-specific (McLellan et a l, 1999)
GSH is synthesised intracellularly in two sequential steps (Fig 15 1) First, the y- 
glutamyl cysteine synthetase (GCS) enzyme catalyses the formation of the dipeptide 
y-glutamyl cysteine in an ATP-consuming step, this is the rate-limiting step for the de 
novo synthesis of GSH Secondly, glycine is incorporated to the dipeptide by the GSH 
synthetase enzyme in another ATP-dependent reaction
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Figure 151 Glutathione metabolism (from Balendiran et al, 2004)
GCS is a heterodimer composed of heavy (GCSH) and light (GCSL) subunits coded 
by separate genes The heavy subunit contains the active site which catalyses the 
synthesis of y-glutamyl cysteine and is feedback-inhibited by GSH, the light subunit 
appears to exert a regulatory function (Rahman et a l, 2000)
y-glutamyl transpeptidase (GGTP) is a membrane-bound enzyme prevalent in cells 
that are specialised in absorption and excretion, such as epithelial cells It is the only 
enzyme able to break down the y-glutamyl linkage and liberate cysteinyl glycine, this 
peptide is subsequently cleaved by dipeptidase, releasing the free amino acids into 
the extracellular space The extracellular concentration of GSH is very low, but it is 
believed that it can still protect cell membranes from oxidative damage It is known 
that GSH can be transported from the liver, usually to the kidneys, which have a high 
transpeptidase activity
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While GGTP transfers the y-glutamyl residue to free amino acids, y-glutamyl 
cyclotransferase converts the residue into 5-oxo-L-proline, releasing the acceptor 
amino acid 5-oxo-L-prolinase (5-OPase)-mediated catalysis then converts 5-oxo-L- 
proline into L-glutamate, which can act as a GSH substrate and start the cycle again 
(McLellan e ta l, 1999)
GSH is a highly reactive molecule and it can donate its y-glutamyl radical to form 
amino acid derivatives or react via its sulphydryl moiety (Fig 1 5 2) Under normal 
conditions, the majority of GSH is in reduced form, it can react directly with free 
radicals, or indirectly through antioxidant enzymes to render the oxidized form, GSSG 
Although direct reaction with free radicals exists, GSH usually acts as a cofactor for 
enzymes such as Se-dependent or independent GSH peroxidases (GPxs) and 
phospholipid hydroperoxide GSH peroxidases Also, GSSG is formed as a by-product 
of nucleotide synthesis
Glutathione (GSH) 
Reduced
” ' lauW iSgR&uSise ft \
Glutathione Peroxidase
Se
Glutathione (GSSG) 
Oxidized
Figure 15 2 Glutathione catabolism (from Balendiran et a / , 2004)
GSSG can be reduced back to GSH by NADPH-dependent glutathione reductase, 
which is a highly efficient enzyme, keeping extremely low GSSG intracellular 
concentrations under normal conditions (Kosower et a l, 1978) The GSSG/GSH ratio 
is an indicator of cellular redox state (Schafer et a l, 2001)
76
Protein and non-protein sulphydryl radicals can be conjugated with GSH, and this 
molecule can also be found in the form of GSH thioesters Xenobiotics can also be 
conjugated with GSH as means of detoxification this function is carried out by GSH 
transferases (GSTs) Conjugates are later exported from the cell by ATP-dependent 
transport
15 3 Regulation of expression
The transcription factor Nrf2 appears to mediate constitutive and inducible expression 
of GSH transferases, enzymes present in the GSH biosynthetic pathway and other 
enzymes able to mediate chemotherapy resistance, such as qumone reductase (Itoh 
et a l, 1997 and 1999) Indeed, Nrf2 knock out mice displayed reduced expression of 
GSTs a, n and n, and also of GCSH, however, GSH synthetase levels were not 
affected (Chanas et a l, 2002)
Nrf2, together with small Maf transcription factors, binds to antioxidant responsive 
elements (ARE) in the DNA, which share a remarkable similarity to those sites that 
are AP-1 responsive Oxidative stimuli, such as UV irradiation, GSH depletion, or 
exposure to cisplatm, cause Nrf2 to dissociate from its inhibitor Keap 1 and migrate to 
the nucleus to initiate transcription AP-1 can be activated through the SAP kinases by 
the same stimuli Response to stress can be inhibited by treatment with antioxidants 
Nrf2 is not the only stress sensor in the cytoplasm, certain proteins homologous to 
members of the GST P family are able to migrate to the nucleus in response to 
oxidative stress The NF-kB pathway is also activated by stressful conditions and 
inhibited by antioxidants (McLellan et a/, 1999) More recently, BRCA1 was also 
shown to stimulate transcription of antioxidant responsive elements, inducing the 
expression of several redox state related genes including GSTs and oxidoreductases 
(Bae et a/,2004)
15 4 Functions
GSH is the major antioxidant present in the cell and it is essential for maintaining the 
intracellular redox balance It is also involved in detoxification and in the immune 
response
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Antioxidation GSH is the major soluble antioxidant present in mammalian cells it can 
protect cells by directly scavenging free radicals or as a cofactor of antioxidant 
enzymes GSH peroxidase and phospholipid hydroperoxide GSH peroxidase can 
convert oxidised lipids back into harmless fatty acids
The redox state of a particular cell can affect a number of signalling pathways 
controlling proliferation, differentiation and morphogenesis Among the signalling 
molecules activated by the redox state -  either by GSH or by free radicals -  are AP-1, 
AP-2, c-jun kinase (JNK), stress-activated protein kinase (SAPK), protein kinase C 
(PKC) and tyrosine kinases (Janssen et a l, 1993, Hayes et a l, 1999) A decrease in 
the level of GSH causes activation of NF-kB, and this activation is inhibited in the 
presence of other antioxidants (Fernandez et a f, 1999)
Detoxification conjugation with GSH is the major Phase II reaction in mammalians, 
particularly for electrophilic substrates like epoxides, alkenes, halides and heavy 
metals (Kaplowitz et a1, 1985) High levels of GSH can be found in the liver, kidney 
and lungs, tissues that are particularly exposed to exogenous toxins 
GSH conjugates are then excreted by an ATP-dependent pump, which explains the 
synergy observed between GSTs and MRPs in several studies (see below)
Immune system modulation there is evidence that the intracellular concentration of 
GSH modulates T-cell functions, such as cytotoxicity, activation, proliferation and 
differentiation (Balendiran e ta /, 2004)
Prooxidation it is known that reduction of certain metal ions by GSH can lead to the 
formation of superoxide anions, which can in turn oxidise a number of different 
molecules This could constitute a novel signalling mechanism (Pompella et a l, 2003, 
Paoiicchi et a l, 2002)
15 5 Glutathione and proliferation
Recent studies suggest a link between redox state/GSTs and stress activated kinases 
such as JNK and apoptosis signalling kinase (ASK) These enzymes are kept in an 
inactive mode in normal, non-stressful conditions GST P1, the most abundant isoform 
of GSTs in non-hepatic tissues, has been recently described as a JNK inhibitor (Adler 
et a l, 1999), apparently, stress causes GST P1 to dissociate from JNK, which is then 
activated by phosphorylation (and subsequent phosphorylation and binding of c-jun)
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and is able to initiate transcription of several stress-response related genes This 
interaction has been further confirmed by studies involving transgenic mice null for 
GST P1 high levels of JNK activity in basal conditions were detected in the transgenic 
tissues (Henderson et a/, 1998) Mouse embryo fibroblasts from GST P1 null mice 
also have a much shorter doubling time than their wild-type counterparts 
Furthermore, the specific GST P inhibitor TER199 was able to activate JNK in human 
HL60 cells (Ruscoe et a f, 2001) The inhibitor TER199 has also been reported to act 
as a myeloproliferative agent (Kauvar et a l, 1998)
It is generally believed that the role of GSTs in drug resistance depends on their 
conjugating activity, namely, that their primary function is to inactivate the drug by 
conjugation with GSH followed by export out of the cell However, a study performed 
on Adriamycin resistant MCF-7 cells failed to detect any form of GSH-Adriamycin 
conjugates An interesting finding of the study was that Adriamycin tended to localise 
in the Golgi apparatus of resistant cells, while it was usually detected in the nucleus of 
sensitive cells (Gaudiano et a l , 2000)
These findings suggest that there might be a function for GSTs beyond that of simple 
detoxification enzymes, and this is of particular importance for cancer therapeutics, 
since the GST P family has been the one most often linked to malignancy and to 
increased resistance to anticancer agents (Tew et a l, 1994, Lee, et a l, 1994) 
Supporting this theory, overexpression of GSTs is found even in cells resistant to 
compounds that are not detoxified by these enzymes Moreover, another family of 
redox state-dependent proteins -  thioredoxins -  has been linked to regulation of cell 
proliferation and sensitivity to chemotherapy (Tew et a l, 1999), further supporting the 
connection that seems to exist between these two events
But GSH could also have a direct role in signalling pathways, regardless of GSTs 
indeed, it has been shown to act as a negative modulator of protein kinase C (PKC) 
(Ward et a l, 1998) p53 function might also be redox sensitive, as shown by in vitro 
studies (Rainwater et a l, 1995, Liu et a l, 1998)
15 6 Glutathione and apoptosis
GSH depletion occurs in cells that are undergoing apoptosis, for example, those that 
have been exposed to an anti-Fas antibody (van den Dobbelsteen et a l, 1996) In this 
case, apoptosis can be delayed by treating the cells with glutathione precursors or 
GSH itself Another way of preventing apoptosis is by overexpression of GSH 
peroxidase (GPx) T47D breast cancer cells transfected with GPx1 were resistant to 
apoptosis triggered by an anti-Fas antibody Resistance was developed without a
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concomitant increase in the expression of antiapoptotic proteins, and could be 
reverted by depletion of GSH Similar events were observed in vivo, with transgenic 
mice overexpressing GPx1 displaying resistance to anti-Fas induced apoptosis 
(Gouaze et a l, 2002)
A similar scenario is also found for p53-dependent apoptosis, it has been shown that 
oxidative damage is a consequence of p53 activation and treatment with antioxidant 
compounds can prevent or revert this damage and inhibit the subsequent apoptotic 
process (Johnson et a/, 1996) The p53 response is complex and still not totally 
understood, but an important subset of genes activated by this protein is related to the 
maintenance of redox balance within the cell, GSTs and GPxs are some of the 
enzymes induced by p53 (Polyak et a l, 1997)
Increased levels of GSH were detected after upregulation of Bcl-2 expression 
(Mirkovic et a l, 1997, Wright et a l, 1998) Bcl-2 overexpressing cells are resistant to 
apoptosis, but their sensitivity can be restored by GSH depletion, indicating that 
glutathione plays a pivotal role in resistance It has also been shown that upregulation 
of this protein affects compartmentalisation of GSH, since it can actually stimulate its 
transport to the nucleus (Voehringer et a l, 1998) The presence of GSH in the nuclear 
compartment can inhibit activation of the serine protease AP24, ultimately responsible 
for DNA fragmentation, thus preventing the nuclear alterations characteristic of 
apoptosis (Wright et a l, 1998), exogenous addition of GSH to cells caused reversible 
AP24 inhibition Similar, though not as potent, inhibition was displayed by other 
reducing agents such as N-acetyl cysteine
As stated in the previous section, GST P1 can act as a JNK inhibitor, since JNK is a 
pro-apoptotic signalling molecule, increased expression of GST P1 could constitute 
another mechanism of resistance to apoptosis
It seems therefore that increased levels of GSH and GSH-related enzymes could 
contribute to chemotherapy resistance not only by inactivating anticancer drugs or 
reverting their oxidative effects, but also by making tumour cells resistant to apoptosis
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15 7 Glutathione, cancer and chemotherapy resistance
The role of GSH in cancer is a dual one, which has not been totally clarified on the 
one hand, it protects cells from oxidative agents, which can cause DN^ damage and 
induce carcinogenesis On the other hand, when present in high levels in tumour cells, 
it can render them resistant to chemotherapy and radiotherapy 
There is evidence that GSH levels are elevated in tumours found in bone marrow, 
breast, colon, larynx and lungs Increased expression of GCS has also been found in 
colon, lung, breast and liver among other types of cancer (Balendiran et a l, 2004) A 
study performed in tumours and paired normal tissue from 41 breast cancer patients 
found that reduced and total GSH contents were dramatically increased in tumoral 
tissue, while several enzymes involved in GSH metabolism displayed elevated activity 
(Perqum et a l, 2000) Ovarian tumoral biopsy samples from patients who had 
developed resistance to alkylating agents after treatment presented GSH levels 10- 
fold higher than those found in the samples before treatment (Britten et a l, 1992) 
Depletion of these levels markedly increases tumour sensitivity to anticancer agents
15 71 Studies in cell lines
Several studies have been carried out to measure differences in GSH metabolism 
between resistant cell lines and their sensitive counterparts High intracellular levels of 
GSH have long been known to correlate with resistance to Cyclophosphamide, 
Melphalan, Mechlorethamine, Nitrosourea, quinone-containmg drugs and sulphydryl- 
reactive chemotherapeutic drugs Increased levels of GSH and GSTs were found in 
K562 cells that had developed resistance to Adriamycin (Kalinina et a/, 2001) 
Similarly, increased levels of GSH were detected in squamous lung carcinoma cell 
lines after combination chemotherapy treatment (Kawai et a l, 2002)
It has been demonstrated that by reducing intracellular GSH levels cells become more 
sensitive to anticancer agents (Chen et a l, 1998) The most commonly used inhibitor 
of GSH synthesis is buthionme sulfoximine (BSO) Early studies on cell lines using 
this compound showed changes in the response to chemotherapy after 
coadministration with BSO No effects were observed with a combination of 
anticancer drugs and oxothiazolidine-4-carboxylate (OTZ), a chemical that stimulates 
GSH synthesis in normal cells (Russo et a/, 1986) However, treatment of MCF-7 
cells with OTZ actually decreased GSH levels and rendered the cells more sensitive
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to treatment with Melphalan (Chen et a l, 1998), indicating a differential regulation of 
GSH levels in normal and transformed cells
Treatment with BSO was shown to revert resistance developed by ovarian cancer 
cells to cyanomorpholino adriamycin, an Adriamycm metabolite (Sheehan et a/,
2000), and also that of neuroblastoma cells to Melphalan (Anderson et al f 2000) The 
most exciting fact about this line of treatment is that it appears that the enhancement 
in cytotoxicity observed after GSH depletion affects only cancerous cells, with no 
additional toxicity for normal cells (Chen et a l, 1998)
It should be noted that the measure of steady-state levels of enzymes or substrates 
does not always give an accurate picture of GSH involvement in resistance As an 
example, Gamcsik et al (2002) found that both Vincristine-resistant and Adriamycin- 
resistant MCF-7 cells had lower steady-state levels of GSH than parental cells, while 
4-hydroperoxycyclophosphamide (4-HCP) resistant MCF-7 cells had increased GSH 
metabolism and steady-state levels When the GSH metabolic rate was analysed in 
the Vincnstine and Adriamycm-resistant ceil lines, it was found to be higher than that 
of parental cells and similar to that of 4-HCP resistant cells
As for the enzymes involved in GSH turnover, enhanced GCS activity has been found 
in many resistant cell lines, while the role of GSH synthetase in the development of 
resistance remains to be determined (McLellan et a l , 1999)
Studies performed on GCS have usually been focused on the catalytic (heavy) 
subunit (GCSH), expression of this protein seems to be upregulated in Cisplatin- 
and/or Melphalan-resistant tumour cell lines, usually correlating with increased GSH 
levels An additional feature of Cisplatin-resistant cell lines is that a concomitant 
increase in MRP levels is usually observed This could be explained by a joint 
regulating mechanism, as suggested by the studies of lida et al (2001) A 
hammerhead ribozyme against GCSH was developed and transfected into Cisplatm 
resistant colon cancer cells not only did transfection decrease GSH levels and 
increase sensitivity to Cisplatin, but it also suppressed expression of MRP1, MRP2 
and MDR1, indicating that drug resistance related proteins are co-ordinately 
expressed (MDR1 is not usually found upregulated concomitantly with GSH turnover 
enzymes, it has actually been reported to be downregulated by ROS (Wartenberg et 
a/, 2001)) This theory is further supported by the positive correlation in the 
expression of GST P1 and MRP found by Yang et al (2000) in bladder carcinoma 
Not only coordinated expression, but also functional synergy between these two 
proteins has been reported melanoma cells transfected with GST P1 displayed an 
increased resistance to Vincristine, which was abolished by treating the cells with the 
MRP1 inhibitors Sulfinpyrazone and Verapamil (Depeille et a l, 2004) A similar effect
82
was observed when treating GST P1-transfected HepG2 cells -  rich in MRP2 -  with 
the MRP inhibitors Sulfinpyrazone or Cyclosporin A (Morrow et a l, 2000)
Little is known about the role of the regulatory (light) subunit (GCSL), though it has 
been shown to be co-ordinately upregulated with its heavy counterpart Whether 
increased expression of both subunits is needed for chemotherapy resistance remains 
unknown (McLellan et a/, 1999) Transfection of GCSL in HeLa cells resulted in an 
increase in GSH synthesis and conferred a modest resistance to Adriamycin, but not 
to Melphalan or Cisplatin (Tipms et a \, 1999), suggesting that GCSL may play a 
secondary, drug-specific role in chemotherapy resistance
Involvement of GSH peroxidase in anticancer drug resistance has been reported 
several times (Black et a l , 1991, Kramer et a l, 1988) There are at least four different 
isoforms of Selenium-dependent peroxidases, of which GPx1 is the most widely 
studied Transfection of this enzyme into a breast cancer cell line resulted in 
increased resistance to hydrogen peroxide (H20 2) and the redox cycling drug 
Menadione (Mirault etal, 1991)
Reduction of peroxides or peroxidation products by GSH generates high levels of 
GSSG, which can then be transported out of the cell by members of the MRP family, 
or reduced to GSH by the NADPH-dependent GSH reductase Slight increases in the 
expression of this enzyme have been observed in Cisplatin and quinone resistant cell 
lines (Black et a l , 1991, Hosking et a l, 1990, Colinas et a l, 1996) Inhibition of GSH 
reductase activity by N,N-b\$ (2-chloroethyl)-N-nitrosourea resulted in decreased GSH 
levels, reduced MRP activity and overall increase in Adriamycin toxicity (Vanhoefer et 
al, 1997)
The GGTP-mediated breakdown of glutathione serves as transport of GSH 
constituents between cells, and increased enzymatic activity could result in higher 
levels of circulating substrates for GSH synthesis, and ultimately increased GSH 
levels Selected cell lines display an increase in GGTP activity that correlates with 
elevated intracellular GSH concentration Also, increased levels of GGTP activity have 
been measured in an ovarian cell line resistant to Cisplatin, Chlorambucil and 5-FU 
(Black et a/, 1991) Contradictory reports have arisen after transfection of prostate 
cells with GGTP Bailey et al (1994) found no change in intracellular GSH levels or in 
sensitivity to Melphalan, Cisplatin or Adriamycin in transfected cells However, a more 
recent study (Hamgan et a l , 1999) performed on a different prostate cell line reported 
increased resistance to Cisplatin after transfection
Much as with GGTP, increased activity of 5-oxo-L-prolinase (5-OPase) can result in 
higher levels of GSH precursors and augmented synthesis However, the importance 
of 5-OPase for cancer treatment lies in its ability to release free cysteine from the
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prodrug L-2-oxothiazolidine-4-carboxylate (OTC), the effect of this drug is to increase 
intracellular GSH levels of cells subjected to oxidative stress The interesting fact is 
that this increase only occurs in normal cells, whereas tumour cells see their GSH 
levels depleted An explanation for this selective effect has been provided by the 
study of 5-OPase expression in normal and tumoral tissue by Western blotting and 
immunohistochemistry enzyme levels were found to be considerably lower in tumours 
than in paired normal tissue (Chen et a l , 1998)
1 572RoleofGSTs
GST polymorphisms have been correlated with an increased susceptibility to lung, 
bladder, gastric, colorectal, skin, breast, kidney and liver cancers (Balendiran et a l , 
2004), suggesting a causative and/or associative relationship between GST activity 
and carcinogenesis
Results obtained in polymorphism-carrying patients depend on the particular isoform 
and type of cancer Low or null expression of GST M1 and 3 is linked with an 
increased risk of bladder and lung cancer (Cartwright et a/, 1982, Nakajima et a/, 
1995, Inskip et a l, 1995) Similarly, higher risk of tumour development has been found 
in patients with low GST P activity in gastrointestinal mucosa (Peters et a/, 1990) 
However, no association was found between GST P1 polymorphisms and lung cancer 
(Harris et a/, 1998) Lack of expression of GST T1 was found to correlate with a 
higher incidence of basal cell carcinomas (Strange et a l, 2001), and also with 
bladder, gastro-intestinal tract and smoking-related tumours (Guengerich et a l, 1995) 
On the other hand, individuals expressing normal GST T1 were found to be at a 
higher risk of developing kidney and liver tumours (Landi et a l, 2000)
It is usually not just the presence of a single polymorphism, but rather the combination 
of several ones, which gives a more accurate picture of the risk a certain person is at, 
therefore, it is not unusual to obtain contradictory results about the association of a 
particular polymorphism with the development of disease
Involvement of GSH and GSTs in the development of resistance to chemotherapy is 
highlighted by the fact that increased levels of GSH and/or GST expression, together 
with increased excretion of GSH conjugates, correlates with a decreased sensitivity to 
a number of anticancer agents This can arise as a result of direct conjugation of 
drugs to GSH, or by antioxidant prevention of damage caused by ROS, the latter 
mechanism is of particular importance against alkylating agents such as Cisplatm and 
also redox cycling drugs such as Adriamycin (McLellan et a l, 1999)
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Enhanced conjugation of anticancer drugs to GSH has been reported in numerous 
occasions and in different cancerous tissues (Dirven et a l , 1994, Hayes et a l, 1995, 
Cnubben et a l, 1998), while a negative correlation between expression of GSTs and 
patient survival has been suggested GST expression is commonly upregulated in 
drug-resistant cell lines, cancerous and pre-cancerous tissue, with GST P1 being the 
isoform most often found overexpressed in human tumours such as lung (Mattern et 
a l, 2002) and bladder (Yang et a l, 2000) Moreover, the presence of GST P1 can act 
as a resistant marker positive staining for GST P1 in breast cancer tumour samples 
was correlated with resistance to chemotherapy in a study performed on 42 female 
patients (Su et a l, 2003) Association of increased GST P1 expression and resistance 
to anticancer drugs -  Cisplatin, in this case -  was also found in head and neck 
carcinoma cell lines and tumours (Cullen et a l, 2003) Indeed, deletion of GST P1 in 
mice dramatically enhanced tumour sensitivity to redox cycling drugs like Adriamycin 
(Henderson et a l, 2005)
Contrasting with these findings, expression of GST -  and particularly of GST P1 - was 
measured in a panel of 12 human glioma cell lines unexpectedly, it was found that 
higher enzyme levels did not translate into resistance to several anticancer agents 
Furthermore, increased expression of GST P1 was correlated with enhanced 
sensitivity to Vincristine (Winter et a l, 2000)
In a different approach, a vector containing antisense GST P1 was transfected into a 
human cholangiocarcinoma cell line, resulting in sensitisation to Adriamycin, Cisplatin 
and Melphalan (Nakajima et a l, 2003) Combination assays were performed in the 
same cell line with Adriamycin and the GST P1 specific inhibitor 0 1-hexadecyl-y- 
glutamyl-S-(benzyl)cysteinyl-D-phenyl glycine ethyl ester the inhibitor was shown to 
have a synergic effect on Adriamycin toxicity
Not just presence, but also intracellular localisation of GSTs could be of importance to 
determine the relative sensitivity of tumour cells to chemotherapy recent studies have 
highlighted the fact that cells positive for nuclear GST P were more resistant to 
Adriamycin than those with negative nuclear staining (Goto et a l, 2001) Further 
studies showed that GST P accumulated in the nucleus in response to several 
anticancer drugs, and that the levels of resistance to Cisplatin and Adriamycin - but 
not to Etoposide or 5-FU - were reduced by an inhibitor of nuclear transport (Goto et 
a l, 2002) These results show a drug-specific inhibitory effect of nuclear GST P 
GST P1 -mediated modulation of cell proliferation was also showed in knock out mice 
animals carrying a GST P1 deletion had an increased ERK1/ERK2 kinase activity, 
and they also had a higher number of circulating white blood cells, as compared to the 
wild-type mice Administration of the GST P1 inhibitor y-glutamyl-S-(benzyl)cysteinyl-
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R-phenyl glycine diethyl ester (TLK199) stimulated proliferation of bone marrow cells 
only in wild-type mice (Ruscoe et a l, 2001) In an interesting turn, deletion of GST P1 
in human lung fibroblasts caused the cells to undergo apoptosis, suggesting a 
protective role for GST P1 in this type of tissue (Ishii et a l, 2003)
Those anticancer drugs that are inactivated through a GSH-dependent mechanism 
are listed in Table 15 1 The mechanisms of resistance to anticancer drugs that 
involve GSH and GSH-related enzymes are listed in Table 15 2
Mechanism Substrates Genes involved
Conjugation Melphalan, Cyclophosphamide, 
Mitoxantrone, Thiotepa, 
Chlorambucil, Nitrosoureas
GST (a, n, ti), GCS, MRPs
Chelation Platinum drugs GCS, MRP2
Free radical scavenging 
peroxide inactivation
and Adnamycin, Daunorubicm, 
Mitomycin C, Tiropazamine, 
Bleomycin
GSH peroxidases, non-Se 
GSH peroxidases, GCS, 
MRP1
Detoxification of 
peroxidation products
lipid Anthracyclines and other redox 
cycling agents (same as above)
GST A4-4, GSH peroxidases
GSH-dependent transport Vincnstine, Daunorubicm MRPs, GCS
Table 151 Anticancer agents that are substrates of GSH-related inactivation (adapted from McLellan et 
al, 1999)
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Mechanism GSH-dependent protection Genes involved
Conjugation with GSH and 
export
Free radical scavenging
Reduction of peroxides and 
lipid peroxidation products
GSH-dependent export of 
unconjugated drugs
Regulation of signalling 
pathways
Inhibition of apoptosis
Conjugation is of particular 
importance to inactivate and 
facilitate export of alkylating 
agents Nitrosoureas can be 
demtrosated by GSTs
Radicals generated by redox 
cycling drugs such as 
anthracyclines are
inactivated by GSH
Peroxide (OH ) and lipid 
hydroperoxides are reduced 
and/or conjugated
Vincristine is transported out 
of the cell by a GSH- 
dependent mechanism 
Cisplatin could be 
complexed with GSH, then 
exported
GSH is modulated by redox 
status and can mediate 
direct or indirect modulation 
of JNK, MAPK, ras, NF-kB, 
SAPK, AP-1
GSH inhibits serine protease 
AP24 Bcl-2 over expression 
increases GSH levels and 
promotes nuclear
localisation Inhibition of 
GSH efflux during apoptosis 
prevents cell death
GSTs (a  and n for alkylating 
agents, jx for nitrosoureas)
GSH synthesis enzymes, 
GSH peroxidases
GSTs (non Se GSH 
peroxidases), Se-dependent 
GSH peroxidases, GST A4- 
4
MRP1, MRP2, GCS, GSTs
GST P1, AP endonuclease, 
Keap 1, CL 100
GSH transporters
Table 15  2 Summary of GSH-related chemotherapy resistance mechanisms (adapted from McLellan et 
al, 1999)
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1 6 Conclusion
Several in vitro studies suggest that enzymes involved in drug metabolism play a role 
in determining tumour sensitivity to anticancer agents, indeed, they have the potential 
to inactivate anticancer drugs and thus reduce therapeutic efficacy However, 
enzymatic inactivation is not a rapid process, or at least is not as effective as efflux 
Also, enzymes do get saturated and this reduces the efficiency with which they 
inactivate drugs This poses a question as to whether drug metabolism enzymes are 
capable of detoxifying anticancer drugs inside tumours and contribute to the 
development of drug resistance
At the same time, the drug metabolism machine is a vastly complex network of 
enzymes working simultaneously and able to affect the expression and/or metabolic 
capacity of each other It is rarely found that a single gene conditions the response to 
a certain stimulus or event, it is often the coordinated effect of a number of different 
genes that eventually determines the outcome of a process A clear example of this is 
shown by the contradictory reports on the influence of P450 polymorphisms in 
tumorigenesis It is known that some of their metabolites are active carcinogens, but 
this is clearly not enough to point them as the sole cause of cancer And as the factors 
that contribute to the development of cancer are multiple, it is difficult to find a 
correlation between overexpression or enhanced activity of a certain enzyme and 
carcinogenesis The same is probably true of anticancer drug resistance both are 
such complex and multi-stepped processes that the influence of a certain enzyme is 
unlikely to cause noticeable effects
The presence of drug metabolism enzymes in hepatic and most extrahepatic tissues 
has been established, albeit with significant differences in the proportion of positive 
samples for each isoform The disparities found between reports that evaluate mRNA 
and those that analyse protein can be easily explained by posttranslational regulatory 
events afftecting particular enzymes, while interstudy inconsistencies in mRNA 
expression could be attributed to the use of different primers and the existence of 
alternative splicing variants The differences in immunohistochemical studies could be 
ascribed to the use of different antibodies, cross-reaction between different isoforms, 
presence of posttranslational modifications that alter recognition by antibodies or loss 
of antigens due to sample treatment
It should also be taken into account that levels of enzymes involved in drug 
metabolism are deeply affected by environmental agents, as large mtenndividua! 
differences in expression show, diet, exposure to pollution and medication can 
significantly alter the expression of drug metabolism enzymes Race, gender and
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levels of female hormones (eg, in premenopausal or postmenopausal women) all 
appear to affect their expression to a certain extent as well, particularly in 
cytochromes P450 The presence of a tumour also seems to influence the expression 
of these enzymes in surrounding tissue, as shown by several studies, it appears that 
the inflammatory reaction generated by the tumour, or perhaps the tumour itself, are 
able to modulate expression of different enzymes in the normal adjacent tissue For 
this reason, it should always be noted whether expression in tumour samples is 
compared to normal adjacent tissue or from cancer-free samples 
Overall, great interindividual differences in enzymatic levels are to be expected due to 
the large number of factors affecting their expression Also, the use of different 
techniques contributes to these divergences, adding extra factors that will affect the 
results Nevertheless, most studies report overexpression of drug metabolism 
enzymes in tumour as compared to normal tissue, indicating that they are either 
involved in malignant transformation or serve as markers of the carcinogenic process 
Either way, the more we understand about cytochromes P450 and GSH-related 
enzymes, the more we will gain insight into the origins of cancer and the development 
of specific therapies to combat it
Drug metabolism enzymes indeed appear to play a role in the development of drug 
resistance, but the nature of this role is still obscure These enzymes certainly have 
the potential to constitute a major resistance mechanism but further studies need to 
be carried out before their significance is revealed
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Aims of thesis
1 The main aim of this project was to establish the role that enzymes involved in 
drug metabolism play in the development of resistance to chemotherapy The first 
thing to examine was whether these enzymes were expressed in tumour tissue and 
also whether their expression patterns were altered in cancer as compared to normal 
tissue Analysis of a database obtained from a whole genome microarray experiment 
was performed and the presence of genes of interest investigated
2 The second aim of this project was to determine the role of cytochromes P450 
in chemotherapy resistance Cytochromes P450 are the most relevant enzymes to 
carry out Phase I drug metabolism in humans, that is, they usually transform active 
drugs into less or non-toxic derivatives (although some agents undergo P450- 
mediated activation) Recombinant cytochrome 3A4 (CYP3A4), CYP1B1 and P450 
NADPH reductase (P450R) were used to study the direct metabolism of anticancer 
drugs by these enzymes The toxicity profile of CYP3A4 and P450R-transfected cell 
lines was also studied in order to find out whether this enzyme is able to confer 
resistance to anticancer drugs Transient transfection of CYP1B1 into MCF-7 cells 
and induction of CYP1B1 expression in HL60 cells were also used to investigate 
possible changes in resistance Finally, expression of CYP1B1 was knocked down 
using siRNA technology in MCF-7 cells pulse-selected with Taxotere
3 The third aim of this project was to investigate alterations in the expression of 
enzymes involved in glutathione (GSH) turnover and correlate them with resistance to 
drugs commonly used in cancer chemotherapy Similar to P450s, GSH transferases 
play a prominent role in Phase II metabolism and GSH is one of the most important 
antioxidant molecules present in the cell For this purpose, expression of key enzymes 
involved in GSH turnover was studied in a panel of pulse-selected cell lines and their 
parent counterparts, expression patterns were then correlated with the toxicity profiles 
of each cell type
4 Finally, to gain insight into the changes undergone by tumour cells after 
exposure to chemotherapy, two metabolically competent cell lines were exposed to 
Taxol, Taxotere and Cisplatin weekly over a period of 6 weeks Resistance profiles 
were then determined for a number of anticancer agents and expression of CYP3A4 
and CYP3A5, as well as that of MDR1 and GSH-related enzymes was studied
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Section 2.0
Materials and Methods
2 1 Ultrapure water
Ultrapure water (UHP) was used in the preparation of all media and solutions This 
water was purified to a standard of 12-18 Mil/cm resistance by a reverse osmosis 
system (Millipore Milll-RO 10 Plus, Elgastat UHP)
2 2 Glassware
The solutions used in the various stages of cell culture were stored in sterile glass 
bottles All sterile bottles and other glassware required for cell culture related 
applications were prepared as follows glassware and lids'were soaked in a 2% RBS- 
25 (AGB Scientific) for 1 hour After this time, they were cleansed and washed in an 
industrial dishwasher, using Neodisher detergent and rinsed twice with UHP The 
resulting materials were sterilised by autoclaving as described in Section 2 3
2 3 Sterilisation Procedures
All thermostable solutions, water and glassware were sterilised by autoclaving at 
121°C for 20 minutes at 15 p s i Thermolabile solutions were filtered through 0 22pm 
sterile filters (Millipore, Millex-GV SLGV025BS) Larger volumes (up to 10 litres) of 
thermolabile solutions were filter sterilised through a micro-culture bell filter (Gelman, 
12158)
2 4 Preparation of cell culture media
Basal media used during cell culture was prepared as follows 10X media was added 
to sterile UHP water, buffered with HEPES (N-(2-Hydroxyethyl) piperazine-N-(2- 
ethanesulfomc acid) and NaHC03 as required and adjusted to pH 7 5 using sterile 1 5 
N NaOH or 1 5 N HCI The media was then filtered through sterile 0 22pm bell filters 
(Gelman, 12158) and stored in sterile 500ml bottles at 4°C Sterility checks were 
performed on all bottles of media by inoculation of media samples on to Colombia 
blood agar (Oxoid, CM217), Sabauraud dextrose (Oxoid, CM217) and Thioglycolate 
broths (Oxoid, CM 173) All sterility checks were then incubated at both 25°C and
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37°C These tests facilitated the detection of bacterial, yeast and fungal 
contamination
Basal media were stored at 4°C for up to three months The HEPES buffer was 
prepared by dissolving 23 8g of HEPES in 80ml UHP water and this solution was then 
sterilised by autoclaving Then 5ml sterile 5N NaOH was added to give a final volume 
of 100ml NaHC03 was prepared by dissolving 7 5g in 100ml UHP water followed by 
autoclaving Complete media was then prepared as follows supplements of 2mM L- 
glutamine (Gibco, 11140-0350) for all basal media and 1ml 100X non-essential ammo 
acids (Gibco, 11140-035) and 100mM sodium pyruvate (Gibco, 11360-035) were 
added to MEM Other components were added as described m Table 2 1 Complete 
media was stored at 4°C for a maximum of one month
Cell Line Basal Media FCS
<%)
Additions
A549 DMEM Ham’s F12 1 1 5 N/A
Caco2 MEM 10 Sodium pyruvate, non-essential ammo 
acids, NaHC03, HEPES
HepG2 MEM 10 Sodium pyruvate, non-essential ammo 
acids, L-glutamine
MDA 231 RPMI 1640 10 Sodium pyruvate, non-essential ammo 
acids
MCF-7 MEM 10 Sodium pyruvate, non-essential ammo 
acids, L-glutamme
BEAS-2B LHC-9 Serum
-free
Retinoicacid, Epinephrin
HL60 RPMI 1640 Phenol 
red free
10 L-glutamine
H1299 RPMI 1640 5 Sodium pyruvate
SKLU-1 MEM 5 Sodium pyruvate, non-essential amino 
acids, L-glutamine
Table 2 1 Additional components in media N/A no additions
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25 Cells and Cell Culture
All cell culture work was carried out in a class II laminar airflow cabinet (Holten 
LaminAir) All experiments involving cytotoxic compounds were conducted in a 
cytogard laminar airflow cabinet (Holten LaminAir Maxisafe) Before and after use the 
laminar airflow cabinet was cleaned with 70% industrial methylated spirits (IMS) Any 
items brought into the cabinet were also swabbed with IMS Only one cell line was 
used in the laminar air-flow cabinet at a time and upon completion of work with any 
given cell line the laminar air-flow cabinet was allowed to clear for at least 15 minutes 
before use to eliminate any possibilities of cross-contamination between the various 
cell lines The cabinets were cleaned weekly with industrial disinfectants (Virkon or 
TEGO) and these disinfectants were alternated every month Details pertaining to the 
cell lines used for the experiments detailed in this thesis are provided in Table 2 2 All 
cells were incubated at 37°C and where required, in an atmosphere of 5% C02 Cells 
were fed with fresh media or subcultured (see Section 2 5 1) every 2-3 days in order 
to maintain active cell growth All of the cell lines listed in Table 2 2 are anchorage- 
dependent cell lines except for HL60, which grow in suspension 
BCMV Neo and BCMV 3A4 cells were kindly provided by Dr Katherine Mace, Nestec, 
Switzerland, while MDA EV and MDA R4 cells were a kind gift of Dr Ian Stratford, 
Manchester University, UK
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Cell Line Details Source
Caco2 Colorectal carcinoma ATCC
HepG2 Liver carcinoma ATCC
HL60 Acute promyelocytic leukaemia ECACC
BCMV3A4 Immortalised normal bronchial cells transfected 
with human CYP3A4 cDNA
Dr Katherine 
Mace, Nestec
BCMV Neo Immortalised normal bronchial cells transfected 
with empty vector
Dr Katherine 
Mace, Nestec
MCF-7 Breast adenocarcinoma ATCC
MDA R4 Breast adenocarcinoma transfected with human 
P450 NADPH reductase cDNA
Dr Ian 
Stratford, 
Manchester 
University
MDA EV Breast adenocarcinoma transfected with empty 
vector
Dr Ian 
Stratford, 
Manchester 
University
A549 Lung adenocarcinoma ATCC
H1299 Large cell lung carcinoma ATCC
SKLU-1 Lung adenocarcinoma ATCC
Table 2 2 Cell lines used in this thesis 
2 51 Subculturing of cell lines
The cell culture medium was removed from the tissue culture flask and discarded into 
a sterile bottle The flask was then rinsed out with 1ml of trypsin/EDTA solution 
(0 25% trypsin (Gibco, 043-05090), 0 01% EDTA (Sigma, E9884) solution in PBS 
(Oxoid, BRI4a)) to ensure the removal of any residual media Trypsin was then added 
to the flask, which was then incubated at 37°C, for approximately 5 minutes, until all of 
the cells detached from the inside surface of the flask The amount of trypsin used 
varies with flask size, i e , 1 ml for T25cm2, 2ml for T75cm2 and 5ml for T175cm2 The
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trypsin was deactivated by adding an equal volume of complete media to the flask 
The cell suspension was removed from the flask and placed in a stenle universal 
container (Sterihn, 128a) and centrifuged at 1000rpm for 5 minutes The supernatant 
was then discarded from the universal and the pellet was suspended in complete 
medium A cell count was performed and an aliquot of cells was used to re-seed a 
flask at the required density
Cells growing in suspension were subcultured in a similar way, except that no trypsin 
was used Cells were mixed to ensure homogeneity and a cell count was performed 
An aliquot of cells was then used to re-seed a flask at the required density, topping 
the flask up with fresh medium
2 5 2 Assessment of cell number and viability
Cells were trypsmised, pelleted and resuspended in media An aliquot of the cell 
suspension was then added to trypan blue (Gibco, 525) at a ratio of 5 1 The mixture 
was incubated for 3 minutes at room temperature A 10jil aliquot of the mixture was 
then applied to the chamber of a glass coverslip enclosed haemocytometer Cells in 
the 16 squares of the four grids of the chamber were counted The average cell 
numbers per 16 squares were multiplied by a factor of 104 and the relevant dilution 
factor to determine the number of cells per ml in the original cell suspension Non- 
viable cells stained blue, while viable cells excluded the trypan blue dye as their 
membrane remained intact, and remained unstained On this basis, percentage 
viability was calculated
2 5 3 Cryopreservation of cells
Cells for cryopreservation were harvested in the log phase of growth and counted as 
described in Section 2 5 2 Cell pellets were resuspended in a suitable volume of
FCS An equal volume of a 10-20% DMSO/FCS solution was added dropwise to the 
cell suspension A total volume of 1ml of this suspension was then placed in cryovials 
(Greiner, 122278) These vials were then placed in the vapour phase of a liquid 
nitrogen container, which was equivalent to a temperature of -80°C After a period of 
four hours, vials were removed from the vapour phase and transferred to the liquid 
phase for storage (- 196°C)
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2 5 4 Thawing of cryopreserved cells
A volume of 5ml of fresh warmed growth medium was added to a sterile universal 
The cryopreserved cells were removed from the liquid nitrogen and thawed at 37°C 
The cells were removed from the vials and transferred to the aliquoted media The 
resulting cell suspension was centrifuged at 1,000 rpm for 5 minutes The supernatant 
was removed and the pellet resuspended in fresh culture medium An assessment of 
cell viability on thawing was then carried out (Section 2 5 2) Thawed cells were then 
added to an appropriately sized tissue culture flask with a suitable volume of growth 
medium and allowed to recover overnight The following day, flasks were fed with 
fresh media to remove any non-viable cells
2 5 5 Monitoring of sterility of cell culture solutions
Sterility testing was performed in the case of all cell culture media and cell culture 
related solutions Samples of prepared basal media were incubated at 37°C for a 
period of seven days This ensured that no bacterial or fungal contamination was 
present in the media
2 5 6 Serum Batch Testing
Batch to batch variation is a major problem associated with the use of FCS in cell 
culture In extreme cases this variation may result in a lack of cell growth, whereas in 
more moderate cases growth may be retarded To avoid the effects of the above 
variation, a range of FCS batches were screened for growth of each cell line A 
suitable FCS was then purchased in bulk for a block of work with each particular cell 
line in use Screening involved seeding cells in 96 well plates and determining growth 
as a percentage of a serum with known acceptable growth rate Logarithmically 
growing cells were seeded into a 96 well plate (Costar, 3599) from a single cell 
suspension at a density of 103 cells/well in 100^1 of medium without FCS IOOjiI 
volumes of medium containing 10% or 20% FCS was added to respective wells on the 
96 well plate, resulting in final dilutions of the FCS to 5% or 10%, respectively The
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first column of each plate was maintained as a control where FCS resulting in a 
known acceptable growth rate was used Plates were placed at 37°C in 5% C02, for 5 
days, after which growth was assessed (see section 2 7 4)
2 6 Mycoplasma analysis of cell lines
Cell lines were tested for possible mycoplasma contamination in house by Ms Ame 
Adams and Mr Michael Henry The protocol used is detailed in the following Sections 
2 6 1 and 2 6 2
2 61 Indirect staining procedure for Mycoplasma analysis
Mycoplasma-negative NRK (Normal rat kidney fibroblast) cells were used as indicator 
cells for this analysis The cells were incubated with a sample volume of supernatant 
from the cell lines in question and then examined for Mycoplasma contamination A 
fluorescent Hoechst stain was used in this analysis The stain binds specifically to 
DNA and so stains the nucleus of the cell in addition to any Mycoplasma present 
Mycoplasma infection was indicated by fluorescent bodies in the cytoplasm of the 
NRK cells
2 6 2 Direct staining procedure for Mycoplasma analysis
Direct staining for Mycoplasma analysis involved inoculating samples on to a 
Mycoplasma culture broth (Oxoid, CM403) This was supplemented with 16% serum, 
0 002% DNA (BDH, 42026), 2*ig/ml fungizone (Gibco, 042 05920), 2x103 units 
penicillin (Sigma, Pen-3) and 10ml of a 25% yeast extract solution Incubation was 
carried out at 37°C for a period of 48 hours Samples of this broth were then streaked 
onto plates of Mycoplasma agar base (Oxoid, CM401) that had been supplemented 
as described above The plates were incubated for three weeks at 37°C while 
exposed to C02 The plates were examined microscopically every 7 days The 
appearance of small oval shaped colonies indicated the presence of Mycoplasma 
infection
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2 7 In vitro toxicity assays
Adherent cells in the exponential phase of growth were harvested by trypsinisation as 
described in section 2 51 Cell suspensions containing 1x104 cells/ml were prepared 
in cell culture medium Volumes of 100^1/well of these cell suspensions were added to 
96-well plates (Costar, 3599) using a multichannel pipette Plates were agitated gently 
in order to ensure even dispersion of cells over a given well Cells were then 
incubated overnight at 37°C in an atmosphere containing 5% C02 Cytotoxic drug 
dilutions were prepared at 2X their final concentration in cell culture medium Volumes 
of the drug dilutions (100^1) were then added to each well using a multichannel 
pipette Plates were then mixed gently as above Cells were incubated for a further 6- 
7 days at 37°C and 5% C02 until the control wells had reached approximately 80-90% 
confluency Assessment of cell survival in the presence of drug was determined by 
the acid phosphatase assay (section 2 7 2) The concentration of drug which caused 
50% cell kill (IC50 of the drug) was determined from a plot of the % survival (relative 
to the control cells) versus cytotoxic drug concentration using Calcusyn software 
In the case of non-adherent cells, a cell suspension containing 5x104 cells/ml was 
prepared in cell culture medium lOOpl/well of this suspension were added to 96-well 
plates using a multichannel pipette Plates were agitated gently to ensure even 
dispersion of cells over a given well After an overnight incubation at 37°C in an 
atmosphere containing 5% C02, cytotoxic drug dilutions were added, as explained 
above Cells were then incubated for a further 72 hours and assessment of cell 
survival determined by the XTT assay (section 2 7 3) IC50 values for each drug were 
calculated as above
2 7 1 Combination toxicity assays
Cells were harvested in the exponential phase of growth as described in section 2 5 1 
Cell suspensions containing 1x104 cells/ml were prepared in cell culture medium 
Volumes of 100^1/well of this cell suspension were added into 96-well plates (Costar, 
3599) using a multichannel pipette Plates were agitated gently in order to ensure 
even dispersion of cells over a given well Cells were then incubated overnight at 
37°C in an atmosphere containing 5% C02 Dilutions of cytotoxic drugs and other 
agents were prepared at 4X their final concentration in media Volumes of 50^1 of the 
drug dilution and 50fil of the combination drug dilution were then added to each
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relevant well so that a total final volume of 200^1 was present in each well All 
potential toxicity-enhancing agents were dissolved in DMSO, ethanol or media Stock 
solutions were prepared at approximately 15mg/10ml media, filter sterilised with a 
0 22nm filter (Millex-GV, SLGV025BS) and then used to prepare all subsequent 
dilutions Cells were incubated for a further 6 days at 37°C in an atmosphere 
containing 5% C02 At this point the control wells would have reached approximately 
80-90% confluency Cell number was assessed using the acid phosphatase assay 
(section 2 7 2) or the XTT assay (section 2 7 3)
2 7 2 Assessment of cell number - Acid Phosphatase assay
Following the incubation period of 6-7 days, media was removed from the plates 
Each well on the plate was washed twice with 100|xl PBS This was then removed and 
100fxl of freshly prepared phosphatase substrate (10mM p-mtrophenol phosphate 
(Sigma 104-0) in 0 1M sodium acetate (Sigma, S8625), 01% triton X-100 (BDH, 
30632), pH 5 5) was added to each well The plates were then incubated in the dark 
at 37°C for 2 hours The enzymatic reaction was stopped by the addition of 50^1 of 1N 
NaOH The plate was read in a dual beam plate reader (Synergy HT, Bio-Tek, USA) 
at 405nm with a reference wavelength of 620nm
2 7 3 Assessment of cell number - XTT assay
50 pi of a phenazine methosulphate solution (PMS, Sigma, P9625, 2 5 mM in PBS) 
were added to 5ml of XTT reagent (sodium 3’-{1-[(phenylamino)-carbonyl]-3,4- 
tetrazolium}-bis(4-methoxy-6-mtro)benzene sulphomc acid hydrate, Sigma, X4251, 1 
mg/ml in complete culture medium) immediately before addition to cells This volume 
was enough for one plate After a 72 hour incubation period, 50 pi of this mixture were 
added to each well The plates were then incubated in the dark at 37°C for 4 hours 
After this incubation period, absorbance was read in a plate reader at 450 nm
100
2 8 Safe handling of cytotoxic drugs
Cytotoxic drugs were handled with extreme caution at all times in the laboratory, due 
to the potential risks in handling these drugs Disposable mtrile gloves (Medical 
Supply Company Ltd) were worn at all times and all work was carried out in cytotoxic 
cabinets (Holten LaminAir Maxisafe) All drugs were stored in a safety cabinet at room 
temperature or in designated areas at 4°C The storage and means of disposal of the 
cytotoxic drugs used in this work are outlined in Table 2 3
Cytotoxic Agent Storage Disposal
Adriamycm 4°C in dark Incineration
Daunorubicin 4°C in dark Incineration
Taxol Room temperature in dark Incineration
Taxotere Room temperature in dark Incineration
Vincristine 4°C in dark Incineration
VP-16 Room temperature in dark Incineration
Irinotecan Room temperature in dark Incineration
Cisplatin Room temperature in dark Incineration
5-Fluorouracil Room temperature in dark Incineration
Mitoxantrone Room temperature in dark Incineration
Mitomycin C 4°C in dark Incineration
Table 2 3 Storage and disposal details for chemotherapeutic agents
2 9 Pulse selection of parent cell lines
A number of drug resistant variants were established from the cell lines Caco2 and 
HepG2 by pulse-selection with Taxol, Taxotere and Cisplatin
2 91 Determination of drug concentration for pulse selection
Cells were seeded into twelve 25cm2 flasks at 1 5 x 105 cells per flask and allowed to 
attach overnight at 37°C The following day media was removed from the flask and a
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range of concentrations of appropriate drug was added to the flasks in duplicate 
Complete media was added to two flasks as a 100% survival control Flasks were 
returned to the 37°C incubator for a 4 hour incubation Drug was then removed and 
the flasks were rinsed and fed with fresh complete media The flasks were then 
incubated for 5-7 days until the cells in the control flasks had reached approximately 
80% confluency At this point, medium was removed from the flasks and cells were 
trypsimsed and counted in duplicate as described in section 2 5 2 The concentration 
of drug that caused appropriate cell kill was determined from a plot of the percentage 
survival relative to the control cells versus cytotoxic drug concentration 
Concentrations chosen for pulse selection of Caco2 and HepG2 gave a 70% kill, i e 
IC70 (Table 2 4)
Cell Line Taxotere (ng/ml) Taxol (ng/ml) Cisplatin (ng/ml)
Caco2 160 2560
HepG2 160 1280 2500
Table 2 4 Concentrations used in pulse-selection 
2 9 2 Pulse selection
Cells at low confluency in 75cm2 flasks were exposed to the chosen concentration of 
Taxol, Taxotere or Cisplatin for 4 hours After this period, the drug was removed and 
the flasks were rinsed and fed with fresh complete media The cells were then grown 
in drug-free media for 6 days, refeeding every 2-3 days This was repeated once a 
week for six weeks If the cells had not recovered sufficiently from the previous pulse, 
a week was skipped, but all cell lines received six pulses
2 10 Western blotting 
2101 Whole cell extract preparation
Cells were grown to 80-90% confluency in 75cm2 flasks Media was removed and 
cells were harvested as described in section 2 5 1 Cells were washed twice with ice- 
cold PBS All procedures from this point forward were performed on ice Cells were
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resuspended in 100-200^1 of NP-40 lysis buffer and incubated on ice for 30 minutes 
Table 2 5 provides the details of the lysis buffer Immediately before use, 10^ 1 of the 
100X stocks listed in Table 2 6 were added to 1ml of lysis buffer
Addition required per 500ml stock Final concentration
425ml UHP water -
25ml 1M Tris-HCI (pH 7 5) 50mM Tris-HCI (pH 7 5)
15ml 5M NaCI 150 mM NaCI
2 5ml NP-40 0 5% NP-40
Table 2 5 NP-40 lysis buffer
-  100X stock Preparation instructions
lOOmMDTT 154mg in 10ml UHP
100mM PMSF 174mg in 10ml 100% ethanol
100X Protease inhibitors 2 5 mg/ml leupeptin, 2 5 mg/ml aprotmin, 15 mg/ml 
benzamidine and 1 mg/ml trypsin inhibitor in UHP water
Table 2 6 NP-40 lysis buffer 100X stocks
After incubation on ice, lysates were centrifuged on a bench centrifuge at 14000rpm 
for 15 minutes at 4°C Supernatant containing extracted protein was transferred to a 
fresh chilled eppendorf tube Protein concentration was quantified using the Biorad 
assay as detailed in section 2 10 2 Samples were then stored in aliquots at -80°C
2 10 2 Protein quantification
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 
5000006) as follows A 2mg/ml bov/ne serum albumin (BSA) solution (Sigma, A9543) 
was prepared freshly in lysis buffer A protein standard curve (0, 0 2, 0 4, 0 6, 0 8 and 
1 Omg/ml) was prepared from the BSA stock with dilutions made in lysis buffer 5pl of 
each sample or BSA dilution were pipetted in duplicate into a 96-well plate The Bio- 
Rad reagent was diluted 1 5 in UHP water and 200mI of this dilution were added to
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each well After a 5 minute incubation, absorbance was assessed at 595nm The 
concentration of the protein samples was determined from the plot of the absorbance 
at 595nm versus concentration of the protein standard
210 3 Gel electrophoresis
Proteins for analysis by Western blotting were resolved using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) The Atto dual mini slab kit was used (AE 6450) The 
stacking and resolving gels were prepared as illustrated in Table 2 7 The gels were 
set in clean 9cm x 8cm gel cassettes, which consisted of 2 glass plates separated by 
a rubber gasket to a width of 1mm The resolving gel was added to the gel cassette 
and allowed to set Once the resolving gel had set, stacking gel was poured on top A 
comb was placed into the stacking gel after pouring, in order to create wells for 
sample loading (maximum sample loading volume of 15-20^1)
Components 10% Resolving Gel 5% Stacking Gel
Acrylamide stock 4 6 ml 670jaI
UHP water 5 6ml 2 7ml
1 875 M Tris-HCI pH 8 8 3 5ml -
1 25 M Tris-HCI pH 6 8 - 500nl
10% SDS 140*iL 40nL
10% NH4- persulfate 140|xL 40|xL
TEMED 5 6hL 4|iL
Table 2 7 Preparation protocol for SDS-PAGE gels (2x0 75mm gels)
The acrylamide stock in Table 2 7 consists of a 30% (29 1) ratio of acrylamide bis- 
acrylamide (Sigma, A2792) In advance of samples being loaded into the relevant 
sample wells, 20\iq of protein was diluted in 10X loading buffer Molecular weight 
markers (Sigma, C4105) were loaded alongside samples The gels were run at 250V 
and 45mA until the bromophenol blue dye front was found to have reached the end of 
the gel, at which time sufficient resolution of the molecular weight markers was 
achieved
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210 4 Western blotting
Western blotting was performed by the method of Towbin et al (1979) Once 
electrophoresis had been completed, the SDS-PAGE gel was equilibrated in transfer 
buffer (25mM Tris (Sigma, T8404), 192mM glycine (Sigma, G7126), pH 8 3-8 5) for 
approximately 30 minutes Five sheets of Whatman 3mm filter paper were soaked in 
freshly prepared transfer buffer These were then placed on the cathode plate of a 
semi-dry blotting apparatus (Bio-rad) Air pockets were then removed from between 
the filter paper Nitrocellulose membrane (Amersham Pharmacia Biotech, RPN 303D), 
which had been equilibrated in the same transfer buffer, was placed over the filter 
paper on the cathode plate Air pockets were once again removed The gels were 
then aligned on to the membrane and covered by five additional sheets of transfer 
buffer soaked filter paper, again removing all air pockets The proteins were 
transferred from the gel to the membrane at a current of 34mA at 15V for 30-40 
minutes, until all colour markers had transferred
Following protein transfer, membranes were stained using Ponceau red (Sigma, 
P7170) to ensure efficient protein transfer The membranes were then blocked for 2 
hours at room temperature using 5% milk powder (Cadburys, Marvel skimmed milk) in 
PBS
Membranes were treated with primary antibody overnight at 4°C and a negative 
control where the membrane was exposed to antibody diluent was also performed All 
antibodies were prepared in 1% Marvel in PBS and are listed in Table 2 8 Primary 
antibody was removed after this period and the membranes rinsed 3 times with PBS 
containing 0 5% Tween 20 (Sigma P1379) for a total of 15-30 minutes 
The secondary antibody (anti mouse IgG, Sigma, A6782, used 1 2000, or anti rabbit 
IgG Sigma, A4914, used 1 1000) was then added for 1 5 hour at room temperature 
The membranes were washed thoroughly in PBS containing 0 5% Tween for 15 
minutes
105
Primary Antibody Dilution
CYP3A4 (Chemicon, USA, AB1254) 1 1000
CYP3A5 (Chemicon, USA, AB1279) 1 500
CYP1B1 (Gentest, USA, 458211) 1 500
ß-actm (Sigma, USA, A5441 ) 1 10,000
MDR1 (Santa Cruz, USA, SC-13131) 1 200
GSTP1 (Calbiochem, UK, 354212) 1 200
GSTA1 (Calbiochem, UK, 354206) 1 200
GCSH (Santa Cruz, USA, SC-28965) 1 200
GCSL (Santa Cruz, USA, SC-28966) 1 200
GGTP (Santa Cruz, USA, SC-20639) 1 200
P450R (Santa Cruz, USA, SC-25270) 1 200
Table 2 8 List of Primary antibodies and dilutions
210 5 Enhanced chemiluminescence (ECL) detection
Immunoblots were developed using an Enhanced Chemiluminescence kit (Amersham, 
RPN2109), which facilitated the detection of bound peroxidase-conjugated secondary 
antibody Following the final washing membranes were subjected to ECL A volume of 
3ml of a 50 50 mixture of ECL reagents was used to cover the membrane The ECL 
reagent mixture was completely removed after a period of one minute and the 
membrane wrapped in clingfilm, carefully removing all excess air bubbles The 
membrane was then exposed to autoradiographic film (Kodak, X-OMATS) for vanous 
times (from 10 seconds to 30 minutes depending on the signal) The exposed 
autoradiographic film was developed for 3 minutes in developer (Kodak, LX-24) The film 
was then washed in water for 15 seconds and transferred to a fixative (Kodak, FX-40) for 
5 minutes After another 5-10 minute wash in water, the film was left to dry at room 
temperature
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211 RT-PCR analysis
2111 Preparation of materials for RNA analysis
Due to the labile nature of RNA and the high abundance of RNase enzymes in the 
environment a number of precautionary steps were followed when analysing RNA 
throughout the course of these studies
• General laboratory glassware and plasticware are often contaminated by RNases 
To reduce this risk, glassware used in these studies was baked at 180°C 
(autoclaving at 121°C does not destroy RNase enzymes) for at least 8hr Sterile, 
disposable plasticware is essentially free of RNases and was therefore used for 
the preparation and storage of RNA without pre-treatment Polyallomer 
ultracentrifuge tubes, eppendorf tubes, pipette tips e tc , were autoclaved before 
use All spatulas which came in to contact with any of the solution components 
were baked, chemicals were weighed out onto baked alummium-foil and a stock of 
chemicals for "RNA analysis only" was kept separate from all other laboratory 
agents All solutions (which could be autoclaved) that came in to contact with RNA 
were prepared from sterile ultra-pure water and treated with 0 1% diethyl 
pyrocarbonate (DEPC) (Sigma, D5758) before autoclaving (autoclaving 
inactivates DEPC)
• Disposable gloves were worn at all times to protect both the operator and the 
experiment (hands are an abundant source of RNase enzymes) This prevents the 
introduction of RNases and foreign RNA/DNA in to the reactions Gloves were 
changed frequently
• All procedures were carried out under sterile conditions where feasible
2 1 1 2  Total RNA extraction from cultured cell lines
Adherent cells were grown in 75cm2 flasks until approximately 80% confluent Media 
was then removed and 1ml of TRI reagent (Sigma, T-9424) was added per 75cm2 
flask for 5 minutes ensuring that all cells were covered with the solution TRI reagent 
is a mixture of guanidine thiocyanate and phenol in a mono-phase solution, it 
effectively dissolves DNA, RNA, and protein on lysis of cell culture samples After 
addition of the reagent, the cell lysate was passed several times through a pipette to 
form a homogenous lysate To ensure complete dissociation of nucleoprotem
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complexes, the sample was allowed to stand for 5 minutes at room temperature 
Subsequently, 0 2ml of chloroform (not containing isoamyl alcohol or any other 
additive) per ml of TRI reagent was added to the cell lysate The sample was covered 
tightly, shaken vigorously for 15 seconds and allowed to stand for 2-15 minutes at 
room temperature The resulting mixture was centrifuged at 13,000rpm for 15 minutes 
at 4°C Centrifugation separated the mixture into 3 phases an organic phase 
(containing protein), an interphase (containing DNA) and a colourless upper aqueous 
phase (containing RNA) The aqueous phase was then transferred to a fresh tube and 
0 5ml of isopropanol per ml of TRI reagent used in sample preparation added and 
mixed The sample was then allowed to stand for 5-10 minutes at room temperature, 
followed by centrifugation at 13,000rpm for 10 minutes at 4°C The RNA precipitate 
formed a pellet on the side and the bottom of the tube The supernatant was removed 
and the RNA pellet was washed by adding 1ml (minimum) of 75% ethanol per 1ml of 
TRI reagent The sample was vortexed and centrifuged at 8000rpm for 5 minutes at 
4°C Samples can be stored in ethanol at 4°C for at least 1 week and up to one year 
at -20°C The RNA pellet was air-dried briefly and resuspended in approximately 50jil 
DEPC-treated H20  The RNA was then stored at -80°C until required for PCR 
analysis
2 1 1 3  RNA quantification using Nanodrop
RNA was quantified spectrophotometrically at 260nm and 280nm using the Nanodrop 
A 1|xl aliquot of suitably diluted RNA was placed on the Nanodrop The software 
calculated the amount of RNA present using the fact that an optical density of 1 at 
260nm is equivalent to 40mg/ml RNA An A26o/A28o ratio is used to indicate the purity 
of the RNA, which was always between 1 8 and 2 1
2 1 1 4  Reverse transcription of RNA isolated from cell lines
The following components were used in the reverse transcriptase (RT) reaction for 
RNA isolated from cell lines 1|il oligo (dT)i2.18 primers (1jxg/ml) (Promega, C1101), 
2jil of total RNA (0 5^ig/ml), and 2\i\ of DEPC-H20  were mixed together and heated at 
70°C for 10 min and then chilled on ice to remove any RNA secondary structure 
formation and allow oligo (dT) primers to bind to the poly (A)+ tail on the mRNA 4^ 1 of
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a 5X buffer (consisting of 250mM Tris-HCI, pH 8 3, 375mM KCI and 15mM MgCI2), 2^ 1 
of DTT (100mM), 1jd of dNTPs (10mM each of dATP, dCTP, dGTP and dTTP), 7\x\ of 
water and 1jxl of Moloney murine leukaemia virus-reverse transcriptase (MMLV-RT) 
(Sigma, M1302) were then added to the heat-denatured RNA complex and the 
mixture was incubated at 37°C for 1 hour to allow the MMLV-RT enzyme to catalyse 
the formation of cDNA on the mRNA template The enzyme was then inactivated and 
the RNA and cDNA strands separated by heating to 95°C for 2 min The cDNA was 
used immediately in the PCR reaction or stored at -20°C until required for analysis
2 1 1 5  Polymerase Chain Reaction (PCR) analysis of cDNA formed from mRNA
isolated from cell lines
PCR reactions were set up as 50jj.I volumes using 5 \i\ of cDNA formed during the RT 
reaction (see Section 2 114) cDNA was amplified for varying cycle numbers but 
where possible amplification was carried out in the exponential phase of amplification 
The sequences of all primers used for PCR in this thesis are shown in Table 2 9 
Each PCR reaction tube contained 5nl 10Xbuffer (100mM Tris-HCI, pH 9 0, 50mM 
KCI, 1% Triton X-100), 2 nl 25mM MgCI2, 1 i^l of first strand target primer (250ng/jxl), 
1^ 1 of second strand target primer (250ng/|il), 0 5nl of first strand endogenous p-actin 
control primer (250ng/|xl), 0 5^ 1 of second strand endogenous p-actin control primer 
(250ng/*il), 1^ 1 of 10mM dNTP (Sigma, DNTP-100), 0 5]il of Taq DNA Polymerase 
enzyme (Sigma, D4545) and 31 5^ 1 UHP 5\i\ of cDNA (pre-heated to 95°C for 3min to 
separate strands and remove any secondary structure if the sample had been stored 
at -20°C) was added to the above The mixture was then heated to 94°C for 5min 
(reduces non-specific binding of primers to template) and the cDNA was then 
amplified by PCR (Techne, PHC-3) using the following program
• 94°C for 3mm (denature double stranded DNA)
• 25-35 cycles 94°C for 30sec (denature double stranded DNA),
X°C for 30sec (anneal primers to cDNA),
72°C for 30sec (extension),
• 72°C for 7min (extension)
• Storage at 4°C
Where X is the annealing temperature varied with primer set used
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Gene Length
(bp)
Annealing
Temperature
(°C)
Size
(bp)
Sequence
p-actin 29 55 383 GAA ATC GTG CGT GAC ATT AAG -GAG
(large) AAGCT
22 TCA GGA GGA GCA ATG ATC TTG A
(3-actin 23 55 142 TGG ACA TCC GCA AAG ACC TGT AC
(small) 22 TCA GGA GGA GCA ATG ATC TTG A
CYP1B1 20 49 316 GTA TAT TGT TGA AGA GAC AG
20 AAA GAG GTA CAA CAT CAC CT
Table 2 9 Sequences of pnmers used for PCR
A 10nl aliquot of tracking buffer, consisting of 0 25% bromophenol blue (Sigma, 
B5525) and 30% glycerol in water, was added to each tube of amplified cDNA 
products 20^1 of cDNA products from each tube were then separated by 
electrophoresis at 100mV through a 2% agarose (Sigma, A9539) gel containing 
ethidium bromide (Sigma, E8751), using TBE (22 5mM Tris-HCI, 22 5mM boric acid 
(Sigma, B7901), 0 5mM EDTA) as running buffer Molecular weight markers “<|>-X174” 
Hae III digest (Sigma, P0672) were run simultaneously as size reference When the 
gels were placed on a transilluminator (UVP Transillummator) the resulting product 
bands were visualised as pink bands due to the intercalation of the cDNA with the 
ethidium bromide The gels were photographed and subjected to densitometric 
analysis
2 12 Determination of CYP3A4 activity by HPLC 
2 12 1 Testosterone 6fl-hydroxylase assay
The detection of Testosterone 6fc-hydroxylase activity in the microsomal fraction of 
recombinant insect cells (microsomes) expressing CYP3A4 and P450 NADPH 
reductase (P450R) (Gentest, 456202) or P450R alone (Gentest, 456244) was 
performed according to Baron eta/ (2001) 50 nl of a 520 |iM solution of Testosterone
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(Sigma, T1500) were prewarmed at 37° C in a total incubation mixture volume of 250 
yil containing potassium phosphate buffer (PBS, pH 7 4), MgCI2 (25 mM, 25 \±) and 
NADPH (6 5 mM, 75 p.1) The reaction was initiated by the addition of 100 ^l of a 
1 mg/ml solution of ice-cold microsomes to the incubation mixture, as recommended 
by the manufacturer After 15 minutes incubation, the reaction was stopped by the 
addition of 750 |il of ethyl acetate containing the internal standard Corticosterone 
(Sigma, C2505) A control reaction was carried out using microsomes from cells 
transfected with P450R alone (Gentest, 456244)
The detection of Testosterone 6p-hydroxylase activity in cultured cells was also 
performed according to Baron et al (2001) 5x105 cells were seeded per 75mm2 flask 
and incubated in standard medium for 24 hs at 37° C Hemin (Sigma, H5533) was 
then added to a final concentration of 5 ng/ml and cells cultured for a further 24 hs, it 
provides a heme group and increases the levels of P450 expression The Hemin- 
containmg medium was then replaced with 4 ml of fresh medium and samples 
incubated for 1 hr at 37° C After this period, Testosterone was added directly into the 
culture medium to a final concentration of 100 ^M Following a 3 hr-incubation, 
approximately 5 ml of medium were removed, transferred to a polypropylene tube and 
mixed with 1 ml of ethyl acetate containing the internal standard Corticosterone 
Extraction of the samples was performed with a method adapted from Baltes et al 
(1998) The combination of reaction mixture or medium and ethyl acetate was mixed 
for 5 minutes on a blood-tube mixer and then centrifuged at 4000 rpm for 5 minutes 
After removing 0 75 ml of the ethyl acetate extract, 1 ml of fresh solvent was added to 
the sample, which was again mixed and centrifuged in the same conditions A further
1 ml of the ethyl acetate extract was removed and pooled with the first 0 75 ml, the 
resulting mixture was pipetted into a glass vial and the solvent evaporated under a 
stream of nitrogen The residue was reconstituted with 80 pi of mobile phase prior to 
HPLC analysis Testosterone and 6p-hydroxy testosterone standards of known 
concentration were processed in the same way
2 12 2 Separation of metabolites by HPLC
A Hypersil BDS C18, 3 ¿iM (10 cm x 0 46 cm) analytical column maintained at room 
temperature (Phenomenex, USA) was used for analysis (Whalley et a l , 2001) For 
each sample, a linear mobile phase (1 25 ml/min) gradient [tetrahydrofuran- 
acetomtrile-water (10 10 80, v/v, mobile phase A) changing to tetrahydrofuran-
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acetomtrile-water (1414 72, v/v, mobile phase B)] was run over 10 min, with a further 
3 min run isocratically The column was re-equilibrated with mobile phase A for 2 min 
before injection of the next sample Detection of metabolites was performed by in-line 
UV detection at 255 nm These conditions allow for a total cycle time of 15 min, 
including the 2 min re-equilibration
Mass of 6p-hydroxy testosterone produced was then calculated by interpolation in a 
standard curve CYP3A activity was then calculated as the measured amount of 6p- 
hydroxy testosterone (in pmoles), divided by the total protein content of the sample (in 
milligrams) and by the total reaction time (in minutes)
2 13 Determination of EROD activity by fluorescence
Ethoxyresorufin O-deethylase (EROD) activity was determined in the microsomal 
fraction of recombinant insect cells (microsomes) expressing CYP1B1 and P450 
NADPH reductase (Gentest, 456220) with a method adapted from Yu et al (2004) An 
incubation mixture containing 100 nM PBS buffer, pH 7 4, 5 nM MgCI2, 1 5 nM EDTA 
and 0 2 pM 7-ethoxyresorufin (Sigma, E3763) was prewarmed at 37°C, reaction was 
initiated by the addition of 100 |xl of a 1 mg/ml solution of ice-cold microsomes to the 
incubation mixture, as recommended by the manufacturer After 30 minutes 
incubation, 100 pi of reaction mixture were transferred to an opaque 96-well plate and 
fluorescence determined at 530nm excitation and 590nm emission in a fluorescence 
plate reader (Synergy HT, Bio-Tek, USA) The sample measurements were compared 
to a resorufin (Sigma, R3257) standard curve A control reaction was carried out using 
microsomes from cells transfected with P450 NADPH reductase alone (Gentest, 
456244)
EROD activity of cells in culture was determined as described in Bandiera ef a/ 
(2005) Briefly, cells were incubated with a 400 nM solution of 7-ethoxyresorufin in 
PBS pH 7 4 at 37°C/5% C02 for 30 minutes After incubation, 200 pi of the cell 
supernatant were transferred to an opaque 96-well plate and fluorescence determined 
as before
Resorufin standards of known concentration were included in the analysis and 
processed in the same way EROD activity was then calculated as the measured 
amount of resorufin (in pmoles), divided by the total protein content of the sample (in 
milligrams) and by the total reaction time (in minutes)
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214 Determination of P450R activity with a colorimetric assay
P450R activity was determined in cell extracts by measuring the amount of 3-(4,5- 
Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) converted to 
formazan with a colorimetric assay Briefly, cells were scrapped from a confluent T75 
flask and washed with ice-cold PBS, they were then resuspended in PBS pH 7 4 
containing 1 mM PMSF, 1 mM DTT, 25 \xglm\ leupeptin, 25 ng/ml aprotinm, 150 ng/ml 
benzamidme and 10 ng/ml trypsin inhibitor The cell suspension was sonicated on ice 
with 4 cycles of 30 seconds each, leaving 10 seconds in between cycles, cells were 
then spun down at 14000 rpm for 15 minutes at 4°C 250 of supernatant were 
transferred to a 24-well plate and 25 \i\ of 100 pM MTT were added 25 \i\ of 0 5 mM 
NADPH were then added to each well and the absorbance at 610 nm read 
immediately every 30 seconds during a 5 minute-interval in a plate reader (Synergy 
HT, Bio-Tek, USA) The response was linear for at least 5 minutes (see section 3 5 2) 
A standard curve of formazan standards of known concentration was measured at the 
same time, and the absorbance values obtained interpolated in the standard curve to 
obtain the respective concentration values P450R activity was expressed as nmol 
formazan produced per mg of total protein per min
215 Determination of NADPH content in cell extracts
NADPH levels were determined in cell extracts by measuring the absorbance at 340 
nm using a spectrophotometer Briefly, cells were scrapped from a confluent T75 flask 
and washed with ice-cold PBS, they were then resuspended in PBS pH 7 4 containing 
1 mM PMSF, 1 mM DTT, 25 jig/ml leupeptin, 25 ng/ml aprotinm, 150 ng/ml 
benzamidme and 10 jig/ml trypsin inhibitor The cell suspension was sonicated on ice 
with 4 cycles of 30 seconds each, leaving 10 seconds in between cycles, cells were 
then spun down at 14000 rpm for 15 minutes at 4°C The supernatant contains both 
NADH and NADPH, both of which absorb at 340 nm For that reason, the NADPH 
present in the supernatant is converted to NADP\ which does not absorb at this 
wavelength, by reaction with glutathione reductase With this purpose, an aliquot of 
the supernatant (100 i^l) was incubated in 0 1 M phosphate buffer pH 7 6 with 0 05 
mM EDTA, 0 05 % Tnton X, 5 jiM oxidated glutathione (GSSG) and 5 IU of
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glutathione reductase for 5 minutes at 25°C The absorbance at 340 nm of the 
supernatant was measured (this value represents the total NADPH and NADH 
contents) and the absorbance value of the post-incubation aliquot (representing total 
NADH content) subtracted to determine the total NADPH content A standard curve of 
NADPH standards of known concentration was measured at the same time, and the 
absorbance values obtained interpolated in the curve to obtain the respective 
concentration values NADPH levels were expressed as nmoles NADPH per mg of 
total protein
2 16 Determination of reactive oxygen species (ROS) by fluorescence
2',7-dichlorodihydrofluorescein diacetate (DCFHDA) is a non-fluorescent compound 
that easily enters the cell by free diffusion through the plasmatic membrane, once 
inside the cytoplasm, this compound loses the diacetyl radical by reaction with cellular 
esterases and remains inside the cell The resulting product, 2\7’-
dichlorodihydrofluorescein (DCFH) is not fluorescent per se, but upon reaction with 
reactive oxygen species (ROS), particularly hydroxyl radical and superoxide, it is 
converted to the fluorescent compound dichlorofluorescem For this assay, 1 875 x 
105 cells were seeded per well in a 24-well plate and incubated for 48 hours at 37°C 
After this incubation, the appropriate concentrations of drug were added in 
quadruplicate and the cells incubated a further 4 hours DCFHDA was then added to 
two of the four wells treated with each drug at a final concentration of 30 nM and 
incubated for 40 minutes The plate was then washed three times with PBS 
Fluorescence was then read at 485 nm excitation and 535 nm emission in a 
fluorescence plate reader (Synergy HT, Bio-Tek, USA) The wells containing drug but 
not DCFHDA acted as blanks for each sample ROS production was expressed as % 
increase in fluorescence relative to untreated control cells
217 Drug metabolism by cells and microsomes
Drug metabolism was investigated in the microsomal fraction of recombinant insect 
cells (microsomes) expressing CYP3A4 and P450 NADPH reductase (P450R) 
(Gentest, 456202), CYP1B1 and P450R (Gentest, 456220) or P450R alone (Gentest, 
456244) 50 |xl of a stock solution of the appropriate chemotherapy drug were
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prewarmed at 37° C in a total incubation mixture volume of 250 pi containing 
potassium phosphate buffer (PBS, pH 7.4), MgCI2 (25 mM, 25 pL) and NADPH (6.5 
mM, 75 fxl). The reaction was initiated by the addition of 100 pi of a 1 mg/ml solution of 
ice-cold microsomes to the incubation mixture, as recommended by the manufacturer. 
After an incubation period of either 30 or 60 minutes, the mixture was either filter 
sterilised and used for toxicity assays, or stored at-80°C until extracted for LC/MS 
analysis.
2.17.1 Extraction of Adriamycin-containing samples for LC/MS analysis
The frozen microsomal preparation was thawed. 20 pi of 33% silver nitrate were then 
added to the extraction tube, followed by 100 pi of Daunorubicin, which acted as an 
internal standard. The pH of the mixture was brought to appropriate levels by the 
addition of 100 |xl of ammonium formate buffer (6.3 % ammonium formate, pH 8.5) 
and 700 pi of ice-cold isopropanol were then added to each tube. The mixture was 
then extracted with 1.4 ml chloroform, mixed on a blood tube mixer for 5 minutes and 
centrifuged at 4000 rpm for another 5 minutes. The liquid was then separated into two 
layers, of which the bottom layer contains the drug. Approximately 1.1 ml of liquid 
from the bottom layer was removed using a glass Pasteur pipette and transferred to a 
glass vial and the solvent evaporated under a stream of nitrogen. Adriamycin 
standards of known concentrations were processed in the same way. Samples were 
reconstituted with 80 pi of mobile phase and injected into the LC/MS for analysis.
2.17.2 LC/MS analysis
The LC-MS instrument used was a GE Healthcare (Amersham Biosciences) Ettan™ 
Multi Dimensional Liquid Chromatographic system (MDLC) interfaced to 
ThermoFinnigan™ PDA detector and a LTQ™ Mass Spectrometer. It was integrated 
into and operated from Thermo Electron’s Xcalibur™ software. The chromatographic 
separation was performed on a Phenomenex® Prodigy ODS(3) 100 A, 5pm, 150 x 2.1 
mm column with a mobile phase of 72:28:0.1 (v/v/v) water-acetonitrile-formic acid 
delivered isocratically at a flow-rate of 200 pl/min. A 20 ul injection volume was used 
automatically through the MDLC autosampler.
Samples were analysed on the mass spectrometer using electro spray ionisation 
(ESI). The sheath gas, auxiliary gas and sweep gas flow rate (arbitrary units) for the 
ESI unit were set to 30, 10, and 1.9 units. The ESI Spray Voltage was 4.5 kV. The
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capillary temperature was 300 °C and the capillary voltage was 39 V Mass spectral 
data were collected in the scan range 200-700 m/z Selected reaction monitoring 
(SRM) mode was used for quantification using the transition ion m/z 544-^397, the 
[M+H+] Adriamycin adduct and 528->363, the [M+H+] Daunorubicin adduct The 
Adriamycin aglycone metabolite was identified by quantification of the ion with a m/z 
of 414
218 Transfection of mammalian cells with exogenous DNA
In order to understand the role of CYP1B1 more clearly, a vector containing the target 
cDNA sequence was transiently transfected into MDA R4 and MCF-7 cells to 
exogenously increase the level of expression of this gene A plasmid containing the 
CYP1B1 cDNA sequence was obtained from Dr Thomas Friedberg (Fig 2 1) and a 
control empty vector was generated from it (see Section 2 18 1) A plasmid containing 
the cDNA sequence for green fluorescent protein (GFP) was purchased from Open 
Biosystems (pEGFP-C1), this plasmid was used to optimise transfection conditions 
and check for efficiency of transfection Stock plasmid was produced by transforming 
competent JM109 cells, growing up a large stock of these and isolating the plasmid 
from them The isolated plasmid was then transfected into the chosen cell line
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SV40 on f1 orj BGH pA
Figure 2.1: Structure of the CYP1B1 plasmid.
2.18.1 Generation of an empty vector plasmid
Digestion of the CYP1B1 plasmid was performed with several restriction enzymes in 
order to find two that would cut the DNA sequence at one site only, linearising the 
plasmid. Generation of linearised plasmid was checked by TAE low melt 1% gel 
electrophoresis of the digestion fragments using the appropriate markers. The 
restriction enzymes Xba I and Acc 65 I were chosen for the next step, where 5 |ig of 
the CYP1B1 were digested with both endonucleases for 1 hour at 37°C to remove the 
gene coding sequence. The restriction digest was again analysed by electrophoresis 
and revealed the presence of the expected 7.2 kb and 1.6 kb fragments, 
corresponding to the vector backbone and the released CYP1B1 cDNA, respectively. 
The restriction digest was heated at 72°C for 10 minutes and placed on ice for 1 
minute. After this step, 1 ¿il of Klenow enzyme was added, together with 20 jil Klenow 
buffer and 1 nl DNTPs. This mixture was incubated for 10 minutes at room 
temperature and then heated at 72°C and placed on ice as before. 2 ¿il of ligase were 
added to the previous solution and combined with 20 \l\ ligation mix. The mixture was 
incubated overnight at 4°C. Ligation of the plasmid was checked by electrophoresis, 
comparing against undigested and linearised plasmid.
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2 18 2 Plasmid preparation
2 18 21 Transformation of JM109 cells
A bacterial cell suspension (100 nl) of competent JM109 (Promega, L2001) was 
mixed with 20 ng DNA and placed on ice for 40 min after which the mixture was heat- 
shocked at 42°C for 90 seconds and then placed on ice for 3 minutes LB broth (1 ml) 
((10 g Tryptone (Oxoid, L42), 5 g Yeast Extract (Oxoid, L21) 5 g NaCI (Merck, 
K1880814))/litre LB, autoclaved before use) was added to the competent cell 
suspension and incubated at 37°C for 1 hour Different volumes of this suspension 
were spread on selecting agar plates (LB agar containing 100 mg/ml Ampicillin) and 
incubated overnight at 37°C Single colonies that grew on these selecting plates were 
incubated into 5 ml LB broth containing Ampicillin and grown for 8 hours with shaking 
at 37°C, cells were then subject to a DNA mini preparation (see section 2 18 2 2) or 
large scale preparation (Section 2 18 2 3) For a large scale DNA preparation this 
culture was then inoculated into 270 ml LB broth containing Ampicillin (100mg/ml) in a 
1 L baffled flask with shaking overnight at 37°C
218 2 2 DNA Mmiprep of plasmid DNA
The Qiagen Plasmid DNA Extraction Mini Kit (Qiagen, 12143) was used according to 
the manufacturer’s instructions to isolate plasmid DNA from a 5 ml culture grown 
overnight in LB broth containing selection antibiotic with shaking at 37°C After 
incubation, the cells were pelleted by centrifugation at 8,500 rpm for 3 minutes 
Pelleted cells were resuspended in 250 ii\ of buffer P1 and the cell suspension was 
transferred to a microcentrifuge tube To this solution, 250 p.\ buffer P2 were added 
and mixed gently A volume of 350 buffer N3 was then added to the solution and 
the tube was mixed immediately This mixture was centrifuged for 10 minutes at 
13,000 rpm The supernatant was applied to a QIAprep spin column and centrifuged 
for 60 seconds The flow-through was discarded The column was washed by adding 
500 \i\ buffer PB and centrifuging for 60 seconds Again, the flow through was 
discarded This step was repeated with 750 ¿il buffer PB The column was centrifuged 
for a further 60 seconds to remove the remaining wash buffer and was then placed in 
a clean microcentrifuge tube To elute the DNA, 50 nl of buffer EB were added to the 
column The column was let stand for 60 seconds and then centrifuged for 60
118
seconds The DNA concentration of the eluate was determined by measuring the 
O D 26onm Plasmid was stored at-20°C until required
218 2 3 DNA Maxiprep of plasmid DNA
Plasmid DNA was purified using an Endofree Plasmid Maxi kit (Qiagen, 12362) 
Following growth of plasmid culture in 270 ml Ampicillin-containing LB broth in 1L 
baffled flask with shaking overnight at 37°C, the culture was split into 2 x 250 ml 
centrifuge bottles and spun at 3,500 rpm for 15 minutes at 4°C Pellets were 
processed immediately or stored at -20°C until required
The bacterial pellet was resuspended in 10 ml buffer P1 To this suspension, 10 ml 
buffer P2 was added, mixed gently and incubated at room temperature for 5 minutes 
A volume of 10 ml chilled buffer P3 was then added to the lysate and mixed gently 
and immediately The lysate was poured into the barrel of a QIAfilter cartridge and 
incubated at room temperature for 10 minutes The cap from the QIA filter outlet 
nozzle was then removed and the plunger gently inserted into the cartridge The cell 
lysate was filtered into a 50 ml tube To the lysate, 2 5 ml buffer ER were added and 
mixed by inverting repeatedly This mixture was incubated on ice for 30 minutes A 
Qiagen-tip 500 column was equilibrated by applying 10 ml buffer QBT and the column 
was allowed to empty by gravity flow The filtered lysate was then applied to the 
Qiagen-tip and also allowed to enter the resin by gravity flow The Qiagen-tip was 
washed twice with 30 ml buffer QC The DNA was then eluted by addition of 15 ml 
buffer QN and the eluate was collected in a 30 ml tube The DNA was precipitated by 
adding 10 5 ml isopropanol to the DNA solution, which was then mixed and 
centrifuged at -10,000 rpm for 30 minutes at 4°C The DNA pellet was washed with 5 
ml of 70% ethanol and again centrifuged at ~10,000rpm for 10 minutes The pellet 
was then air-dried and dissolved in 500 nl buffer TE The DNA concentration was 
determined by measunng the OD260nm
2 18 3 Optimisation of plasmid transient transfection
Transient transfection was initially optimised for MDA R4 cells Cell suspensions of 
different concentrations (5 x 104, 1 x 105 and 2 x 105 cells/ml) were prepared in 
complete growth medium, 5 ml of these suspensions were seeded in a T25 flask 
Lipofectamine 2000 (Invitrogen, 11668019) and GFP plasmid DNA were prepared
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with the volumes of Lipofectamine 2000 and cDNA being varied Different amounts of 
plasmid DNA and Lipofectamine 2000 were tested in order to ascertain the most 
efficient transfection conditions, as follows,
• 4*igGFPcDNA 10 nl Lipofectamine 2000
• 8 |ig GFP cDNA 20 nl Lipofectamine 2000
Briefly, the plasmid was incubated at room temperature in serum-free medium 
(OptiMEM) for 5 minutes The appropriate volume of Lipofectamine 2000 was also 
incubated in OptiMEM in the same conditions Both solutions were combined, mixed 
gently and allowed to form complexes over a 20-minute incubation at room 
temperature A 1 ml aliquot of this complex was added to each T25 flask and mixed 
gently The cells were trypsmised 48 hours after transfection, diluted to a 
concentration of 200 cells/^il and loaded onto a Guava flow cytometer (Guava 
Technologies, USA) A total of 5000 cells per sample were counted and plotted with 
the Guava Express program as green fluorescence versus forward scatter The 
proportion of green fluorescent cells was calculated by the Guava software and 
expressed as % of the total number of cells The conditions chosen were 1 x 105 
cells/ml, 4 ng GFP cDNA 10 \x\ Lipofectamine 2000, which gave over 50% 
transfection efficiency
The transient transfection protocol was also optimised for MCF-7 cells To this end, 
cell suspensions of different concentrations were prepared at different concentrations 
(1 x 105, 2 x 105 and 4 x 105 cells/ml) in complete growth medium, 2 ml of these 
suspensions were seeded 24 hours before transfection in each well of a 6-well plate 
Again, different amounts of plasmid DNA and Lipofectamine 2000 were tested in order 
to ascertain the most efficient transfection conditions, as follows,
• 2 5 jig GFP cDNA 9 \l\ Lipofectamine 2000
• 5|xgGFPcDNA 18 \i\ Lipofectamine 2000
A 500 \i\ aliquot of these complexes was added to each well of a 6-well plate and 
mixed gently The cells were trypsmised 48 hours after transfection and loaded onto a 
Guava flow cytometer, as before The proportion of green fluorescent cells was 
calculated by the Guava software and expressed as % of the total number of cells 
The conditions chosen were 2 x 105 cells/ml, 2 5 *ig GFP cDNA 9 |xl Lipofectamine 
2000, which gave over 50% transfection efficiency
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2 19 RNA interference (RNAi)
RNAi using small interfering RNAs (siRNAs) was carried out to silence the expression 
of specific genes The siRNAs used were chemically synthesized and purchased from 
Ambion Inc These siRNAs were 21-23 bps in length and were introduced to the cells 
via reverse transfection with the transfection agent siPORT™ NeoFX™ (Ambion inc , 
4511)
2191 Transfection optimisation
In order to determine the optimal conditions for siRNA transfection, an optimisation 
with an siRNA for kinesin (Ambion Inc , 16704) was carried out for each cell line Cell 
suspensions were prepared at 5 x 104 and 75 x 104 cells per ml Solutions of 
negative control and kinesin siRNAs at a final concentration of 30 nM were prepared 
in optiMEM (Gibco™, 31985) NeoFX solutions at a range of concentrations were 
prepared in optiMEM in duplicate and incubated at room temperature for 10 minutes 
After incubation, either negative control or kinesin siRNA solution was added to each 
NeoFX concentration, these solutions were mixed well and incubated for a further 10 
minutes at room temperature Replicates of 10 \i\ of the siRNA/NeoFX solutions were 
added to a 96-well plate The cell suspensions were then added to each plate at a 
final cell concentration of 5 x 103 and 7 5 x 103 cells per well The plates were mixed 
gently and incubated at 37°C for 24 hours After this period, the transfection mixture 
was removed from the cells and the plates were fed with fresh medium The plates 
were then assayed for changes in proliferation at 72 hours using the acid 
phosphatase assay Optimal conditions for transfection were determined as the 
combination of conditions which gave the greatest reduction in cell number after 
kinesin siRNA transfection and also the least cell kill in the presence of transfection 
reagent The optimised conditions for the cell lines are shown in Table 2 10
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Cell line Seeding density per Volume NeoFX per well (nl)
well
MCF-7 Txt 7 5 x 103 06
Tab le  2 1 0  Optimised conditions for siRN A transfection
219 2 Toxicity assays on siRNA-transfected cells
To assay for changes in sensitivity to chemotherapeutic agents, siRNA experiments in 
96-well plates were set up using the optimised conditions and the appropriate siRNAs, 
as listed in Table 2 11 Transfection medium was removed after 24 hours and 
replaced with fresh growth medium Concentrations of the chemotherapeutic agent 
(2X) were added to the plates in replicates of four 48 hours after transfection The 
plates were assayed for changes in proliferation at 72 hours using the acid 
phosphatase assay
Target name Ambion IDs
Scrambled Negative control #2
CYP1B1 1 2253
CYP1B1 2 105952
CYP1B1 3 112548
Tab le  2 11 List of s iRN As used
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2 20 Statistics
Analysis of the significance of the difference in the mean IC50 value calculated from 
toxicity assays was performed using an unpaired, two-tailed student t-test assuming 
unequal variances, which was run on Microsoft Excel
A p value > 0 05 was deemed not significant 
A p value < 0 05 was deemed significant 
A p value < 0 005 was deemed highly significant
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ISection 3.0
Results
/
3.1 Expression of drug metabolism-related genes in normal 
and tumour breast tissue
Expression of enzymes involved in drug metabolism has been readily detected in 
every different type of tissue studied to date, both normal and tumour, techniques 
employed for detection include RT-PCR, Western blot, immunocytochemistry and 
immunohistochemistry Enzymatic activity measurements have also been performed 
in tissue homogenates and/or isolated microsomes, which are cell fractions mainly 
composed of endoplasmic reticulum membranes Although the presence of metabolic 
enzymes in both normal and tumour tissue has been demonstrated, reports 
attempting to compare the relative expression of these enzymes in malignant versus 
normal tissue have generated contradictory results
Microarray technology constitutes a more recent approach for the detection and 
quantification of gene expression in a particular type of tissue This technique allows 
for direct analysis of the expression of thousands of different genes at the same time, 
it is therefore a powerful tool for the study of differential patterns of expression in 
normal and tumour tissue
3 11 Analysis of drug metabolism-related genes in normal and tumour breast 
tissue using microarrays
Whole genome expression microarrays were used in our centre in an attempt to 
identify differences in the expression profiles of normal and malignant breast tissue 
samples This study involved the analysis of 106 breast cancer biopsies, of which 84 
were classified as invasive ductal carcinoma, 17 were invasive lobular and 5 were 
tumours of special type (2 tubular and 3 mucinous) Samples were removed pnor to 
any treatment with Tamoxifen or chemotherapeutic agents Information was gathered 
regarding tumour size, grade, presence of lymph node metastasis, oestrogen receptor 
staining and age of patient at diagnosis, and the follow-up information was also 
recorded Microarray analysis was performed on all 106 cases and also on 20 normal 
breast tissue specimens Following preliminary analysis, 2 tumour specimens and 3 
normal specimens were removed from the study Extraction of mRNA from tissue 
samples was performed by Dr Lorraine O’Dnscoll and Dr Elaine Kenny, while 
microarray testing was carried out by Dr Patnck Gammell, Dr Padraig Doolan and
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Helena Joyce Data analysis was performed by Mr Jai Prakash Mehta and Mr Eoin 
Ryan Correlation analysis was performed by Dr O’Dnscoll
The presence of several different drug metabolism-related enzymes was detected in 
both normal and tumour tissue, as shown in Tables 31 1 , 3 1 2  and 3 1 3
Gene ID Gene name Normal (%) Tumour (%)
NM_000499 CYP1A1 23 5 6 7
NM_000761 CYP1A2 88 96
NM_000104 CYP1B1 100 100
NM_000762 CYP2A6 35 3 30 5
NM_000767 CYP2B6 0 4 8
NM_000770 CYP2C8 11 8 4 8
NM_030878 CYP2C8 59 31 4
NM_000771 CYP2C9 176 57
NM_000772 CYP2C18 412 152
NM_000106 CYP2D6 11 8 52 4
AF182276 CYP2E1 47 77
NM_000775 CYP2J2 35 3 79
NM_024514 CYP2R1 11 8 33 3
BCO12027 CYP2U1 0 1
NM_017781 CYP2W1 47 33 3
NM_017460 CYP3A4 58 8 61 9
NM_022820 CYP3A43 11 8 95
NM_000777 CYP3A5 58 8 133
NM_000765 CYP3A7 23 5 30 5
NM_000941 NADPH cytochrome P450 oxidoreductase 82 95
T ab le  3 1 1  Expression of members of the P450 superfamily expressed in breast tissue sam ples as 
percentage of sam ples positive for each particular gene
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Gene ID Gene name Normal (%) Tumour (%)
NM_000846 Glutathione transferase A1 23 5 18 1
NM_000847 Glutathione transferase A3 59 10 5
NM_001512 Glutathione transferase A4 100 100
NM_015917 Glutathione transferase K1 100 100
NM_000561 Glutathione transferase M1 94 1 76 2
NM_000848 Glutathione transferase M2 941 95 2
A1459140 Glutathione transferase M3 94 81
NM_000850 Glutathione transferase M4 52 9 21 9
NM_000851 Glutathione transferase M5 100 92 4
NM_004832 Glutathione transferase 01 100 100
NM_000852 Glutathione transferase P1 100 100
NM_000853 Glutathione transferase T1 76 5 80
NM_000854 Glutathione transferase T2 23 5 39
NM_001498 Gamma glutamyl cysteine synthetase, heavy subunit 100 98 1
NM_002061 Gamma glutamyl cysteine synthetase, light subunit 100 981
NM_005265 Gamma glutamyl transpeptidase 88 2 971
NM_000581 Glutathione peroxidase 1 100 100
NM_002083 Glutathione peroxidase 2 23 5 50 5
NM_002084 Glutathione peroxidase 3 94 1 981
NM_002085 Glutathione peroxidase 4 100 100
NM_003996 Glutathione peroxidase 5 59 1 9
NM_000637 NADPH Glutathione reductase 471 61
Tab le  3 1 2  Expression of glutathione-related genes in breast tissue sam ples expressed as percentage 
of sam ples positive for each particular gene
Gene ID Gene name Normal (%) Tumour (%)
NM_001621 Aryl hydrocarbon receptor 100 981
NM_014862 Aryl hydrocarbon receptor nuclear translocator protein 2 17 6 75 2
Tab le  3 1 3  Expression of drug metabolism-related transcnption factors in breast tissue samples 
expressed as percentage of samples positive for each particular gene
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As seen in the above tables, presence of drug metabolism-related genes is a 
common event in both normal and tumour tissue Some of these genes also show 
differential regulation, their expression levels significantly changed in malignant as 
compared to normal tissue Amongst the P450s, CYP2C8, CYP2D6, CYP2E1 and 
CYP2J2 show increased frequency of expression in tumour as compared to normal 
tissue, on the other hand, CYP1A1, CYP2C18, CYP2W1 and CYP3A5 are more 
commonly found in normal than in tumour tissue As for the glutathione (GSH)-related 
genes, only two appear to be differentially regulated in tumour and normal tissue 
Expression of GSH transferase (GST) M4 is less frequent in tumour than in normal 
samples, while that of GSH peroxidase 2 is more common in tumour tissue The aryl 
hydrocarbon receptor nuclear translocator protein 2 is also considerably more 
frequent m tumour than in normal samples, suggesting that it could be used as a 
biomarker of disease
Alterations in expression can be seen in a different aspect in Table 3 14, which 
shows significant changes in the expression of genes involved m drug metabolism as 
detected in normal and tumour tissue In this table, changes in expression are stated 
as fold change between normal and tumour sample values, these values are related 
to the intensity of microarray probe binding and are expressed in arbitrary units For 
every gene of interest, the microarray platform used has 11 different probes, Table 
3 14 refers to the results obtained with specific probes, hence the existence of more 
than one entry for a single gene
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Probe set Gene name Normals Tumours
Fold
change p value
202435_s_at CYP1B1 649 973 1.5 0.018
214320_x_at CYP2A6 37 472 12.8 0.008
1494_f_at CYP2A6 37 394 10.7 0.023
200736_s_at Glutathione peroxidase 1 4152 1867 -2.2 <0.001
214091_s_at Glutathione peroxidase 3 2159 169 -12.8 <0.001
201348__at Glutathione peroxidase 3 3189 210 -15.2 <0.001
201106_at Glutathione peroxidase 4 5192 2084 -2.50 <0.001
225609_at Glutathione reductase 259 494 1.9 <0.001
235405_at Glutathione S-transferase A4 58 173 3.0 <0.001
202967_at Glutathione S-transferase A4 314 204 -1.5 0.005
217751_at Glutathione S-transferase kappa 1 1294 953 -1.4 0.027
227163_at Glutathione S-transferase omega 2 60 323 5.3 <0.001
203815_at Glutathione S-transferase theta 1 550 242 -2.3 0.019
201415_at Glutathione synthetase 273 491 1.8 <0.001
Tab le  3 .1 .4 : List of drug metabolism-related genes with significant changes in expression levels in 
tumour relative to normal breast tissue. Fold change is calculated as intensity values of nomal/intensity 
values of tumours.
As can be seen in list of genes in Table 3.1.4, frequency of expression does not 
necessarily correlate with changes in the expression levels of a particular gene; many 
of the genes listed in Tables 3.1.1-3.1.3 are not differentially expressed in malignant 
as compared to normal tissue. The P450s in this list are upregulated in tumour tissue, 
in accordance with the general tendency observed in P450 expression studies. The 
GSH-related genes, on the other hand, appear to be preferentially downregulated in 
tumour tissue, with the exception of GSH reductase, GST omega 2, GSH synthetase 
and one of the probes of GST A4.
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For those genes that were significantly expressed (i e , present in 15-85% of 
samples), the possibility of a correlation between level of expression and overall 
survival, relapse-free survival, relevance as a positive (good) or negative (bad) 
prognostic factor, age at diagnosis, oestrogen receptor status, lymph node spread, 
tumour type, tumour size and tumour grade was analysed The results are shown in 
Tables 3 15 and 3 16
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mRNA OS G/B RFS G/B Age at 
Diagnosis
ER Status Lymph Node Tumour 
Spread Type
Tumour Size Tumour
Grade
CYP2A6 N N/A N N/A N N N N N N
CYP2C8 N N/A N N/A N N N N N N
CYP2C18 N N/A N N/A N N N N N N
CYP2D6 N N/A N N/A N Y
(ER+)
N N N, but p=0.053 
(p a  smaller)
N
CYP2E1 N N/A N N/A N N N N N N
CYP2J2 N N/A N N/A N N N N N
CYP2R1 N
(but p=0.0814)
P -  good N N/A N N N N N N
CYP2W1 N N/A N N/A N N N N N N
CYP3A4 N N/A N N/A N N N N N N
CYP3A7 N N/A N N/A N N N N N N
ARNT2 Y
(p=0.0018)
G Y
(p=-0.0094)
G N N but p=0.052 
(p a  ER+)
N N p a  lower 
grade
Tab le  3 .1 .5 : Correlation between m RNA expression of P450s and A R N T2  and overall survival (OS), relapse-free survival (R F S ), age at diagnosis, oestrogen receptor (E R )  
status, lymph node spread, tumour type, tumour size and tumour grade. G : good prognostic factor. B: bad prognostic factor, a: directly proportional to. p: probability value. 
Y : yes. N: no. N/A: not analysed.
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mRIMA OS G/B RFS G/B Age at Diagnosis ER Status Lymph Node 
Spread
Tumour
Type
Tumour
Size
Tumour
Grade
GSTA1 Y
(p=0.0028)
B Y
(p=0.0131)
B N N N N N
GSTM1 N N/A N N/A N N N N N N
GST M3 N N/A N N/A N N N N N N
GST M4 N N/A N N/A Y
(p=0.030; older age)
N --------- N N N
GST T1 N N/A N N/A N N N
(but p=0.054)
N N N
GSTT2 N N/A N N/A Y
(p a  older patients)
N N N N N
Glutathione Peroxidase 2 N N/A N N/A N N N N N
NAPDH Glutathione 
Reductase
N N/A N N/A N N N N N N
Tab le  3 .1 .6 : Correlation between GSH-related gene expression and overall survival (O S), relapse-free survival (R F S ) , age at diagnosis, oestrogen receptor (E R )  status, 
lymph node spread, tumour type, tumour size and tumour grade. G : good prognostic factor. B: bad prognostic factor, a: directly proportional to. p: probability value. Y : yes. 
N: no. N/A: not analysed.
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As seen in the previous tables, both ARNT2 and GST A1 significantly correlate with 
patient survival Patient disease-free survival was plotted relative to the presence or 
absence of GST A1 and ARNT2 (Figs 3 1 1 A and B)
Survival Functions
0 1000 2000 3000
cendfsur
B Survival Functions
Aryl hydrocarbon 
receptor nuclear 
translocate i2 202986_at
 Absent
 Present
-(- Absent-censored 
-f- Present-censored
cendfsur
Figure 3 11 Censored disease-free survival data of patients with positive (present) or negative (absent) 
expression of G S T  A1 (A ) and A RN T2 (B ) Cum survival cumulative survival C end fsu r censored 
disease-free survival
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Fig 3 11 shows graphs that present “censored” data this means that the data have 
been corrected by taking into account those patients for whom complete follow-up 
information was not available This is a common event in this type of studies some 
patients move to a different place, or no longer attend follow-up clinics Their data are 
therefore included in the study, but only up to the last time that information was 
available on their status After that, they’re no longer considered for the statistics 
calculations
As seen in these graphs, presence of GST A1 is a strong predictor of poor prognosis, 
while ARNT2 is associated with a longer period of disease-free survival
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3 2 Anticancer drug metabolism by cytochromes P450
A number of chemotherapeutic drugs are metabolised by cytochromes P450, among 
them, Adriamycin has been reported to undergo metabolism by CYP3A4 to generate 
less active compounds (Baumhakel et al, 2001) In contrast, 5-fluorouracil is 
metabolised by enzymes involved in thymidine synthesis and catabolism and is not a 
substrate of P450s Even though expression of CYP1B1 has been reported to confer 
resistance to Taxotere, no CYP1B1 metabolites of this drug have been descnbed to 
date
Insect cells are widely used to express recombinant human proteins, as they can 
perform post-translational modifications in a similar -  albeit not identical - way to 
mammalian cells In these cells, recombinant baculovirus particles are used as 
vectors to transfect foreign cDNA
Recombinant insect cells have been developed, which are infected with baculovirus 
carrying human cytochrome P450 and P450 NADPH reductase (P450R) or P450R 
cDNA alone, control cells are transfected with wild type baculovirus containing no 
foreign cDNA The microsomal fractions of these cells, which consists of fragments of 
endoplasmic reticulum, display high levels of P450 activity and are commercially 
available These fractions, termed microsomes, were used to study the metabolism of 
anticancer drugs by cytochromes P450 and P450R
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3 21 Drug metabolism by CYP3A4
3 2 11 Measurement of testosterone p-hydroxylase activity in CYP3A4 
microsomesi
An HLPC method was adapted (from Whalley et a/, 2001, see Section 2 12) and 
optimised for the detection of CYP3A4 activity This method is based on the 
metabolism of testosterone, which is converted to 6iJ-hydroxy testosterone by 
members of the CYP3A subfamily Testosterone and its metabolite can then be 
separated by reverse-phase HPLC and quantified by UV absorbance An internal 
standard, corticosterone, is added to each sample at a known concentration as means 
of reference In the optimised conditions, 6p-hydroxy testosterone elutes at around 
four minutes, while intact testosterone does so at eleven minutes, corticosterone 
elutes at about nine minutes (Fig 3 2 1)
Microsomes expressing CYP3A4 and P450R or P450R alone were incubated with 
testosterone for 15 minutes at 37°C The reaction mixture was then extracted and 
testosterone and its metabolites separated by HPLC
As seen in Fig 32  1 and Table 3 2 1, CYP3A4-expressmg microsomes possess 
significant testosterone 6p-hydroxylase activity The presence of metabolite was 
undetectable in P450R microsomes
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F igu re  3 .2 .1 : Determination of C Y P 3 A  activity on C YP3A 4 microsomes by H PLC . Testosterone elutes at 
approximately 12 minutes, while 6p-hydroxy testosterone does so at approximately 4 minutes, 
corticosterone, used here as internal standard, elutes at approximately 8 minutes. Yellow line: P450R  
microsomes. Blue line: CYP3A4+P450R  microsomes.
CYP3A activity
(pmol/mg x min)
P450R microsomes n.d.
CYP3A4 + P450R microsomes 0.353+/-0.086
Tab le  3 .2 .1 : Measurement of testosterone 6p-hydroxylase activity on C Y P3A 4  microsomes by H PLC . 
Activity is expressed as pmoles of 6IJ-hydroxy testosterone produced per minute per mg of total protein. 
M icrosomes were incubated for 15 minutes at 37°C in a reaction mixture containing testosterone, 
NADPH, MgCb and microsomal protein in P B S , pH 7.4. Results are expressed as mean +/- SD , 
representing the average of three independent experiments, n.d.: not detectable.
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3 212  CYP3A4 metabolism and drug toxicity in A549 cells
In order to study the degree to which P450 activity affects the toxicity of anticancer 
drugs, in vitro toxicity assays were performed on A549 cells, where the drug in 
question was incubated with recombinant insect cell microsomal fractions before 
being added to the cells (see Section 2 17) A549 cells were chosen for these assays 
since they display no measurable testosterone 6p-hydroxylase activity as measured 
by HPLC, even after treatment with inducers such as Phénobarbital (data not shown) 
These cells were exposed to different concentrations of Adnamycin, Vincnstine and 5- 
fluorouracil, which had been preincubated with the microsomal fractions of insect cells 
infected with either human CYP3A4 and P450R or P450R cDNA alone Independent 
experiments were earned out, in which the drug was incubated with microsomes for 
either 30 minutes or 1 hour
As seen in Figs 3 2 2 and 3 2 3, preincubation of 5-fluorouracil with CYP3A4- 
expressing microsomes or with microsomes expressing P450R alone yielded the 
same toxicity curve In the case of Vincristine and especially Adnamycin, a time- 
dependent decrease in drug toxicity was observed compared to the effect of 
preincubation with P450R microsomes, as the decrease was more evident after 1 
hour incubation This could be attnbuted to CYP3A4-mediated drug inactivation
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5FU toxicity in A549 cells
5FU C c  (ng/ml)
Adriamycin toxicity in A549 cells
Adriam ycin C c (ng/ml)
F igu re  3 .2 .2 : Drug toxicity on A549 cells as determined by the acid phosphatase assay. A  known 
concentration of either 5-fluorouracil, Adriamycin or Vincristine w as incubated with insect cell microsomes 
containing either C YP3A 4 and P450R or P450R  alone at 37°C for 30 minutes prior to addition to cells. 
The reaction mixture also contained 25 mM MgCh and 6.5 mM NADPH in potassium phosphate buffer 
(P B S , pH 7.4). Results are the average of three independent experiments.
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5FU toxicity in A549 cells
10  100 1000 
5FU C c  (ng/ml)
10000
P450R rricrosom es
C YP3A4+F450R
rricrosom es
— ♦ —  P450R rricrosom es
— m —  CYP3A4+R450R 
rricrosom es
Adriamycin toxicity in A549 cells
10 100 1000 
Adriam ycin C c  (ng/ml)
Vincristine toxicity in A549 cells
0.1 1 10 
Vincristine C c (ng/ml)
100
P450R rricrosom es
CYP3A4+R450R
rricrosom es
F ig u re  3 .2 .3 : Drug toxicity on A549 cells as determined by the acid phosphatase assay. A  known 
concentration of either 5-fluorouracil, Adriamycin or Vincristine w as incubated with insect cell microsomes 
containing either C YP3A 4 and P450R or P450R alone at 37°C for an hour prior to addition to cells. The 
reaction mixture also contained 25 mM MgCh and 6.5 mM NADPH in potassium phosphate buffer (P B S , 
pH 7.4). Results are the average of three independent experiments.
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3 2 2 Drug metabolism by CYP1B1
3 2 21 Measurement of EROD activity in CYP1B1 microsomes
Members of the CYP1 family, CYP1A1, CYP1A2 and CYP1B1, are capable of 
metabolising 7-ethoxy resorufin into the fluorescent compound resorufin, this reaction 
is referred to as ethoxy resorufin O-deethylation (EROD) EROD activity of CYP1B1 
and P450R-contammg microsomes was determined by fluorescence at vanous time 
points and subsequently compared to that of microsomes containing P450R alone 
(see section 2 13)
As shown in Fig 32 4 and Table 3 2 2, CYP1B1 microsomes display readily 
measurable EROD activity
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Figure 3 2 4 ER O D  activity measured at various time points and expressed as pmoles of resorufin 
produced per mg of total protein After addition of 7-ethoxy resorufin, m icrosomes were incubated at 
37°C for the indicated periods of time The reaction mixture also contained 25 mM MgCh and 6 5 mM 
NADPH in potassium phosphate buffer (P B S , pH 7 4) The graph represents the average of two 
independent experiments
EROD activity
(pmol resorufin/min/mg total protein)
P450R microsomes n d
CYP1B1 microsomes 1203
Table 3 2 2  Measurement of ER O D  activity on CYP1B1 microsomes by fluorescence Activity is 
expressed as pmoles of resorufin produced per minute per mg of total protein Microsomes were 
incubated for 25 minutes at 37°C in a reaction mixture containing 7-ethoxy resorufin, NADPH, MgCI2 and 
microsomal protein in P B S , pH 7 4 n d not detectable Results are expressed as mean and represent 
the average of two independent experiments
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3 2 2 2 CYP1B1 metabolism and drug toxicity in A549 cells
A similar approach to that of CYP3A4 was taken with CYP1B1 on A549 cells 
Although transfection of CYP1B1 has been reported to confer resistance to Taxotere, 
no Taxotere metabolites could be detected after incubation of the drug with CYP1B1 
in a number of different conditions (Bourmque et a/, 2002) Toxicity of Taxol - a 
structurally and mechanistically related drug - was also tested, while 5-fluorouracil 
again acted as control
Figures 32 5 and 32 6 show that preincubation with CYP1B1 does not affect the 
toxicity of any of the drugs tested on A549 cells, at any of the two time points 
analysed (in independent experiments) In the case of 5-fluorouracil this is to be 
expected, since the drug does not undergo metabolism by this cytochrome Similarly, 
Taxol has not yet been confirmed as a CYP1B1 substrate As for Taxotere, the 
inability of CYP1B1 to inactivate the drug is consistent with the fact that no CYP1B1- 
generated Taxotere metabolite has been detected to date Altogether, these results 
suggest that Taxotere resistance ansing from CYP1B1 transfection is not due to direct 
inactivation of the drug by this enzyme
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5FU toxicity in A549 cells
1 10 100 1000 10000  
5FU C c (ng/ml)
F ig u re  3 .2 .5 : Drug toxicity on A549 ceils as determined by the acid phosphatase assay. A  known 
concentration of either 5-Fluorouracil, Taxol or Taxotere w as incubated with insect cell microsomes 
containing either CYP1B1 and P450R or P450R alone at 37°C for 30 minutes prior to addition to cells. 
The reaction mixture also contained 25 mM MgCh and 6.5 mM NADPH in potassium phosphate buffer 
(P B S , pH 7.4). The results represent the average of three independent experiments.
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5FU toxicity in A549 cells
1 10 100 1000 10000 
5FU C c (ng/ml)
Taxol toxicity in A549 cells
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F ig u re  3 .2 .6 : Drug toxicity on A549 cells as determined by the acid phosphatase assay. A  known 
concentration of either 5-Fluorouracil, Taxol or Taxotere w as incubated with insect cell microsomes 
containing either CYP1B1 and P450R or P450R alone at 37°C for 1 hour prior to addition to cells. The 
reaction mixture also contained 25 mM MgCh and 6.5 mM NADPH in potassium phosphate buffer (P B S , 
pH 7.4). The results represent the average of three independent experiments.
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3.2.3 Drug metabolism by P450R
3.2.3.1 P450R metabolism and drug toxicity in MDA 231 cells
In order to study the degree to which P450R activity affects anticancer drug-induced 
toxicity, in vitro toxicity assays were performed on MDA 231 cells transfected with 
P450R (MDA R4) or an empty vector (MDA EV), where the drug in question was 
preincubated with recombinant insect cell microsomal fractions expressing P450R or 
control microsomes, which display no measurable enzymatic activity.
B Adriamycin toxicity in MDA EV cells
■Control microsomes 
P450R microsomes
0.1 10 1000 
Adriamycin Cc (ng/ml)
F igu re  3 .2 .7 : Toxicity induced by 5-fluorouracil (A) and Adriamycin (B ) preincubated for 30 minutes with 
microsomes expressing P450R or control microsomes in MDA 231 EV  cells. Control m icrosomes display 
no measurable P450R enzymatic activity. The results represent the average of three independent 
experiments.
• Control microsomes 
P450R microsomes
5FU toxicity in MDA EV cells
10 100 1000 
5FU C c  (ng/ml)
10000
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A Mitomycin C toxicity in MDA EV cells
Control microsomes 
P450R microsomes
Mitomycin C Cc (ng/ml)
B
Vincristine toxicity in MDA EV cells
Control microsomes 
P450R microsomes
Vincristine Cc (ng/ml)
Figure 3 2 8 Toxicity induced by Mitomycin C (A) and Vincristine (B) preincubated for 30 minutes with 
microsomes expressing P450R or control microsomes in MDA 231 EV cells Control microsomes display 
no measurable P450R enzymatic activity The results represent the average of three independent 
experiments
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A
I
5FU toxicity in MDA R4 cells
Control mcrosomes 
R450R mcrosomes
5FU Cc (ng/ml)
B Adnamycm toxicity in MDA R4 cells
Adriamycln Cc (ng/ml)
F ig u re  3 2 9 Toxicity induced by 5-fluorouracil (A) and Adnamycm (B ) preincubated for 30 minutes with 
microsomes expressing P450R  or control microsomes in MDA 231 R4 cells Control m icrosomes display 
no measurable reductase enzymatic activity The results represent the average of three independent 
experiments
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A Mitomycin C toxicity in MDA R4 cells
—♦— Control microsomes 
— P450R microsomes
1000 10000 
Mitomycin C Cc (ng/ml)
100000
B
Vincristine toxicity in MDA R4 cells
—♦— Control microsomes 
-m—  P450R microsomes
0.01 0.1 1 10 100 
Vincristine Cc (ng/ml)
F ig u re  3 .2 .10 : Toxicity induced by Mitomycin C (A) and Vincristine (B ) preincubated for 30 minutes with 
microsomes expressing P450R or control microsomes in MDA 231 R4 cells. Control microsomes display 
no measurable reductase enzymatic activity. The results represent the average of three independent 
experiments.
Preincubation with P450R-expressing microsomes substantially decreased 
Adriamycin-induced toxicity in both MDA 231 EV and R4 cells (Figs. 3.2.7 to 3.2.10), 
indicating that the effect is independent of the expression of endogenous P450R. 
Mitomycin C also appeared to have less toxicity on A549 cells after incubation with 
P450R. Toxicity of Mitomycin C was higher in MDA R4 cells, but it should be noted 
that this drug is activated by cellular P450R to more toxic metabolites. On the other 
hand, toxicity of Vincristine and 5-fluorouracil was unaffected by preincubation with 
the enzyme. These results suggest that Adriamycin is inactivated to some extent by 
P450R before the drug is added to the cells, thereby reducing its cytotoxic effects.
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3 2 3 3 Adriamycm metabolism by P450R microsomes
In order to study the metabolism of Adriamycin by P450R, this drug was incubated for 
1 hour with either P450R-expressmg or control microsomes The reaction mixture was 
then extracted and analysed by liquid chromatography followed by mass spectrometry 
(LC/MS) LC/MS operation was earned out by Dr Robert O’Connor Fig 3 2 11 shows 
the position of the standard peaks in the conditions used for the analysis, Adnamycin 
eluted at approximately 4 5 minutes, while Daunorubicin (used as internal standard) 
did so at approximately 10 minutes Adnamycin aglycone, the main metabolite of 
Adnamycin generated by P450R (Cummings et a l , 1992), eluted at approximately 13 
minutes
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Figure 3 211 LC/MS analysis of a mixture of Adnamyicin (A), Daunorubicin (B ) and Adnamycin 
aglycone (C ) standards Adnamycin eluted at approximately 4 5 minutes, Daunorubicin (used as internal 
standard) at approximately 10 minutes and Adnamycin aglycone at approximately 13 minutes
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No Adriamycin aglycone was detected after incubation of Adriamycin with control 
microsomes obtained from empty vector-transfected cells, as expected (Fig 3 2 12) 
However, this metabolite was not detected after incubation of P450R-expressmg 
microsomes either (Fig 3 2 13) This result is unexpected and suggests that either no 
aglycone metabolite was generated under the expenmental conditions used or that 
the amount produced was below the limit of detection of the LC/MS method
D \robV VdataV5tti nov2006Vcontiolu1 08/11/2006 15 40 21
A RT 0 00 17 00
0  RT 0 00 17 00
N l 6 23E4 
Base Peakm/z- 
413 00-415 OOF 
ITMS + c ESI Full ms[ 
200 00-900 00] MS 
controlul
F ig u re  3 2 12 LC/MS analysis of Adriamycin samples after a 1 hour incubation with control microsomes 
Adriamycin (A ) eluted at approximately 4 5 minutes Daunorubicin (B , used as internal standard) at 
approximately 10 minutes and Adriamycin aglycone (C ) at approximately 13 minutes The results shown 
here are representative of three experiments
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F ig u re  3 2 1 3  LC/MS analysis of Adriamycin samples after a 1 hour incubation with P450R-expressing 
microsomes Adriamycin (A ) eluted at approximately 4 5 minutes, Daunorubicm (B , used as internal 
standard) at approximately 10 minutes and Adriamycin aglycone (C ) at approximately 13 minutes The 
results shown here are representative of three experiments
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3 3 Role of CYP3A4 in chemotherapy resistance
CYP3A4 is by far the most relevant cytochrome P450 involved in drug metabolism, 
responsible for the inactivation of about half of all known drugs Substrates of 
CYP3A4 include several anticancer agents, such as Taxol, Ifosfamide, Tamoxifen, 
VP-16 and Vinca alkaloids
Expression of CYP3A4 is very low in cell lines, the mechanism underlying this effect 
has not been completely elucidated, but decreased levels of specific transcnption 
factors have been suggested as a possible cause (Martinez et a/, 2002) The 
resultant low CYP3A4 activity makes it difficult to find a suitable model for the study of 
this P450, transfection of CYP3A4 cDNA can bring the enzyme levels closer to the 
values found in normal body cells, generating useful models for the study of this 
particular protein
3 31 Expression of CYP3A4 in BCMV cells
BEAS-2B are normal human bronchial cells immortalized with the SV40 virus BCMV 
cells are BEAS-2B vanants that have been transfected with a vector containing either 
the cDNA of CYP3A4 under the control of the CMV early promoter, or an empty 
vector They are denominated as BCMV 3A4 or BCMV Neo, respectively These cells 
were a gift from Dr Katherine Mace, from the Department of Nutntion, Nestle 
Research Center They constitute an interesting model to study the effects of CYP3A4 
overexpression on the resistance to anticancer agents
BCMV 3A4 cells express high levels of CYP3A4 mRNA and protein, as shown by RT- 
PCR (Fig 3 3 1) and Western blotting (Fig 3 3 2)
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CYP3A4 
R-act in
F ig u re  3 31 RT-PCR showing CYP3A4 mRNA expression in BCMV Neo and BCMV 3A4 cells
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F ig u re  3 3 2 Western blot showing CYP3A4 protein expression in BCMV Neo and BCMV 3A4 cells 
CYP3A4-expressmg microsomes were used as positive control
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3 3 2 Testosterone 6p-hydroxylase activity in BCMV cells
CYP3A activity was measured in BCMV cells by HLPC using the testosterone 6S- 
hydroxylation assay (see Section 2 12 Testosterone metabolites were separated by 
reverse-phase HPLC and quantified by UV absorbance An internal standard, 
corticosterone, was added to each sample at a known concentration as means of 
reference In the optimised conditions, 6p-hydroxy testosterone elutes at four minutes, 
while unmodified testosterone does so at ten minutes, corticosterone elutes at nine 
minutes
As it can be seen in Table 33 1 and Fig 3 3 3, BCMV 3A4 cells exhibit readily 
measurable testosterone 6p-hydroxylase activity In contrast, no testosterone 
metabolite could be detected in BCMV Neo cells
CYP3A activity
(pmol/mg x min)
BCMV Neo n d
BCMV 3A4 0 066
Table 3 3 1 CYP3A activity expressed as pmol of metabolite (6ft-hydroxy testosterone) per mg of total 
protein per minute of incubation Cells were incubated for one hour at 37°C in a reaction mixture 
containing testosterone, NADPH, MgCI2 and total cell protein in PBS, pH 7 4 n d not detectable 
Results represent the average of two independent experiments
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Figure 3.3.3: Testosterone metabolites detected by HPLC in BCMV cells. A, complete chromatogram. B, 
zoom in at approximately 4 minutes. Yellow line: BCMV Neo cells. Blue line: BCMV 3A4 cells. 
Testosterone elutes at approximately 12 minutes, while 6p-hydroxy testosterone does so at 
approximately 4 minutes. Corticosterone, used here as internal standard, elutes at approximately 8 
minutes.
3.3.3 Anticancer drug-induced toxicity in BCMV cells
BCMV Neo and BCMV 3A4 cells were exposed to increasing concentrations of 
anticancer drugs to determine the drug IC50 (i.e., the concentration that results in 
50% of cell death as compared to an untreated control). The anticancer agents used 
for these experiments were Adriamycin, 5-fluorouracil and Cisplatin. Adriamycin is 
known to be detoxified by CYP3A4; 5-fluorouracil and Cisplatin, on the other hand, 
are not metabolised by P450s.
5FU toxicity BCMV cells
10 100 1000 10000 
5 FU  C c  (n g /m l)
F igu re  3 .3 .4 : 5-fluorouracil IC50 as determined by the acid phosphatase assay in BCM V Neo and BCM V 
3A4 cells. Results represent the average of three independent experiments.
Cell line 5-FU IC50 Fold resistance t-test
(ng/ml) (p value)
BCMV Neo 674±112 1
BCMV 3A4 1233±182 1.83 0.016
Tab le  3 .3 .2 : 5-fluorouracil fold resistance in BCM V 3A4 as compared to empty vector transfected cells. 
Results are expressed as mean +/- SD  and represent the average of three independent experiments.
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Adriamycin toxicity BCMV cells
10 100 
Adriam ycin Cc (ng/ml)
BCMV Neo 
BCMV 3A4
1000
Figure 3.3.5: Adriamycin IC50 as determined by the acid phosphatase assay in BCMV Neo and BCMV 
3A4 cells. Results represent the average of three independent experiments.
Cell line Adriamycin IC50 Fold resistance t-test
(ng/ml) (p value)
BCMV Neo 6300±400 1
BCMV 3A4 11400±900 1.8 0.004
Table 3.3.3: Adriamycin fold resistance in BCMV 3A4 as compared to empty vector transfected cells. 
Results are expressed as mean +/- SD and represent the average of three independent experiments.
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Cisplatin toxicity BCMV cells
BCMV Neo 
BCMV 3A4
10 100 1000 10000 
Cisplatin Cc (ng/ml)
Figure 3.3.6: Cisplatin IC50 as determined by the acid phosphatase assay in BCMV Neo and BCMV 3A4 
cells. Results represent the average of three independent experiments.
Cell line Cisplatin IC50 Fold resistance t-test
(ng/ml) (p value)
BCMV Neo 240±30 1
BCMV 3A4 260±40 1.07 0.545
Table 3.3.4: Cisplatin fold resistance in BCMV 3A4 as compared to empty vector transfected cells. 
Results are expressed as mean +/- SD and represent the average of three independent experiments.
As expected, transfection of CYP3A4 enhanced cell resistance to the toxic effects of 
Adriamycin, presumably by protecting cells by drug inactivation (Table 3.3.3). 
However, BCMV 3A4 cells also displayed significant resistance to 5-fluorouracil when 
compared to BCMV Neo cells (Table 3.3.2). This is unexpected, since the literature 
shows no relationship between 5-fluorouracil and CYP3A4. Resistance was more 
evident at intermediate concentrations of drug.
Cisplatin toxicity was unaffected by CYP3A4 transfection (Table 3.3.4), suggesting 
that the increase in resistance is not general for all types of anticancer drugs.
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3.3.4 Inhibition of testosterone 6p-hydroxylase activity by 17 AEE
17a-ethynyl estradiol (17 AEE) causes non-competitive inactivation of members of the 
CYP3A subfamily (Guengerich, 1990). Inhibition of CYP3A by 17 AEE results from an 
irreversible modification of the P450 active site by the binding of this chemical 
compound. 17 AEE inhibited testosterone 6p-hydroxylase activity of CYP3A4 + 
P450R microsomes in a concentration-dependent fashion (Fig. 3.3.7), as measured 
by HPLC (see section 2.12). Inhibition, though readily measurable, was not as strong 
as that of ketoconazole, used as positive control.
CYP3A4 activity - Effect of 17AEE
Control 17 AEE1.5mg/ml 17AEE3mg/ml 17AEE6mg/ml Ketoconazole
0.5mg/ml
Figure 3.3.7: Dose-dependent inhibition of CYP3A4-mediated testosterone 6|3-hydroxylase activity by 17 
AEE on CYP3A4 and P450R-expressing microsomes. Microsomes were incubated for 15 minutes at 
37°C in a reaction mixture containing testosterone, NADPH, MgCI2 and microsomal protein in PBS, pH 
7.4, as well as different concentrations of 17 AEE (replaced with PBS for the control). CYP3A activity was 
then measured by HPLC and expressed as % relative to control. Ketoconazole was used as a positive 
control. Results represent the average of two independent experiments.
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3.3.4 Effect of CYP3A4 inhibition on anticancer drug-induced toxicity
CYP3A4-transfected cell lines did show an increase in resistance to Adriamycin and 
5-fluorouracil. However, stable transfection requires the integration of foreign DNA 
into the cell’s genome; integration can take place anywhere in the genome and can 
disrupt the normal function of endogenous genes. In order to confirm that increased 
CYP3A4 activity was responsible for the observed increase in resistance, BCMV 3A4 
cells were exposed to Adriamycin, Cisplatin and 5-fluorouracil in the presence of the 
CYP3A inhibitor 17 AEE.
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Figure 3.3.8: Effect of Adriamycin and 17 AEE combination on the viability of BCMV 3A4 cells as 
determined by the acid phosphatase assay. Results represent the average of two independent 
experiments.
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Cisplatin +17 AEE BCMV 3A4 cells
Control Cisplatin 285ng/ml t7AEE 285ng/ml 142ng/ml 17AEE 142ng/ml
62.5ng/ml 17AEE-*Cisplatin 17AEE-*Cisplatin
Figure 3.3.9: Effect of Cisplatin and 17 AEE combination on the viability of BCMV 3A4 cells as 
determined by the acid phosphatase assay. Results represent the average of three independent 
experiments.
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5-FU + 17 AEE BCMV 3A4 cells
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Figure 3.3.10: Effect of 5-fluorouracil and 17 AEE combination on the viability of BCMV 3A4 cells as 
determined by the acid phosphatase assay. Results represent the average of three independent 
experiments.
As shown in Fig. 3.3.8, the combination of non-toxic concentrations of Adriamycin and 
17 AEE resulted in a decrease of about 10% in cell viability. This effect was not 
observed with Cisplatin (Fig. 3.3.9). In the case of 5-fluorouracil, there is no apparent 
change in viability, but the observed trend is similar to that of Adriamycin (Fig. 3.3.10).
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3.4 Role of CYP1B1 in chemotherapy resistance
Recent studies have raised great interest on CYP1B1 and its role in malignant 
transformation and drug resistance This protein is consistently overexpressed in 
tumour cells as compared to their normal counterparts (see section 1 4 5), although its 
precise role in cancer development is yet to be defined Similarly, even though 
transfection of CYP1B1 resulted in an increased resistance to Taxotere in cultured cell 
lines, no actual metabolite could be detected when the drug was incubated with 
recombinant CYP1B1 enzyme in all different conditions tested (Boumique et a l , 
2002), these results were confirmed by experiments performed with CYP1B1 
microsomes (see section 3 2 2 2 )  Thus, even though there seems to be a clear 
connection between CYP1B1 and drug resistance, the nature of this connection 
remains obscure
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3 41 Expression of CYP1B1 mRNA in HL60 cells
HL60 cells were originally obtained from a patient suffenng from acute promyelocytic 
leukaemia, they display myeloblast-like morphology and have been shown to express 
CYP1B1 (Nagai et a l , 2002) Expression levels of this enzyme are increased in 
response to treatment with differentiating agents such as retinoic acid and 2,3,7,8- 
Tetrachlorodibenzo-p-dioxin (TCDD) (Fig 3 4 1) U937 lymphoma cells, however, do 
not appear to express CYP1B1, even after treatment with the inducer
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Figure 34 1 CYP1B1 mRNA expression as detected by RT-PCR in HL60 and U937 cell lines Cells 
were exposed to 3 22 ng/ml TCDD or vehicle (toluene) for 72 hours pnor to mRNA extraction
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3 4 2 EROD activity in HL60 cells
EROD activity was measured in HL60 cells with a protocol similar to the one used for 
the CYP1B1 microsomes activity assay (see section 2 13) Cells were resuspended in 
7-ethoxy resorufin-containmg PBS and incubated at 37°C Supernatant samples were 
removed at various time points and the amount of resorufin produced was measured 
by fluorescence against a blank of HL60 cells in PBS As seen in Fig 3 4 2, the cells 
displayed low but measurable activity
EROD activity HL60 cells
Fluorescence blank 
■*—HL60
Time (minutes)
Figure 3 4 2 EROD activity measured at various time points and expressed as fluorescence detected at 
530nm (excitation)/590nm (emission) After addition of 7-ethoxy resorufin, cells were incubated at 37°C 
for the indicated penods of time Samples were removed and spun down, and the amount of Resorufin 
present in the supernatant determined by fluorescence HL60 cells without Resorufin were used as 
fluorescence blank
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3.4.3 Taxotere-induced toxicity in HL60 ceils in the presence and absence of 
ANF
EROD activity, displayed by members of the CYP1A and CYP1B subfamilies, can be 
inhibited by the addition of a-naphthoflavone (ANF). In an attempt to establish the 
effect of CYP1 inhibition in drug resistance, HL60 cells were exposed to a non-toxic 
concentration of either Taxotere or ANF, or to a combination of both doses. The 
resulting effect on cell survival was quantified by the XTT assay (see section 2.7.3).
Taxotere and ANF combination toxicity in HL60
cells
Control Taxotere 12.5uM ANF 12.5uM
ANF+Taxotere
Figure 3.4.3: Taxotere-induced toxicity in HL60 cells in the presence or absence of 12.5 pM ANF as 
measured by the XTT assay. The Taxotere concentration used was 1.07 ng/ml. The results represent the 
average of three independent experiments.
As seen in Fig. 3.4.3, a slightly (about 5% kill) toxic concentration of ANF synergises 
with a non-toxic concentration of Taxotere to give a cell kill value of approximately 
30%. These results suggest that CYP1 inhibition could enhance Taxotere toxicity in 
HL60 cells.
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3.4.4 Drug-induced cytotoxicity in the presence and absence of ANF
In an effort to better understand the effect on ANF in anticancer drug resistance, HL60 
cells were exposed to different concentrations of 5-fluorouracil, Adriamycin, Taxol and 
Taxotere in the presence and absence of 12.5 pM ANF.
5FU Toxicity in HL60 cells
Control 
ANF 12.5 uM
100 1000 10000 
5FU Cc (ng/ml)
B Adriamycin Toxicity in HL60 cells
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Figure 3.4.4: 5-fluorouracil (A) and Adriamycin (B)-induced cytotoxicity in HL60 cells as determined by 
the XTT assay in the presence and absence of 12.5 pM ANF. Results represent the average of at least 
three independent experiments.
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Taxol Toxicity in HL60 cells
Control 
ANF 12.5 uM
1 10 100 
Taxol Cc (ng/ml)
B Taxotere Toxicity in HL60 cells
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Figure 3.4.5: Taxol (A) and Taxotere (B)-induced cytotoxicity in HL60 cells as determined by the XTT 
assay in the presence and absence of 12.5 pM ANF. Results represent the average of at least three 
independent experiments.
A tendency towards increased sensitisation in the presence of ANF is observed in 
Figs. 3.4.4 and 3.4.5. The fact that ANF appears to increase the toxicity of all the 
drugs tested suggests that enhanced sensitivity arises from a general toxic effect of 
ANF, rather than from inhibition of CYP1B1. It should be noted that out of the drugs 
tested only Taxotere has been reported as a CYP1B1 substrate.
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3 4 5 Determination of CYP1B1 induction in HL60 cells by TCDD
TCDD is a well-known ligand of the aryl hydrocarbon receptor (AhR) Upon entrance 
into the cell, TCDD binds the receptor, which translocates into the nucleus and 
stimulates transcription of its target genes These genes include members of the 
CYP1 family, such as CYP1A1 and CYP1B1 Induction of CYP1B1 expression by 
TCDD has been well documented in a number of different cell lines 
A time-dependent increase in CYP1B1 expression was detected in HL60 cells by RT- 
PCR after treatment with 3 22 ng/ml TCDD, as shown in Fig 3 4 6 EROD activity was 
also measured in vehicle (toluene) and TCDD-treated HL60 cells (see section 2 13) 
and revealed that an approximately 10-fold raise in CYP1 activity paralleled the 
increase in mRNA expression (Fig 3 4 7 and Table 3 4 1)
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Figure 3 4 6 Induction of CYP1B1 expression by 3 22 ng/ml TCDD in HL60 cells Cells were treated with 
TCDD for 24, 48, 72 or 96 hours, or with toluene for 96 hours before mRNA extraction
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EROD activity HL60 cells
Vehicle (Toluene) 
TCDD
Time (minutes)
Figure 3 4 7 EROD activity in HL60 cells after treatment with either vehicle or 10 nM TCDD for 72 hs 
Activity was measured at various time points and expressed as fluorescence 530/590nm After addition 
of 7-ethoxy resorufin, cells were incubated at 37°C for the indicated periods of time Samples were 
removed and spun down, and the amount of resorufin present in the supernatant determined by 
fluorescence (530 nm excitation 590 nm emission) Results represent the average of three independent 
experiments
EROD activity
(pmoles resorufin/mg total protein/minute)
HL60 + toluene 0 079+/-0 071
HL60 + TCDD 0 725+/-0 772
Table 3 41 EROD activity of HL60 cells treated with TCDD or vehicle (toluene) for 72 hours Activity is 
expressed as pmoles resorufin per mg of total protein per minute Results are expressed as mean +/- SD 
and represent the average of three independent experiments
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3 4 6 Determination of anticancer drug toxicity after treatment with TCDD
Toxicity assays were carried out on HL60 cells that had been treated with 3 22 ng/ml 
TCDD or an equal volume of vehicle (toluene) for 72 hours The drugs used in these 
assays were 5-fluorouracil, Cisplatin, Taxol and Taxotere
As can be seen in Figs 3 4 8 and 3 4 9, treatment with TCDD did not appreciably 
affect cell sensitivity towards any of the drugs tested, suggesting that a substantial 
increase in CYP1B1 mRNA expression and activity does not alter anticancer drug 
toxicity in HL60 cells
5FU toxicity m HL60 cells
Toluene
TCDD
5FU Cc (ng/ml)
B
Cisplatin toxicity in HL60 cells
Cisplatin Cc (ug/ml)
—♦ — Toluene 
—*— TCDD
Figure 3 4 8 5-fluorouracil (A) and Cisplatin (B)-mduced toxicity in HL60 cells as determined by the XTT 
assay after treatment with either vehicle (toluene) or 3 22 ng/ml TCDD for 72 hours Results represent 
the average of at least two independent experiments
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A Taxol toxicity in HL60 cells
Taxol Cc (ng/ml)
♦— Toluene 
^-TCDD
B
Taxotere toxicity in HL60 cells
Taxotere Co (ng/ml)
♦ -Toluene 
- a— TCDD
Figure 3 49  Taxol (A) and Taxotere (B)-induced toxicity in HL60 cells as determined by the XTT assay 
after treatment with either vehicle (toluene) or 3 22 ng/ml TCDD for 72 hours Results represent the 
average of at least two independent experiments
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3 4 7 Expression of CYP1B1 in MCF-7 cells and their resistant vanants
CYP1B1 expression is abundant in hormone-dependent tissues such as uterus, ovary 
and breast (Tsuchiya et a /, 2005) A breast cell line, MCF-7, was then chosen as a 
model in which to study expression of CYP1B1
MCF-7 cells were onginally denved from breast carcinoma and were pulse-selected 
by Dr Yizheng Liang with Adriamycin (4 pulses, once a week for 4 hours, with 250 
ng/ml Adnamycin), Cisplatin (9 pulses, once a week for 4 hours, with 800, 100, 300, 
300, 300, 300, 300, 350, 350 ng/ml Cisplatin) and Taxotere (6 pulses, once a week for 
4 hours, except for the first one which was for a half hour, with 50, 10, 10, 13, 13, 13 
ng/ml Taxotere) to generate the MCF-7 Adr, MCF-7 CisPt and MCF-7 Txt variants, 
respectively Toxicity assays were earned out in these cells with the acid phosphatase 
assay to establish their resistance profile (Tables 3 4 2 and 3 4 3) MCF-7 Adr were 
4 9-fold more resistant to Adnamycin than parent MCF-7 cells, similarly, MCF-7 CisPt 
were 3 6-fold more resistant to Cisplatin and MCF-7 Txt displayed a 2 75-fold increase 
in resistance against Taxotere as compared to MCF-7 cells Some cross-resistance 
was observed in MCF-7 CisPt cells with Taxotere, but it was not important with other 
drugs or in any of the other cell lines Interestingly, MCF-7 Adr cells were more 
sensitive to 5-fluorouracil, Cisplatin and Taxotere than parent cells
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IC50s (ng/ml) MCF-7 MCF-7 CisPt MCF-7 Txt MCF-7 Adr
5-FU 336+-/87 234+/-15 270+/-27 151+/-81
Adriamycin 43 1+/-2 7 47 0+/-9 5 58 0+/-5 9 211+/-158
Cisplatin 580+/-120 2084+/-237 489+/-219 92 3+/-35 4
Taxotere 1 1+/-0 2 2 1+/-0 3 3 1+/-0 7 0 3+/-0 2
Table 3 4 2 5-fluorouracil, Adnamycin, Cisplatin and Taxotere IC50 values in MCF-7 cells and their 
pulse-selected variants as determined by the acid phosphatase assay Results are expressed as mean 
+/- SD and represent the average of at least two independent experiments
Fold resistance 
(relative to parent) MCF-7 MCF-7 CisPt MCF-7 Txt MCF-7 Adr
5-FU 1 0 7 0 8 0 4
Adnamycin 1 1 1 1 3 4 9
Cisplatin 1 3 6 0 8 0 2
Taxotere 1 1 8 2 8 0 2
Table 3 4 3 Fold resistance of MCF-7 pulse-selected variants as compared to parent cells
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Expression of CYP1B1 was measured in MCF-7 cells and their resistant vanants by 
RT-PCR (Fig 3 410 ) The mRNA levels of this enzyme were dramatically upregulated 
in MCF-7 Txt cells as compared to parent cells, this increase in CYP1B1 expression 
was not observed in MCF-7 Adr cells
Figure 3 410 Expression of CYP1B1mRNA in MCF-7 cells and their resistant vanants by RT-PCR
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3.4.8 EROD activity in MCF-7 and MCF-7 Txt cells
In order to confirm that the increase in CYP1B1 transcription resulted in enhanced 
enzymatic activity, EROD activity was measured in MCF-7 and their Taxotere- 
selected variants. Activity was low but indeed detectable, while no measurable activity 
could be detected in parent MCF-7 cells (Fig. 3.4.11 and Table 3.4.4).
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Figure 3.4.11: EROD activity of MCF-7 cells. Activity was measured at various time points and 
expressed as fluorescence 530/590nm. After addition of 7-ethoxy resorufin, cells were incubated at 37°C 
for the indicated periods of time. Samples were removed and spun down, and the amount of resorufin 
present in the supernatant determined by fluorescence (530 nm excitation; 590 nm emission). Results 
represent the average of at least two independent experiments.
EROD activity
(pmoles resorufin/mg total protein/minute)
MCF-7 n.d.
MCF-7 Txt 0.026
Table 3.4.4: EROD activity of MCF-7 cells and their Taxotere-selected variant. Activity is expressed as 
pmoles resorufin per mg of total protein per minute, n.d.: not detectable. Results are expressed as mean 
and represent the average of at least two independent experiments.
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3 4 9 Expression of CYP1B1 in a panel of pulse-selected cells of various origins
In order to find out whether increased expression of CYP1B1 was a common effect of 
Taxotere pulse selection, a panel of cell lines -  colon carcinoma Caco2, squamous 
cell lung carcinoma SK-MES-1, pancreatic carcinoma BxPc-3 and hepatoma cell line 
.  HepG2 -  and their Taxotere-selected variants were analysed for CYP1B1 mRNA 
expression (Fig 3 4 12) Like MCF-7 cells, HepG2 cells displayed an increase in 
CYP1B1 expression after pulse selection with Taxotere However, no CYP1B1 mRNA 
was detected in any of the other cell lines In the case of HepG2 cells, only the 
Taxotere-selected variants showed increased expression of CYP1B1 mRNA, while 
Cisplatin and Taxol-selected HepG2 cells displayed no detectable levels of CYP1B1 
mRNA
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Figure 3 4 12 Expression of CYP1B1 mRNA in a panel of cell lines pulse-selected with Taxotere and 
their respective parent cells by RT-PCR HL60 cells treated with TCDD were used as positive control 
UHP water was used as negative control
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3 410 Effect of Taxotere on CYP1B1 expression in a panel of breast cell lines
CYP1B1 is commonly expressed in hormone-dependent tissue, such as prostate, 
breast and endometrium, and its expression can be affected by the oestrogen 
receptor (ER) status of cells (see section 1 4 3  1) In order to find out whether 
Taxotere is able to induce CYP1B1 expression, a panel of breast cell lines -  MCF-7, 
MDA 453, BT-20 and MDA 231 -  was selected for analysis MCF-7 and MDA 453 
cells are ER positive, while BT-20 and MDA 231 cells are ER negative These cells 
were exposed to 80 ng/ml of Taxotere for 4 hs and expression of CYP1B1 was then 
measured by RT-PCR and compared to that of untreated cells
CYP 
0-act
Figure 3 4 13 Expression of CYP1B1 by RT-PCR in a panel of breast cell lines after Taxotere treatment 
Cells were exposed to 80 ng/ml Taxotere or medium for 4 hours before mRNA extraction
As can be seen in Figure 3 4 13, a single 4 hour pulse of Taxotere did appear to 
increase expression of CYP1B1 in MDA 453 and BT-20 cells No apparent effect on 
expression was observed in MCF-7 or MDA 231 cells after Taxotere treatment In the 
case of MCF-7, this might suggest that the observed increase in CYP1B1 expression 
in MCF-7 Txt cells is associated with the increase in resistance observed in cells that 
had been pulse-selected for a longer penod of time On the other hand, expression of 
CYP1B1 is regulated by the AhR, the lack of CYP1B1 induction by Taxotere could be 
attnbuted to the fact that this receptor is only present at low levels or is non-functional
180
3 411 Effect of TCDD on CYP1B1 expression in a panel of breast cell lines
In order to find out whether activation of the AhR can induce CYP1B1 expression in 
the panel of cell lines studied, cells were treated with TCDD, a well-known AhR 
agonist, for 4 hours Expression of CYP1B1 mRNA was then analysed and revealed 
upregulation of this enzyme in all cell lines tested in response to TCDD treatment (Fig 
3 4 14) This result suggests that activation of the AhR by TCDD is able to induce 
CYP1B1 mRNA expression in the panel of breast cell lines, independently of ER 
status
Figure 3 4 14 Expression of CYP1B1 by RT-PCR in a panel of breast cell lines after TCDD treatment 
Cells were treated with 3 22 ng/ml TCDD or vehicle (toluene) for 4 hours before mRNA extraction
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3.4.12 CYP1B1 siRNA transfection in MCF-7 Txt cells
CYP1B1 is upregulated in MCF-7 Txt cells, which show an approximate 3-fold 
increase in Taxotere resistance (see section 3.4.7). In order to investigate the role of 
CYP1B1 in Taxotere resistance in these cells, siRNA transfections were carried out in 
order to knock-down the expression of the gene of interest. Three pre-designed 
siRNAs were used for CYP1B1; cells were transfected and then exposed to different 
concentrations of Taxotere (see section 2.19).
CYP1B1 siRNA transfection in MCF-7 Txt cells
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Figure 3.4.15: Effect of CYP1B1 siRNA transfection on Taxotere toxicity in MCF-7 Txt cells. Control cells 
received only fresh medium. Scrambled siRNA-transfected cells received a nonsense siRNA sequence. 
Results represent the average of two independent experiments.
As seen in Fig. 3.4.15, all three CYP1B1 siRNAs decreased the cell survival value in 
the absence of Taxotere, suggesting that knock-down of this enzyme is detrimental for 
cell viability. Transfection of CYP1B1 siRNAs 1 and 2 did not result in appreciable 
enhancement of Taxotere toxicity, but siRNA 3 appeared to increase the cytotoxic 
effect of this drug, particularly at low concentrations.
■ Control
■ Scrambled
□ siRNA 1
□ siRNA2
■ siRNA 3
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3 413 Transfection of CYP1B1 into mammalian cells
In order to further investigate the role of CYP1B1 in anticancer drug resistance, it was 
decided to transiently transfect a cell line with this enzyme and then evaluate possible 
changes in the resistance profile associated with the overexpression of CYP1B1 The 
chosen cell line for these assays was MDA 231 R4, since it had been transfected 
before (with the P450R cDNA) and also expressed high levels of P450R, which are 
needed for optimal CYP1B1 function
A range of different conditions were tested for transfection, changing the cell density, 
amount of cDNA and transfection reagent (Lipofectamine 2000) used, these assays 
were earned out using a GFP plasmid (see section 2 18 3) GFP-transfected cells emit 
green fluorescence that is easily visible under a fluorescence microscope and can be 
readily quantified by flow cytometry
48 hours after GFP transfection using the optimised conditions, cells readily displayed 
green fluorescence, as seen in Figs 3 4 16 A and B The transfection efficiency 
obtained with these conditions was approximately 55%, as measured by flow 
cytometry (Fig 3 4 17)
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Figure 3.4.16: GFP transfection of MDA R4 cells. A, transfected cells visualised under normal light. B, 
transfected cells visualised under fluorescent light.
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Figure 3.4.17: Efficiency of GFP transfection as measured by flow cytometry (Guava). Transfected cells 
display high values of green fluorescence and are shown in red. Non-fluorescent cells are shown in 
green. Pink lines represent gating of fluorescence values. Transfected cell efficiency is calculated as 
percentage of green fluorescent cells in the total number of cells in the sample (determined as a measure 
of forward light scatter).
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After optimising transfection conditions, MDA R4 cells were transfected with a 
CYP1B1 plasmid obtained from Dr Thomas Friedberg This plasmid had previously 
been used to transiently transfect COS cells An empty vector (EV) plasmid was 
generated by releasing the CYP1B1 cDNA from the backbone with restnction 
enzymes (see section 2 18 1) and used as control for transfections 
Expression of CYP1B1 protein was analysed by Western blot As shown in Fig 
3 4 18, no detectable protein was found in CYP1B1-transfected cells
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Figure 3 418 Expression of CYP1B1 protein in transfected MDA R4 cells by Western blot CYP1B1 
microsomes were used as positive control
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Since transfection of MDA R4 cells had been unsuccessful, it was decided to transfect 
MCF-7 cells instead. These cells express measurable levels of P450R that can 
support CYP1B1 function (Chen et a!., 1995). Transfection conditions were again 
optimised for this cell line, this time using 6-well plates (see section 2.18.3). 
Transfection of GFP into MCF-7 cells using the optimised conditions gave 
approximately 52% transfection efficiency, as measured by flow cytometry (Fig. 
3.4.19).
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Figure 3.4.19: Efficiency of GFP transfection as measured by flow cytometry (Guava). Transfected cells 
display high values of green fluorescence and are shown in red. Non-fluorescent cells are shown in 
green. Pink lines represent gating of fluorescence values. Transfected cell efficiency is calculated as 
percentage of green fluorescent cells in the total number of cells in the sample (determined as a measure 
of forward light scatter).
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Expression of CYP1B1 was analysed in CYP1B1 and empty vector-transfected MCF- 
7 cells by Western blot As shown in Fig 3 4 20, no apparent difference in CYP1B1 
levels was found between MCF-7 cells transfected with the empty vector or the 
CYP1B1 plasmid
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Figure 3 4 20 Expression of CYP1B1 protein in transfected MCF-7 cells by Western blot CYP1B1 
microsomes were used as positive control
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3 5 Role of P450 NADPH reductase in chemotherapy 
resistance
Activity of cytochromes P450 is highly dependent on P450 NADPH reductase 
(P450R), this enzyme is needed for the electron donation process that is the core of 
the P450 oxidation cycle P450R can also metabolise drugs on its own, independently 
of cytochromes P450, the best-studied example of a drug biotransformed in this way 
is Mitomycin C, although Adnamycin is also known to undergo metabolism by P450R 
(Cummings et a l , 1998, Bartoszek et a l , 1992) Reduction of these drugs generates 
more toxic compounds and also free radicals, the contnbution of free radicals to the 
toxic effects of these drugs remains undetermined
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3 51 P450R expression in MDA 231 cells
MDA 231 cells were originally denved from breast adenocarcinoma Human P450R 
cDNA-transfected MDA 231 cells (MDA R4) were a generous gift from Dr Ian 
Stratford, from Manchester University P450R-transfected cells show a substantial 
increase in P450R expression as compared to empty vector transfected MDA 231 
cells (MDA EV) (Fig 3 5 1 ) These cells were used as a model to investigate the role 
of P450R in the development of drug resistance
Figure 3 5 1 Expression of P450R protein as detected by Western blot on MDA 231 cells HepG2 cells 
were used as positive control
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3.5.2 P450R activity in MDA 231 cells
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) is converted 
by P450R to formazan, a blue compound that absorbs at 610nm. The increase in 
absorbance at 610nm can then be directly correlated to the conversion of MTT to 
formazan by P450R. Formazan production by MDA EV and MDA R4 cell extracts was 
measured spectrophotometrically and expressed as nmoles formazan produced per 
mg of total protein (see section 2.14). As can be seen in Fig. 3.5.2, the increase in 
absorbance was linear up to 5 minutes. MDA R4 cells showed over a 7-fold increase 
in formazan production compared to MDA EV cells (Table 3.5.1).
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Figure 3.5.2: Increase in absorbance at 610 nm observed in MDA EV and MDA R4 cells. Total cell 
extracts were incubated at 37°C with MTT and NADPH for 5 minutes. Readings were taken every 30 
seconds.
P450R activity (nmoles formazan/mg total
protein/minute)
MDA EV 303+/-25
MDA R4 2169+/-220
Table 3.5.1: P450R activity in MDA 231 cells expressed as nmoles of formazan produced per mg of total 
protein per minute. Results are expressed as mean +/- SD and represent the average of five independent 
experiments.
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3 5 3 Anticancer drug-induced toxicity in MDA 231 cells
In order to find out more about the role of P450R expression in anticancer drug 
resistance, MDA EV and MDA R4 cells were exposed to a senes of commonly used 
drugs and their IC50s determined by the acid phosphatase assay 
It is known that P450R activates Mitomycin C by reacting with this drug to form a 
quinone intermediate that alkylates DNA, causing cell damage and inducing apoptosis 
(Rooseboom et a /, 2004) As expected, MDA R4 cells were more sensitive to 
Mitomycin C exposure than MDA EV cells, suggesting that increased P450R activity 
results in enhanced Mitomycin C activation and greater cytotoxicity (Table 3 5 2)
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Drug MDA 231 EV IC50 
(ng/ml)
MDA 231 R4 IC50 
(ng/ml)
Fold
sensitisation
(R4/EV)
t-test
(P
value)
5-fluorouracil 1039+/-169 375+/-31 2 8 0 018
Adriamycin 21 1+/-0 2 9 0+/-2 4 2 4 0 012
Cisplatin 421+/-55 374+/-19 1 1 0 272
Mitomycin C 356+/-S2 53 9+/-10 3 6 6 0 008
Mitoxantrone 3 5+/-0 5 4 0+/-1 4 0 8 0 723
Taxol 1 1+/-0 2 1 2+/-0 3 0 9 0 656
Taxotere 0 34+/-0 05 0 25+/-0 04 1 4 0 065
Vincristine 1 4+/-0 1 1 3+/-0 3 1 1 0 460
VP-16 130+/-30 172+/-11 0 8 0 126
Table 3 5 2 IC50 values and fold resistance of MDA EV cells as compared to MDA R4 cells A p value of 
<0 05 was deemed significant Results are expressed as mean +/- SD and represent the average of six 
independent experiments
As shown in Table 3 5 2, the toxicity Mitomycin C was dramatically increased by 
overexpression of P450R, as expected from known activation of this drug by P450R 
Increased sensitivity to Adnamycin was also observed in MDA R4 cells, this drug 
appears to share a similar activation mechanism with Mitomycin C, although 
contradictory reports exist on the subject
The toxicity of Cisplatin, Mitoxantrone, Taxol, Vincristine and VP-16 did not exhibit any 
changes after P450R transfection Overexpression of P450R appeared to confer a 
slight sensitisation to Taxotere, albeit non-significant, this was unexpected, since 
Taxotere-mediated cytotoxicity is largely due to interferences with microtubule 
dynamics and has not been reported as influenced by a reductive environment The 
most unexpected result was that of 5-fluorouracil, which was significantly more toxic to 
MDA R4 than to MDA EV cells This increase in toxicity is hard to explain, for this drug 
does not appear to interact directly with P450R (see section 3 2  3 1) P450R is a 
reductase and, as such, is associated with the oxidative status of the cell, the 
observed alterations in drug toxicity might be attnbuted to changes in this status
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3 5 4 NADPH levels in MDA 231 cells
NADPH is an essential cofactor of P450R, apart from being an antioxidant molecule 
that can protect cells from vanous sources of oxidative stress Overexpression of 
P450R is expected to deplete cellular levels of NADPH, since increased enzymatic 
activity will be accompanied by the exhaustion of NADPH from cellular pools Indeed, 
this is what was observed when NADPH levels were measured in MDA EV and MDA 
R4 cells by a spectrophotometnc method (see section 2 15) As seen in Fig 3 5 3 A 
and B and Table 3 5 3, absolute NADPH levels were extremely vanable in MDA EV 
and MDA R4 cells, however, when NADPH contents were expressed relative to MDA 
EV levels, a consistent decrease of NADPH was shown for MDA R4 as compared to 
MDA EV cells
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ANADPH levels Experiment 1 Experiment 2 Experiment 3
(nmoles NADPH/mg total 
protein)
M D A E V  0.167 0791 ÔÔ5Ô
M D AR4 0.076 0.442 0.017
B
Relative NADPH levels MDA cells
MDAEV MDAR4
Figure 3.5.3: NADPH levels as determined by absorbance at 340 nm in MDA EV and MDA R4 cells. 
NADPH levels are expressed as nmoles NADPH per mg of total protein (A) or as % relative to MDA EV 
levels (B). Results represent the average of three independent experiments.
NADPH levels NADPH levels
(nmoles/mg total protein) (% relative to MDA EV cells)
MDA EV 0.336+/-0.399 100
MDA R4 0.178+/-0.230 45+/-11
Table 3.5.3: NADPH levels in MDA 231 cells expressed as nmoles NADPH per mg of total protein, or as 
% NADPH content relative to that of MDA EV cells. Results are expressed as mean +/- SD and represent 
the average of four independent experiments.
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3 5 5 Glutathione-related protein expression in MDA 231 cells
As seen in section 3 5 4, MDA R4 cells display decreased levels of NADPH as a 
consequence of P450R overexpression A major reduction in NADPH levels would 
mean that these cells have decreased antioxidant defences and are therefore more 
sensitive to reactive oxygen species (ROS)-mediated damage In this situation, it 
might be expected that the cells increase the levels of other antioxidants to protect 
themselves from the detrimental effects of ROS Glutathione (GSH) is the most 
abundant non-protein antioxidant present in the cell, it is synthesised by y-glutamyl 
cysteine synthetase (GCS), which consists of two subunits, one heavy, termed GCSH, 
and one light, termed GCSL GSH is then conjugated to toxic agents by GSH 
transferases (GSTs), of which the most important is GST P1 Expression of GCSH, 
GCSL and GST P1 was analysed in MDA EV and MDA R4 cells by Western blot 
Figs 3 5 4 and 3 5 5 show upregulation of GST P1, GCSH and GCSL in MDA R4 
cells as compared to MDA EV cells It is likely that MDA R4 cells increase the 
expression of these enzymes in order to reduce the toxic effects of ROS generated by 
P450R overexpression
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Figure 3 5 4 Western blot analysis of GST P1 protein expression in MDA 231 cells
GCSL
Figure 3 5 5 Western blot analysis of GCSH and GCSL protein expression in MDA 231 cells HepG2 
cells were used as positive control
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3 5 6 Oxidative stress in MDA 231 cells
One of the possible explanations for the increased sensitivity of MDA R4 cells to 
anticancer drugs is that oxidative stress levels would be increased in these cells, 
making them more susceptible to substances that can affect their already altered 
redox equilibnum These cells have lower levels of the antioxidant NADPH, also, 
GSH-related enzymes are upregulated, suggesting that cells have been exposed to 
oxidative stimuli To test this theory, oxidative stress levels were determined in MDA 
EV and MDA R4 cells using the ROS-sensitive probe dichlorofluorescein diacetate 
(DCFHDA) This is a non-fluorescent compound that diffuses freely through the cell 
membrane and is hydrolysed in the cytoplasm to dichlorofluorescein (DCFH), a more 
polar compound that remains inside the cell DCFH is not fluorescent either, but 
reacts with ROS present in the intracellular compartment to generate a fluorescent 
compound, the observed increase in fluorescence after a certain incubation period is 
directly proportional to the amount of ROS present in the cell (see section 2 16)
As seen in Fig 3 5 6, ROS are increased in MDA R4 cells at basal levels, consistent 
with the decrease in antioxidant NADPH The levels of ROS are also increased in 
response to Adnamycin and Mitomycin C, which undergo redox cycling by P450R, 
generating free radicals in the process, the generation of these free radicals could 
explain the observed increase in ROS However, this effect is also seen after 5- 
fluorouracil treatment This drug has several reported mechanisms of action, but none 
of them involve changes in the oxidative status of cells
Resveratrol is a polyphenol with antioxidant properties, although it has also been 
reported to induce the generation of ROS in tumour cell lines (Tmhofer et a l , 2001) 
The opposing effects of this drug on ROS levels can be seen in Fig 3 5 6 treatment 
with Resveratrol reduced ROS from their basal levels in MDA R4 cells, but it 
increased the levels of ROS in MDA EV cells
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Figure 3.5.6: Oxidative stress levels before and after treatment with different anticancer drugs measured 
by labelling with DCFHDA and expressed as percent fluorescence relative to basal MDA EV cell levels. 
The concentrations used were 22.8 ng/ml Resveratrol, 1.16 fig/ml Adriamycin, 1.3 |ig/ml 5-fluorouracil 
and 0.7 ng/ml Mitomycin C. Results represent the average of three independent experiments.
ROS levels (% relative to basal 
MDA EV levels)
MDA EV MDA R4
Control 100 205+/-36
Resveratrol 157+/-33 159+/-80
Adriamycin 68+/-27 235+/-76
5-fluorouracil 85+/-11 231+/-97
Mitomycin C 133+7-45 219+/-59
Table 3.5.4: Oxidative stress levels before and after treatment with different anticancer drugs as 
measured by labelling with DCFHDA and expressed as percent fluorescence relative to basal MDA EV 
cells levels. Results are expressed as mean +/- SD and represent the average of three independent 
experiments.
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3.6 Role of glutathione turnover in chemotherapy resistance
In-depth investigations have been earned out on glutathione (GSH)-related enzymes 
(GSH transferases, GSH synthetases and other metabolic enzymes such as GSH 
peroxidases) in order to define their role in the development of resistance to 
chemotherapy Techniques employed included overexpression of these enzymes by 
transfection and also inhibition of their expression by antisense or dominant negative 
transfection A number of studies report increased expression of GSH-related 
enzymes in resistant cell lines as compared to their parental counterparts Several 
reports have also shown enhanced cell resistance to different chemotherapy drugs as 
a consequence of transfection of these enzymes, however, the levels of resistance 
achieved after transfection of a single gene are usually modest This suggests that 
resistance does not depend on the expression of a single enzyme, but rather on a 
coordinated system that includes several enzymes and also different kinds of proteins, 
such as efflux pumps (especially members of the MRP family)
In order to study the changes in GSH turnover that are associated with the resistant 
phenotype, the expression of several GSH-related enzymes was analysed by Western 
blot in a panel of cancer cell lines and their pulse-selected counterparts Changes in 
GSH metabolism are usually associated with the development of resistance to 
platinum compounds and to anthracyclins such as Adnamycin, based on this concept, 
cell lines were chosen which had been previously pulse-selected with these drugs 
Parental (non-selected) cells were also tested, while cells that had been pulsed with 
the same protocol but using a different drug (such as Taxotere) were included in the 
analysis as well
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3 6 1 Drug resistance profiles of chosen cell lines
A number of cell lines have been developed in our centre by repeated pulsing with 
anticancer drugs Dr Laura Breen generated a number of resistant vanants by pulse 
selection of lung carcinoma cells with Taxol and Carboplatm She then determined 
their toxicity profiles by the acid phosphatase assay and calculated the IC50 values 
for a number of drugs, as well as the fold resistance
A549 lung carcinoma cells were pulsed with Carboplatin (100 pg/ml) and Taxol (150 
ng/ml) to generate the A549 Cpt and A549 Tax vanants, respectively Their drug 
resistance profile is shown in Table 3 6 1
IC50 (ng/ml) A549 A549-Tax Fold A549-Cpt Fold
resistance resistance
Adnamycin 17 3 ± 0 2 31 9 ± 4 9 1 8 13 3 ± 1 8 0 8
Taxol 1 1 ± 0 1 6 ± 0 5 5 5 0 5 ± 0 1 0 5
Taxotere 0 8 ± 0 9 1 5 ± 0 2 1 8 0 3 ± 0 1 0 3
Carboplatin 5900 ±200 7300 ±300 1 3 9600 ±2200 1 6
Cisplatin 584 ± 32 518 ±22 0 9 1377 ±427 2 4
5-FU 151 ± 14 290 ± 1 0 1 9 205 ± 26 1 4
VP-16 117 ± 18 484 ±81 4 1 106 ± 1 2 0 9
Vincristine 3 7 ± 0 5 6 0 ± 0 2 1 6 4 4 ± 0 9 1 2
Table 3 61 Drug resistance profile of A549 cells and their pulse-selected variants IC50 values are 
expressed as mean +/- SD and represent the average of three independent experiments Fold resistance 
is calculated as average IC50 selected variant/average IC50 parent (from Dr Laura Breen, Ph D thesis)
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H1299 lung carcinoma cells were also pulse-selected with Taxol (150 ng/ml) and 
Carboplatin (50 i^g/ml) Their toxicity profile is shown in Table 3 6 2
IC50 (ng/ml) H1299 H1299 Tax Fold
resistance
H1299 Cpt Fold
resistance
Adriamycm 30 3+/-0 9 29 8+/-1 3 1 27 4+/-1 7 0 9
Taxol 4 0+/-0 3 17 7+/-0 7 4 4 4 7+/-0 3 1 2
Taxotere 0 8+/-0 1 1 9+/-0 2 2 5 0 5+/-0 2 0 6
Carboplatin 3700+/-600 6200+/-500 1 7 7500+/-900 2
Cisplatin 437+/-30 655+/-196 1 5 673+/-86 1 5
5-FU 152+/-15 270+/-10 1 8 148+/-2 1
VP-16 111+/-12 122+/-19 1 1 156+/-10 1 4
Vincristine 2 4+/-0 1 5 4+/-1 2 3 1 8+/-0 3 0 8
Table 3 6 2 Drug resistance profile of H1299 cells and their pulse-selected variants IC50 values are 
expressed as mean +/- SD and represent the average of three independent experiments Fold resistance 
is calculated as average IC50 selected variant/average IC50 parent (from Dr Laura Breen, Ph D thesis)
Finally, the SKLU-1 lung carcinoma cell line was pulse-selected with Taxol (10 ng/ml) 
to generate the SKLU-1 Tax vanant or with Carboplatin (50 ^ig/ml) to generate SKLU- 
1 Cpt cells Their toxicity profiles are shown in Table 3 6 3
IC50 (ng/ml) SKLU-1 SKLU-1 Fold SKLU-1 Fold
Tax resistance Cpt resistance
Adnamycin 27 7+/-0 4 55 8+/-5 1 2 1 78 0+/-10 8 2 9
Taxol 1 2+/-0 1 6 2+/-0 5 5 10 5+/-0 6 8 5
Carboplatin 2800+/-200 3700+/-900 1 3 4000+/-200 1 4
Cisplatin 406+/-21 566+/-46 1 4 1177+/-75 2 9
5-FU 1223+/-74 1210+/-215 1 553+/-8 0 5
VP-16 116+/-6 162+/-17 1 4 240+/-13 2 1
Vincnstine 0 7+/-0 3 1 3+/-0 1 1 8 1 0+/-0 3 1 4
Table 3 6 3 Drug resistance profile of SKLU-1 cells and their pulse-selected variants IC50 values are 
expressed as mean +/- SD and represent the average of three independent experiments Fold resistance 
is calculated as average IC50 selected variant/average IC50 parent (from Dr Laura Breen, Ph D thesis)
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MCF-7 breast carcinoma cells were pulse-selected by Dr Yizheng Liang with 
Adriamycin, Cisplatin and Taxotere to generate the MCF-7 Adr, MCF-7 CisPt and 
MCF-7 Txt vanants The protocol used for their selection as well as their resistance 
profile can be seen in section 3 4 7
3 6 2 Selection of proteins involved in GSH metabolism
To gam insight into the alterations of GSH metabolism that occur in cancer cells, a 
senes of key proteins and enzymes were selected for analysis 
y-glutamyl cysteine synthetase (GCS) is the key enzyme in the synthesis of GSH It is 
composed of two subunits a heavy one, named the catalytic subunit or GCSH, and a 
light one, termed the regulatory subunit or GCSL Increased expression of GCS, 
especially GCSH, leads to higher levels of GSH, and this event is associated with 
enhanced drug resistance, especially against platinum compounds and 
anthracyclines The involvement of GCSL in the development of resistance remains to 
be fully explained
y-glutamyl transpeptidase (GGTP) is a membrane protein and the main enzyme 
responsible for GSH breakdown In spite of this, high levels of expression of GGTP 
have been shown to correlate with drug resistance, since increased turnover of GSH 
also results in higher levels of substrates for its synthesis
GSH transferases play a central role in drug metabolism attachment of a GSH moiety 
to the drug greatly facilitates its excretion The most widely expressed of these 
enzymes is GST P1, which is also the most studied This enzyme has a demonstrated 
role in drug resistance, as shown by a number of studies (see section 1 5 7 2) 
overexpression results in increased resistance to chemotherapy drugs such as 
Cisplatin and Adnamycin GST A1 is also relevant to drug metabolism, although its 
role in chemotherapy resistance has not been completely elucidated 
Expression of these enzymes was analysed by Western blot in our panel of resistant 
cell lines and their parental counterparts
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3 6 3 GCSH expression in a panel of pulse-selected cell lines by Western blot
Expression of GCSH was quite even across the cell line panel, with few exceptions 
(Fig 3 6 1) MCF-7 Adr displayed a slightly increased expression, suggesting that 
pulse selection with Adnamycin can induce GCSH protein expression On the 
contrary, MCF-7 Txt showed a marked decrease in GCSH levels Expression of 
GCSH was largely unchanged in A549, H1299 and SKLU-1 cells
Figure 3 61 Expression of GCSH in some of the cell lines from our panel by Western blot
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Expression of GCSL did not always parallel that of GCSH, even though they are two 
subunits of the same enzyme (Fig 3 6 2) GCSL levels were not appreciably changed 
in any of the resistant vanants analysed as compared to parent cells
3 6 4 GCSL expression in a panel of pulse-selected cell lines by Western blot
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Figure 3 6 2 Expression of GCSL in the cell panel by Western blot
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3 6 5 GGTP expression in a panel of pulse-selected cell lines by Western blot
Expression of GGTP was not measurable all across the panel MCF-7 parent cells 
and resistant vanants displayed no detectable levels of this enzyme (Fig 3 6 3) On 
the other hand, Taxol-selected H1299 cells showed decreased GGTP expression, 
while H1299 Cpt did not show any appreciable differences in GGTP levels as 
compared to parent cells, a similar profile was also observed in A549 parent and 
pulse-selected cells Expression of GGTP was slightly increased in both SKLU-1 Cpt 
and SKLU-1 Tax as compared to parent cells
Figure 3 6 3 Expression of GGTP in the cell panel by Western blot
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3 6 6 GST P1 expression in a panel of pulse-selected cell lines by Western blot
Expression of GST P1 was not measurable in all the cell lines analysed similar to the 
case of GGTP, no staining was detected in MCF-7 parent or pulse-selected cells (Fig 
3 6 4) On the contrary, GST P1 levels were readily detectable A549 and SKLU-1 
variants and also in parent cells Both resistant variants showed no major changes in 
expression as compared to parent cells
Figure 3 6 4 Expression of GST P1 in the cell panel by Western blot
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3 6 7 GST A1 expression in a panel of pulse-selected cell lines by Western blot
Expression of GST A1 was largely unchanged in all MCF-7 resistant variants as 
compared to the parent cells (Fig 3 6 5) In contrast, A549 Cpt cells displayed a slight 
decrease in the expression of this enzyme, while expression of GST A1 in A549 Tax 
cells appeared somewhat increased GST A1 levels were increased in SKLU-1 
variants as compared to parent cells, especially in SKLU-1 Tax cells
Figure 3 6 5 Expression of GST A1 in the cell panel by Western blot
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3 7 Pulse selection of cell lines
When cells are exposed to toxic compounds, they activate a senes of defence 
mechanisms aimed at decreasing the compound concentration (i e by active efflux or 
deactivation) and/or inhibiting its toxic effects (i e increased expression of 
antiapoptotic proteins or DNA repair enzymes) A single toxin usually activates several 
different mechanisms, which is to be expected, since multiple means of defence can 
inhibit toxic effects more effectively
These phenomena are observed in normal and also in cancer cells Exposure of 
cancer cells to chemotherapeutic drugs and the subsequent study of the defence 
mechanisms activated in response to this treatment can shed light on how these cells 
become resistant to the drugs and also how this resistance might be reverted
3 7 1 Pulse selection of Caco2 and HepG2 cells
Caco2 and HepG2 cell lines were exposed to IC70 concentrations (i e , the drug 
concentration which causes 70% cell death as compared to an untreated control) of 
different chemotherapeutic drugs in order to study which defensive mechanisms are 
activated by cells upon exposure to cytotoxic drugs As it can be seen in Tables 3 7 1 
and 3 7 2, the concentrations used for pulse selection are considerably lower than the 
reported achievable plasma concentrations (Alberts et a l , 1997, Ricotti et a l , 2003, 
Scnpture et a t , 2005) Caco2 cells are denved from a colon carcinoma, and were 
chosen because of their metabolic competence, literature shows they are able to 
produce metabolites similar to those found in the body (Lampen et a l , 1998) HepG2 
cells are derived from a hepatic carcinoma and have been reported as useful models 
to study regulation of drug metabolism enzymes (Wilkenmg et a l , 2003) These cells 
therefore have the potential to inactivate several different chemotherapy drugs by 
biotransformation
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Cell line Drugs used for pulse selection Concentration used
(ng/ml)
Caco2 Taxol 2560
Taxotere 160
HepG2 Taxol 1280
Taxotere 160
Cisplatin 2500
Table 3 7 1 Cell lines and drugs used in pulse selection experiments
Drug Achievable plasma concentration
(ng/ml)
Taxol 1200-5300
Taxotere 3670
Cisplatin 10000-100000
Table 3 7 2 Achievable drug concentrations as measured in patient plasma samples dunng 
pharmacokinetic studies
3 7 2 Toxicity profiles of pulse-selected cell lines
After the six-pulse treatment was completed, IC50 values of pulse-selected cell lines 
were determined by in vitro toxicity assays and compared to those of the parent 
(untreated) cells The drugs chosen for these expenments were Cisplatin, Innotecan, 
Taxol, Taxotere and Vincristine Taxol, Taxotere and Vincristine are CYP3A and 
MDR1 substrates, whereas Cisplatin is neither, being biotransformed largely through 
other metabolic routes Innotecan constitutes a special case, since it is inactivated by 
CYP3A4 but the contnbution of this pathway to the overall detoxification is low (Kehrer 
et a l , 2002)
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IC50s
(ng/ml)
Cisplatin Irinotecan Taxol Taxotere Vincristine
Caco2 420+/-30 2040+/-440 29 7+/-2 9 11 4+/-2 2 2 4+/-0 4
Caco2Txt
Caco2Txol
330+/-40
480+/-60
2170+/-10
2230+/-440
384+/-44
306+/-8
51 S+/-8 9 
41 6+/-7 2
81 4+/-8 9 
103+/-28
Table 3 7 3 ICSOs of Caco2 cells and their pulse-selected variants Results are expressed as mean +/- 
SD and represent the average of at least three experiments
IC50s
(ng/ml)
Cisplatin Irinotecan Taxol Taxotere Vincristine
HepG2 810+/-150 580+/-50 9 1+/-4 0 1 1+/-0 2 12 4+/-1 9
HepG2Txt 869+/-130 530+/-100 91 6+/-29 0
\
4 2+/-1 2 18 9+/-2 8
HepG2Txol 920+/-150 560+/-360 41 9+/-5 4 2 6+/-0 7 30 4+/-1 2
HepG2CisPt 820+/-20 470+/-80 10 9+/-0 5 0 8+/-0 3 10 4+/-1 7
Table 3 7 4 IC50s of HepG2 cells and their pulse-selected variants Results are expressed as mean +/- 
SD and represent the average of at least three experiments
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Fold
resistance
Cisplatin Irinotecan Taxol Taxotere Vincristine
Caco2 1 1 1 1 1
Caco2Txt 0.8 0.9 12.9 5 33.6
Caco2Txol 1.2 0.9 10.3 5.3 42.5
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Figure 3.7.1: Fold resistance of pulse-selected Caco2 cell lines relative to parental cells.
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Fold
resistance
Cisplatin Irinotecan Taxol Taxotere Vincristine
HepG2 1 1 1 1 1
HepG2Txt 1 1 6.4 3.8 1.5
HepG2Txol 1.1 1.4 2.6 5.9 2.5
HepG2CisPt 1 0.8 1.2 0.7 0.8
HepG2 HepG2Txt HepG2Txol HepG2CisR
Figure 3.7.2: Fold resistance of pulse-selected HepG2 cell lines relative to parental cells.
As seen in Table 3.7.3 and Fig. 3.7.1, Caco2 cells acquired a substantial level of 
resistance following pulse selection with Taxol and Taxotere. Remarkable resistance 
was developed against the drug that cells were pulsed with and cross-resistance was 
also observed against taxanes and Vincristine; all three drugs are both cytochrome 
P450 and MDR1 substrates. No appreciable resistance was developed against either 
Cisplatin or Irinotecan.
In a similar way, HepG2 pulse-selected cells also developed resistance to the taxanes 
and to Vincristine, while no substantial change in sensitivity was observed against 
Cisplatin or Irinotecan (Table 3.7.4 and Fig. 3.7.2). Cisplatin pulse-selected HepG2 
cells did not display any apparent changes in sensitivity to any of the tested drugs.
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3.7.3 CYP3A4 expression in Caco2 pulse-selected cells
Expression of CYP3A4 in both parent and Taxol and Taxotere-selected Caco2 cells 
as detected by Western blot is shown below. An increase in CYP3A4 protein levels 
was observed in both pulse-selected variants as compared to parent Caco2 cells (Fig.
3.7.3).
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3.7.4 CYP3A4 expression in HepG2 pulse-selected cells
Expression of CYP3A4 in both parent and selected HepG2 cells as detected by 
Western blot is shown in Fig. 3.7.4. A slight increase in CYP3A4 protein levels was 
observed in all pulse-selected variants as compared to parent HepG2 cells.
Figure 3.7.4: Expression of CYP3A4 in HepG2 cells and pulse-selected variants by Western blot.
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3.7.5 CYP3A5 expression in Caco2 pulse-selected cells
Expression of CYP3A5 in both parent and Taxol and Taxotere-selected Caco2 cells 
as detected by Western blot is shown in Fig. 3.7.5. As seen in the densitometry graph, 
Caco2Txt cells only display a modest increase in CYP3A5 expression, while the effect 
on Taxol variants is more patent.
Figure 3.7.5: Expression of CYP3A5 in Caco2 cells and pulse-selected variants by Western blot.
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3.7.6 CYP3A5 expression in HepG2 pulse-selected cells
Expression of CYP3A5 in both parent and pulse-selected HepG2 cells as detected by 
Western blot is shown in Fig. 3.7.6. HepG2CisPt and HepG2Txol cells displayed a 
modest increase in CYP3A5 levels, while HepG2Txt cells do not show altered 
CYP3A5 expression as compared to HepG2 cells.
Figure 3.7.6: Expression of CYP3A5 in HepG2 cells and pulse-selected variants by Western blot.
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3.7.7 Expression of CYP3A4 and CYP3A5 in other pulse-selected cell lines
Expression of CYP3A4 and CYP3A5 was also analysed in H1299 parent and 
Carboplatin and Taxol-selected cells, as well as on MCF-7 parent cells and resistant 
variants developed by pulse selection with Adriamycin and Taxotere. As seen in Fig. 
3.7.7, pulse-selected MCF-7 cells did not show any change in CYP3A4 or CYP3A5 
expression relative to MCF-7 cells, while the levels of these proteins were actually 
decreased in H1299 as compared to parent cells.
Figure 3.7.7: Expression of CYP3A4 (A and B) and CYP3A5 (C and D) proteins in H1299 cells (A and C) 
and MCF-7 cells (B and D) and pulse-selected variants by Western blot.
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Expression of MDR1 in both parent and Taxol and Taxotere-selected Caco2 cells as 
detected by Western blot is shown in Fig. 3.7.8. Both selected variants displayed a 
marked increase in MDR1 expression.
3.7.8 MDR1 expression in Caco2 pulse-selected cells
X
o
X1- 1-
CM C\l CM
O
O 8 8(0 ro ro
o O O
MDR1
G-actin
Figure 3.7.8: Expression of MDR1 in Caco2 cells and pulse-selected variants by Western blot.
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3.7.9 MDR1 expression in HepG2 pulse-selected cells
MDR1 expression was analysed by Western blot in parent HepG2 cells and their 
selected variants. As seen in Fig. 3.7.9, MDR1 expression was clearly upregulated in 
pulse-selected HepG2 variants, especially HepG2Txol and HepG2Txt. MDR1 was not 
detectable in parent HepG2 cells.
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3.7.10 Expression of GSH-related proteins in Caco2 pulse-selected cells
Pulse-selected Caco2 cells displayed much higher levels of resistance than HepG2 
cells. Expression of key enzymes related to GSH turnover was therefore analysed in 
Caco2 parent and pulse-selected variants by Western blot in an attempt to investigate 
whether GSH turnover was affected in these cells by repeated drug exposure. Fig.
3.7.10 A shows increased expression of GCSH in both Caco2 variants with respect to 
parent cells. This increase in expression of GCSH is paralleled by higher levels of 
GCSL in pulse-selected cells as compared to their parental counterparts (Fig. 3.7.10 
B).
Figure 3.7.10: Expression of GCSH (A) and GCSL (B) in Caco2 cells and pulse-selected variants by 
Western blot.
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As shown in the previous figures, expression of GSH synthetase subunits is 
increased, which suggests that the levels of GSH are higher in pulse-selected cells. 
GSH can either be transferred to toxic compounds by GSTs to facilitate their excretion 
or be broken down by GGTP and its components reused to synthesise new GSH 
molecules. Expression of GGTP is remarkably increased in Caco2 pulse-selected 
cells, especially in Caco2Txt cells (Fig. 3.7.11 A); this enzyme is almost absent in 
parent Caco2 cells. A similar increase was also observed for GST P1, the most 
important of the GSTs (Fig. 3.7.11 B); again, the increase in expression was more 
patent in Caco2Txt cells. These results suggest altered GSH turnover in pulse- 
selected Caco2 cells.
X * B 8 *\— 1— 1—CM CM CM CM CM CMO o O Q O oO o o O o oCO <0 CO CO CO CO
O O O O o o
Figure 3.7.11: Expression of GGTP (A) and GST P1 (B) in Caco2 parent and pulse-selected variants by 
Western blot.
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3.7.11 Reversion of resistance in Caco2 and HepG2 pulse-selected cells by 
GF120918A
Several inhibitors of MDR1 have been identified, including Verapamil, Cyclosporin A 
and GF120918. Most of these inhibitors act as competitors for MDR1 substrates, thus 
decreasing the amount of drug that is actively pumped out of the cell and 
subsequently enhancing the toxic effects; GF120918 is an example of a non­
competitive inhibitor. Taxotere and Taxol are MDR1 substrates; cells that express 
high levels of MDR1 become resistant to these drugs, but the combination of Taxotere 
or Taxol with an MDR1 inhibitor greatly enhances the toxicity of a slightly or even non­
toxic concentration of anticancer drug. In these cells, non-MDR1 substrate drugs such 
as Cisplatin show no increase in toxicity after simultaneous treatment with an MDR1 
inhibitor, which is to be expected.
The Caco2 and HepG2 pulse-selected variants displayed an increased resistance to 
Taxol, Taxotere and Vincristine, all of them MDR1 substrates; this pointed to a 
prominent role for MDR1 in the development of resistance. In an effort to find out 
more about the role of this pump in the pulse-selected cells, combination assays were 
performed using GF120918 and either Taxotere or Cisplatin at low or non-toxic 
concentrations.
As can be seen in Fig. 3.7.12, inhibition of MDR1 increased Taxotere-induced toxicity 
in parent Caco2 cells; this effect was much more pronounced in both selected 
variants, suggesting an increased dependence on MDR1 activity in these cells (Fig. 
3.7.13). As expected, enhancement of toxicity was not observed with Cisplatin in 
Caco2 parent (Fig. 3.7.14) or pulse-selected variants (Fig. 3.7.15).
GF120918 also synergised with Taxotere to induce greater toxicity in HepG2 parent 
cells (Fig. 3.7.16). However, contrary to what was observed for Caco2 cells, this effect 
was similar, or even decreased, in pulse-selected variants (Fig. 3.7.17). No 
enhancement of Cisplatin toxicity was observed in HepG2 parent (Fig. 3.7.18) or 
selected variants (Fig. 3.7.19) after simultaneous treatment with GF120918, 
suggesting an MDR1-exclusive phenomenon.
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Taxotere + GF120918 Caco2 cells
Control Taxotere 0.8 GF120918 GF120918 GF120918 GF120918 GF120198 GF120918
ng/ml 300ng/ml 300ng/ml+Txt 150ng/ml 150ng/mHTxt 75ng/ml 75ng/ml+Txt
Figure 3.7.12: Modulation of Taxotere toxicity in Caco2 cells by GF120918. Results represent the 
average of at least three experiments.
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Control Taxotere 3.2 GF120918 GF120918 GF120918 GF120918 GF120198 GF120918 
ng/ml 300ng/ml 300ng/ml+Txt 150ng/ml 150ng/ml+Txt 75ng/ml 75ng/ml+Txt
Figure 3.7.13: Modulation of Taxotere toxicity in Caco2 Taxol (A) and Taxotere (B) pulse-selected cells
by GF120918. Results represent the average of at least three experiments.
Figure 3.7.14: Modulation of Cisplatin toxicity in Caco2 cells by GF120918. Results represent the 
average of at least three experiments.
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A Cisplatin +GF120918 Caco2Txol cells
Ccrtrd Cispl^in28.6n9rni GF12D918300n^rH GF12091B GF120910150ntfrr1 GF120818 GF12019B75ntf rri GF12O018
300n^ rrl-O sPt 15Cki^  rrl-OsPt 75n»irrl-OiPt
B Cisplatin + GF120918 Caco2Txt cells
Cartrd C)spHm28 6rtf rrl GF120018300^1* GF120918 GF1208181SChtfrri GF120918 GF12019875ng/rr1 GF120918
30Chgini<lsPt 150ng^nHa*R 75ngfn1Ci*Pt
Figure 3.7.15: Modulation of Cisplatin toxicity in Caco2 Taxol (A) and Taxotere (B) pulse-selected cells
by GF120918. Results represent the average of at least three experiments.
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Taxotere + GF120918 HepG2 cells
Control Taxotere 0.8 
ng/ml
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Taxotere + GF120918 HepG2CisPt cells
'
Control Taxotere 0.8 GF120918 GF120918 GF120918 GF120918 GF120198 GF120918
ng/ml 300ng/ml 300ng/ml+Txt 150ng/ml 150ng/ml+Txt 75ng/ml 75ng/ml+Txt
Figure 3.7.16: Modulation of Taxotere toxicity in HepG2 parent (A) and Cisplatin pulse-selected cells (B)
by GF120918. Results represent the average of at least three experiments.
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Taxotere + GF120918 HepG2Txt cells
Control Taxotere 0.8 GF120918 GF120918 GF120918 GF120918 GF120198 GF120918
ng/ml 300ng/ml 300ng/ml+Txt 150ng/ml 150ng/ml+Txt 75ng/ml 75ng/ml+Txt
Figure 3.7.17: Modulation of Taxotere toxicity in HepG2 Taxol (A) and Taxotere (B) pulse-selected cells
by GF120918. Results represent the average of at least three experiments.
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Figure 3.7.18: Modulation of Cisplatin toxicity in HepG2 parent (A) and Cisplatin pulse-selected (B) cells
by GF120918. Results represent the average of at least three experiments.
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A Cisplatin + GF120918 HepG2Txol cells
B Cisplatin + GF120918 HepG2Txt cells
Control Cisplatin 28.6 GF120918 GF120918 GF120918 GF120918 GF120198 GF120918
ng/ml 300ng/ml 300ng/ml+CisPt 150ng/ml 150ng/ml+CisPt 75ng/ml 75ng/ml+CisPt
Figure 3.7.19: Modulation of Cisplatin toxicity in HepG2 Taxol (A) and Taxotere (B) pulse-selected cells
by GF120918. Results represent the average of at least three experiments.
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3.7.12 Reversion of resistance in Caco2 and HepG2 pulse-selected cells by
Sulindac
Sulindac is a well-known inhibitor of MRP1 (O’Connor et al., 2004). Simultaneous 
incubation of Sulindac with Adriamycin, an MRP1 substrate, did not result in a 
significant increase in toxicity in either Caco2 or Caco2Txol cells (Figs. 3.7.20 and 
3.7.21 A); however, some synergy was observed between these two drugs in 
Caco2Txt cells, especially at the highest concentration of Sulindac (Fig. 3.7.21 B). No 
major effects in toxicity resulted from combination with Sulindac in HepG2 parent or 
selected cells, suggesting that MRP1 does not play a major role in the observed 
increase in resistance (Figs. 3.7.22 and 3.7.23).
Adriamycin + Sulindac Caco2 cells
140
120
' "" : ■ 5
100
f
AH
SVi; '
"  V i
OU ■ 
60
c
40
20 ■
0
Central A*ianydn10ngfrri 20ugfrrl Silindac 20ug/rr1 10ug/n1 Sulindac 10ugirr1 5ugfr»1 SUInd* 5ugfrr1
SjHrKkc-Atfriarrydn 3jlin<fcc-A<*ianyan SUinckc-tfcfrianydn
Figure 3.7.20: Modulation of Adriamycin toxicity by Sulindac in Caco2 cells. Results represent the 
average of three independent experiments.
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Adriamycin + Sulindac Caco2Txol cells
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Figure 3.7.21: Modulation of Adriamycin toxicity by Sulindac in Caco2 Taxol (A) and Taxotere (B) pulse-
selected cells. Results represent the average of three independent experiments.
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Figure 3.7.22: Modulation of Adriamycin toxicity by Sulindac in HepG2 parent (A) and Cisplatin pulse-
selected (B) cells. Results represent the average of three independent experiments.
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Figure 3.7.23: Modulation of Adriamycin toxicity by Sulindac in HepG2 Taxol (A) and Taxotere (B) pulse- 
selected cells. Results represent the average of three independent experiments.
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3.7.13 Reversion of resistance in Caco2 and HepG2 pulse-selected cells by 17 
AEE
In order to find out whether the increased expression of CYP3A could protect pulse- 
selected cells against the toxic effects of anticancer drugs, cells were treated with 
Taxol, a CYP3A4 substrate, in the presence or absence of 17 AEE. As shown in Figs. 
3.7.25, 3.7.28 and 3.7.29, combination of 17 AEE and Taxol, a CYP3A substrate, did 
not appear to substantially enhance the effect of the anticancer drug in any of the 
pulse-selected cell lines tested, even at the highest concentrations of 17 AEE. This 
suggests that CYP3A does not play a relevant role in the resistance developed by 
these variants. A similar result was obtained when treating cells with Cisplatin in the 
presence or absence of 17 AEE (Figs. 3.7.26, 3.7.27, 3.7.30 and 3.7.31). A slight non­
dose-dependent enhancement of Taxol toxicity was observed in Caco2 cells in the 
presence of 17 AEE (Fig. 3.7.24), indicating that CYP3A expression might at least 
partially protect these cells against Taxol-induced toxicity; however, this effect was not 
observed in HepG2 cells (Fig. 3.7.28 A).
Taxol + 17AEE Caco2
Control Taxol 18ngAnl 285ngAnl 17AEE 285ngAnl 142ngAnl 17AEE 142ngAnl 71ngAnl 17AEE 71ngAnl
17AEE+Txol 17AEE+Txd 17AEE+Txd
Figure 3.7.24: Modulation of Taxol toxicity by 17 AEE in Caco2 cells. Results represent the average of
four independent experiments.
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Taxol + 17AEE Caco2Txol
Control Tixol 18ng/ml 285ng/ml 17AEE 285n9/ml 142ng/ml 17AEE 142ng/ml 71nfl/ml17AEE 71nt>/ml
17AEE+TxdI 17AEE+Txo) 17AEE+Txoi
B
Figure 3.7.25: Modulation of Taxol toxicity by 17 AEE in Caco2 Taxol (A) and Taxotere (B) pulse-
selected cells. Results represent the average of four independent experiments.
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Figure 3.7.26: Modulation of Cisplatin toxicity by 17 AEE in Caco2 cells. Results represent the average 
of four independent experiments.
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Figure 3.7.27: Modulation of Cisplatin toxicity by 17 AEE in Caco2 Taxol (A) and Taxotere (B) pulse-
selected cells. Results represent the average of four independent experiments.
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AB
Figure 3.7.28: Modulation of Taxol toxicity by 17 AEE in HepG2 parent (A) and Cisplatin pulse-selected
(B) cells. Results represent the average of at least three independent experiments.
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Taxol + 17AEE HepG2Txol cells
Control Taxol 17.22ngAnl 285ng/ml 17AEE 285ng/ml 142ng/ml 17AEE 142ng/ml 71nflAnl 17AEE 71ng/ml
17AEE+Txol 17AEE+Txol 17AEE+Txol
B
Figure 3.7.29: Modulation of Taxol toxicity by 17 AEE in HepG2 Taxol (A) and Taxotere (B) pulse-
selected cells. Results represent the average of at least three independent experiments.
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A
Cisplatin + 17AEE HepG2 cells
B
Figure 3.30: Modulation of Cisplatin toxicity by 17 AEE in HepG2 parent (A) and Cisplatin pulse-selected 
(B) cells. Results represent the average of at least three independent experiments.
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Figure 3.7.31: Modulation of Cisplatin toxicity by 17 AEE in HepG2 Taxol (A) and Taxotere (B) pulse-
selected cells. Results represent the average of at least three independent experiments.
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3 7 1 4  Reversion of resistance in Caco2 pulse-selected cells by simultaneous 
treatment with 17 AEE and GF120918
Previous results obtained with GF120918A and 17 AEE alone suggested that the 
increased expression of MDR1 in pulse-selected cells played a far more important 
role in the development of resistance than that of P450s Indeed, MDR1 appeared to 
be the main mechanism of resistance in these cells P450s may then be considered 
as a second line of defence against cytotoxic drugs, relevant only where MDR1 is 
inactive or as and adjuvant to MDR1 activity In order to test this hypothesis, Caco2 
pulse-selected and parent cell lines were exposed to Taxol in the presence of either 
GF120918A, 17 AEE or both As shown in Fig 3 7 33 B, 17 AEE treatment of 
Caco2Txt cells in the presence of GF120198A did not further increase Taxol toxicity, 
suggesting that CYP3A activity is not an important resistance mechanism in these 
cells, even after inhibition of MDR1 However, 17 AEE did enhance Taxol toxicity in 
the presence of GF120918A in Caco2Txol cells (Fig 3 7 33 A), suggesting that 
CYP3A might act as a second-order defence in these cells Caco2 parent cells only 
showed a slight increase in toxicity at the highest concentration of 17 AEE (Fig 
3 7 32)
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Taxol + GF120918 + 17AEE in Caco2 cells
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Figure 3.7.32: Triple combination assay showing modulation of Taxol toxicity by 17 AEE in the presence 
of GF120918A in Caco2 cells. Results represent the average of at least four independent experiments.
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Taxol + GF120918 + 17AEE in Caco2Txol cells
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Figure 3.7.33: Triple combination assay showing the effect of Taxol and 17 AEE in the presence of 
GF120918A in Caco2 Taxol (A) and Taxotere (B) pulse-selected cells. Results represent the average of 
at least four independent experiments.
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Section 4.0
Discussion
/The work described in this thesis attempted to increase our understanding of the role 
of drug metabolism enzymes in anticancer drug resistance using several different 
approaches
• Analysis of drug metabolism-related gene expression using whole genome 
gene expression microarray technology
• Use of recombinant P450s to study the direct inactivation of anticancer drugs
•  ^Use of transfected and/or inducer-treated cell lines overexpressing
cytochromes P450 or NADPH P450 reductase
• Use of siRNA to knock-down the expression of CYP1B1
• Comparative analysis of glutathione-related enzyme expression in parent and 
pulse-selected cells
• Study of resistance mechanisms developed by pulse selection of cells
These results are now discussed in the context of previously published reports
4.1 Expression of drug metabolism-related genes in normal 
and tumour breast tissue
4 11  Expression of drug metabolism-related genes in breast samples by 
microarray analysis
A number of studies have clearly demonstrated that cytochromes P450 and other 
metabolic enzymes are commonly expressed in both normal and tumour tissue (see 
section 1 4 5) Literature also suggests a differential regulation of these enzymes in 
malignant cells, although the nature of these differences is still a matter of 
controversy
The usual techniques employed to analyse expression of genes of interest in tissue 
samples are RT-PCR, Western blot and immunohistochemistry, these traditional 
techniques are widely used and highly efficient, although they do require optimisation 
Their main disadvantage is that they only allow for the analysis of one or a few genes 
at a time It is believed that the expression of hundreds or even thousands of genes is 
altered in cells that have undergone malignant transformation, analysis of these 
changes therefore requires techniques with higher throughput capacity In recent 
years, the use of gene expression microarrays has emerged as a remarkably powerful 
tool that allows for the simultaneous measurement of expression of thousands of
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genes. Microarrays are now widely used to identify genes involved in a particular 
process, such as malignant transformation or development of drug resistance.
Van’t Veer et al. (2002) recently carried out a DNA microarray analysis on 117 breast 
tumour samples with the aim of finding a signature gene expression that could 
accurately detect those breast tumours with a high chance of developing metastasis in 
lymph node negative patients. These samples were analysed with a microarray 
platform containing some 25,000 genes, of which 5,000 were found to be significantly 
up or downregulated. Of these, 231 genes were associated with disease outcome; 
further analysis of the genes present in the latter group allowed for the detection of a 
subset of 70 genes that could correctly predict disease outcome in 83% of cases. No 
genes related to drug metabolism made it to the final subset, which suggests that their 
involvement in breast tumour progression is limited. However, changes in the 
expression of a number of cytochromes P450 and GSH-related proteins associated 
with prognosis were reported. It was found that expression of CYP3A7, CYP1A1, 
GSH peroxidase 5 and aryl hydrocarbon receptor interacting protein was increased in 
those samples with better prognosis (lower chance of developing metastasis).
Analysis of a large number of breast tumour samples was performed in our centre by 
Dr. Lorraine O’Driscoll et al. using whole genome gene expression microarrays; the 
results obtained are predominantly in agreement with previous findings (see section 
1.4.5). A large proportion of the samples studied expressed a variety of drug 
metabolism-related genes. In many cases, significant alterations in gene expression 
were found in tumour as compared to normal samples.
It is known that the expression of CYP2J2 increases cell proliferation and inhibits 
apoptosis (Jiang et al., 2005), so it is not unexpected that CYP2J2 mRNA was more 
often expressed in tumours than in normal tissue. CYP2W1, however, has recently 
been hailed as a tumour-specific P450 (Karlgren et al., 2006), with no or very low 
levels of CYP2W1 mRNA and protein found in normal adult tissues, so it was 
unexpected to find that mRNA expression of this enzyme in normal tissue was more 
frequent than in tumour samples. The low prevalence of CYP1A1 mRNA expression 
found in this analysis is in correlation with the results of El-Rayes et al. (2003), who 
found lower frequency of CYP1A1 expression in tumour as compared to normal 
tissue. Iscan et al. (2001) also found very low levels of this enzyme in both breast 
tumour samples and their surrounding normal tissue by RT-PCR analysis. However, 
these authors found decreased expression of CYP2E1 in tumour samples by 
immunoblotting, which is in contradiction with the observed mRNA expression 
frequencies in our results. These inconsistencies could be attributed to
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posttranscriptional events, since mRNA levels do not always correlate with protein 
levels.
GSH transferase M4 (GST M4) mRNA expression was found to be more common in 
normal than tumour tissue. The role played by this enzyme in cancer remains 
obscure, but a recent study suggested an association between GST M4 
polymorphisms and lung cancer risk, implying that the activity of this enzyme might be 
involved in tumour development (Liloglou et aI., 2002). Expression of GSH peroxidase 
2 mRNA was also found to be more frequently expressed in tumour as compared to 
normal breast tissue. This enzyme is believed to act as an anticarcinogenic factor, 
since knock-out mice for GSH peroxidase 2 show enhanced gastrointestinal tumour 
formation (Brigelius-Flohe et al., 2006). Expression of GSH peroxidase 2 has been 
established in breast tissue (Chu et al., 1999) and increased expression of this 
enzyme has recently been reported in lung adenocarcinomas and in normal alveolar 
epithelium from smokers as compared to normal lung tissue from non-smokers 
(Woenckhaus et al., 2006). This enzyme can protect cells from free radicals and also 
regulate proliferation and apoptosis through redox signalling (Brigelius-Flohe et al.,
2001) and thus its increased expression may confer a survival advantage to tumour 
cells.
4.1.2 Potential biomarkers identified in the microarray study
Differential mRNA expression of ARNT2 was one of the major findings in our study, 
with expression in tumour tissue being much more prevalent than in normal tissue 
samples and significantly correlating with better prognosis. To date, no correlation has 
been reported in the literature between expression of this gene and cancer 
progression or survival.
Upon binding a specific ligand, the aryl hydrocarbon receptor (AhR) dimerises with the 
AhR nuclear translocator protein (ARNT) and activates the transcription of its target 
genes. ARNT2 is a homolog of ARNT with a more restricted pattern of expression, 
commonly found in the central nervous system (Maltepe et al., 2000), although its 
expression has also been reported in other developing organs such as kidney 
(Freeburg et a/., 2004). The main function of ARNT2 appears to be in brain 
development, since mice deficient in this gene showed defects in their secretory 
neurons (Hosoya et al., 2001). It has also been suggested that ARNT2 plays a wider 
role in development: disruption of ARNT2 expression in fertilised zebrafish eggs 
cause severe defects in brain, eyes, heart and gut development (Hsu et al., 2001).
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Increased expression of ARNT2 in tumour tissue could explain the low levels of 
CYP1A1 observed: it has been reported that a zebrafish homologue of ARNT2 
repressed 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-dependent CYP1A 
transcription (Wang et a/., 2000). Moreover, it was shown that ARNT2 dimerises with 
the hypoxia-inducible factor-1 (HIF-1) to induce the expression of genes in response 
to oxygen deprivation (Maltepe et a/., 2000). Formation of ARNT2/HIF-1 complexes in 
teratocarcinoma cells increased VEGF expression and tumour angiogenesis, as well 
as enhancing cell proliferation. The presence of ARNT2 therefore seems to improve 
growth efficiency in tumours, which might explain why tumour samples showed 
increased expression of this factor. However, this does not explain why ARNT2- 
positive tumours are associated with better prognosis. Indeed, statistical analysis 
revealed that ARNT2 expression correlates with overall survival and disease-free 
survival.
It should be noted that Van’t Veer et al. (2002) also found increased mRNA 
expression of an AhR-related element, the aryl hydrocarbon interacting protein, in 
samples from patients that had a better prognosis. This points to the AhR receptor 
pathway as a commonly altered target in breast cancer; its deregulation, however, 
appears to be associated with good prognosis.
The AhR receptor pathway was initially considered to be involved mainly in the 
metabolism of polycyclic aromatic hydrocarbon and halogenated hydrocarbons; more 
recent studies have shown that the AhR is implicated in such essential cell functions 
as growth, proliferation, apoptosis and epithelial-mesenchymal transition (Schlezinger 
et al., 2006). The role of the AhR in these phenomena remains undefined, as there is 
evidence that it can both increase and inhibit cell proliferation, as well as protect cells 
from apoptosis or induce cell death. One of the best characterised mechanisms of 
growth inhibition by the AhR involves repression of oestrogen receptor (ER) signalling; 
it is then not unreasonable to believe that ER+ tumours would display impaired growth 
and decreased proliferation rates. It should also be noted that even though ER 
expression did not significantly correlate with ARNT2 expression, the P value was 
almost at the limit of significance (P=0.052). This would suggest that many of the 
tumours expressing ARNT2 were also ER+. AhR signalling, helped by ARNT2, might 
then slow down the progression of these tumours. This model would explain the better 
prognosis observed in patients with ARNT2-overexpressing tumours.
It should be noted that ER+ tumours are associated with better survival; since many of 
the tumours expressing ARNT2 are also ER+, the better survival rates associated with 
ARNT2 might just be due to the fact that this protein is linked with ER+ status, which 
in turn is associated with better survival. Increased ARTN2 mRNA expression might
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thus not directly" impair tumour progression but rather be associated with the better 
prognosis-related ER+ status Even if this were the case, ARNT2 would still be useful 
in prediction of prognosis and might also be used as a marker of disease, since it is 
considerably upregulated in tumour as opposed to normal tissue (see Table 3 1 3)
Expression of GST A1 was associated with decreased overall and relapse-free 
survival This might be related to therapy efficacy, since expression of GST A1 in cell 
lines is associated with an increase in resistance to Carboplatin and 
Cyclophosphamide (Tanner et a/, 1997) Increased expression of GST A1 in tumour 
tissue would mean enhanced inactivation of anticancer drugs that could result in 
treatment failure
Several reports have tried to establish a correlation between GST A1 expression in 
tumours and disease prognosis, sometimes generating contradictory results Early 
studies carried out in breast cancer patients failed to establish a correlation between 
GST expression and clmicopathological features such as disease-free and overall 
survival (Peters et a l, 1993, Alpert et a l, 1997) Confirming these results, Wrigley et 
al (1996) failed to find an association between the expression of any of the GSTs 
analysed and response to treatment, overall survival and disease-free survival in 
ovarian cancer Similarly, another study carried out in ovarian cancer samples 
reported lack of correlation between GST expression and resistance to 
Cyclophosphamide and/or Carboplatin (Tanner et a/, 1997) However, mean plasma 
concentrations of GST A1 were found to be significantly increased at the time of 
relapse in dogs with lymphoma (Hahn et a l, 1999), suggesting that this isozyme might 
be of use as a marker of disease progression
A more recent analysis performed by Sweeney et al (2003) found that patients 
homozygous for a GST A1 polymorphism that results in reduced expression of the 
enzyme showed a significant difference in 5-year survival after breast cancer 
treatment when compared to heterozygous patients, indeed, low expression of GST 
A1 correlated with reduced risk of death in the 5 years following diagnosis Lower 
expression of GST A1 in the liver would mean that drugs such as Cyclophosphamide 
are inactivated in a slower manner, leaving more drug available in the circulation and 
improving therapy efficacy
In conclusion, gene expression microarray analysis makes possible the study of 
alterations in the expression of thousands of genes during cancer development and 
progression, providing an accurate picture of what is happening inside the cell As 
shown by our results, it can also help to elucidate the connection between gene
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expression and cancer phenotype or therapy outcome, -thereby improving, our. __ __ 
knowledge of the disease and providing biomarkers for -diagnosis a n d '--  
characterisation
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4.2 Anticancer drug metabolism by cytochromes P450
4 2 1 Anticancer drug metabolism by CYP3A4
The microsomal fractions of insect cells infected with recombinant baculovirus 
carrying human cytochrome P450 cDNAs are a useful tool for the study of P450- 
mediated drug metabolism They display higher levels of activity, as shown in section
3 2 11 by measuring testosterone 6p-hydroxylase (CYP3A) activity However, 
testosterone 6(3-hydroxylase activity of CYP3A4 microsomes, calculated as 
0 353±0 086 pmol substrate/mg total protein/minute, is still substantially lower than 
that reported for human liver (0 5-9 nmol/mg/mm, Draper et a/, 1998) or small 
intestine microsomes (0 4-2 4 nmol/mg/mm, Obach et a l, 2001) Still, they constitute 
valuable models to investigate the effect of CYP3A4 activity on anticancer drugs 
Incubation of Vincristine and especially Adriamycin, but not 5-fluorouracil, with 
CYP3A4 microsomes in the presence of the appropriate cofactors appreciably 
decreased drug-induced toxicity in A549 cells As mentioned before, both Adriamycin 
and Vincristine are CYP3A4 substrates (Lewis et a l, 1992, Yao et a l, 2000), whereas 
5-fluorouracil does not interact directly with P450s A549 cells display no measurable 
endogenous CYP3A activity, so the contribution of endogenous anticancer drug 
metabolism is negligible The observed decrease in toxicity was time-dependent, 
which suggests it is related to enzymatic activity Indeed, CYP3A4 ts known to convert 
most of its substrates into less or non-toxic derivatives, mainly by increasing their 
hydrophillicity and thus facilitating conjugation and excretion The reduced toxicity of 
these drugs after preincubation with CYP3A4-containmg microsomes could then be 
explained by enzymatic inactivation These results demonstrate that CYP3A4 has the 
potential to reduce the toxicity of certain anticancer drugs
4 2 2 Anticancer drug metabolism by CYP1B1
Contrasting with the results obtained with CYP3A4, preincubation of 5-fluorouracil, 
Taxol or Taxotere with CYP1B1-containing microsomes did not affect the toxicity 
induced by these drugs on A549 cells Ethoxyresorufin-O-deethylase (EROD) activity 
measured in CYP1B1 microsomes was substantially (about three orders of 
magnitude) higher than that previously reported from human renal tumours, which 
ranged from 62 to 995 fmol/mg of microsomal protein/min (McFadyen eta! , 2004)
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Transfection of CYP1B1 cDNA has been reported to confer Taxotere resistance"-to —— : 
Chinese hamster V79 cells (McFadyen et a l, 2001), because this enzyme is involved 
in the metabolism of endogenous factors, it was thought that it would inactivate 
Taxotere, transforming it into less-toxic derivatives However, incubation of Taxotere 
with CYP1B1 microsomes did not produce any metabolites, even after addition of 
enzyme activators and changes in 10 different incubation factors that might affect the 
reaction (Bourmque et a l, 2002) CYP1B1 reaction with 17(3 oestradiol, a known 
endogenous substrate, generated the expected metabolite in most conditions tested 
by the authors The study could only show that Taxotere effectively bound CYP1B1 
and acted as an effector of this enzyme These results are in agreement with our 
findings
Our results would suggest that CYP1B1 does not mediate the direct inactivation of 
Taxotere and that other factors are responsible for the observed increase in Taxotere 
resistance in CYP1B1-transfected cells
4 2 3 Anticancer drug metabolism by P450R
It is known that upon reaction with P450R, Adriamycin loses its sugar moiety to 
generate an aglycone metabolite (Fig 4 2 1) This metabolite is generally considered 
as less toxic than the parent drug, although several studies have shown that it still 
retains some toxicity, including induction of cytochrome C release from isolated 
mitochondria (Clementi et a/, 2003) and alteration of sugar metabolism in 
erythrocytes (Misiti et a l, 2003)
Preincubation of P450R-expressing microsomes reduced the toxic effects of 
Mitomycin C and especially Adriamycin, two well-known substrates of P450R, on 
MDA 231 cells This effect was not observed with 5-fluorouracil or Vincristine, which is 
to be expected, since these drugs are not known to be directly inactivated by P450R 
The effect was observed on both MDA EV (empty vector-transfected) and MDA R4 
(P450R-transfected), indicating that the decrease in toxicity is independent of 
endogenous P450R expression These results suggest that P450R activity can 
decrease the cytotoxicity of Adriamycin and Mitomycin C in tumour cells
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Figure 4 21 Metabolism of Adnamycin (also known as Doxorubicin) to less toxic denvatives (from 
Shairoz Ramji, M Sc thesis)
However, the aglycone metabolite could not be detected by LC/MS after incubation of 
Adnamycin with P450R-expressing microsomes for 1 hour Given that preincubation 
of P450R microsomes with Adnamycin reduced the toxicity of the drug on MDA 231 
cells, it appears that the drug is indeed being converted to less toxic metabolites by 
reaction with P450R This suggests that either the method is not appropriate for 
detection of Adnamycin aglycone or that the aglycone is unstable and is degraded 
before it can be detected Direct injection of Adnamycin aglycone resulted in a readily 
detectable peak (see Fig 3 2 11), so it seems unlikely that this metabolite is degraded 
inside the mass spectrometer, unless it is present at extremely low concentrations 
Also, it should be taken into account that the method used for analysis was designed 
for the detection of anthracyclines and not their metabolites, the same is true of the 
extraction method This method has not been optimised for the detection of the 
Adnamycin aglycone and thus it could be that the metabolite is either lost during 
extraction or degraded during sample processing
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4.3 CYP3A4 and drug resistance
One of the major difficulties in the study of cytochromes P450 is the extremely low 
levels of enzyme expression displayed by cell lines CYP3A4 activity is undetectable 
in many cell lines, which makes it very hard to find a suitable model to study the role 
of this enzyme in the development of drug resistance
Transfection of cell lines with P450 cDNAs provides a solution to this problem Indeed, 
CYP3A4-transfected BCMV 3A4 cells showed remarkable expression of this enzyme 
as shown by RT-PCR and Western blotting CYP3A activity could also be measured 
in this cell line, although it was considerably (about 6 times) lower than that found in 
CYP3A4 microsomes It should be noted, though, that metabolite levels were 
measured in culture medium from a confluent flask, so activity refers to total protein 
rather than to microsomal protein, as is the case in CYP3A4 microsomes The two 
values are therefore not directly comparable
Toxicity assays carried out on these cells show a modest (1 8-fold) increase in 
Adnamycm resistance displayed by BCMV 3A4 as compared to BCMV Neo (empty 
vector-transfected) cells, this is to be expected, since this drug is a CYP3A4 substrate 
and can therefore be inactivated by the overexpressed enzyme Indeed, reduction in 
Adriamycm toxicity was observed after preincubation of this drug with CYP3A4 
microsomes (see section 3 2 12) However, the magnitude of this increase was small, 
suggesting that even though CYP3A4 can protect BCMV 3A4 cells from Adriamycm- 
induced toxicity, the overall contribution of this enzyme to drug resistance is low 
Another explanation for these results would be that P450R activity is too low in BCMV 
cells to support CYP3A4 metabolism, however, testosterone 6P-hydroxylase activity 
was readily detected in these cells, suggesting that P450R activity levels are not 
hindering CYP3A4 metabolism Furthermore, BCMV 3A4 cells were shown to 
efficiently activate the procarcinogen aflatoxm B1 (Van Vleet et a l, 2002) Cisplatin 
toxicity was unaffected by CYP3A4 transfection, which again was anticipated, as this 
enzyme does not appear to play a role in Cisplatin metabolism 5-fluorouracil 
metabolism is not related to P450s and no direct inactivation could be shown by 
preincubation of the drug with CYP3A4 microsomes (see section 3 2 12), however, 
BCMV 3A4 cells also showed a modest (1 8-fold) yet significant (p=0 016) increase in 
resistance to this drug when compared to empty vector-transfected cells 
Furthermore, the magnitude of this increase was about the same as that observed for 
Adriamycin
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In order to confirm that the observed increase in Adriamycin resistance was due to 
enhanced CYP3A4 activity, BCMV cells were treated with a non-toxic dose of this 
drug in the presence of the CYP3A inhibitor 17 a-ethynyl oestradiol (17 AEE) 17 AEE 
showed strong and dose-dependent inhibition of testosterone 6p-hydroxylase activity 
in CYP3A4-expressing microsomes Combination assays showed a slight 
enhancement of cell kill in BCMV 3A4 cells after simultaneous treatment with these 
drugs, the effect, though modest (about 10% kill), was reproducible and was not 
observed with Cisplatin, which was expected Combination of a non-toxic dose of 5- 
fluorouracil with 17 AEE did not result in increased cell kill, although it resulted in a 
similar trend as that observed with Adriamycin
No association between CYP3A4 activity and 5-fluorouracii toxicity has ever been 
reported in the literature Transfected cell lines were selected with neomycin during 
the cloning process and were also cultured in neomycin-containing medium for two 
passages after thawing, to ensure the presence of the plasmid A possible explanation 
for the results obtained could be that prolonged culture in selecting medium has 
affected cell sensitivity to toxic drugs, increasing cell resistance However, toxicity of 
Cisplatin was not altered in CYP3A4-transfected cells Furthermore, both BCMV Neo 
and BCMV 3A4 would have been cultured in the same conditions, including passaging 
in selecting medium, and thus should display similar responses to 5-fluorouracil- 
induced toxicity The CYP3A4 cDNA could have integrated anywhere in the genome 
of stably transfected cells, there is a possibility that integration could have disrupted 
the expression of genes that affect 5-fluorouracil toxicity It could also be speculated 
that CYP3A4 overexpression generates increased levels of an endogenous 
metabolite that increases resistance to 5-fluorouracil, this, however, is only a 
conjecture and would need much further analysis in order to be confirmed The 
mechanism by which CYP3A4 transfection enhances resistance to 5-fluorouracil in 
BCMV 3A4 cells remains to be explained
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4.4 CYP1B1 and drug resistance
4 41 Effect of CYP1B1 inhibition on anticancer drug toxicity in HL60 cells
Cytochrome P450 1B1 (CYP1B1) has been the object of intensive research in past 
years After a number of studies found the expression of this P450 to be upregulated 
in malignant as compared to normal tissue (see section 1 4 5 2), further investigations 
revealed that CYP1B1 transfection increased Taxotere resistance in V79 cells 
(McFadyen et a l, 2001) The link between CYP1B1 expression and Taxotere 
resistance is still unexplained
In agreement with previous findings, incubation of Taxotere with CYP1B1 did not 
affect the toxicity induced by this drug on A549 cells (see section 3 2 2 2) Indeed, it 
has been reported that no Taxotere metabolite could be detected after incubation of 
this drug with CYP1B1 in a number of different conditions (Bourmque et a/, 2002) 
The toxicity induced by 5-fluorouracil and Taxol was also unaffected by this treatment, 
which is to be expected, since none of them have been reported to undergo 
metabolism by CYP1B1 (see section 3 2 2 2)
Treatment of HL60 cells with a non-toxic concentration of Taxotere in the presence of 
the CYP1 inhibitor a-naphthoflavone (ANF) enhanced the anticancer drug toxicity by 
about 30% (see section 3 4 3) This result suggested that inhibition of CYP1B1 by 
ANF was enhancing the cytotoxicity of Taxotere, presumably by impairing its 
inactivation HL60 cells express CYP1B1 mRNA, as shown by RT-PCR, and their 
levels of EROD activity, catalysed by the CYP1 family, are low but readily 
measurable It should be noted that CYP1A1 and CYP1A2 also display EROD activity, 
so the levels of activity measured cannot be attributed solely to CYP1B1 
With the aim of investigating whether the observed increase in toxicity in the presence 
of ANF was a Taxotere-exclusive effect, toxicity of 5-fluorouracil, Adriamycin and 
Taxol was also evaluated in the presence of ANF in HL60 cells A similar 
enhancement of toxicity was observed with all of these drugs, particularly with 
Taxotere and 5-fluorouracil ANF is generally considered non-hazardous, but an early 
report showed that treatment with this compound induced liver carcinogenesis in rats 
(Liehr et a l, 1991), ANF-DNA adducts were later identified in the liver of treated 
animals
Enhancement of Taxotere toxicity by CYP1B1 inhibition is to be expected, considering 
the existent link between enzyme transfection and Taxotere resistance However, 
increased resistance to 5-fluorouracil, Adriamycin or Taxol by CYP1B1-transfected
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cells has not been reported Enhancement of the toxicity of drugs with such different 
structures and mechanisms of action suggests that the effect observed in HL60 cells 
is due to ANF toxicity synergismg with the effect of anticancer drugs, rather than due 
to inhibition of drug metabolism by CYP1B1 Indeed, DNA damage could sensitise 
cells against anticancer drugs, explaining the general increase in their toxicity It 
should also be noted that even though EROD activity was measurable in HL60 cells, 
the observed levels were very low, thereby resting importance to the effect of CYP1B1 
in drug resistance
4 4 2  Effect of CYP1B1 induction by TCDD on anticancer drug toxicity in HL60 
cells
TCDD is a classic agonist of the AhR Upon binding this ligand, the activated receptor 
translocates to the nucleus and induces the transcription of a number of genes 
involved in drug metabolism, but also in proliferation, cell growth and apoptosis 
Induction of CYP1B1 expression in HL60 cells by TCDD treatment was confirmed by 
RT-PCR Increased CYP1B1 mRNA levels were paralleled by a significant raise in 
EROD activity, which was readily detected and measured as approximately 10-fold 
increase over vehicle (toluene)-treated cells Again, it should be noted that this 
increase might also occur as a consequence of CYP1A1 and/or CYP1A2 induction by 
TCDD
Toxicity of 5-fluorouracil, Cisplatin, Taxol and Taxotere was determined in HL60 cells 
after treatment with TCDD or vehicle for 72 hours Although treatment with TCDD did 
significantly increase EROD activity in HL60 cells, it did not appear to alter the toxicity 
induced by any of the drugs tested These results suggest that a substantial increase 
in CYP1 activity does not affect anticancer drug toxicity in HL60 cells It could be 
argued that the levels of CYP1B1 activity, though considerably increased as 
compared to untreated HL60 cells, were still too low to produce a significant effect 
However, it should be noted that the levels of activity measured are well within the 
range of activity values measured in tumours (62 to 995 fmol/mg of microsomal 
protein/min (McFadyen et a l, 2004), while EROD activity in HL60 cells was measured 
in total cell lysates and is then expressed as pmol/mg of total protein/min) The 
relatively high (as compared to values reported in the literature) levels of EROD 
activity observed in HL60 cells would suggest that P450R activity in these cells is high 
enough to support the activity of CYP1 enzymes These results therefore may reflect 
in vivo events
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It should be noted that TCDD treatment results in a number of alterations in gene 
expression, i.e., it does not only result in CYP1B1 upregulation. In a recent report, 
Sarioglu et al. (2006) describe 89 proteins that are up- or downregulated in rat 
hepatoma 5L cells in response to TCDD treatment, many of them involved in cell 
cycle regulation, growth factor signalling and apoptosis.
4.4.3 Effect of Taxotere on CYP1B1 expression in MCF-7 cells
CYP1B1 is responsible for the metabolism of a number of endogenous substrates and 
is involved in steroid hormone synthesis and turnover. It is not unexpected then that 
CYP1B1 expression is constitutive and found at high levels in steroidogenic tissues 
such as breast, uterus and placenta (Dasmahapatra et al., 2002; Tsuchiya et al., 
2005). A connection has been shown between the ER and the AhR pathways (Spink 
et al., 1998); indeed, oestrogen is required for maximal expression of CYP1B1 in 
MCF-7 cells (Spink et al., 2003). Furthermore, oestrogen has been shown to induce 
CYP1B1 expression in ER positive MCF-7 cells (Tsuchiya et al., 2004). This effect of 
oestrogen appears to be tissue-specific, for ER negative cells do not appear to induce 
CYP1B1 expression after treatment with oestrogen.
CYP1B1 is expressed at high levels in hormone-dependent tissues such as breast, 
which constitutes a suitable model to study the regulation of CYP1B1 expression. 
MCF-7 parent and pulse-selected cells were chosen for further studies on CYP1B1 
expression.
It is a common feature of cytochromes P450 that the expression of a particular 
enzyme is induced by its substrate (see section 1.4.1); expression of CYP1B1 was 
then analysed in MCF-7 parent cells and also in resistant variants developed in this 
centre by pulse selection with Adriamycin and Taxotere. CYP1B1 mRNA levels were 
dramatically increased in MCF-7 Txt cells as compared to parent and Adriamycin- 
selected cells; the increase in mRNA levels was paralleled by higher levels of EROD 
activity, which was undetectable in MCF-7 parent cells. MCF-7 Txt cells also showed 
an approximately 3-fold increase in resistance to Taxotere as compared to parent 
MCF-7 cells.
In order to find out whether pulse selection with Taxotere had a general effect on 
CYP1B1 expression, a panel of Taxotere-selected cell lines -  hepatoma cell line 
HepG2, colon carcinoma Caco2, pancreatic carcinoma BxPc-3 and squamous cell 
lung carcinoma SK-MES-1 -  and their parental counterparts were subjected to RT- 
PCR analysis. CYP1B1 mRNA expression was increased in Taxotere-selected
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HepG2 cells, but no CYP1B1 was detected in Caco2, BxPc-3 or SK-MES-1 cells, 
suggesting that the effect of Taxotere on CYP1B1 expression is tissue-specific. 
Parent HepG2 cells or variants pulse-selected with Cisplatin and Taxol did not display 
CYP1B1 mRNA expression, suggesting a Taxotere-specific effect. CYP1B1 
expression is not induced in HepG2 cells after treatment with TCDD (Spink et al., 
1994), so it is unexpected that the levels of this enzyme are increased after treatment 
with Taxotere. However, it should be noted that only acute changes in expression 
were evaluated after TCDD treatment, while MCF-7 Txt and HepG2 Txt cells have 
been exposed to Taxotere on a regular basis and for a much longer period of time. 
These cells also display changes in their resistance profile, so in this case the 
induction of CYP1B1 mRNA expression could be associated with the observed 
increase in resistance.
The effect of Taxotere on CYP1B1 mRNA expression was further analysed in a panel 
of breast cell lines, ER-positive MCF-7 and MDA 453 cells and ER negative BT-20 
and MDA 231 cells. These cells were exposed to a high concentration of Taxotere for 
4 hours before extracting mRNA for RT-PCR analysis. RT-PCR results showed that a 
short pulse of Taxotere induced a modest increase in the expression of CYP1B1 in 
MDA 453 and BT-20 cells, suggesting that this effect is not dependent on ER status; 
an increase in CYP1B1 mRNA expression was not observed in MDA 231 cells. 
Curiously, the effect was not observed in MCF-7 cells either, suggesting that the 
increase in CYP1B1 expression in MCF-7 Txt cells was a consequence of repeated 
exposure to Taxotere, perhaps associated with the development of a resistant 
phenotype.
CYP1B1 expression is usually regulated through the AhR pathway. In order to confirm 
the functionality of this pathway, the panel of breast cell lines was also exposed to 
TCDD for 4 hours. Induction of CYP1B1 mRNA was observed in all cell lines 
irrespective of ER status, suggesting that disruption of the AhR pathway is not a 
cause of the observed lack of acute CYP1B1 mRNA induction by Taxotere in MCF-7 
and MDA 231 cells.
4.4.4 Effect of CYP1B1 siRNA transfection on Taxotere resistance in MCF-7 Txt 
cells
Both expression and activity of CYP1B1 were increased after pulse selection of MCF- 
7 cells with Taxotere; resistance to this drug was also considerably increased. siRNA
261
gene expression knock-down was carried out in MCF-7 Txt cells in order to determine 
the role of CYP1B1 in the observed increase in resistance in these cells.
Transfection of three different CYP1B1 siRNAs directed to three different sites in the 
CYP1B1 mRNA molecule resulted in decreased cell survival in basal conditions (i.e., 
in the absence of drug). This suggests that CYP1B1 expression can somehow 
promote cell survival, and that reduced mRNA levels of this enzyme are detrimental to 
cells. The effect was not pronounced, but it was appreciable. Furthermore, this result 
would also explain the sensitisation to anticancer drugs of HL60 cells after CYP1B1 
inhibition by ANF (see Section 4.4.1).
In contrast, no major effect on Taxotere toxicity was detected in CYP1B1 siRNA- 
transfected MCF-7 Txt cells. Only a slight enhancement was observed with siRNA 3, 
which was significant at a Taxotere concentration of 0.25 ng/ml (p=0.038). This could 
be due to the low levels of CYP1B1 activity measured in these cells (see section 
3.4.8). It should be noted that the Taxotere concentrations used for this experiment 
were quite low and caused little change in cell survival in control cells; however, when 
siRNA experiments were optimised in this centre it was observed that drug 
concentrations resulting in approximately 20% kill or lower showed best the effect of 
gene expression knock-down. Taxotere concentrations were then chosen for these 
experiments with this in mind.
4.4.5 CYP1B1 cDNA transfection in MCF-7 cells
In spite of the growing interest in CYP1B1 and the uncertainties that still exist about its 
precise role in drug resistance, transfection of this enzyme into mammalian cells has 
been successfully attempted very few times. Indeed, CYP1B1 transfection has only 
been reported for V79 hamster ovary cells (Luch et al., 1998) and COS-1 green 
monkey kidney cells (Bandiera et al., 2005). V79 cells were stably transfected and 
showed high EROD activity levels (1-10 pmol resorufin/mg total protein/min), while 
COS-1 cells were only transiently transfected and displayed much lower EROD 
activity (about 0.05 pmol resorufin/mg total protein/min without cotransfection with 
P450R and 0.1 pmol resorufin/mg total protein/min with cotransfection with P450R. 
These values were also normalised by the authors to transfection efficiency). To date, 
no successful transfection of a human cell line has been reported.
MDA R4 cells are MDA 231 breast carcinoma cells transfected with P450R cDNA 
(Patterson et al., 1997). These cells had already been successfully transfected and 
also expressed high levels of P450R, which is essential to support CYP1B1 activity,
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so they were chosen as recipients for transient transfection with a CYP1B1 cDNA 
plasmid Optimisation of transfection conditions was performed using a GFP plasmid 
and it was shown that more than 50% of MDA R4 cells readily expressed GFP as 
confirmed by fluorescence microscopy and flow cytometry However, no measurable 
CYP1B1 protein could be detected by Western blot in cells transfected with the 
CYP1B1 plasmid using the optimised conditions It was thought then that transfection 
had been unsuccessful because MDA R4 cells could not support two large plasmids 
Taxotere-selected MCF-7 cells showed increased levels of CYP1B1 mRNA These 
cells have been shown to express P450R at high enough levels to support CYP1B1 
activity (Chen e ta l, 1995) Optimisation of transfection conditions on MCF-7 cells was 
again performed with a GFP plasmid, again, transient transfection of GFP resulted in 
more than 50% of cells expressing high levels of green fluorescence as measured by 
flow cytometry However, no CYP1B1 protein could be detected by Western blot in the 
cells transfected with optimised conditions Transfection of CYP1B1 was also carried 
out on MDA 453 cells, with the same results (data not shown)
It appears from transfection optimisation experiments that cells are readily 
transfected, yet for some reason CYP1B1 is not expressed The CYP1B1 plasmid is 
larger than the GFP plasmid, but not to the point where it could affect transfection 
efficiency It could be argued that the plasmid containing the CYP1B1 cDNA might 
have integrated at a site in the chromosome which would not have allowed its 
transcription, however, it is unlikely that this would have happened in three different 
experiments and with three different cell lines
Regulation of CYP1B1 expression is very complex and can occur at different sites, 
indeed, it is known that CYP1B1 mRNA levels do not always correlate with protein 
expression Several reasons for this lack of correlation have been suggested among 
them is the belief that a certain level of mRNA should be reached before transcription 
can occur (McFadyen et a/, 2003) Another possible explanation could be the 
degradation of CYP1B1 newly synthesized protein (Bandiera et a l, 2003) These 
results could suggest that there is an endogenous factor in breast cell lines that 
prevents the overexpression of CYP1B1 exogenous protein
Recent studies have reported regulation of CYP1B1 expression by methylation 
(Nakajima et a/, 2003, Widschwendter et a/, 2004, Tokizane et a l, 2005) It is 
possible that the CYP1B1 promoter might have been methylated upon entrance into 
the cell, thereby inhibiting its transcription The presence of endogenous inhibiting 
factors could also silence the expression of the CYP1B1 cDNA However, the 
expression of plasmid CYP1B1 is under the control of the CMV promoter, a strong 
enhancing element, which makes it quite unlikely that transcription of the plasmid
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cDNA would be affected by endogenous factors However, the presence of an 
endogenous inhibiting factor might explain why no human cell line has been 
successfully transfected to date
A possible explanation for the lack of CYP1B1 expression in these cells would be that 
the gene is transcribed but the mRNA is unstable and is degraded before any 
translation can occur A variety of CYP1B1 polymorphisms have been described and 
differences do exist in the stability of the various alleles, however, these differences r 
refer to the translated protein and not to mRNA levels
In conclusion, transfection of CYP1B1 cDNA was attempted in three different breast 
cell lines and although the plasmid appears to have been taken up by the cells, no 
CYP1B1 protein could be detected These results could suggest that an endogenous 
inhibitory molecule is preventing exogenous CYP1B1 protein expression, although the 
nature of this molecule and the mechanism it uses to silence expression remain 
unknown It is possible that a number of different factors are at play at the same time 
and that the combination of events results in silencing of CYP1B1 plasmid expression 
Further studies are needed in order to identify the factor or factors responsible for lack 
of exogenous CYP1B1 expression in these cells
In summary, CYP1B1 expression appears to be connected with resistance to certain 
anticancer drugs, most notably Taxotere It is possible that the increased levels of 
CYP1B1 reported in tumour as compared to normal tissue are simply due to the fact 
that expression of this enzyme is associated with carcinogenesis, or with the resistant 
phenotype, rather than being directly involved in drug resistance However, knock­
down and/or inhibition of CYP1B1 appears to be detrimental to some cells, this 
suggests that CYP1B1 is not a simple resistance-associated marker but an enzyme 
with a role in promotion of survival CYP1B1 does not appear to enhance Taxotere 
resistance by direct inactivation of the drug, so if this enzyme does affect cell 
sensitivity to this drug the effect is likely to be exerted through an indirect mechanism 
It could be speculated that an endogenous metabolite of this enzyme is responsible 
for the promotion of cell survival, but further studies are needed to clarify this
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4.5 P450 NADPH reductase and drug resistance
4 51 Effect of P450R transfection on anticancer drug-induced toxicity in MDA 
231 cells
P450 NADPH reductase (P450R) function is essential for cytochrome P450 activity 
This enzyme provides the electrons used in all P450-mediated reactions using 
NADPH as a cofactor Given that P450R is always present in tissues expressing 
cytochromes P450 and also that it is able to metabolise drugs by itself, its possible 
involvement in drug resistance was investigated
MDA 231 R4 cells are breast adenocarcinoma cells transfected with human P450R 
cDNA They express high levels of this enzyme when compared to MDA 231 EV 
empty-vector transfected cells, as confirmed by Western blot and activity assays 
These cells were used as models to study how P450R affects drug resistance For 
this, toxicity assays were performed with a panel of commonly used anticancer drugs 
on P450R and empty vector-transfected cells
MDA R4 cells were significantly more sensitive to Mitomycin C than MDA EV cells 
Mitomycin C requires activation by P450R to generate metabolites that are much 
more toxic than the parent drug (Cummings et a l, 1998), it is easy to see then why 
MDA R4 cells are more susceptible to the effects of this drug It is likely that 
Mttomycm C undergoes metabolic activation in P450R-overexpressing cells, 
generating toxic compounds and enhancing the cytotoxicity of the anticancer drug 
Conversely, transfection of P450R did not seem to affect the sensitivity of MDA 231 
cells to Cisplatin, Mitoxantrone, Taxol, Vincristine or VP-16, which was expected, 
since none of these drugs have a reported interaction with P450R A slight increase in 
sensitivity to Taxotere was observed following transfection, although it was not 
significant Still, sensitisation of MDA cells following P450R transfection was an 
unexpected finding, for Taxotere exerts its toxic effects through disruption of 
microtubule dynamics, no apparent connection exists between microtubules and 
redox cell status Overexpression of P450R increases oxidative stress in MDA R4 
cells (see Section 4 5 2) and this might increase their sensitivity to cytotoxic drugs, 
however, it is difficult to explain why this effect was observed with Taxotere and not 
with other drugs, even those that, like Taxol, have a very similar mechanism of action
Another noteworthy result was the observed sensitisation of MDA R4 cells to 
Adriamycin The increased toxicity of Adriamycin is in opposition with the results
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obtained in the P450R microsome preincubation assays (see section 3 2 3) in this 
case, preincubation with P450R-expressing microsomes decreased drug toxicity on 
MDA 231 cells This would suggest that P450R decreases Adriamycm-mediated 
toxicity, presumably through partial drug inactivation However, P450R-mediated 
activation of Adriamycin can also occur
The planar nucleus of Adriamycin is a quinone and as such can undergo one-electron 
reduction by P450R to generate the semiquinone form (Bartoszek et a/, 1992) The 
semiqumone is an unstable intermediate that can react with molecular oxygen, 
donating an electron to regenerate the parent quinone and produce superoxide anion 
in the process The superoxide anion is not very toxic per se, but can undergo 
successive reactions to generate hydrogen peroxide and hydroxyl radical, which is 
considered as the most toxic of the reactive oxygen species (ROS) Furthermore, 
metabolism of Adriamycin by P450R appears to generate an alkylating metabolite that 
was detected in the culture medium but not in cell lysates (Bartoszek et a l, 1992), the 
authors concluded that it must be unstable in the intracellular environment This 
metabolite could be detected by HPLC but could not be identified and it seemed to be 
responsible for the observed increase in toxicity, as the presence of several ROS 
scavengers did not prevent the enhanced cytotoxic effect of Adriamycin High doses 
of GSH, however, did completely abrogate the increase in Adriamycin toxicity GSH is 
the most abundant non-protein antioxidant present in the cell, but it is also a cofactor 
of GSTs, which are responsible for the detoxification of a number of drugs, including 
Adriamycin (McLellan et a l, 1999) The lack of effect of other free radical scavengers 
would indicate that GSH prevents the increase in cytotoxicity by neutralising a toxic 
compound rather than by acting as an antioxidant
In summary, preincubation of Adriamycin with P450R leads to partial inactivation of 
the drug, but treatment of P450R overexpressing cells with Adriamycin means that 
alkylating agents and toxic free radicals are generated inside the cell and contribute to 
the cytotoxicity of the drug The results obtained suggest that the increase in 
sensitivity observed in P450R-transfected cells is due to the generation of short-lived 
species during Adriamycin redox cycling, while preincubation of the drug with P450R 
most probably generates inactive or less active metabolites It should also be noted 
that there was no change in Mitoxantrone toxicity after P450R transfection 
Mitoxantrone was initially developed as an Adriamycin analogue and both drugs are 
similar in many ways However, Mitoxantrone has a reduced ability to generate free 
radicals compared to the anthracyclmes (Hande et a/, 1998), suggesting that free 
radical generation could be responsible for the differential toxicity observed with the 
two drugs
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Our results are in agreement with those of Bartoszek et al. (1992), who found that 
incubation of MCF-7 cells with Adriamycin in the presence of exogenous recombinant 
P450R significantly increased the toxic effects of the drug. This increase in cytotoxicity 
was not observed when the drug was preincubated with P450R prior to addition to the 
cells, suggesting that the enhanced toxicity was mediated by short-lived species 
generated in situ.
However, Ramji et al. (2003) failed to detect any changes in Adriamycin toxicity in 
MDA R4 as compared to MDA EV cells. These authors had confirmed reduction of 
Adriamycin by P450R by NADPH consumption assays with recombinant enzyme; they 
also found that the rate of Adriamycin reduction correlated with P450R activity in 17 
samples of human liver microsomes. These results suggested that P450R had the 
potential to increase Adriamycin cytotoxicity by reductive activation in transfected cell 
lines, but toxicity assays showed that the sensitivity of MDA R4 cells was similar to 
that of empty vector-transfected MDA EV cells. The results reported by these authors 
are in direct contradiction with the findings of this thesis. However, an explanation for 
this discrepancy can be found in the different methods used to assess toxicity: while 
the acid phosphatase assay was employed to assay Adriamycin toxicity in MDA 231 
cells, Ramji et al. used the MTT assay. This assay is based on the reduction of 3-(4,5- 
Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) by cellular 
reductases to the coloured compound formazan. As can be seen in section 3.5.2, 
P450R readily converts MTT to formazan, to such an extent that this reaction was 
used to quantify enzymatic activity. It is not unreasonable to assume then that the 
same number of MDA R4 cells would convert more MTT to formazan than that of 
MDA EV cells, thereby making it difficult to ascertain any low-grade increase in 
sensitivity. Indeed, toxicity assays were performed in parallel in MDA R4 and MDA EV 
cells using two different endpoint assays, the acid phosphatase and XTT, an 
equivalent of MTT with a water-soluble product (formazan has little solubility in water 
and needs to be dissolved in DMSO before absorbance readings). Results obtained 
with the XTT assay suggested an increase in resistance to all the drugs tested for 
MDA R4 as compared to MDA EV cells (data not shown), while acid phosphatase 
assays showed either sensitisation or no change in toxicity. This suggests that the 
XTT and MTT assays do not provide reliable results when used with P450R- 
transfected cells.
Sensitisation to 5-fluorouracil after P450R transfection was another unexpected 
finding. This effect was not due to direct inactivation of the drug by P450R, as shown 
by the P450R microsome preincubation assays (see section 3.2.3.1); this is to be
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expected, as no interaction of this drug with P450R has been reported The observed 
enhancement of 5-fluorouraci! toxicity must then be due to a pharmacodynamic effect 
NADPH is a key compound required for 5-fluorouracil catabolism, this drug is a 
pyrimidine analogue, and as such undergoes the same metabolic reactions as 
endogenous pyrimidines (Fig 4 1) Reduction of these compounds by NADPH is 
followed by opening of the pyrimidine ring and generation of a beta ammoacid, which 
is later excreted
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Figure 4 51 Pyrimidine catabolism (from www-medlib med Utah edu/NetBiochem/pupyr)
Overexpression and consequent increased activity of P450R would result in depletion 
of NADPH from the cell pool An important decrease in NADPH levels could impair 5- 
fluorouracil catabolism, leaving additional drug available to exert its toxic effects This 
could explain the increase in sensitivity shown by MDA R4 cells Incidentally, NADPH 
is also required as a thioreductase cofactor for the de novo synthesis of 
deoxynucleotides Decreased levels of NADPH could then result in diminished DNA 
synthesis and subsequent inhibition of DNA damage repair
Two papers have been recently published (Hwang et a l, 2001, Liu et a l, 2002) about 
the role of ferredoxin reductase in drug resistance Ferredoxin reductase is the only 
mammalian mitochondrial cytochrome P450 NADPH reductase, which means that 
both ferredoxin reductase and P450R have exactly the same role, differing only in
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their subcellular localisation (Hwang et a/., 2001). The aforementioned studies have 
found that high levels of ferredoxin reductase sensitise cells against oxidative stress 
induced by p53 signalling after 5-fluorouracil and Adriamycin treatment. Depletion of 
NADPH levels has been pointed as the mechanism by which this enzyme exerts its 
sensitising effects. The model proposed by the authors involves p53, which is 
activated by anticancer drugs and in turn induces expression of ferredoxin reductase; 
increased levels of this enzyme impair ROS detoxification, generating mitochondrial 
and DNA damage and enhancing p53 function, thereby entering a positive feedback 
loop.
In summary, transfection of P450R sensitises MDA R4 cells to 5-fluorouracil 
cytotoxicity, presumably by depleting NADPH cell levels, which in turn impair drug 
catabolism and DNA repair and also increase oxidative stress by decreasing 
antioxidant reserves in the cell. Increased oxidative stress due to NADPH depletion 
could also be partly responsible for the observed sensitisation to Adriamycin.
4.5.2 Oxidative stress in MDA 231 cells
P450R uses NADPH as a source of electrons and transfers them to diverse 
acceptors, so it was expected that reduced NADPH levels would be decreased in 
MDA R4 cells as compared to MDA EV cells. Indeed, even though the levels of 
NADPH in MDA 231 cells were extremely variable, MDA R4 NADPH levels were 
consistently about half of those measured in MDA EV cells. This suggests that even 
though there might be large variations in NADPH levels, MDA R4 cells show a definite 
decrease of this antioxidant.
NADPH is an essential antioxidant and contributes to ROS detoxification (Liu et al.,
2002). The decrease in NADPH levels would be expected to result in an increase in 
other antioxidant defences, in an attempt to reduce oxidative damage. GSH is the 
most important non-protein antioxidant present in the cell and both subunits of the 
enzyme responsible for its synthesis, GCSH and GCSL, are upregulated in MDA R4 
as compared to MDA EV cells. This increase in GSH synthesis is likely to result in 
increased GSH levels, although the drop in NADPH might mean that GSH is used up 
to detoxify ROS. GST P1 was also induced in MDA R4 cells, suggesting that 
conjugation with GSH is increased as a detoxification mechanism.
Finally, production of ROS was measured in MDA EV and MDA R4 cells at basal and 
drug-induced conditions. ROS levels were increased in MDA R4 cells to about double 
the values measured in MDA EV cells in basal conditions, suggesting that the
269
depletion of NADPH levels increases cellular oxidative stress by impairing ROS 
detoxification The levels of ROS were not significantly affected in MDA EV cells after 
treatment with 5-fluorouracil, although they did appear to increase slightly with 
Mitomycin C Surprisingly, administration of Adriamycin slightly decreased ROS levels 
in MDA EV cells, suggesting that overexpression of P450R is necessary for ROS 
generation in these cells
The levels of ROS in MDA R4 cells were dramatically increased after treatment with 
Mitomycin C, Adriamycin and 5-fluorouracil These results suggest that the increased 
sensitivity to these drugs observed in MDA R4 cells is at least in part due to increased 
ROS production and subsequent cellular damage In the case of Mitomycin C, it has 
been reported that ROS production, though it occurs, does not contnbute to the 
overall toxic effects of the drug (Cummings et a/, 1998) In the case of Adriamycin, 
the role of ROS in cytotoxicity remains to be elucidated, while 5-fluorouracil appears 
to exert its toxic effect in part through a p53-mediated increase in ROS production 
In the case of Resveratrol, a dual effect was observed in MDA cells while this 
compound increased ROS levels in MDA EV cells, it decreased the basal levels of 
ROS in MDA R4 cells, though not to those measured in MDA EV cells This is 
consistent with the dual role reported for Resveratrol in the oxidative status of cells 
while this compound is generally considered to be an antioxidant and a free radical 
scavenger (Sgambato et a l, 2001, Leonard et a l, 2003, Lorenz et a l, 2003), it has 
also been found that it induces ROS-mediated apoptosis in CEM-C7H2 leukaemia 
cells (Tinhofer ef a/, 2001) Indeed, treatment of these cells with Resveratrol 
significantly increased ROS levels after only 30 minutes This compound also induced 
the production of ROS in blood platelets (Olas et a l, 1999) The effect of Resveratrol 
depended on the concentration at which it was used at the lowest concentrations 
tested (up to 12 5 ng/ml), this compound caused an increase in superoxide 
production, while it inhibited it at higher concentrations (up to 100 ng/ml)
It has recently been reported that transfection of P450R in V79 hamster cells resulted 
in increased oxidative DNA damage even in the absence of any exogenous 
compound (Heine ef a l, 2006) The addition of buthionme sulfoximine (BSO), an 
inhibitor of GSH synthesis, increased the levels of DNA damage, indicating that cells 
are heavily reliant on GSH production to counteract the increase of harmful oxidative 
species Moreover, transfection of CHLA-20 neuroblastoma cell lines with GFP 
increased cell sensitivity to Carboplatm, VP-16 and Melphalan, as well as to high 
concentrations of Adriamycin (Goto et a l, 2003) GFP-transfected cells were found to 
have much higher GSH levels than untransfected and vector-transfected cells
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Simultaneous treatment of GFP-transfected cells with VP-16 and the antioxidant N- 
acetyl cysteine abrogated the observed increase in sensitivity The authors concluded 
that ROS generated by GFP could only enhance VP-16 toxicity in cooperation with 
endogenous ROS It was also shown that sensitisation was dependent on p53 
expression, as p53 non-functional cells did not increase their GSH levels upon 
transfection with GFP
As seen in previous results, oxidative stress levels are increased in MDA R4 as 
compared to MDA EV cells This means that MDA R4 cells are subject to constant 
oxidative damage due to a decrease in their antioxidant defences It is not unexpected 
then that these cells also display enhanced sensitivity to anticancer agents, especially 
those that can increase ROS levels either directly through redox cycling or indirectly 
via p53-mediated induction
In summary, P450R plays a role in drug resistance independently of cytochromes 
P450 This enzyme can partially inactivate drugs, as in the case of Adriamycin, but it 
can also enhance their effect by redox cycling and generation of more toxic 
compounds (ROS and also alkylating metabolites), or through depletion of NADPH 
levels, which decreases cellular defences against oxidative damage Expression of 
P450R in tumour cells (which has been reported in many occasions, see section 
1 4 5) might therefore modulate the toxicity of certain drugs, this makes it an attractive 
target for the enhancement of chemotherapy efficacy
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4 6 Glutathione-related genes and drug resistance
Deregulation of glutathione (GSH) metabolism as a consequence of malignant 
transformation has been thoroughly studied in the past years, and has been shown to 
be associated with enhanced drug resistance in tumours (Hao et a l, 1994, Perquin et 
a l, 2000) Alterations observed usually include elevated GSH levels, increased 
expression of GSH transferases (GSTs) and also enhanced expression of partner 
proteins such as MRP1 These alterations are the consequence of changes in the 
expression of a number of GSH-related genes, including GSH synthetases, 
peroxidases and also enzymes involved in GSH turnover The contribution of each 
one of these genes has been analysed in cell lines by transfection and knock-out of 
expression Each gene appears to play only a modest role in resistance, however, co- 
transfection of two or more of these genes results in dramatic increases in resistance 
(O’Brien et a l, 2000)
These results suggest that it is the overall deregulation of GSH metabolism, rather 
than the involvement of a single gene, which ultimately confers cells increased drug 
resistance For this reason, the expression of a number of key genes involved in GSH 
metabolism was analysed in a panel of four pulse-selected cell lines and their parental 
counterparts
GSH synthesis is mainly mediated by y-glutamyl cysteine synthetase (GCS), an 
enzyme composed of two subunits a heavy or catalytic subunit (GCSH) and a light or 
regulatory one (GCSL) Increased activity of GCS resulted in higher rates of GSH 
synthesis that correlated with VP-16 and Adriamycin resistance in MCF-7 cells 
(Gamcsik et a l, 2002) Inhibition of GCS with buthionme sulfoximine (BSO) reversed 
Cisplatin resistance in a panel of renal carcinoma cell lines (Asakura et a l, 2005) 
GCSH has been shown to play a significant role in resistance, even on its own 
transfection of a ribozyme against GCSH decreased GSH levels and increased 
sensitivity to Cisplatin in human colon cancer cells (lida et a/, 2001) In addition, 
knock-down of GCSH also suppressed the expression of MRP1, MRP2 and MDR1, 
once more pointing to a coordinated regulation of defence mechanisms against toxic 
insults The role of GCSL is less clear, as most studies have only analysed GCSH 
expression and the levels of GCSL do not always correlate with those of GCSH, this 
suggests a differential regulation of the two subunits However, ribozyme knock-down 
of GCSL in A549 cells decreased the levels of Cisplatin resistance in these cells more 
efficiently than knock-down of GCSH (Inoue et a l, 2003)
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Expression of GCSH did not appear to be significantly affected by pulse selection in 
some of the cell lines analysed, indeed, A549 Carboplatin and Taxol-selected variants 
showed no change in GCSH expression as compared to parent cells Similarly, H1299 
and SKLU-1 pulse-selected cells displayed no major changes in expression as 
compared to parent cells The most significant results were observed in MCF-7 cells 
Adriamycin-selected MCF-7 cells showed a modest increase in the expression of this 
enzyme, while GCSH levels were decreased by half in MCF-7 Txt cells These results 
are in agreement with previous findings increased GCSH expression usually 
correlates with increased GSH levels, which have been reported to confer resistance 
mainly to drugs such as the anthracyclines and platinum derivatives Enhanced 
synthesis of GSH could therefore be pointed as a possible cause of the increase in 
resistance observed in MCF-7 Adr cells However, it is difficult to explain why the 
levels of GCSH were not also increased in Cisplatm-selected MCF-7 cells 
Expression of GCSL did not always correlate with that of GCSH, suggesting that both 
subunits are independently regulated in these cells The levels of this enzyme were 
largely unaffected by pulse-selection in all the resistant variants as compared to 
parent cells
The membrane-bound y-glutamyl transpeptidase (GGTP) is the enzyme responsible 
for degrading extracellular GSH to its component aminoacids An interesting feature of 
this process is that GGTP-expressing cells may extract GSH from the extracellular 
environment, generating free aminoacids that then enter the cell and are reused for 
intracellular GSH synthesis Indeed, this mechanism has been demonstrated in non­
small cell lung cancers, which are able to extract circulating GSH to increase 
intracellular synthesis and GSH levels (Blair et a l, 1997) Overexpression of GGTP 
usually correlates with high GSH levels (Black et a i, 1991) Moreover, GGTP activity 
and GSH levels were significantly higher in high grade and metastatic soft tissue 
sarcomas than in less aggressive tumours (Hochwald et a l, 1997)
Expression of GGTP was decreased in the Taxol-resistant variants of A549 and 
H1299 cells as compared to parent and Carboplatin-selected cells This is consistent 
with the fact that increased GSH levels confer protection particularly to drugs such as 
platinum compounds However, both SKLU-1 variants showed slightly increased 
levels of this enzyme Expression of GGTP was not detectable in MCF-7 parent or 
pulse-selected cells
GSTs are responsible for the generation of GSH-conjugates and play a prominent role 
in the detoxification of a number of compounds Several families of GSTs exist (see
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section 1.3.2.1) and each is composed of one or more isoforms, of which the best 
studied is GST P1. Transfection of a cholangiocarcinoma cell line with a GST P1 
antisense vector resulted in significant increase of Adriamycin, Cisplatin and 
Melphalan toxicity (Nakajima et a/., 2003); similar results were obtained when treating 
cells with a specific GST P1 inhibitor. On the other hand, increased expression of 
GST P1 was associated with resistance to anticancer agents in breast (Su et al.,
2003) and head and neck cancer (Cullen et al., 2003). No correlation between GST 
P1 expression and response to chemotherapy was found in non small cell lung cancer 
patients (Unsal et a!., 2003). However, acquired resistance to Cisplatin and 
Adriamycin in a small cell lung cancer cell line was correlated with increased GST P1 
levels (Hao et al., 1994).
Expression of GST P1 was common across the lung cell lines, showing no apparent 
changes in expression in pulse-selected as compared to parent cells. Expression of 
GST P1 could not be detected in MCF-7 parent or pulse-selected cells. These results 
suggest that regulation of GST P1 expression is tissue and/or cell specific.
GST A1 has also been associated with anticancer drug resistance: transfection of 
GST A1 protected endothelial cells from arrest mediated by the alkylating agent 
Busulfan (Ritter et al., 2002). Several studies have also shown that GST A1 and 
MRP1 or MRP2 work synergistically to increase anticancer drug resistance in tumour 
cells (Morrow et al., 1998; Paumi etal., 2001; Smitherman eta!., 2004).
Expression of GST A1 was again largely unchanged in all MCF-7 and A549 resistant 
variants as compared to parent cells, although A549 Tax cells - but not A549 Cpt cells 
-  appeared to show a slight increase in GST A1 levels when compared to parent 
A549 cells. SKLU-1 cells, however, showed dramatic upregulation of this enzyme 
particularly in the Taxol-selected cells.
Overall, alterations in the expression of GSH-linked enzymes were readily detected in 
pulse-selected cells as compared to their parent counterparts; however, these 
alterations were not substantial nor consistently associated with resistance to a 
certain drug or group of drugs, or with the level of resistance. For example, GCSH 
levels were increased in Adriamycin-resistant MCF-7 cells as compared to parent 
MCF-7 cells, but no change with respect to parent cells was observed in Cisplatin- 
resistant MCF-7 cells. These results suggest that higher GSH levels associated with 
increased expression of this enzyme are not always a limiting factor in protecting 
these cells against platinum compounds.
Expression of GST P1, which is considered as the most important of the GSTs and 
also the one that has a clearer association with drug resistance, was not majorly 
affected by pulse selection in the two cell lines where it was present. However,
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expression of GST A1 was upregulated in SKLIM pulse-selected cell lines, 
suggesting that higher levels of this enzyme are associated with increased drug 
resistance in these cells These results are in agreement with the findings discussed 
in section 4 1, where GST A1 expression in tumour samples was correlated with poor 
prognosis
In summary, alterations in the expression of GSH-linked enzymes are a common 
event in the pane! of pulse-selected cell lines studied However, no correlation was 
found between the expression of one or a set of these enzymes and the levels or 
resistance to certain drugs or groups of drugs These results suggest a complex and 
cell-specific regulation of the expression of GSH-related enzymes
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4.7 Pulse selection of cell lines
4.7.1 Toxicity profiles of pulse-selected cells
Exposure of cancer cells to anticancer drugs can affect patterns of gene expression 
and ultimately result in the development of resistance. Cells that have been 
repeatedly exposed to drugs commonly used in chemotherapy constitute a good 
model to identify changes undergone by tumour cell lines after drug treatment and to 
investigate the association of these changes with the resistant phenotype.
Two protocols have been used to study this process: the continuous growth of cells in 
the presence of drug, and the periodic exposure of cells to high doses of drugs for a 
brief period of time, separated by regular intervals. This second method resembles the 
treatment given to patients, who usually receive chemotherapy treatment once every 
1-3 weeks, allowing for recovery in between cycles.
The aim of these studies was to analyse changes in the expression of drug- 
metabolism enzymes, especially cytochromes P450, caused by pulse selection. Even 
though biopsy samples usually display readily measurable P450 activity, most cell 
lines have lost P450 expression and/or ability of induction. This is a common 
phenomenon and appears to be due to alterations in specific transcription factors 
(Rodriguez-Antona et a/., 2002). Pulse selection was therefore performed on two 
metabolically competent cell lines, that is, cells that still retain P450 expression and/or 
induction capacity.
Caco2 cells were originally derived from colon adenocarcinoma. They express several 
enzymes related to drug metabolism, as well as transporters and efflux pumps; they 
have been reported to generate metabolites similar to those observed in vivo and are 
thus considered metabolically competent (Lampen et a/., 1998). HepG2 cells are 
derived from a hepatoma and as such express a number of enzymes usually found in 
liver. This cell line has been deemed as useful to study the regulation of drug- 
metabolism enzymes (Wilkening et al., 2003).
Caco2 and HepG2 cells were exposed to pharmacologically achievable levels of 
Taxol, Taxotere or Cisplatin in order to examine the resistance mechanisms activated 
upon exposure to chemotherapy drugs. Pulse selection with Taxol or Taxotere 
resulted in a marked increase in resistance for both cell lines; cross-resistance was 
also observed against both taxanes and also to Vincristine. No significant change in 
sensitivity was observed against either Cisplatin or Irinotecan. In the case of Cisplatin-
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selected HepG2 cells, no change in sensitivity was observed against any of the drugs 
tested, even Cisplatin.
The levels of resistance to Taxol, Taxotere and Vincristine achieved for Caco2 pulse- 
selected cells ranged from about 5 to 40-fold as compared to parent cells, while for 
HepG2 cells they were between approximately 1.5 and 6-fold. These levels of 
resistance were stable after weeks in culture and relate to observed in vivo levels of 
resistance, which are usually about 5 to 10-fold (Simon et ai, 1994). Taxol, Taxotere 
and Vincristine are all substrates of CYP3A, so the observed increase in resistance 
could be attributed to enhanced inactivation by this subfamily of enzymes. However, 
the three drugs are also substrates for the efflux pump MDR1. Furthermore, 
resistance to agents that affect microtubule dynamics, as is the case for these drugs, 
can also arise from alterations in drug binding affinity and changes in tubulin subtype 
or expression (Fojo et al., 2005). Any of these phenomena -  or a combination of the 
three -  might explain the observed increase in resistance to the three drugs, as well 
as the lack of change in Cisplatin and Irinotecan toxicity; neither of these drugs 
undergoes significant metabolism by CYP3A (this enzyme can inactivate Irinotecan, 
but this is only a minor pathway of drug detoxification) or are substrates of MDR1 or 
affect microtubule dynamics.
For Caco2 cells, the levels of Taxol resistance were higher than those observed for 
Taxotere, even in cells that had been Taxotere-selected. In HepG2 cells, curiously, 
even though cross-resistance to the other taxane was observed, resistance to 
Taxotere was higher in cells that had been pulse-selected with Taxol and viceversa. 
This suggests differential regulation of Taxol and Taxotere resistance in these two cell 
lines. It also suggests that response to drugs of such similar structure and mechanism 
of action as the two taxanes is also quite different. Furthermore, cross-resistance to 
Vincristine was of much higher magnitude than resistance to taxanes in Caco2 cells; 
once again, this phenomenon was not observed in HepG2 cells, where resistance to 
Vincristine, although significant, was still lower than that observed for the taxanes. 
Altogether, these results highlight the cell type-specificity of the response to drug 
exposure.
4.7.2 Changes in protein expression in pulse-selected cells
Analysis of P450 expression by Western blot showed modest (about 1.5 to 3-fold) 
induction of CYP3A4 and CYP3A5 protein expression as a result of the selection 
process in almost all of the pulse-selected cell lines tested. Increase in CYP3A protein
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expression in Taxol and Taxotere-selected cells was expected, as P450s are usually 
induced by their substrates. Expression of CYP3A4 has been reported to increase in 
response to Taxol treatment in human hepatocytes (Nallani et al., 2004); this study did 
not find substantial changes in CYP3A4 expression after Taxotere treatment. CYP3A4 
levels were also increased after selection with Cisplatin, which is not a P450 
substrate; this is an unexpected result and points to an increase in CYP3A expression 
as part of a general defence system against toxic compounds. The levels of induction 
of CYP3A4 and CYP3A5 in both Caco2 and HepG2 pulse-selected cells were similar, 
suggesting a common response to drug exposure.
On the other hand, expression of CYP3A4 and CYP3A5 was unchanged, or even 
decreased, after pulse-selection in H1299 and MCF-7 cells. These results highlight 
the importance of using metabolically competent cells for P450 expression analysis. 
Metabolically competent cells retain expression of cytochromes P450 and, more 
importantly, inducible regulation of this expression.
Expression of MDR1 was also induced in selected cell lines and at much higher levels 
than those of CYP3A. Parent Caco2 and HepG2 cells displayed only very low levels 
of this efflux pump, which was significantly upregulated upon pulse selection with 
Taxol, Taxotere and also Cisplatin, albeit at much lower levels of induction than those 
observed with the taxanes. This latter result is unexpected for, as stated before, 
Cisplatin is not an MDR1 substrate. However, induction of both CYP3A4 and MDR1 
expression has been reported to occur in response to Cisplatin treatment (Masuyama 
et al., 2005). Again, this suggests that cells activate a number of different defence 
mechanisms upon exposure to toxic compounds, some of which would be useful for 
the detoxification of the specific toxin and also some that would not.
Supporting this observation, analysis of GSH-related enzymes in Caco2 variants -  the 
most resistant cells obtained after pulse selection -  revealed that the two subunits of 
the key enzyme involved in GSH synthesis were upregulated in the selected variants 
as compared to parent cells. This was true especially of GCSH, which showed a 
modest increase in expression, while levels of GCSL not always paralleled this 
increase. Higher levels of induction were observed for GGTP and GST P1, especially 
in Caco2Txt cells, indicating that GSH turnover is altered in these cells in response to 
pulse selection.
Modulation of Taxol toxicity by GSH is evident, for treatment with the GCS inhibitor 
BSO sensitises MCF-7 and A549 cells to the toxic effects of this drug (Liebmann et 
al., 1993). However, transfection of lung cancer cells with GST P1 did not cause an 
appreciable effect in Taxol toxicity (Miyara et al., 1996). In the case of Taxotere, GST 
P1 appears to be at least partially responsible for the inactivation of the drug, since
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inhibition of this enzyme enhanced Taxotere cytotoxicity in human gastrointestinal 
cancer cell lines (Park et al., 2002). Moreover, Taxotere induced ROS production and 
GSH depletion in hepatocellular carcinoma SMMC-7721 cells (Geng et al., 2003). 
Finally, a recent study has found that expression of genes involved in regulation of the 
redox environment, such as GSTs, is elevated in patients with poor response to 
Taxotere treatment (Iwao-Koizumi et al., 2005). These results suggest that GSH- 
related genes can modulate taxane-induced cytotoxicity and that the increase in their 
expression might be at least partially responsible for the enhanced resistance of 
pulse-selected Caco2 cells.
4.7.3 Role of MDR1 in the observed increase in resistance in pulse-selected 
cells
Given the fact that MDR1 has a proven association with drug resistance, combination 
assays were performed with GF120918, a well-known non-competitive inhibitor of 
MDR1. GF120918, also known as Elacridar, can efficiently inhibit MDR1 without any 
noticeable effect on MRP1 function (Evers et al., 2000).
This compound elicited a remarkable synergistic response when used together with 
Taxotere on Caco2 parent cells and resistant variants, suggesting that MDR1 plays a 
relevant role in the development of resistance in these selected cells. Sensitisation to 
Taxotere was more patent in pulse-selected variants than in parent cells, indicating 
that resistant cells are more dependent on MDR1 function. Such an effect was not 
observed when Cisplatin was used in combination with the inhibitor; this is to be 
expected, since this drug is not an MDR1 substrate.
The effect of GF120918 was also observed in parent HepG2 cells, even though these 
cells displayed almost no measurable expression of MDR1 by Western blot. Some 
studies have suggested that even a low level of MDR1 might be enough to protect 
cells from the toxic effects of drugs (Allen et al., 2000). Sensitisation was also 
observed in HepG2Txol and HepG2Txt in the presence of GF120918, although the 
effect was modest in magnitude. Only a minimum effect was observed in HepG2CisPt 
variants, even though Western blots showed induction of MDR1 in these cells. Again, 
Cisplatin showed negligible synergy with GF120198. The synergy between Taxotere 
and GF120918 was much stronger in Caco2 cells, consistent with the fact that these 
cells developed much higher levels of resistance than HepG2.
In conclusion, inhibition of MDR1 dramatically reverts the observed increase of 
resistance in Caco2 and, to a lesser extent, in HepG2 pulse-selected cells. These
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results indicate that MDR1 is at least partly responsible for the resistant phenotype of 
these cells.
4.7.4 Role of MRP1 in the observed increase in resistance in pulse-selected 
cells
Sulindac belongs to the non-steroid anti-inflammatory drug group and, as many other 
members of this group, has been shown to inhibit MRP1 without any noticeable effect 
in MDR1 activity (O’Connor et al., 2004). Inhibition of MRP1 by Sulindac did not result 
in major enhancement of Adriamycin toxicity in any of the cell lines tested, whether 
parent or pulse-selected, indicating that MRP1 activity is not heavily involved in the 
observed increase in resistance. This is not unexpected, since the taxanes are poor 
MRP1 substrates.
A slight sensitisation to Adriamycin toxicity was observed in Caco2 and especially 
Caco2Txt cells, but not in Caco2Txol. The decrease in cell survival after simultaneous 
treatment with Adriamycin and Sulindac was about 20%, as compared to the effect of 
Adriamycin alone.
As for HepG2 parent cells, a similar level of sensitisation was observed in the parent 
cell line, while none of the resistant variants displayed any appreciable increase in 
Adriamycin toxicity in the presence of Sulindac.
4.7.5 Role of CYP3A in the observed increase in resistance in pulse-selected 
cells
The estrogen 17 AEE is used in oral contraception and is also a well-known, non­
competitive CYP3A inhibitor. Indeed, incubation of CYP3A4-expressing microsomes 
with increasing concentrations of this compound resulted in dose-dependent inhibition 
of testosterone 6p-hydroxylase activity (see section 3.3.4).
Treatment of pulse-selected cells with Taxol, a CYP3A substrate, in the presence of 
17 AEE did not significantly affect the toxicity of the anticancer drug, suggesting that 
increased CYP3A activity is not a main protective mechanism against Taxol in these 
cells. A slight increase in Taxol toxicity was observed in parent Caco2 cells, 
suggesting that CYP3A activity might be a second-line mechanism of defence against 
Taxol in non-pulsed cells. However, this effect was not observed in parent HepG2 
cells.
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Taxol is metabolised by both CYP2C8 and CYP3A4; it is generally considered that the 
main detoxification pathway is that involving CYP2C8, while CYP3A4 constitutes only 
a minor pathway. However, the main metabolic pathway of Taxol detoxification in 
colorectal cancer microsomes was carried out by CYP3A (Martinez et al., 2002). 
Induction of CYP3A4 expression has been reported to modify Taxol pharmacokinetics 
(Monsarrat et al., 1998), indicating that this enzyme might play a more prominent role 
in Taxol metabolism than previously thought. Furthermore, it was found that 
expression of tumour CYP3A4 mRNA might predict the response to Taxol treatment in 
breast cancer patients (Miyoshi et al., 2002). These results suggest that CYP3A is a 
relevant enzyme for Taxol metabolism, particularly in colorectal cancer.
No significant effect in toxicity was observed when treating any of the cell lines 
simultaneously with Cisplatin and 17 AEE as compared to Cisplatin alone, as 
expected.
4.7.6 Role of CYP3A in the observed increase in resistance in pulse-selected 
cells after MDR1 inhibition
Pulse-selected cells showed increased expression of CYP3A4 and CYP3A5. This 
increase, however, did not appear to be directly related to the observed enhancement 
in drug resistance. Indeed, MDR1 seems to be the predominant mechanism of 
resistance in these cell lines; however, it was hypothesised that other mechanisms 
might take over if MDR1 is inhibited.
In order to investigate the possibility of P450s acting as a second-line defence 
mechanism to MDR1, Caco2 parent and pulse-selected cells were simultaneously 
exposed to Taxol, GF120918 and 17 AEE. These cells showed the highest MDR1 
activity and also the highest levels of resistance. Simultaneous treatment with non­
toxic concentrations of Taxol and GF120918 resulted in an increase in Taxol toxicity in 
these cells, as expected. Addition of 17 AEE resulted in a further 20% increase in 
toxicity in Caco2Txol cells. This effect was not seen in Caco2Txt cells, although it is 
difficult to assess any further increase in toxicity due to the low cell survival obtained 
with the combination of Taxol and GF120918. Caco2Txol cells are less resistant to 
Taxol than Caco2Txt cells (10-fold versus 13-fold); increased resistance to Taxol 
might be related to the lack of synergy observed between Taxol, GF120918 and 17 
AEE. A slight increase in Taxol toxicity was observed in Caco2 parent cells at the 
highest concentration of 17 AEE.
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Efflux pumps are usually considered as a low affinity, high capacity detoxification 
mechanism, while enzymes involved in drug metabolism exhibit high affinity and low 
capacity. When cells are exposed to high concentrations of drug, it is likely that the 
cell will rely on quick detoxification of large amounts of toxic compounds; thus it is not 
unexpected that efflux pumps such as MDR1 are more relevant to pulse-selected cell 
resistance than drug metabolism enzymes. However, these enzymes, although 
dealing with low amounts of drug at a time, have a high affinity for their substrates and 
also a high processing efficiency. Therefore, they might constitute a solid second-line 
defence mechanism against toxic insults.
However, it should also be noted that expression of MDR1 was increased to much 
higher levels than that of CYP3A4 or CYP3A5; it is therefore not unlikely to assume 
that the levels of CYP3A-mediated metabolism were simply not high enough to 
compare with MDR1 -mediated efflux. It might also be the case that CYP3A4 and 
MDR1 work in synergy to increase resistance. Indeed, it has been known for some 
time that GSTs and certain members of the MRP family work in synergy, that is, 
MRP1 can pump a GSH-conjugated drug easier than the drug alone. Consistent with 
this, transfection of both proteins confers a synergistic resistance that is larger than 
that expected based on the toxicity profiles resulting from the transfection of each 
protein alone. The multidrug resistance pump MDR1 and CYP3A4 have overlapping 
substrates and inducers; thus they appear to be connected in some way. Some 
studies show that MDR1 can pump out CYP3A4 metabolites (Hochman et al., 2001), 
while others have indicated that the presence of MDR1 enhances CYP3A4 activity 
(Baron et al., 2001; Chan et al., 2004). The extent of this interaction and its potential 
impact in chemotherapy resistance have not been fully elucidated.
In summary, it appears that, upon exposure to toxic insults, tumour cells activate a 
number of defence mechanisms, including cytochromes P450, GSH-related enzymes 
and efflux pumps such as MDR1. This appears to be a general response, 
independent of the characteristics of the toxin (as exemplified by the increase in 
CYP3A and MDR1 expression caused by Cisplatin pulse selection in HepG2 cells), 
although not every single mechanism is induced for every drug (as seen in the lack of 
MRP1 involvement in some pulse-selected cells). MDR1 appears to be the main 
resistance mechanism for drugs that are substrates of this pump in pulse-selected 
cells, possibly due to the fact that this protein can pump considerable amounts of drug 
out of the cell in a short period of time and thus is more efficient than drug-metabolism 
enzymes in detoxification. However, CYP3A appears to be a second-line defence
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mechanism against certain drugs for some cells, more relevant when MDR1 is 
inhibited.
Section 5.0
Conclusions and future work
5.1 Conclusions
The main aim of this thesis was to investigate the role played by drug metabolism 
enzymes in the development of resistance to anticancer drugs. With this purpose, a 
number of different approaches were taken, which aimed to show different aspects of 
the relationship between drug metabolism and drug resistance.
The first aim of this thesis, to find whether drug metabolism enzymes were expressed 
in tumour tissue and whether their expression was altered relative to normal tissue, 
was achieved through analysis of whole genome expression microarray data. 
Microarrays revealed that these enzymes were readily expressed in tumour tissue and 
that frequency and levels of expression were differentially altered in tumour as 
compared to normal samples.
The second aim of this thesis, to investigate the role of cytochromes P450 in 
anticancer drug resistance, was achieved by using different approaches. Experiments 
with microsomes showed that CYP3A4 and P450R are able to reduce the toxic effects 
of anticancer drugs, while the same could not be shown for CYP1B1. Transfection of 
cells with CYP3A4 and P450R revealed that overexpression of these enzymes affects 
the resistance profile of transfected cells. Transfection of CYP1B1 could not be 
accomplished, presumably due to the existence of intracellular regulatory molecules. 
Knock-down of CYP1B1 expression did show a new role for this enzyme, namely the 
promotion of cell survival.
The third aim of this project, to investigate changes in the expression of glutathione- 
related enzymes in pulse-selected cells, was achieved by Western blotting analysis. 
Changes were detected but could not be correlated to cell type, resistance to a certain 
drug or group of drugs or with levels of resistance.
The final aim of this project was to analyse the changes undergone by cancer cells 
after repeated exposure to anticancer drugs. Changes in the expression of drug 
metabolism enzymes and efflux pumps were detected, as were functional alterations 
resulting from these changes in pulse-selected cells.
Other important findings in this thesis are presented here as a summary.
1. Analysis of microarray data indicates that the mRNA of enzymes
involved in drug metabolism is indeed expressed at significant 
levels in both normal and tumour tissue. Examination of these
results also shows that the expression of several of these mRNAs is
285
altered in tumour as compared to normal tissue samples. Two 
genes of interest emerged from the microarray data obtained in this 
centre as possible markers of prognosis: ARTN2 and GST A1 were 
revealed as gene markers of potential clinical interest. ARNT2 was 
associated with better prognosis, while GST A1 expression 
correlated with poor survival.
2. Vincristine and especially Adriamycin were partially inactivated in a 
time-dependent fashion by incubation with the microsomal fraction 
of recombinant insect cells overexpressing CYP3A4; this effect was 
not observed with 5-fluorouracil, which unlike the other two drugs 
mentioned is not a P450 substrate.
3. CYP1B1 does not appear to directly inactivate any of the drugs 
tested, including Taxotere.
4. Transfection of CYP3A4 conferred modest (about 1.8-fold) levels of 
resistance against Adriamycin and, unexpectedly, 5-fluorouracil to 
lung epithelial cells. The increase in Adriamycin resistance can be 
explained by the inactivation of the drug by CYP3A4, since 
simultaneous treatment with a CYP3A inhibitor abrogated the 
decrease in sensitivity. The enhanced resistance to 5-fluorouracil 
developed by these cells is harder to explain; it does not appear to 
be due to a general increase in cell resistance as a consequence of 
the long-term exposure of cells to a selecting agent, for the toxicity 
of Cisplatin remained unaffected.
5. Simultaneous treatment of HL60 cells with 5-fluorouracil, 
Adriamycin, Taxol and Taxotere and a CYP1 inhibitor increased the 
cytotoxic effects of these drugs by about 20%. This appears to be a 
general, non-specific toxic effect, since it was observed with all of 
the drugs tested, even those that are not known to interact with 
P450s.
6. Treatment of HL60 cells with TCDD greatly induced the expression 
and activity of CYP1B1; however, this induction did not result in 
changes in the toxicity profile of these cells. This could be due to 
the diverse effects of TCDD on protein expression.
7. Expression and activity of CYP1B1 were significantly increased in 
MCF-7 cells pulse-selected with Taxotere as compared to parent 
cells. Knock down of CYP1B1 expression by siRNA did not have a 
major effect on Taxotere toxicity, but it did decrease cell viability (by
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over 20%), suggesting that CYP1B1 expression can promote 
survival in MCF-7 Txt cells.
8. Transfection of CYP1B1 into three different breast cell lines was 
unsuccessful due to the apparent existence of regulatory controls 
that impede expression of CYP1B1 cDNA.
9. Mitomycin C and Adriamycin were inactivated by incubation with the 
microsomal fraction of recombinant insect cells overexpressing 
P450R; this effect was not observed with 5-fluorouracil or 
Vincristine.
10. MDA 231 cells transfected with P450R (MDA R4) were more 
sensitive to Mitomycin C, Adriamycin and, unexpectedly, 5- 
fluorouracil (about 3, 2 and 7-fold, respectively). It has long been 
known that Mitomycin C is activated by P450R to more toxic 
compounds, while Adriamycin metabolism by this enzyme produces 
alkylating agents that cause more damage than the parent 
compound; the latter reaction also generates ROS. MDA R4 cells 
appeared to be more sensitive to oxidative stress than their empty 
vector-transfected counterparts, providing a plausible explanation 
for their increased sensitivity to anticancer agents.
11. Alterations in the expression of GSH-related enzymes were 
common in a panel of pulse-selected cell lines. Taxol and Taxotere- 
selected Caco2 cells showed the most dramatic changes, with 
increased expression of GCSH, GCSL, GST P1 and GGTP, while 
Carboplatin and Taxol-selected SKLU-1 cells showed modest 
increases in the expression of GCSL, GGTP, GST P1 and GST A1. 
Changes in expression patterns were dependent on the drug used 
for pulse selection, although no clear correlation could be 
established between level of resistance to a particular drug and a 
particular enzyme.
12. Pulse selection of Caco2 and HepG2 cells with Taxol or Taxotere 
generated resistant variants that showed resistance to the drug they 
had been pulsed and also cross-resistance to taxanes and 
Vincristine. HepG2 cells pulse-selected with Cisplatin showed no 
appreciable change in their toxicity profile. Expression of CYP3A4 
and CYP3A5 was modestly increased in these variants, as was that 
of GCSH, GGTP and GST P1, suggesting that cells have a general, 
non-specific response against toxic compounds, activating the
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expression of several different genes involved in xenobiotic 
defence. MDR1 levels were dramatically increased.
13. Simultaneous treatment of parent and pulse-selected cells with 
Taxol and a CYP3A inhibitor did not enhance the toxicity of the 
anticancer agent, suggesting that CYP3A activity is not required to 
sustain the resistant phenotype.
14. Treatment of pulse-selected cells with Taxotere in the presence of 
an MDR1 inhibitor caused almost complete reversion of the 
observed resistance to this drug, indicating that cells depend on the 
activity of this efflux pump to resist the toxic effects of Taxotere.
15. Simultaneous treatment of pulse-selected cells with Taxol and an 
MDR1 inhibitor in the presence of a CYP3A inhibitor did increase 
Taxol toxicity by about 20% in Taxol-selected Caco2 cells, 
suggesting that drug inactivation by CYP3A is a second line of 
defence that might become relevant to these cells when MDR1 is 
inhibited. MDR1 therefore appears to be the main mechanism of 
resistance in taxane pulse-selected cells.
The study of drug metabolism in cancer and its possible contribution to chemotherapy 
resistance is complicated by the difficulty in finding a suitable model; this is especially 
true of cytochromes P450. As mentioned before, most commonly used cell lines have 
lost expression of P450s, to the point that no enzymatic activity or even protein 
expression can be detected. Induction of P450 expression by treatment with chemical 
compounds can increase P450 levels to values similar or equivalent to those found in 
vivo. However, the high redundancy of the P450 system means that chemical 
inducers are rarely specific. Also, pharmacodynamic effects other than cytochrome 
P450 induction exerted by these compounds cannot be ruled out. P450-transfected 
cell lines represent therefore the best model to study drug metabolism in cancer cell 
lines. Yet regulation of the expression of some P450 isoenzymes appears to be tightly 
controlled and this makes it difficult for these enzymes to be expressed in transfected 
cell lines. This difficulty in finding an appropriate model that accurately reflects in vivo 
events makes it hard to appreciate the real contribution of cytochromes P450 to drug 
resistance. Models available at the moment usually display P450 activities that are still 
several orders of magnitude below levels measured in liver or intestine microsomes. 
Yet it should be noted that these tissues are specialized in detoxification, particularly 
the liver, and that P450 activity values in other tissue types are very likely not as high.
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Microsomes from recombinant insect cells transfected with cytochromes P450 and 
P450R are also good models to study drug metabolism in vitro. They display high 
levels of activity and are available commercially for most of the P450 isoenzymes with 
a known involvement in drug metabolism.
Drug metabolism enzymes appear to be involved in the development of anticancer 
drug resistance: their expression is generally increased in resistant cell lines, 
particularly in the case of P450s, and their transfection into drug-sensitive cells 
increases the levels of resistance. However, their involvement seems limited, as even 
when they are overexpressed they only appear to confer modest levels of resistance 
to tumour cell lines. The high-affinity, high-efficiency and low-capacity characteristics 
of the xenobiotic metabolism system cannot provide detoxification as effectively as 
efflux pumps can, so the level of resistance conferred by drug metabolism enzymes is 
much smaller than that conferred by efflux pumps.
Overall, it appears that individual enzymes involved in drug metabolism have little or 
no impact in the development of resistance against anticancer agents. It seems more 
likely that a general defence system is activated when cells are faced with 
environmental toxins, which includes several different types of drug metabolism 
enzymes as well as efflux pumps and antioxidant compounds; it is also likely that this 
system includes a number of antiapoptotic proteins as well.
A recent approach to enhance the efficacy of chemotherapy uses efflux pump 
inhibitors as adjuvants to decrease the amount of drug that is being pumped out of the 
cell. Inhibition of P450s or GSTs could also increase intratumoral drug levels and thus 
amplify the efficacy of treatment; indeed such an approach has already been tested 
by using Ketoconazole, a well-known P450 inhibitor, in conjunction with anticancer 
drugs. However, because these enzymes are responsible for detoxification, this would 
also increase the general toxic effects of the drug; for drugs with such a narrow 
therapeutic window as anticancer drugs, co-administration with inhibitors of their 
metabolism could be highly dangerous or indeed fatal. It is therefore unlikely that 
P450 or GST inhibitors will gain widespread use as chemotherapy adjuvants.
In spite of a number of disparities, most studies report increased expression of 
enzymes involved in drug metabolism in tumour as compared to normal tissue, 
indicating that these enzymes are either involved in malignant transformation or serve 
as markers of the carcinogenic process. Xenobiotic-related enzymes could then be 
useful as biomarkers of disease, progression and also therapy outcome, as has been 
previously shown. The existence of tumour-specific isoforms is particularly promising, 
for they would be excellent markers of malignancy. The existence of these tumour- 
specific enzymes would also be used for the design of pro-drugs that can be
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specifically activated at the site of the tumour, thereby reducing toxicity and side 
effects
To conclude, it should be noted that cancer is a multifactonal disease and this 
explains its many features The fact that a particular molecule or pathway might be 
relevant to the development of resistance to anticancer drugs does not necessarily 
mean that this sole molecule or pathway is responsible for the cell’s fate It is the 
interaction of complex regulatory pathways, rather than the contribution of single 
molecules, that will eventually lead cells to express a certain phenotype In this 
context, drug metabolism enzymes can certainly confer tumour cells a survival 
advantage, but they are only one of many factors that will influence the cell’s fate in 
the balance between death and survival
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5 2 Future work
In order to complete the work on microarrays, real time PCR (qRT-PCR) analysis will 
be carried out on the breast samples to validate the microarray results
Transfection of cell lines of different origin with CYP3A4 cDNA would provide new 
models to study the effect of this enzyme on 5-fluorouracil-induced toxicity These 
models could provide an explanation for the increased resistance to 5-fluorouracil 
observed in BCMV 3A4 cells BCMV cells, on the other hand, could also provide a 
useful model to study CYP3A4 and MDR1 interactions and possible cooperation in the 
development of resistance BCMV Neo and BCMV 3A4 could be transfected with an 
MDR1 plasmid and toxicity assays performed on BCMV MDR1, BCMV 3A4 and 
BCMV 3A4-MDR1 to analyse the contribution of each gene to drug resistance and 
possible synergistic effects
Expression of CYP1B1 is regulated by methylation in prostate cell lines and treatment 
with the methylase inhibitor 5-aza-2’-deoxycytidine (AzaC) can induce mRNA 
expression in these cells (Tokizane et a l , 2005) The panel of breast cell lines used to 
study CYP1B1 mRNA expression could be treated with AzaC to investigate whether 
CYP1B1 expression is also regulated by methylation in breast cell lines 
CYP1B1 siRNA transfection was toxic to MCF-7 Txt cells, transfection could also be 
carried out in different cell lines, derived from breast and also other hormone- 
responsive tissues such as ovary, to find out whether this is a general effect Also, 
toxicity profiles of CYP1B1 inhibitors such as a-napthoflavone in MCF-7 Txt and also 
other cell lines would expand our knowledge of the toxic effects of CYP1B1 inhibition 
in cancer cell lines
It appears that Taxotere can induce CYP1B1 mRNA expression, this could be 
confirmed by transfecting cells with a plasmid containing the luciferase gene under the 
control of the CYP1B1 promoter Treatment of transfected cells with Taxotere would 
then confirm whether this drug can directly induce the expression of this enzyme It 
would also be interesting to investigate wheter Taxotere has an effect on CYP1A1 and 
CYP1A2 expression Breast cells could also be incubated with Taxotere and other 
anticancer drugs in the presence of exogenous recombinant CYP1B1 to find out 
whether exogenously generated metabolites of this enzyme can promote cell survival
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Overexpression of P450R can sensitise cells against anticancer drugs such as 
Adriamycin and 5-fluorouracil Combination assays with a P450R inhibitor such as 
diphenyJiodonium chloride on P450R-expressing cells would reveal more about the 
relevance of this enzyme in drug resistance Also, ferredoxin reductase was reported 
as an essential gene for survival, transfection of cells with ferredoxin reductase siRNA 
caused cell death (Hwang et a l , 2001) Transfection of P450R-expressmg cells 
HepG2 with P450R siRNA could reveal whether the same is true of P450R 
ROS production is increased in MDA R4 cells as compared to MDA EV cells after 
treatment with Mitomycin C, Adriamycin and 5-fluorouracil The study of ROS 
production after treatment with other drugs such as Taxotere or Vincristine would 
reveal more about ROS generation in response to anticancer drugs
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